HUMANA INC.
Forward-Looking Statements
Some of the statements under “Business,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in this report may contain forward-looking statements which reflect our current views with respect to future events and financial performance. These forward-looking statements are made within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we are including this statement for purposes of complying with these safe harbor provisions. We have based these forward-looking statements on our current expectations and projections about future events, trends and uncertainties. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, including the information discussed under the section entitled “Risk Factors” in this report. In making these statements, we are not undertaking to address or update them in future filings or communications regarding our business or results. Our business is highly complicated, regulated and competitive with many different factors affecting results.
PART I
ITEM 1. BUSINESS
General
Headquartered in Louisville, Kentucky, Humana Inc. and its subsidiaries, referred to throughout this document as “we,” “us,” “our,” the “Company” or “Humana,” is a leading health and well-being company committed to helping our millions of medical and specialty members achieve their best health. Our successful history in care delivery and health plan administration is helping us create a new kind of integrated care with the power to improve health and well‐being and lower costs. Our efforts are leading to a better quality of life for people with Medicare, families, individuals, military service personnel, and communities at large. To accomplish that, we support physicians and other health care professionals as they work to deliver the right care in the right place for their patients, our members. Our range of clinical capabilities, resources and tools, such as in‐home care, behavioral health, pharmacy services, data analytics and wellness solutions, combine to produce a simplified experience that makes health care easier to navigate and more effective.
As of December 31, 2019,2022, we had approximately 17 million members in our medical benefit plans, as well as approximately 5 million members in our specialty products. During 2019,2022, 82% of our total premiums and services revenue were derived from contracts with the federal government, including 15%14% derived from our individual Medicare Advantage contracts in Florida with the Centers for Medicare and Medicaid Services, or CMS, under which we provide health insurance coverage to approximately 701,400771,900 members as of December 31, 2019.2022.
Humana Inc. was organized as a Delaware corporation in 1964. Our principal executive offices are located at 500 West Main Street, Louisville, Kentucky 40202, the telephone number at that address is (502) 580-1000, and our website address is www.humana.com. We have made available free of charge through the Investor Relations section of our web site our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, and, if applicable, amendments to those reports filed or furnished pursuant to Section 13(a) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission.
This Annual Report on Form 10-K, or 20192022 Form 10-K, contains both historical and forward-looking information. See Item 1A. – Risk Factors in this 20192022 Form 10-K for a description of a number of factors that may adversely affect our results or business.
Business Segments
We manageDuring December 2022, we realigned our business with threereportablebusinesses into two distinct segments: Insurance and CenterWell. The Insurance segment includes the businesses that were previously included in the Retail and Group and Specialty and Healthcare Services. Beginning January 1, 2018, we exited the individual commercial fully-insured medical health insurance business,segments, as
well as certain otherthe Pharmacy Benefit Manager, or PBM, business in 2018, and therefore no longer report separately the Individual Commercial segment and the Other Businesses categorywhich was previously included in the current year. Previously,Healthcare Services segment. The CenterWell segment (formerly Healthcare Services) represents our payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. In addition to the Other Businesses categorynew segment classifications being utilized to assess performance and allocate resources, we believe this simpler structure will create greater collaboration across the Insurance and CenterWell businesses and will accelerate work that is underway to centralize and integrate operations within the organization.Prior period segment financial information has been recast to conform to the 2022 presentation. For a recast of prior period segment financial information, refer to Note 18 to the audited Consolidated Financial Statements included businesses that were not individually reportable because they did not meet the quantitative thresholds required by generally accepted accounting principles, primarily our closed-blockin Part II, Item 8, "Financial Statements and Supplementary Data" of commercial long-term care insurance policies which were sold in 2018. The this Form 10-K.
Our tworeportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below.customers. These segment groupings are consistent with information used by our Chief Executive Officer, the chief operating decision maker,Chief Operating Decision Maker, to assess performance and allocate resources. See For additional information on our business segments and segment financial information, refer to Note 18 to the consolidated financial statementsaudited Consolidated Financial Statements included in Part II, Item 8. - Financial8, "Financial Statements and Supplementary Data for segment financial information.Data" of this Form 10-K.
Our Products
Our medical and specialty insurance products allow members to access health care services primarily through our networks of health care providers with whom we have contracted. These products may vary in the degree to which members have coverage. Health maintenance organizations, or HMOs, include comprehensive managed care benefits generally through a participating network of physicians, hospitals, and other providers. Preferred provider organizations, or PPOs, provide members the freedom to choose any health care provider. However, PPOs generally require the member to pay a greater portion of the provider’s fee in the event the member chooses not to use a provider participating in the PPO’s network. Point of Service, or POS, plans combine the advantages of HMO plans with the flexibility of PPO plans. In general, POS plans allow members to choose, at the time medical services are needed, to seek care from a provider within the plan’s network or outside the network. In addition, we offer services to our health plan members as well as to third parties that promote health and wellness, including pharmacy, solutions, provider services, and clinical programs,home solutions, as well as services and capabilities to advance population health. At the core of our strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics. Three core elements of the model are to improve the consumer experience by simplifying the interaction with us, engaging members in clinical programs, and offering assistance to providers in transitioning from a fee-for-service, or FFS, to a value-based arrangement. Our approach to primary, physician-directed care for our members aims to provide quality care that is consistent, integrated, cost-effective, and member-focused. The model is designed to improve health outcomes and affordability for individuals and for the health system as a whole, while offering our members a simple, seamless healthcare experience. The discussion that follows describes the products offered by each of our segments.
Our RetailInsurance Segment Products
ThisThe Insurance segment is comprised of products serving Medicare and state-based contract beneficiaries sold on a retail basis to individuals including medical and supplemental benefit plansplans. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision and life insurance benefits, as well as administrative services only, or ASO. In addition, our Insurance segment includes our military services business as well as the operations of our PBM business. These products are described in the discussion that follows.
The following table presents our premiums and services revenue for the RetailInsurance segment by product for the year ended December 31, 2019:2022:
| | | | | | | | | | | | | | |
| | Insurance Segment Premiums and Services Revenue | | Percent of Consolidated Premiums and Services Revenue |
| | (dollars in millions) |
Premiums: | | | | |
Individual Medicare Advantage | | $ | 65,591 | | | 70.9 | % |
Group Medicare Advantage | | 7,297 | | | 7.9 | % |
Medicare stand-alone PDP | | 2,269 | | | 2.5 | % |
Total Medicare | | 75,157 | | | 81.3 | % |
Medicare Supplement | | 743 | | | 0.8 | % |
Commercial fully-insured | | 3,733 | | | 4.0 | % |
Total fully-insured | | 4,476 | | | 4.8 | % |
Medicaid and other | | 6,376 | | | 6.9 | % |
Specialty | | 1,703 | | | 1.8 | % |
Total premiums | | 87,712 | | | 94.8 | % |
Services | | 850 | | | 0.9 | % |
Total premiums and services revenue | | $ | 88,562 | | | 95.8 | % |
| | | | |
|
| | | | | | | |
| | Retail Segment Premiums and Services Revenue | | Percent of Consolidated Premiums and Services Revenue |
| | (dollars in millions) |
Premiums: | | | | |
Individual Medicare Advantage | | $ | 43,128 |
| | 67.0 | % |
Group Medicare Advantage | | 6,475 |
| | 10.1 | % |
Medicare stand-alone PDP | | 3,165 |
| | 4.9 | % |
Total Retail Medicare | | 52,768 |
| | 82.0 | % |
State-based Medicaid | | 2,898 |
| | 4.5 | % |
Medicare Supplement | | 588 |
| | 0.9 | % |
Total premiums | | 56,254 |
| | 87.4 | % |
Services | | 17 |
| | — | % |
Total premiums and services revenue | | $ | 56,271 |
| | 87.4 | % |
Medicare
We have participated in the Medicare program for private health plans for over 30 years and have established a national presence, offering at least one type of Medicare plan in all 50 states. We have a geographically diverse membership base that we believe provides us with greater ability to expand our network of PPO and HMO providers. We employ strategies including health assessments and clinical guidance programs such as lifestyle and fitness programs for seniors to guide Medicare beneficiaries in making cost-effective decisions with respect to their health care. We believe these strategies result in cost savings that occur from making positive behavior changes.
Medicare is a federal program that provides persons age 65 and over and some disabled persons under the age of 65 certain hospital and medical insurance benefits. CMS, an agency of the United States Department of Health and Human Services, administers the Medicare program. Hospitalization benefits are provided under Part A, without the payment of any premium, for up to 90 days per incident of illness plus a lifetime reserve aggregating 60 days. Eligible beneficiaries are required to pay an annually adjusted premium to the federal government to be eligible for physician care and other services under Part B. Beneficiaries eligible for Part A and Part B coverage under traditional fee-for-service Medicare are still required to pay out-of-pocket deductibles and coinsurance. Throughout this document this program is referred to as Medicare FFS. As an alternative to Medicare FFS, in geographic areas where a managed care organization has contracted with CMS pursuant to the Medicare Advantage program, Medicare beneficiaries may choose to receive benefits from a Medicare Advantage organization under Medicare Part C. Pursuant to Medicare Part C, Medicare Advantage organizations contract with CMS to offer Medicare Advantage plans to provide benefits at least comparable to those offered under Medicare FFS. Our Medicare
Advantage, or MA, plans are discussed more fully below.in the following sections. Prescription drug benefits are provided under Part D.
Individual Medicare Advantage Products
We contract with CMS under the Medicare Advantage program to provide a comprehensive array of health insurance benefits, including wellness programs, chronic care management, and care coordination, to Medicare eligible persons under HMO, PPO, and Private Fee-For-Service, or PFFS, and Special Needs Plans, including Dual Eligible Special Needs, or D-SNP, plans in exchange for contractual payments received from CMS, usually a fixed payment per member per month. With each of these products, the beneficiary receives benefits in excess of Medicare FFS, typically including reduced cost sharing, enhanced prescription drug benefits, care coordination, data analysis techniques to help identify member needs, complex case management, tools to guide members in their health care decisions, care management programs, wellness and prevention programs and, in some instances, a reduced monthly Part B premium. Most Medicare Advantage plans offer the prescription drug benefit under Part D as part of the basic plan, subject to cost sharing and other limitations. Accordingly, all of the provisions of the Medicare Part D program described in connection with our stand-alone prescription drug plans in the following section also are applicable to most of our Medicare Advantage plans. Medicare Advantage plans may charge beneficiaries monthly premiums and other copayments for Medicare-covered services or for certain extra benefits. Generally, Medicare-eligible individuals enroll in one of our plan choices between October 15 and December 7 for coverage that begins on the following January 1.
Our Medicare HMO and PPO plans, which cover Medicare-eligible individuals residing in certain counties, may eliminate or reduce coinsurance or the level of deductibles on many other medical services while seeking care from participating in-network providers or in emergency situations. Except in emergency situations or as specified by the plan, most HMO plans provide no out-of-network benefits. PPO plans carry an out-of network benefit that is subject to higher member cost-sharing. In some cases, these beneficiaries are required to pay a monthly premium to the HMO or PPO plan in addition to the monthly Part B premium they are required to pay the Medicare program.
Most of our Medicare PFFS plans are network-based products with in and out of network benefits due to a requirement that Medicare Advantage organizations establish adequate provider networks, except in geographic areas that CMS determines have fewer than two network-based Medicare Advantage plans. In these areas, we offer Medicare PFFS plans that have no preferred network. Individuals in these plans pay us a monthly premium to receive typical Medicare Advantage benefits along with the freedom to choose any health care provider that accepts individuals at rates equivalent to Medicare FFS payment rates.
CMS uses monthly rates per person for each county to determine the fixed monthly payments per member to pay to health benefit plans. These rates are adjusted under CMS’sa risk-adjustment model which usesadjusts premiums paid to Medicare Advantage, or MA, plans according to health status indicators, or risk scores, to improve the accuracy of payment.covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997 (BBA) and the Benefits Improvement and Protection Act of 2000 (BIPA), generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to account for members with predictably higher costscertain demographic characteristics and uses principal hospital inpatient diagnoses as well as diagnosis data from ambulatory treatment settings (hospital outpatient department and physician visits) to establish the risk-adjustment payments.health status of our enrolled members. Under the risk-adjustment methodology, all health benefit organizationsMA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines. The CMS is phasing-inrisk-adjustment model uses the process of calculating risk scores using diagnosesdiagnosis data, collected from providers, to calculate the Risk Adjustment Processing System, or RAPS,health status-related risk-adjusted premium payment to diagnoses data from the Encounter Data System, or EDS. The RAPS process requires MA plans, which CMS further adjusts for coding pattern differences between the health plans and the government fee-for-service (FFS) program. We generally rely on providers, including certain providers in our network who are our employees, to apply a filter logic basedcode their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on CMS guidelines and only submit diagnoses that satisfy those guidelines. For submissions through EDS, CMS requires MA plansthese providers to submitdocument appropriately all medical data, including the encounterdiagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and CMS will applypayment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment filtering logic to determine the risk scores.model. For 2019, 25% of the risk score was calculated from claims data submitted through EDS. CMS will increase that percentage to 50% in 2020 and has proposed to increase that percentage to 75% in 2021. For moreadditional information, refer to Note 17 to the consolidated financial statementsaudited Consolidated Financial Statements included in Part II, Item 8. – Financial8, "Financial Statements and Supplementary DataData" and Part I, Item 1A. - Risk Factors.1A, "Risk Factors" of this Form 10-K.
At December 31, 2019,2022, we provided health insurance coverage under CMS contracts to approximately 3,587,2004,565,600 individual Medicare Advantage members, including approximately 701,400771,900 members in Florida. These Florida contracts accounted for premiums revenue of approximately $9.5$13.2 billion, which represented approximately 22.0%20% of our individual Medicare Advantage premiums revenue, or 15.0%14% of our consolidated premiums and services revenue for the year ended December 31, 2019.2022.
Our HMO, PPO, and PFFSindividual Medicare Advantage products covered under Medicare Advantage contracts with CMS are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May 1 of the calendar year in which the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare Advantage products have been renewed for 2020,2023, and all of our product offerings filed with CMS for 20202023 have been approved.
Individual Medicare Stand-Alone Prescription Drug Products
We offer stand-alone prescription drug plans, or PDPs, under Medicare Part D, including a PDP offering co-branded with Wal-Mart Stores, Inc., or the Humana-Walmart plan. Generally, Medicare-eligible individuals enroll in one of our plan choices between October 15 and December 7 for coverage that begins on the following January 1. Our stand-alone PDP offerings consist of plans offering basic coverage with benefits mandated by Congress, as well as plans providing enhanced coverage with varying degrees of out-of-pocket costs for premiums, deductibles, and co-insurance. Our revenues from CMS and the beneficiary are determined from our PDP bids submitted annually to CMS. These revenues also reflect the health status of the beneficiary and risk sharing provisions as more fully described in Note 2 to the consolidated financial statementsaudited Consolidated Financial Statements included in Item 8. – Financial Statements and Supplementary Data, titled “Medicare Part D.” Our stand-alone PDP contracts with CMS are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May 1 of the calendar year in which the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare stand-alone PDP products have been renewed for 2020,2023, and all of our product offerings filed with CMS for 20202023 have been approved.
We have administered CMS’s Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program since 2010. This program allows individuals who receive Medicare’s low-income subsidy to also receive immediate prescription drug coverage at the point of sale if they are not already enrolled in a Medicare Part D plan. CMS temporarily enrolls newly identified individuals with both Medicare and Medicaid into the LI-NET prescription drug plan program, and subsequently transitions each member into a Medicare Part D plan that may or may not be a Humana Medicare plan.
Group Medicare Advantage and Medicare stand-aloneStand-Alone PDP
We offer products that enable employers that provide post-retirement health care benefits to replace Medicare wrap or Medicare supplement products with Medicare Advantage or stand-alone PDPs from Humana. These products are primarily offered as PPO plans on the same Medicare platform as individual Medicare Advantage plans. These plans offer the same types of benefits and services available to members in our individual Medicare plans discussed previously, and can be tailoredhowever, group Medicare Advantage plans typically have richer benefit offerings than individual Medicare Advantage plans, including prescription drug coverage in the gap, for instance, due to the desire of many customers to closely match an employer’s post-retirementtheir pre-retirement benefit structure.
Medicare Supplement
We also offer Medicare supplement products that help pay the medical expenses that Medicare FFS does not cover, such as copayments, coinsurance and deductibles.
State-based Medicaid Contracts
OurThrough our state-based contracts, allow us towe serve members enrolled in state-basedMedicaid, a program funded by both the federal and state governments and administered by states to care for their most vulnerable populations. Within federal guidelines, states determine whom to cover, but general categories for traditional Medicaid programs includinginclude: children and parents receiving assistance through Temporary Assistance to Needy Families or TANF,(TANF); Aged, Blind, and Disabled or ABD,(ABD) individuals; and Medicaid Expansion adults. Through Medicaid Managed Long-Term Support Services or LTSS, and the CMS Financial Alignment dual eligible demonstration programs. TANF and ABD(MLTSS) programs, are traditional Medicaidstates offer programs that are state and federally funded and provide cash assistance and supportiveto deliver support services to assist qualifying aged, blind, or disabled individuals, as well as families with children under age 18, helping them achieve economic self-sufficiency. LTSS is a state and federally funded program that offers states a broad and flexible set of program design options and refers to the delivery of long-term support services for our memberspeople who receive home and community or institution-based services for long-term care. Our contracts are generally for three to five year terms.
We have contracts in multiple states to serve Medicaid eligibleMedicaid-eligible members, inincluding Florida, Kentucky, Louisiana, Ohio, South Carolina and Kentucky under traditional programs, as well as contracts in Florida under the LTSS program. Prior toWisconsin. The Louisiana contract was effective January 1, 2020, our Kentucky Medicaid contract was subject to a 100% coinsurance contract with CareSource Management Group Company, ceding all the risk to CareSource. Effective January 1, 2020, we terminated the reinsurance agreement with CareSource and assumed full administration of our Kentucky Medicaid contract.2023.
Medicare beneficiariesWe also serve members who also qualify for both Medicaid dueand Medicare, referred to low income or special needs are known as dual eligible beneficiaries, or dual eligibles. The"dual eligible", through our Medicaid, Medicare Advantage, and stand-alone prescription drug plans. As the dual eligible population represents a disproportionate share of Medicaidcosts, Humana is participating in varied integration models designed to improve health outcomes and Medicarereduce avoidable costs. States require special coordinating contracts for plans to offer Medicare Advantage dual eligible special needs plans, or D-SNPs. These programs largely operate separateseparately from traditional Medicaid and LTSS programs. We currently serve dual eligible members under CMS’s dual eligible demonstration program in Illinois.
As part of our individual Medicare Advantage products, we also offer Dual-Eligible Special Needs Plans (D-SNP). In connection with offering a D-SNP in a particular state, we are required to enter into a special coordinating contract with the applicable state Medicaid agency. To meet federal requirements that took effect in 2021, states have begun to implement new D-SNP requirements to strengthen Medicaid-Medicare integration requirements for D-SNPs. Some states are also moving to support the dual eligible population by linking D-SNP participation to enrollment in a plan that also participates in a state-based Medicaid program to coordinate and integrate both Medicare and Medicaid benefits. Beginning in 2021, based on new federal requirements, states are expected to strengthen Medicaid-Medicare integration requirements for D-SNPs.
We currently serve dual eligible members under the CMS stand-alone dual eligible demonstration program in Illinois, and continue to serve other dual eligible members enrolled in our Medicare Advantage and stand-alone prescription drug plans.
Our Group and Specialty Segment Products
The Group and Specialty segment consists of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision and life insurance benefits, as well as administrative services only, or ASO products as described in the discussion that follows. The following table presents our premiums and services revenue for the Group and Specialty segment by product for the year ended December 31, 2019:
|
| | | | | | | |
| | Group and Specialty Segment Premiums and Services Revenue | | Percent of Consolidated Premiums and Services Revenue |
| | (dollars in millions) |
External Revenue: | | | | |
Premiums: | | | | |
Fully-insured commercial group | | $ | 5,123 |
| | 8.0 | % |
Specialty | | 1,571 |
| | 2.4 | % |
Total premiums | | 6,694 |
| | 10.4 | % |
Services | | 790 |
| | 1.2 | % |
Total premiums and services revenue | | $ | 7,484 |
| | 11.6 | % |
Intersegment services revenue | | $ | 18 |
| | n/a |
|
n/a – not applicable
Group Commercial Coverage
Our commercial products sold to employer groups include a broad spectrum of major medical benefits with multiple in-network coinsurance levels and annual deductible choices that employers of all sizes can offer to their employees on either a fully-insured, through HMO, PPO, or POS plans, or self-funded basis. Our plans integrate clinical programs, plan designs, communication tools, and spending accounts.
Our administrative services only, or ASO products are offered to small group and large group employers who self-insure their employee health plans. We receive fees to provide administrative services which generally include the processing of claims, offering access to our provider networks and clinical programs, and responding to customer service inquiries from members of self-funded employers. These products may include all of the same benefit and product design characteristics of our fully-insured HMO, PPO, or POS products described previously. Under ASO contracts, self-funded employers generally retain the risk of financing the costs of health benefits, with large group customers retaining a greater share and small group customers a smaller share of the cost of health benefits. All small group ASO customers and many large group ASO customers purchase stop loss insurance coverage from us to cover catastrophic claims or to limit aggregate annual costs.
Employers can customize their offerings with optional benefits such as dental, vision, and life products. We also offer optional benefits such as dental and vision to individuals.
Military Services
Under our TRICARE contracts with the United States Department of Defense, or DoD, we provide administrative services to arrange health care services for the dependents of active duty military personnel and for retired military personnel and their dependents. We have participated in the TRICARE program since 1996 under contracts with the DoD. Under our contracts, we provide administrative services while the federal government retains all of the risk of the cost of health benefits. Accordingly, we account for revenues under the current contract net of estimated health care costs similar to an administrative services fee only agreement.
On January 1, 2018, we began to deliver services under the T2017 East Region contract. The T2017 East Region contract is a consolidation of the former T3 North and South Regions, comprising thirty-twocomprises 32 states and approximately 6 million TRICARE beneficiaries. The T2017 East Region
contract, is a 5-year contractwhich was originally set to expire on December 31, 2022, was subsequently extended by the DoD and is subjectcurrently scheduled to renewalsexpire on January 1December 31, 2023, unless further extended.
In December 2022, we were awarded the next generation of eachTRICARE Managed Care Support Contracts, or T-5, for the TRICARE East Region by the Defense Health Agency of the DoD. The contract is expected to go into effect in 2024. Until then the T2017 contract remains in place. Under the terms of the award, our service area covers approximately 4.6 million beneficiaries in a region consisting of 24 states and Washington, D.C. The length of the contract is one base year during its term at the government's option.with eight annual option periods, which, if all options are exercised, would result in a total contract length of nine years.
Our Healthcare ServicesCenterWell Segment Products
The products offered by our Healthcare ServicesCenterWell segment are key to our integrated care delivery model. This segment is comprised of stand-alone businesses that offer services includingincludes our pharmacy, solutions, provider services, clinicaland home solutions operations. The CenterWell segment also includes our strategic partnerships with Welsh, Carson, Anderson & Stowe, or WCAS, to develop and operate senior-focused, payor-agnostic, primary care services, and predictive modeling and informatics services to other Humana businesses,centers, as well as externalour minority ownership interest in hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health plan members, external health plans, and other employers and/or individuals and are described in the discussion that follows. Ourlower drug costs. For information on our intersegment revenue is described inrevenues, refer to Note 18 to the consolidated financial statementsaudited Consolidated Financial Statements included in Part II, Item 8. – Financial8, "Financial Statements and Supplementary Data. Data" of this Form 10-K.
The following table presents our services revenue for the Healthcare ServicesCenterWell segment by line of business for the year ended December 31, 2019:2022:
|
| | | | | | | |
| | Healthcare Services Segment Services Revenue | | Percent of Consolidated Premiums and Services Revenue |
| | (dollars in millions) |
Intersegment revenue: | | | | |
Pharmacy solutions | | $ | 22,189 |
| | n/a |
|
Provider services | | 2,344 |
| | n/a |
|
Clinical care services | | 616 |
| | n/a |
|
Total intersegment revenue | | $ | 25,149 |
| | |
External services revenue: | | | | |
Pharmacy solutions | | $ | 186 |
| | 0.3 | % |
Provider services | | 306 |
| | 0.5 | % |
Clinical care services | | 140 |
| | 0.2 | % |
Total external services revenue | | $ | 632 |
| | 1.0 | % |
| | | | | | | | | | | | | | |
| | CenterWell Segment Services Revenue | | Percent of Consolidated Premiums and Services Revenue |
| | (dollars in millions) |
Intersegment revenues: | | | | |
Home solutions | | $ | 553 | | | n/a |
Pharmacy | | 9,841 | | | n/a |
Provider services | | 2,979 | | | n/a |
Total intersegment revenues | | $ | 13,373 | | | |
External services revenue: | | | | |
Home solutions | | $ | 2,333 | | | 2.5 | % |
Pharmacy | | 1,025 | | | 1.1 | % |
Provider services | | 568 | | | 0.6 | % |
Total external services revenue | | $ | 3,926 | | | 4.2 | % |
| | | | |
n/a – not applicable
Pharmacy solutions
HumanaOur pharmacy business includes the operations of CenterWell Pharmacy Solutions®(our mail-order pharmacy business), or HPS, manages traditional prescription drug coverage for both individualsCenterWell Specialty Pharmacy, and employer groups in addition to providing a broad array of pharmacy solutions. HPS also operates prescription mail order servicesother retail pharmacies located within CenterWell Primary Care clinics for brand, generic, and specialty drugs, over the counter medications and diabetic supplies, through Humana Pharmacy, Inc.and hospice pharmacy drugs.
Provider servicesServices
We operate full-service, multi-specialty medicalvalue-based senior focused primary care centers in a number of states, including Georgia, Florida, Kansas, Louisiana, Missouri, Nevada, North Carolina, South Carolina, Texas, Arizona and Texas,
Kentucky staffed by primary care providers and medical specialists with a primary focus on the senior population. We operatepopulation under our Primary Care Organization, or PCO. PCO operates these clinics primarily under the Conviva Partners inCare Centers and CenterWell Senior Primary Care or Family Physicians Group brands. Our primary care delivery subsidiaries operate our medical center business through both employed physicians and care providers, and through third party management service organizations with whom we contract to arrange for and manage certain clinical services. PCO currently operates 235 primary care clinics and employs approximately 670 primary care providers. PCO serves approximately 247,900 patients, primarily under risk sharing arrangements with Humana Medicare Advantage health plans, third party Medicare Advantage health plans and CMS administered risk sharing arrangements for Medicare FFS.
WePCO also operateoperates a Medical Services Organization, or MSO, through Conviva that coordinates medical care for Medicare Advantage beneficiaries in Florida and Texas. This MSO provides resources in care coordination, financial risk management, clinical integration and patient engagement that help physicians improve the patient experience as well as care outcomes. Conviva’s MSO collaborates with physicians, medical groups and integrated delivery systems to successfully transition to value-based care by engaging, partnering and offering practical services and solutions.
In February 2020, Partners inour Primary Care Organization entered into a strategic partnership with Welsh, Carson, Anderson & Stowe, or WCAS, to accelerate the expansion of our primary care model. In May 2022, we established a second strategic partnership with WCAS to develop additional centers between 2023 and 2025. As of December 31, 2022, there were 50 primary care clinics operating under the partnership and we intend to open a minimum of 50approximately 100 additional payor-agnostic, senior-focused primary care centers over the next three
years and in 2018 we acquired Family Physicians Group, or FPG, serving Medicare Advantage and Managed Medicaid HMO patients through its senior focused clinics in Greater Orlando, Florida. Also, during 2018, we acquiredfuture periods under the remaining equity interest in Miami, Florida based MCCI Holdings, LLC, or MCCI, a privately held management service organization and healthcare that primarily coordinates medical care for Medicare Advantage beneficiaries in Florida and Texas. Seeexisting arrangements. For additional information, refer to Note 34 to the consolidated financial statementsaudited Consolidated Financial Statements included in Part II, Item 8. - Financial8, "Financial Statements and Supplementary Data.Data" of this Form 10-K.
Home Solutions
Clinical care servicesCenterWell Home Health
Via in-home care, telephonic health counseling/coaching, and remote monitoring, weWe are actively involved in the care management of our customers with the greatest needs. Clinical care services include the operations of Humana At Home, Inc., or Humana At Home®. As a chronic-care provider ofneeds via in-home care for seniors,care. On August 17, 2021, we provide innovative and holistic care coordination services for individuals living with multiple chronic conditions, individuals with disabilities, fragile and aging-in-place members and their care givers. We focus our deployment of these services in geographies with a high concentration of members living with multiple chronic conditions. The clinical support and care provided by Humana At Home is designed to improve health outcomes and result in a higher number of days members can spend at their homes instead of in an acute care facility. At December 31, 2019, we have enrolled approximately 868,800 members, with complex chronic conditions participating in a Humana Chronic Care Program, reflecting enhanced predictive modeling capabilities and focus on proactive clinical outreach and member engagement, particularly for our Medicare Advantage membership. These members may not be unique to each program since members have the ability to enroll in multiple programs. We believe these initiatives lead to better health outcomes for our members and lower health care costs.
We have committed additional investments in our home care capabilities with our acquisition of a 40% minority interest infully acquired Kindred at Home, Inc., or Kindred at Home, and Curo Health Services, or Curo, which combined createsKAH, the nation'snation’s largest home health and hospice provider with locations in 40 states, providing extensive geographic coverage with approximately 65% overlap with our individual Medicare Advantage business. See Note 4membership. Our home solutions geographic scale and clinical breadth provides the opportunity to offer care beyond our health plan members. We have fully-integrated the consolidated financial statements included in Item 8. - Financial Statements and Supplementary Data.
We are committed to the integrated physical and mentalhome health of our members. Accordingly, we take a holistic approach to healthcare, offering care management and wellness programs. These programs use our capabilities that enableoperations, now branded CenterWell Home Health, allowing us to createaccelerate clinical innovation and the development and roll out of a value-based operating model at scale, more complete viewclosely aligning incentives to focus on improving patient outcomes and reducing the total cost of an individual’scare. This is critical to deploying a value-based, advanced home health designedmodel at scale that makes it easier for patients and providers to connect, coordinate and simplify healthbenefit from our full continuum of home-based capabilities, leveraging the best channel to deliver the right care while reducing costs. These capabilities include our health care analytics engine, which reviews billions of clinical data points on millions of patients each day to provide members, providers, and payers real-time clinical insights to identify evidence-based gaps-in-care, drug safety alerts and other critical health concerns to improve outcomes. Additionally, our technology connects Humana and disparate electronic health record systems to enableneeded at the exchange of essential health information in real-time to provide physicians and care teams with a single, comprehensive patient view.right time.
Our care management programs take full advantage ofOnehome
Onehome serves as the population health, wellness and clinical applications offered by CareHub, our clinical management tool used by providers and care managers acrossconvener for the company to help our members achieve their best health, to offer various levels of support, matching the intensity of the support tovalue-based model meeting the needs of health plans by serving their members through a full-risk model for integrated home-based services. Onehome manages a full range of post-acute patient needs, integrating and coordinating with ongoingphysicians, hospitals and health challenges through telephonicplans for the provision of home health and onsite programs. These programs include Personal Nurse, chronic condition management, and case managementinfusion services as well as programs supporting maternity, cancer, neonatal intensivethe distribution of durable medical equipment, or DME, at patients’ homes. Onehome served 15% of our MA members with our value-based model as of December 31, 2022.
Hospice
Hospice care unit,is an important offering in the full continuum of care we offer patients, and transplant services.
Wellness
We offer wellness solutionswe have been successful in delivering the desired patient experience and outcomes through partnership models, including our Go365 wellness and loyalty rewards program, employee assistance program, and clinical programs. These programs, when offered collectively to employer customers as our Total Health product, turn any standard plan of the employer's choosing into an integrated health and well-being solution that encouragesthrough participation in these programs.
Our Go365 program provides our members with access to a science-based, actuarially driven wellness and loyalty program that features a wide range of well-being tools and rewards that are customized to an individual’s needs and
wants. A key element of the program includes a sophisticated health-behavior-change model supported by an incentive program.
Our Individual Commercial Segment Products
Our individual health plans were marketed under the HumanaOne brand. We offered products bothCMS hospice Value-Based Insurance Design, or VBID, model. As such, on and off of the public exchange.
We discontinued substantially all off-exchange individual commercial medical plans effective January 1, 2017, andAugust 11, 2022, we exited our remaining individual commercial medical business effective January 1, 2018.
Other Businesses
Other Businesses includes those businesses that do not align with the reportable segments previously described, primarily our closed-block long-term care insurance policies, which were sold in 2018. For a detailed discussion ofcompleted the sale of a 60% interest in Humana’s Kindred at Home Hospice subsidiary, or KAH Hospice, to Clayton, Dubilier & Rice, or CD&R. Upon closing, KAH Hospice was restructured into a new stand-alone company. We continue to own a 40% minority ownership in hospice operations. For additional information on the
sale of KAH Hospice, refer to Note 3 to the consolidated financial statementsaudited Consolidated Financial Statements included in Part II, Item 8. – Financial8, "Financial Statements and Supplementary Data.Data" of this Form 10-K.
Membership
The following table summarizes our total medical membership (in thousands) at December 31, 2019,2022, by market and product:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Insurance | | | | | | | | | | | | | | |
| Individual Medicare Advantage | Group Medicare Advantage | Medicare stand- alone PDP | Medicare Supplement | State- based contracts and Other | Fully- insured commercial Group | ASO | Military services | | | Total | Percent of Total | | | | | | | | | | |
Florida | 771.9 | | 7.3 | | 158.3 | | 17.3 | | 835.0 | | 105.2 | | 32.2 | | — | | | | 1,927.2 | | 11.30 | % | | | | | | | | | | |
Kentucky | 112.8 | | 75.2 | | 169.5 | | 9.3 | | 172.9 | | 73.7 | | 145.8 | | — | | | | 759.2 | | 4.40 | % | | | | | | | | | | |
Texas | 366.5 | | 4.3 | | 239.5 | | 26.8 | | 2.0 | | 78.8 | | 40.8 | | — | | | | 758.7 | | 4.40 | % | | | | | | | | | | |
California | 103.7 | | 1.4 | | 401.3 | | 17.7 | | 4.0 | | — | | — | | — | | | | 528.1 | | 3.10 | % | | | | | | | | | | |
Georgia | 278.4 | | 2.8 | | 94.7 | | 9.0 | | — | | 64.4 | | 72.3 | | — | | | | 521.6 | | 3.10 | % | | | | | | | | | | |
North Carolina | 217.7 | | 163.8 | | 115.3 | | 6.2 | | — | | — | | — | | — | | | | 503.0 | | 2.90 | % | | | | | | | | | | |
Ohio | 176.0 | | 18.8 | | 104.3 | | 34.1 | | — | | 24.2 | | 23.9 | | — | | | | 381.3 | | 2.20 | % | | | | | | | | | | |
Tennessee | 184.4 | | 7.5 | | 88.5 | | 7.9 | | 36.1 | | 29.6 | | 15.5 | | — | | | | 369.5 | | 2.20 | % | | | | | | | | | | |
Illinois | 157.4 | | 30.4 | | 126.8 | | 6.8 | | 17.1 | | 16.3 | | 2.5 | | — | | | | 357.3 | | 2.10 | % | | | | | | | | | | |
Missouri/Kansas | 109.9 | | 7.4 | | 150.9 | | 10.9 | | — | | 23.0 | | 22.7 | | — | | | | 324.8 | | 1.90 | % | | | | | | | | | | |
Louisiana | 211.3 | | 14.5 | | 50.5 | | 4.1 | | — | | 22.9 | | 18.1 | | — | | | | 321.4 | | 1.90 | % | | | | | | | | | | |
Wisconsin | 69.0 | | 6.9 | | 74.7 | | 7.2 | | 45.1 | | 39.8 | | 23.9 | | — | | | | 266.6 | | 1.60 | % | | | | | | | | | | |
Indiana | 122.2 | | 11.2 | | 86.4 | | 12.7 | | — | | 12.5 | | 7.9 | | — | | | | 252.9 | | 1.50 | % | | | | | | | | | | |
Virginia | 140.7 | | 3.2 | | 100.6 | | 6.5 | | — | | — | | — | | — | | | | 251.0 | | 1.50 | % | | | | | | | | | | |
New York | 107.5 | | 10.7 | | 120.4 | | 8.3 | | 1.1 | | — | | — | | — | | | | 248.0 | | 1.50 | % | | | | | | | | | | |
Michigan | 113.9 | | 27.9 | | 87.6 | | 4.6 | | — | | 0.7 | | 1.7 | | — | | | | 236.4 | | 1.40 | % | | | | | | | | | | |
Alabama | 93.3 | | 86.1 | | 47.6 | | 4.1 | | — | | — | | — | | — | | | | 231.1 | | 1.40 | % | | | | | | | | | | |
South Carolina | 154.7 | | 0.4 | | 49.1 | | 6.3 | | 17.5 | | — | | — | | — | | | | 228.0 | | 1.30 | % | | | | | | | | | | |
Pennsylvania | 87.7 | | 4.5 | | 116.1 | | 5.4 | | — | | — | | — | | — | | | | 213.7 | | 1.30 | % | | | | | | | | | | |
Arizona | 118.8 | | 0.4 | | 70.9 | | 8.2 | | — | | 9.7 | | 5.1 | | — | | | | 213.1 | | 1.20 | % | | | | | | | | | | |
Military services | — | | — | | — | | — | | — | | — | | — | | 5,959.9 | | | | 5,959.9 | | 34.90 | % | | | | | | | | | | |
Others | 867.8 | | 80.4 | | 1,098.3 | | 100.2 | | 6.5 | | 55.5 | | 17.7 | | — | | | | 2,226.4 | | 12.90 | % | | | | | | | | | | |
Totals | 4,565.6 | | 565.1 | | 3,551.3 | | 313.6 | | 1,137.3 | | 556.3 | | 430.1 | | 5,959.9 | | | | 17,079.2 | | 100.0 | % | | | | | | | | | | |
|
| | | | | | | | | | | | | | | | | | | | | |
| Retail Segment | | Group and Specialty Segment |
|
|
| (in thousands) |
| Individual Medicare Advantage | Group Medicare Advantage | Medicare stand- alone PDP | Medicare Supplement | State- based contracts | | Fully- insured commercial Group | ASO | Military services | Total | Percent of Total |
Florida | 701.4 |
| 10.2 |
| 188.6 |
| 16.5 |
| 460.9 |
| | 145.4 |
| 36.9 |
| — |
| 1,559.9 |
| 9.4 | % |
Texas | 285.9 |
| 244.5 |
| 292.3 |
| 19.5 |
| — |
| | 140.8 |
| 31.0 |
| — |
| 1,014.0 |
| 6.1 | % |
Kentucky | 98.0 |
| 65.6 |
| 201.4 |
| 6.1 |
| — |
| | 106.6 |
| 135.3 |
| — |
| 613.0 |
| 3.7 | % |
California | 83.9 |
| 0.7 |
| 436.7 |
| 20.7 |
| — |
| | — |
| — |
| — |
| 542.0 |
| 3.3 | % |
Georgia | 144.4 |
| 2.0 |
| 113.3 |
| 11.4 |
| — |
| | 135.6 |
| 71.3 |
| — |
| 478.0 |
| 2.9 | % |
Illinois | 126.2 |
| 25.0 |
| 172.0 |
| 7.7 |
| 8.1 |
| | 36.8 |
| 76.7 |
| — |
| 452.5 |
| 2.7 | % |
Ohio | 150.3 |
| 23.3 |
| 153.2 |
| 42.8 |
| — |
| | 33.0 |
| 31.4 |
| — |
| 434.0 |
| 2.6 | % |
Missouri/Kansas | 98.1 |
| 4.8 |
| 189.0 |
| 12.1 |
| — |
| | 38.9 |
| 26.0 |
| — |
| 368.9 |
| 2.2 | % |
North Carolina | 179.2 |
| 0.4 |
| 148.6 |
| 6.5 |
| — |
| | — |
| — |
| — |
| 334.7 |
| 2.0 | % |
Tennessee | 153.9 |
| 4.9 |
| 104.8 |
| 7.0 |
| — |
| | 38.3 |
| 14.0 |
| — |
| 322.9 |
| 1.9 | % |
Louisiana | 167.3 |
| 13.8 |
| 55.5 |
| 3.1 |
| — |
| | 52.7 |
| 19.4 |
| — |
| 311.8 |
| 1.9 | % |
Wisconsin | 63.5 |
| 5.7 |
| 104.6 |
| 7.0 |
| — |
| | 65.9 |
| 32.9 |
| — |
| 279.6 |
| 1.7 | % |
Indiana | 113.9 |
| 7.1 |
| 121.9 |
| 10.2 |
| — |
| | 19.3 |
| 11.8 |
| — |
| 284.2 |
| 1.7 | % |
Virginia | 132.2 |
| 3.8 |
| 139.5 |
| 9.2 |
| — |
| | — |
| — |
| — |
| 284.7 |
| 1.7 | % |
Michigan | 70.9 |
| 18.9 |
| 118.7 |
| 4.7 |
| — |
| | 1.8 |
| — |
| — |
| 215.0 |
| 1.3 | % |
Arizona | 92.8 |
| 0.4 |
| 88.0 |
| 7.4 |
| — |
| | 21.5 |
| 8.1 |
| — |
| 218.2 |
| 1.3 | % |
Pennsylvania | 56.6 |
| 2.2 |
| 139.4 |
| 5.6 |
| — |
| | — |
| — |
| — |
| 203.8 |
| 1.1 | % |
South Carolina | 99.4 |
| 0.5 |
| 59.0 |
| 5.9 |
| — |
| | — |
| — |
| — |
| 164.8 |
| 1.0 | % |
Military services | — |
| — |
| — |
| — |
| — |
| | — |
| — |
| 5,984.3 |
| 5,984.3 |
| 35.9 | % |
Others | 769.3 |
| 91.5 |
| 1,538.7 |
| 95.0 |
| — |
| | 72.0 |
| 34.4 |
| — |
| 2,600.9 |
| 15.6 | % |
Totals | 3,587.2 |
| 525.3 |
| 4,365.2 |
| 298.4 |
| 469.0 |
| | 908.6 |
| 529.2 |
| 5,984.3 |
| 16,667.2 |
| 100.0 | % |
Provider Arrangements
We provide our members with access to health care services through our networks of health care providers whom we employ or with whom we have contracted, including hospitals and other independent facilities such as outpatient surgery centers, primary care providers, specialist physicians, dentists, and providers of ancillary health care services
and facilities. These ancillary services and facilities include laboratories, ambulance services, medical equipment services, home health agencies, mental health providers, rehabilitation facilities, nursing homes, optical services, and pharmacies. Our membership base and the ability to influence where our members seek care generally enable us to obtain contractual discounts with providers.
We use a variety of techniques to provide access to effective and efficient use of health care services for our members. These techniques include the coordination of care for our members, product and benefit designs, hospital inpatient management systems, the use of sophisticated analytics, and enrolling members into various care management programs. The focal point for health care services in many of our HMO networks is the primary care provider who, under contract with us, provides services to our members, and may control utilization of appropriate services by directing or approving hospitalization and referrals to specialists and other providers. Some physicians may have arrangements under which they can earn bonuses when certain target goals relating to the provision of quality patient care are met. We have available care management programs related to complex chronic conditions
such as congestive heart failure and coronary artery disease. We also have programs for prenatal and premature infant care, asthma related illness, end stage renal disease, diabetes, cancer, and certain other conditions.
We typically contract with hospitals on either (1) a per diem rate, which is an all-inclusive rate per day, (2) a case rate for diagnosis-related groups (DRG), which is an all-inclusive rate per admission, or (3) a discounted charge for inpatient hospital services. Outpatient hospital services generally are contracted at a flat rate by type of service, ambulatory payment classifications, or APCs, or at a discounted charge. APCs are similar to flat rates except multiple services and procedures may be aggregated into one fixed payment. These contracts are often multi-year agreements, with rates that are adjusted for inflation annually based on the consumer price index, other nationally recognized inflation indexes, or specific negotiations with the provider. Outpatient surgery centers and other ancillary providers typically are contracted at flat rates per service provided or are reimbursed based upon a nationally recognized fee schedule such as the Medicare allowable fee schedule.
Our contracts with physicians typically are renewed automatically each year, unless either party gives written notice, generally ranging from 90 to 120 days, to the other party of its intent to terminate the arrangement. Most of the physicians in our PPO networks and some of our physicians in our HMO networks are reimbursed based upon a fixed fee schedule, which typically provides for reimbursement based upon a percentage of the standard Medicare allowable fee schedule.
The terms of our contracts with hospitals and physicians may also vary between Medicare and commercial business. A significant portion of our Medicare network contracts, including those with both hospitals and physicians, are tied to Medicare reimbursement levels and methodologies.
Capitation
We offer providers a continuum of opportunities to increase the integration of care and offer assistance to providers in transitioning from a fee-for-service to a value-based arrangement. These include performance bonuses, shared savings and shared risk relationships. For some of our medical membership, we share risk with providers under capitation contracts where physicians and hospitals accept varying levels of financial risk for a defined set of membership, primarily HMO membership. Under the typical capitation arrangement, we prepay these providers a monthly fixed-fee per member, known as a capitation (per capita) payment, to cover all or a defined portion of the benefits provided to the capitated member.
We believe these risk-based modelsvalue-based arrangements represent a key element of our integrated care delivery model at the core of our strategy. Our health plan subsidiaries may enter into these risk-based contractsvalue-based arrangements with third party providers or our owned provider subsidiaries.
At December 31, 2019,2022, approximately 1,289,1001,850,500 members, or 7.7%10.8% of our medical membership, were covered under risk-based contracts,shared risk value-based arrangements, which provide all member benefits, including 1,116,0001,563,700 individual Medicare Advantage members, or 31.1%34.2% of our total individual Medicare Advantage membership.
Physicians under capitation arrangements typically have stop loss coverage so that a physician’s financial risk for any single member is limited to a maximum amount on an annual basis. We typically process all claims and monitormeasure the financial performance and solvency of our capitated providers.providers and require guarantees in certain instances. However, we delegated claim processing functions under capitation arrangements covering approximately 203,800250,900 HMO members, including 196,300246,100 individual Medicare Advantage members, or 17.6%15.7% of the 1,116,0001,563,700 individual Medicare Advantage members covered under risk-basedvalue-based contracts at December 31, 2019,2022, with the provider assuming substantially all the risk of coordinating the members’ health care benefits. Capitation expense under delegated arrangements for which we have a limited view of the underlying claims experience was approximately $1.9$3.0 billion, or 3.6%3.9% of total benefits expense, for the year ended December 31, 2019.2022. We remain financially responsible for health care services to our members in the event our providers fail to provide such services.
Accreditation Assessment
Our accreditation assessment program consists of several internal programs, including those that credential providers and those designed to meet the audit standards of federal and state agencies as well as external accreditation standards. We also offer quality and outcome measurement and improvement programs such as the Health Care Effectiveness Data and Information Set, or HEDIS, which is used by employers, government purchasers and the National Committee for Quality Assurance (NCQA) to evaluate health plans based on various criteria, including effectiveness of care and member satisfaction.
Providers participating in our networks must satisfy specific criteria, including licensing, patient access, office standards, after-hours coverage, and other factors. Most participating hospitals also meet accreditation criteria established by CMS and/or The Joint Commission.
Recredentialing of participating providers occurs every three years, unless otherwise required by state or federal regulations. Recredentialing of participating providers includes verification of their medical licenses, review of their malpractice liability claims histories, review of their board certifications, if applicable, and review of applicable quality information. A committee composed of a peer group of providers reviews the applications of providers being considered for credentialing and recredentialing.
We maintain accreditation for certain of our health plans and/or departments from NCQA, the Accreditation Association for Ambulatory Health Care (AAAHC), and/or URAC. Certain commercial businesses, such as those impacted by a third-party labor agreement or those where a request is made by the employer, may require or prefer accredited health plans.
NCQA reviews our compliance based on standards for quality improvement, population health management, credentialing, utilization management, network management, and member experience. We have achieved and maintained NCQA accreditation in many of our commercial, Medicare and Medicaid HMO/markets for HMO, POS, and PPO marketsproducts, and our wellness program, Go365. Humana’s pharmacy organization is accredited by URAC.
Sales and Marketing
We use various methods to market our products, including television, radio, the Internet, telemarketing, and direct mailings.
At December 31, 2019,2022, we employed approximately 1,400 sales representatives, as well as approximately 1,4001,900 telemarketing representatives who assisted in the marketing of Medicare products, including Medicare Advantage and PDP, in our Retail segment and specialty products in our Group and SpecialtyInsurance segment, including making appointments for sales representatives with prospective members. We have a marketing arrangement with Wal-Mart Stores, Inc., or Wal-Mart, for our individual Medicare stand-alone PDP offering. We also sell group Medicare Advantage products through large employers. In addition, we market our Medicare and individual specialty products through licensed independent brokers and agents. For our Medicare products, commissions paid to employed sales representatives and independent brokers and agents are based on a per unit commission structure, regulated in structure and amount by CMS. For our individual specialty products, we generally pay brokers a commission based on premiums, with commissions varying by market and premium volume. In addition to a commission based directly on premium volume for sales to particular
customers, we also have programs that pay brokers and agents based on other metrics. These include commission bonuses based on sales that attain certain levels or involve particular products. We also pay additional commissions based on aggregate volumes of sales involving multiple customers.
In our Group and SpecialtyInsurance segment, individuals may become members of our commercial HMOs and PPOs through their employers or other groups, which typically offer employees or members a selection of health insurance products, pay for all or part of the premiums, and make payroll deductions for any premiums payable by the employees. We attempt to become an employer’s or group’s exclusive source of health insurance benefits by offering a variety of HMO, PPO, and specialty products that provide cost-effective quality health care coverage consistent with the needs and expectations of their employees or members. We use licensed independent brokers, independent agents, digital insurance agencies, and employees to sell our group products. Many of our larger employer group customers are
represented by insurance brokers and consultants who assist these groups in the design and purchase of health care products. We pay brokers and agents using the same commission structure described above for our specialty products.
Underwriting
Since 2014, the Patient Protection and Affordability Care Act and The Health Care and Education Reconciliation Act of 2010, which we collectively refer to as the Health Care Reform Law, requires certain group health plans to guarantee issuance and renew coverage without pre-existing condition exclusions or health-status rating adjustments. Accordingly, certain group health plans are not subject to underwriting. Further, underwriting techniques are not employed in connection with our individual Medicare, military services, or Medicaid products because government regulations require us to accept all eligible applicants regardless of their health or medical history.
Competition
The health benefits industry is highly competitive. Our competitors vary by local market and include other managed care companies, national insurance companies, and other HMOs and PPOs. Many of our competitors have a larger membership base and/or greater financial resources than our health plans in the markets in which we compete. Our ability to sell our products and to retain customers may be influenced by such factors as those described in Item 1A. – Risk Factors in this 20192022 Form 10-K.
Government Regulation
Diverse legislative and regulatory initiatives at both the federal and state levels continue to affect aspects of the nation’s health care system, including the Health Care Reform Law.Law at the federal level and laws in certain states limiting the entry of new providers or services though a certificate of need, or CON, process.
Our management works proactively to ensure compliance with all governmental laws and regulations affecting our business. We are unable to predict how existing federal or state laws and regulations may be changed or interpreted, what additional laws or regulations affecting our businesses may be enacted or proposed, when and which of the proposed laws will be adopted or what effect any such new laws and regulations will have on our results of operations, financial position, or cash flows.
For a description of certain material current activities in the federal and state legislative areas, see Item 1A. – Risk Factors in this 20192022 Form 10-K.
Certain Other Services
Captive Insurance Company
We bear general business risks associated with operating our Company such as professional and general liability, employee workers’ compensation, cybersecurity, and officer and director errors and omissions risks. Professional and general liability risks may include, for example, medical malpractice claims and disputes with members regarding benefit coverage. We retain certain of these risks through our wholly-owned, captive insurance subsidiary. We reduce exposure to these risks by insuring levels of coverage for losses in excess of our retained limits with a number of third-party insurance companies. We remain liable in the event these insurance companies are unable to pay their portion of the losses.
Centralized ManagementIntercompany Services
We provide centralized managementintercompany services to each of our health plans and to our business segments from our headquarters and service centers. These services include management information systems, product development and administration, finance, human resources, accounting, law, public relations, marketing, insurance, purchasing, risk management, internal audit, actuarial, underwriting, claims processing, billing/enrollment, and customer service.
Through intercompany service agreements approved, if required, by state regulatory authorities, Humana Inc., our parent company, charges a managementservices fee for reimbursement of certain centralized services provided to its subsidiaries.subsidiaries to the extent that Humana Inc. is the service provider.
Employees
Human Capital Management
Our associates are essential to our success in delivering on our core strategy, and creating positive healthcare experiences for our members. We are committed to recruiting, developing, and retaining strong, diverse teams, actively promoting a culture of inclusion and diversity. As of December 31, 2019,2022, we had approximately 46,000 employees and approximately 1,200 additional medical professionals working under management agreements primarily between us and affiliated physician-owned associations. 67,100 associates.
Our Culture
We believe that our members’ experience is linked to our associates’ experience and that engaged, productive associates are the key to building a healthy company and a caring environment where our associates go above and beyond for our members, driving innovation, and offering fulfilling experiences that incentivizes them to stay with us over the long-term. We provide opportunities for our associates to add to their personal well-being experiences that go beyond health to enhance their individual need for purpose, belonging and security. We regularly measure our success and opportunities to advance engagement through methods like a third-party administered Associate Experience Survey and continuous listening campaigns. Continuous listening involves our proactive solicitation, analysis and response to associate feedback. Pulse surveys are sent to associates throughout the year to get feedback on how we’re doing, allowing us to assess our approach to work and act when needed. We believe this helps to strengthen our culture and support associate engagement. We also provide survey results to our entire associate population and encourage leaders to use the information to create open, honest action plans with their teams to build upon and further deepen our collective engagement.
Our culture is further strengthened by optimizing the well-being and effectiveness of our workforce. Through alternative work styles, we help associates work more productively, communicate more easily and collaborate more freely. Alternate work styles enable associates to work from a job-appropriate location of their choice for all or some portion of their work schedule and to create a work schedule that better fits the diverse demands of today’s work environment. When managed effectively, alternative work styles can enhance a company’s employment brand, foster the development and effective delivery of innovative and diverse business solutions, right-size a company’s energy-consumption footprint, and increase associate engagement and well-being.
Similar to many companies, we experienced lower engagement and higher turnover in 2022 and 2021 than in prior years. Our associate voluntary turnover rate, or VTR, for 2022 was 17.0%, up from 15.1% in 2021. However, associate engagement and well-being rates remained higher than average, despite challenges posed by the Great Resignation, COVID-19 and workforce optimization efforts to fulfill our commitment to execute on our value creation initiative to allow for increased investment in our Medicare Advantage benefits and healthcare services capabilities.
Inclusion and Diversity
Our Office of Inclusion & Diversity, or I&D Office, efforts are led by our Chief Inclusion and Diversity Officer, who reports directly to the Chief Administrative Officer. The I&D Office connects to business groups across the enterprise to cultivate a diverse and inclusive culture that is representative of the communities we serve. By prioritizing I&D across our business, we enable associates to bring their whole selves to work, while also driving the innovation and insights needed to better serve our diverse members and communities. We strive to accelerate our culture of inclusion to build deep relationships and create simple, personalized experiences for all of our stakeholders.
To help integrate inclusion and diversity into the fabric of the organization from the top down, the Executive Inclusion & Diversity Council is led by our President and CEO, with top priorities consisting of (i) leading and informing the strategy to drive the hiring, development, promotion and retention of our full diverse workforce; (ii) creating and maintaining an inclusive culture; (iii) reviewing our supply base and spend for diversification
opportunities; and (iv) improving transparency and accountability to sustain outcomes. We are committed to having balanced diversity at all levels and have developed a pathway for diverse talent within our recruiting initiatives. We’ve also incorporated balanced interview panels into our interview process, through which we strategically engage a broad spectrum of interviewers that bring greater diversity and perspective. This proven best practice strengthens the candidate experience and hiring of diverse talent, ensuring we get the right talent for any given role, and minimizes the potential for personal blind spots when evaluating candidates.
Our inclusion and diversity objectives also aim to build an awareness of biases and beliefs, identify differences and similarities of our multi-generational workforce and enable associates to leverage differences to drive innovation and create value. We are committed to growing our associates’ inclusion skills and diversity knowledge and provide a variety of associate training programs and workshop opportunities in areas of unconscious bias, disability awareness, cultural competency, racial equity, and social justice, among others. It is also our fundamental belief that every person has the right to a safe workplace. This includes having freedom of gender identity and expression, which we have good relations withincluded within our employeesnon-discrimination and anti-harassment policies.
Our associates’ vast experiences and perceptions, unique characteristics, backgrounds and beliefs, drive the groundbreaking, strategic thinking that gives our Company its competitive edge in a diverse marketplace. Our approach fosters innovative thinking and creativity, expands insights and generates better business outcomes.
Pay and Benefits Philosophy, Compensation and Financial Security
We believe all of our associates have not experienced any work stoppages.the right to receive a fair living wage and we are committed to maintaining a pay and benefits philosophy that is market-based and recognizes an associate’s contributions so that we can attract and retain an engaged, talented team. Our Company’s pay and benefits structure is designed to motivate, incentivize and reward our associates - at all levels of the organization - for their skill development, demonstration of our values and performance. While our programs vary by location, associate type and business, they generally include:
| | | | | | | | |
Financial | Health | Life |
Competitive Base Pay | Medical, Dental and Vision Benefits | Paid Time Off, Paid Holidays, Paid Volunteer Time Off and Jury Duty Pay |
Associate Incentive Plan (Annual Bonus) | Supplemental Health Benefits | Adoption Assistance |
Supplemental Pay (Including Overtime) | Long-term Care Insurance | Paid Parental Leave Program (6 weeks) |
Recognition Pay and Service Awards | Wellness and Rewards Program | Paid Caregiver Time Off Program (2 weeks) |
401(k) Retirement Savings Plan with Company Match Program | Health Plan Incentives | Employee Assistance Program |
Life Insurance | On-site Health and Fitness Centers | Associate Discount Programs and Services |
Short- and Long-Term Disability Insurance | On-site Health Screenings and Vaccinations | Helping Hands Program |
Tuition Assistance Program | | Transit Services |
Talent Development and Growth Opportunities
We champion the individual goals and development of our associates, and provide a number of programs and resources to support their efforts. We provide opportunities for our associates to earn professional certifications through continued education programs and to participate in instructor-led and online courses designed to strengthen soft and hard-skills and enhance leadership development. Our Career Cultivation team sponsors workshops and events to promote associate accountability within their personal and professional growth as part of overall career development. Our associates are also encouraged to participate in mentoring programs with people of various backgrounds and cultures. We view mentoring as an essential development tool for sharing skills and knowledge so we can all succeed. Our commitment to mentoring feeds the successful future of our Company. Additionally, we utilize development programs to enhance talent within our organizations through targeted internal initiatives, where we aim to upskill and reskill existing associates for opportunities in new career pathways.
Additional information related to our human capital can be found by referencing our Definitive Proxy Statement of the Annual Meeting of Stockholders scheduled to be held on April 20, 2023 appearing under the caption "Human Capital Management."
Information About Our Executive Officers
Set forth below are names and ages of all of our current executive officers as of February 1, 2020,2023, their positions, and the date first elected as an executive officer:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Name | | Age | | Position | | First Elected Officer | | |
Bruce D. Broussard | | 60 | | President and Chief Executive Officer, Director | | 12/11 | | (1) |
| | | | | | | | |
Vishal Agrawal, M.D. | | 48 | | Chief Strategy and Corporate Development Officer | | 12/18 | | (2) |
| | | | | | | | |
Andrew C. Agwunobi, M.D. | | 57 | | Segment President, Home Solutions | | 02/22 | | (3) |
| | | | | | | | |
Samir M. Deshpande | | 58 | | Chief Information Officer | | 07/17 | | (4) |
| | | | | | | | |
Susan M. Diamond | | 49 | | Chief Financial Officer | | 07/19 | | (5) |
| | | | | | | | |
John-Paul W. Felter | | 39 | | Senior Vice President, Chief Accounting Officer and Controller | | 08/22 | | (6) |
| | | | | | | | |
William K. Fleming, PharmD | | 55 | | Segment President, Pharmacy Solutions & Chief Corporate Affairs Officer | | 03/17 | | (7) |
| | | | | | | | |
Timothy S. Huval | | 56 | | Chief Administrative Officer | | 12/12 | | (8) |
| | | | | | | | |
George Renaudin II | | 54 | | President, Medicare & Medicaid | | 02/23 | | (9) |
| | | | | | | | |
Susan D. Schick | | 60 | | Segment President, Group and Military Business | | 09/21 | | (10) |
| | | | | | | | |
Joseph C. Ventura | | 46 | | Chief Legal Officer | | 02/19 | | (11) |
|
| | | | | | | | |
Name | | Age | | Position | | First Elected Officer | | |
Bruce D. Broussard | | 57 | | President and Chief Executive Officer, Director | | 12/11 | | (1) |
| | | | | | | | |
Vishal Agrawal, M.D. | | 45 | | Chief Strategy and Corporate Development Officer | | 12/18 | | (2) |
| | | | | | | | |
Heather M. Carroll Cox | | 49 | | Chief Digital Health and Analytics Officer | | 08/18 | | (3) |
| | | | | | | | |
Sam M. Deshpande | | 55 | | Chief Technology and Risk Officer | | 07/17 | | (4) |
| | | | | | | | |
Susan M. Diamond | | 46 | | Segment President, Home Business | | 07/19 | | (5) |
| | | | | | | | |
William K. Fleming, PharmD | | 52 | | Segment President, Clinical and Pharmacy Solutions | | 03/17 | | (6) |
| | | | | | | | |
Christopher H. Hunter | | 51 | | Segment President, Group and Military Business | | 01/14 | | (7) |
| | | | | | | | |
Timothy S. Huval | | 53 | | Chief Administrative Officer | | 12/12 | | (8) |
| | | | | | | | |
Brian A. Kane | | 47 | | Chief Financial Officer | | 06/14 | | (9) |
| | | | | | | | |
William H. Shrank, M.D., MSHS | | 48 | | Chief Medical and Corporate Affairs Officer | | 04/19 | | (10) |
| | | | | | | | |
Joseph C. Ventura | | 43 | | Chief Legal Officer | | 02/19 | | (11) |
| | | | | | | | |
T. Alan Wheatley | | 52 | | Segment President, Retail | | 03/17 | | (12) |
| | | | | | | | |
Cynthia H. Zipperle | | 57 | | Senior Vice President, Chief Accounting Officer and Controller | | 12/14 | | (13) |
| |
(1) | Mr. Broussard currently serves as Director, President and Chief Executive Officer (Principal Executive Officer), having held these positions since January 1, 2013. Mr. Broussard was elected President upon joining the Company in December 2011 and served in that capacity through December 2012. Prior to joining the Company, Mr. Broussard was Chief Executive Officer of McKesson Specialty/US Oncology, Inc. US Oncology was purchased by McKesson in December 2010. At US Oncology, Mr. Broussard served in a number of senior executive roles, including Chief Financial Officer, Chief Executive Officer, and Chairman of the Board. |
| |
(2) | Dr. Agrawal currently serves as Chief Strategy and Corporate Development Officer, having joined the company in December 2018. Prior to joining the company, Dr. Agrawal was Senior Advisor for The Carlyle Group L.P., having held that position from October 2017 to December 2018. Previously, Dr. Agrawal was President and Chief Growth Officer of Ciox Health, the largest health information exchange and release of information services organization in the U.S. from December of 2015 to October 2018. Prior to joining Ciox Health, Dr. Agrawal served as President of Harris Healthcare Solutions from January 2013 to December 2015. |
| |
(3) | Ms. Cox currently serves as Chief Digital Health and Analytics Officer, having joined the Company in August 2018. Prior to joining the Company, Ms. Cox served as Chief Technology and Digital Officer at USAA, where she led the teams responsible for designing and building personalized and digitally-enabled end-to-end experiences for USAA members. Prior to USAA, Heather was the CEO of Citi FinTech at Citigroup, Inc., helping the company adapt to a future dominated by mobile technology, and she headed Card Operations, reshaping customer and digital experience for Capital One. |
| |
(4) | Mr. Deshpande currently serves as Chief Technology and Risk Officer, having been elected to this position in August 2019, from his prior role as Chief Risk Officer. Before joining Humana in July 2017, Mr. Deshpande spent 17 years at Capital One in key leadership positions, most recently as Business Chief Risk Officer for the U.S. and international card business. He previously served as the Business Chief Risk Officer and Head of Enterprise Services for the Financial Services Division, responsible for Business Risk, Data Science, Data Quality, Process Excellence and Project Management. He also led marketing and analysis for the Home Loans, Auto Finance, and Credit Card businesses, with responsibilities for business strategy, credit, product and marketing. |
| |
(5) | Susan M. Diamond currently serves as Segment President, Home Business, having been elected to this position in July 2019. Ms. Diamond joined the Company in June 2004 and has spent the majority of her Humana career in various leadership roles in the Medicare business, with a particular passion and emphasis on growth and consumer segmentation strategies for the Company’s Individual Medicare Advantage and Stand Alone Part D offerings. Ms. Diamond also served for two and a half years as the Enterprise Vice President of Finance, where she was responsible for enterprise planning and forecasting, trend analytics and had responsibility for each of the Company’s line of business CFOs and controllers. |
| |
(6) | Dr. Fleming currently serves as Segment President, Clinical and Pharmacy Solutions, where he is responsible for Humana’s Clinical Solutions (strategy, quality, trend, and operations), Pharmacy Solutions (PBM, mail, specialty, retail), and Enterprise Clinical Operating Model, having held this position since December 2019. Prior to that, Dr. Fleming held positions of Segment President, Healthcare Services as well as President of the Company’s pharmacy business. Dr. Fleming joined the Company in 1994. |
| |
(7) | Mr. Hunter currently serves as Segment President, Group and Military Business, having been elected to this position in August 2018 after having previously served as the Company’s Chief Strategy Officer since January 2014. Prior to joining the Company, Mr. Hunter served as President of Provider Markets at The TriZetto Group, Inc. from July 2012 until December 2013, and as Senior Vice President, Emerging Markets at BlueCross BlueShield of Tennessee from 2009 through July 2012. While at BlueCross BlueShield of Tennessee, Mr. Hunter was simultaneously President and Chief Executive Officer of Onlife Health, a national health and wellness subsidiary of BlueCross BlueShield of Tennessee. |
| |
(8) | Mr. Huval currently serves as Chief Administrative Officer, having been elected to this position in July 2019, from his previous role as Chief Human Resources Officer. Prior to joining the Company, Mr. Huval spent 10 years at Bank of America in multiple senior-level roles, including Human Resources executive and Chief Information Officer for Global Wealth & Investment Management, as well as Human Resources executive for both Global Treasury Services and Technology & Global Operations. |
| |
(9) | Mr. Kane currently serves as Chief Financial Officer, having been elected to this position in June 2014. Prior to joining the Company, Mr. Kane spent nearly 17 years at Goldman, Sachs & Co. As a managing director, he was responsible for client relationships as well as for leading strategic and financing transactions for a number of companies in multiple industries. |
| |
(10) | Dr. Shrank currently serves as Chief Medical and Corporate Affairs Officer, having been elected to this position in July 2019, from his previous role as Chief Medical Officer. Before joining Humana in April 2019, Dr. Shrank served as Chief Medical Officer, Insurance Services Division at the University of Pittsburgh Medical Center, from 2016-2019, where he oversaw approximately $9 billion in annual health care expenditures for approximately 3.5 million members in Medicare, Medicaid, behavioral health, Managed Long Term Social Supports and commercial lines of business. He also developed and evaluated population health programs to further advance the medical center’s mission as an integrated delivery and financing system. Prior to that, Dr. Shrank served as Senior Vice President, Chief Scientific Officer, and Chief Medical Officer of Provider Innovation at CVS Health from 2013 to 2016. Prior to joining CVS Health, Dr. Shrank served as Director, Research and Rapid-Cycle Evaluation Group, for the Center for Medicare and Medicaid Innovation, part of CMS from 2011 to 2013, where he led the evaluation of all payment and health system delivery reform programs and developed the rapid-cycle strategy to promote continuous quality improvement. Dr. Shrank began his career as a practicing physician with Brigham and Women’s Hospital in Boston and as an Assistant Professor at Harvard |
(1)Mr. Broussard currently serves as Director, President and Chief Executive Officer (Principal Executive Officer), having held these positions since January 1, 2013. Mr. Broussard was elected President upon joining the Company in December 2011 and served in that capacity through December 2012. Prior to joining the Company, Mr. Broussard was Chief Executive Officer of McKesson Specialty/US Oncology, Inc. US Oncology was purchased by McKesson in December 2010. At US Oncology, Mr. Broussard served in a number of senior executive roles, including Chief Financial Officer, Chief Executive Officer, and Chairman of the Board.
Medical School. His research at Harvard focused on improving(2)Dr. Agrawal currently serves as Chief Strategy and Corporate Development Officer, having joined the qualityCompany in December 2018. Prior to joining the Company, Dr. Agrawal was Senior Advisor for The Carlyle Group L.P., having held that position from October 2017 to December 2018. Previously, Dr. Agrawal was President and Chief Growth Officer of prescribingCiox Health, the largest health information exchange and release of information services organization in the U.S. from December of 2015 to October 2018. Prior to joining Ciox Health, Dr. Agrawal served as President of Harris Healthcare Solutions from January 2013 to December 2015.
(3)Dr. Agwunobi currently serves as Segment President, Home Solutions, having joined Humana in February 2022. Prior to joining the Company, Dr. Agwunobi served as Interim President of the University of Connecticut (UConn) from May 2021 until February 2022, and the useChief Executive Officer and Executive Vice President for Health Affairs for UConn Health from 2014 to February 2022.
(4)Mr. Deshpande currently serves as Chief Information Officer, having been elected to this position in July 2021, from his prior role as Chief Technology and Risk Officer. Before joining the Company in July 2017, Mr. Deshpande spent 17 years at Capital One in key leadership positions, most recently as Business Chief Risk Officer for the U.S. and international card business. He previously served as the Business Chief Risk Officer and Head of chronic medications.Enterprise Services for the Financial Services Division, responsible for Business Risk, Data Science, Data Quality, Process Excellence and Project Management. He also led marketing and
analysis for the Home Loans, Auto Finance, and Credit Card businesses, with responsibilities for business strategy, credit, product and marketing.
(5)Ms. Diamond currently serves as Chief Financial Officer, having been elected to this position in June 2021, from her prior role as Segment President, Home Business. Ms. Diamond joined the Company in June 2004 and has published more than 200 papersspent the majority of her career in various leadership roles in the Medicare and Home businesses, with a particular passion and emphasis on these topics.growth and consumer segmentation strategies for the Company’s individual Medicare Advantage and Stand Alone Part D offerings. Ms. Diamond also served for two and a half years as the Enterprise Vice President of Finance, where she was responsible for enterprise planning and forecasting, trend analytics and had responsibility for each of the Company’s line of business CFOs and controllers.
| |
(11) | Mr. Ventura currently serves as Chief Legal Officer. He joined the Company in January 2009 and since then has held various positions of increasing responsibility in the Company's Law Department, including most recently, Senior Vice President, Associate General Counsel & Corporate Secretary from July 2017 until February 2019. |
| |
(12) | Mr. Wheatley currently serves as Segment President, Retail, having held this position since March 2017. During his 25-year career with the Company, Mr. Wheatley has served in a number of key leadership roles, including Vice President of Medicare Service Operations and President of the East Region, one of the Company’s key Medicare geographies. |
| |
(13) | Mrs. Zipperle currently serves as Senior Vice President, Chief Accounting Officer and Controller, having held this position since December 2014. Mrs. Zipperle previously served as the Vice President - Finance from January 2013 until her election to her current role, and as the Assistant Controller from January 1998 until January 2013. |
(6)Mr. Felter currently serves as Senior Vice President, Chief Accounting Officer and Controller, having been elected to this position in August 2022. Before joining the Company, Mr. Felter served as Senior Director - Investment Finance for OneAmerica Financial Partners, Inc. from May 2022 until June 2022. Prior to OneAmerica, Mr. Felter spent nearly 11 years as a Senior Manager at Ernst & Young LLP where he oversaw large audit engagements for public and private entities with a concentration in the health insurance sector.
(7)Dr. Fleming currently serves as Segment President, Pharmacy Solutions and Chief Corporate Affairs Officer, having been elected to this position in July 2021, from his prior role as Segment President, Clinical and Pharmacy Solutions. Prior to that, Dr. Fleming held positions of Segment President, Healthcare Services as well as President of the Company’s pharmacy business. Dr. Fleming joined the Company in 1994.
(8)Mr. Huval currently serves as Chief Administrative Officer, having been elected to this position in July 2019, from his previous role as Chief Human Resources Officer. Prior to joining the Company, Mr. Huval spent 10 years at Bank of America in multiple senior-level roles, including Human Resources executive and Chief Information Officer for Global Wealth & Investment Management, as well as Human Resources executive for both Global Treasury Services and Technology & Global Operations.
(9)Mr. Renaudin currently services as President, Medicare & Medicaid, having been elected to this position in February 2023.He joined the Company in April 2004 and since then has held various leadership roles of increasing responsibility, most recently holding the position of President, Medicare.
(10)Ms. Schick currently serves as Segment President, Group and Military Business, having been elected to this position in September 2021.Ms. Schick joined the Company in February 2020 in the role of Senior Vice President, Employer Group.Before she joined the Company, Ms. Schick spent 16 years in a range of senior-level leadership roles at United Healthcare in its Medicaid and Commercial businesses.
(11)Mr. Ventura currently serves as Chief Legal Officer. He joined the Company in January 2009 and since then has held various positions of increasing responsibility in the Company's Law Department, including most recently, Senior Vice President, Associate General Counsel & Corporate Secretary from July 2017 until February 2019.
Executive officers are elected annually by our Board of Directors and serve until their successors are elected or until resignation or removal. There are no family relationships among any of our executive officers.
ITEM 1A. RISK FACTORS
Risks Relating to Our Business
If we do not design and price our products properly and competitively, if the premiums we charge are insufficient to cover the cost of health care services delivered to our members, if we are unable to implement clinical initiatives to provide a better health care experience for our members, lower costs and appropriately document the risk profile of our members, or if our estimates of benefits expense are inadequate, our profitability may be materially adversely affected. We estimate the costs of our benefits expense payments, and design and price our products accordingly, using actuarial methods and assumptions based upon, among other relevant factors, claim payment patterns, medical cost inflation, and historical developments such as claim inventory levels and claim receipt patterns. We continually review these estimates, however theseThese estimates involve extensive judgment, and have considerable inherent variability because they are extremely sensitive to changes in claim payment patterns and medical cost trends. Any reserve, including a premium deficiency reserve,Accordingly, our reserves may be insufficient.
We use a substantial portion of our revenues to pay the costs of health care services delivered to our members. These costs includemembers, including claims payments, capitation payments to providers (predetermined amounts paid to cover services), and various other costs incurred to provide health insurance coverage to our members. These costs also include estimates of future payments to hospitals and others for medical care provided to our members.members, and various other costs. Generally, premiums in the health care business are fixed for one-year periods. Accordingly, costs we incur in excess of our benefit cost projections generally are not recovered in the contract year through higher premiums. We estimate the costs of our future benefit claims and other expenses using actuarial methods and assumptions based upon claim payment patterns, medical inflation, historical developments, including claim inventory levels and claim receipt patterns, and other relevant factors. We also record benefits payable for future payments. We continually review estimates of future payments relating to benefit claims costs for services incurred in the current and prior periods and make necessary adjustments to our reserves, including premium deficiency reserves where appropriate. However, these estimates involve extensive judgment, and have considerable inherent variability that is sensitive to claim payment patterns and medical cost trends. Many factors may and often do cause actual health care costs to exceed what was estimated and used to set our premiums. These factors may include:
•increased use of medical facilities and services;
services, and the increased cost of such services;
•increased use or cost of prescription drugs, including specialty prescription drugs;
•the introduction of new or costly treatments, includingprescription drugs, or new technologies;
•our membership mix;
•variances in actual versus estimated levels of cost associated with new products, benefits or lines of business, product changes or benefit level changes;
•changes in the demographic characteristics of an account or market;
•changes or reductions of our utilization management functions such as preauthorization of services, concurrent review or requirements for physician referrals;
•changes in our purchase discounts or pharmacy volume rebates received from drug manufacturers;manufacturers and wholesalers, which are generally passed on to clients in the form of steeper price discounts;
•catastrophes, including acts of terrorism, public health emergencies, epidemics or severe weather (e.g.pandemics (such as the spread of COVID-19 or natural disasters (such as hurricanes and earthquakes); which could occur more frequently or with more intense effects as a result of the impact of global climate change;
•medical cost inflation; and
•government mandated benefits, member eligibility criteria, or other legislative, judicial, or regulatory changes, including any that result from the Health Care Reform Law.changes.
Key to our operational strategy is the implementation of clinical initiatives that we believe provide a better health care experience for our members, lower the cost of healthcare services delivered to our members, and appropriately document the risk profile of our members. Our profitability and competitiveness depend in large part
on our ability to
appropriately manage health care costs through, among other things, the application of medical management programs such as our chronic care management program.
While we proactively attempt to effectively manage our operating expenses, increases or decreases in staff-related expenses, any costs associated with exiting products, additional investment in new products (including our opportunities in the Medicare programs, state-based contracts, and expansion of clinical capabilities as part of our integrated care delivery model), investments in health and well-being product offerings, acquisitions, new taxes and assessments, (including the non-deductible health insurance industry fee), inflation,and implementation of regulatory requirements may increase our operating expenses.
Failure to adequately price our products or estimate sufficient benefits payable or effectively manage our operating expenses, may result in a material adverse effect on our results of operations, financial position, and cash flows.
We are in a highly competitive industry. Some of our competitors are more established in the health care industry in terms of a larger market share and have greater financial resources than we do in some markets. In addition, other companies may enter our markets in the future, including emerging competitors in the Medicare program or competitors in the delivery of health care services. We believe that barriers to entry in our markets are not substantial, so the addition of new competitors can occur relatively easily, and customers enjoy significant flexibility in moving between competitors. Contractscompetitors through the Medicare Annual Enrollment Period. In addition, contracts for the sale of group commercial products are generally bid upon or renewed annually. While health plans compete on the basis of many factors, including service and the quality and depth of provider networks, we expect that price will continue to be a significant basis of competition. In addition to the challenge of controlling health care costs, we face intense competitive pressure to contain premium prices. Factors such as business consolidations, strategic alliances, legislative reform, and marketing practices create pressure to contain premium price increases, despite being faced with increasing medical and administrative costs.
The policies and decisions of the federal and state governments regarding the Medicare Advantage and Prescription Drug Plans, military and Medicaid programs in which we participate have a substantial impact on our profitability. These governmental policies and decisions, which we cannot predict with certainty, directly shape the premiums or other revenues to us under the programs, the eligibility and enrollment of our members, the services we provide to our members, and our administrative, health care services, and other costs associated with these programs. Legislative or regulatory actions, such as changes to the programs in which we participate, those resulting in a reduction in premium payments to us, an increase in our cost of administrative and health care services, or additional fees, taxes or assessments, may have a material adverse effect on our results of operations, financial position, and cash flows.
Premium increases, introduction of new product designs, and our relationships with our providers in various markets, among other issues, could also affect our membership levels. Other actions that could affect membership levels include our possible exit from or entrance into Medicare or commercial markets, or the termination of a large contract.
If we do not compete effectively in our markets, if we set rates too high or too low in highly competitive markets to keep or increase our market share, if membership does not increase as we expect, if membership declines, or if we lose membership with favorable medical cost experience while retaining or increasing membership with unfavorable medical cost experience, our results of operations, financial position, and cash flows may be materially adversely affected.
If we fail to effectively implement our operational and strategic initiatives, including our Medicare initiatives, and our state-based contracts strategy, our business may be materially adversely affected, which isare of particular importance given the concentration of our revenues in these products.products, our state-based contracts strategy, the growth of our CenterWell businesses, and our integrated care delivery model, our business may be materially adversely affected. In addition, there can be no assurances that we will be successful in maintaining or improving our Star ratings in future years.
Our future performance depends in large part upon our ability to execute our strategy, including opportunities created by the expansion of our Medicare programs, the successful implementation of our integrated care delivery model and our strategy with respect to state-based contracts, including
those covering members dually eligible for the Medicare and Medicaid programs.
programs, the growth of our pharmacy, provider services, and home solutions businesses, and the successful implementation of our integrated care delivery model.
We have made substantial investments in the Medicare program to enhance our ability to participate in these programs. We have increased the size of our Medicare geographic reach through expanded Medicare product offerings. We offer both stand-alone Medicare prescription drug coverage and Medicare Advantage health plans with prescription drug coverage in addition to our other product offerings. We offer a Medicare prescription drug plan in 50 states as well as Puerto Rico and the District of Columbia. The growth of our Medicare products is an important part of our business strategy.strategy, and the attendant concentration of revenues intensifies the risks to us inherent in Medicare products. Any failure to achieve this growth may have a material adverse effect on our results of operations, financial position, or cash flows. In addition, the expansion of our Medicare products in relation to our other businesses may intensify the risks to us inherent in Medicare products. There is significant concentration of our revenues in Medicare products, with approximately 82% of our total premiums and services revenue for the year ended December 31, 2019 generated from our Medicare products, including 15% derived from our individual Medicare Advantage contracts with CMS in Florida. These expansion efforts may result in less diversification of our revenue stream and increased risks associated with operating in a highly regulated industry, as discussed further below.
The achievement of Starstar ratings of 4-Star4-star or higher qualifies Medicare Advantage plans for premium bonuses. Our Medicare Advantage plans' operating results may be significantly affected by their star ratings. Despite our operational efforts to improve our star ratings, there can be no assurances that we will be successful in maintaining or improving our star ratings in future years. In addition, audits of our performance for past or future periods may result in downgrades to our Starstar ratings. Accordingly, our plans may not be eligible for full level quality bonuses, which could adversely affect the benefits such plans can offer, reduce membership and/or reduce profit margins.
If we fail to properly maintain the integrity of our data, to strategically maintain existing or implement new information systems, or to protect our proprietary rights to our systems, our business may be materially adversely affected.
Our business depends significantly on effective information systems and the integrity and timeliness of the data we use to run our business. Our business strategy involves providing members and providers with easy to use products that leverage our information to meet their needs. Our ability to adequately price our products and services, provide effective and efficient service to our customers, and to timely and accurately report our financial results depends significantly on the integrity of the data in our information systems. As a result of our past and on-going acquisition activities, we have acquired additional information systems. We have reduced the number of systems we operate, have upgraded and expanded our information systems capabilities, and are gradually migrating existing business to fewer systems. Our informationThese systems require an ongoing commitment of significant resources to maintain, protect, and enhance existing systems and develop and integrate new systems to keep pace with continuing changes in information processing technology, evolving industry and regulatory standards, and changing customer preferences.preferences, and even with such resources there is no assurance that we will be able to do so. If the information we rely upon to run our businesses was found to be inaccurate or unreliable or if we fail to improve service levels or maintain effectively our information systems and data integrity, we could have operational disruptions, have problems in determining medical cost estimates and establishing appropriate pricing, have customer and physician and other health care provider disputes, have regulatory or other legal problems, difficulty preventing and detecting fraud, have increases in operating expenses, loseloss of existing customers, have difficulty in attracting new customers, or suffer other adverse consequences.consequences, each of which may result in a material adverse effect on our results of operations, financial position, and cash flows.
We depend on independent third parties for significant portions of our systems-related support, equipment, facilities, and certain data, including data center operations, data network, voice communication services and pharmacy data processing. This dependence makes our operations vulnerable to such third parties' failure to perform adequately under the contract, due to internal or external factors. A change in service providers could result in a decline in service quality and effectiveness or less favorable contract terms which may adversely affect our operating results.
We rely on our agreements with customers and service providers, confidentiality agreements with employees, and our trade secrets and copyrights to protect our proprietary rights. These legal protections and precautions may not prevent misappropriation of our proprietary information. In addition, substantial litigation regarding intellectual property rights exists in the software industry, including litigation involving end usersThe misappropriation of software products. We expect software products to be increasingly subject to third-party infringement claims as the number of products and competitors in this area grows.
There can be no assurance that our information technology, or IT, process will successfully improve existing systems, develop new systems to support our expanding operations, integrate new systems, protect our proprietary information defend against cybersecurity attacks, or improve service levels. In addition, there can be no assurance that additional systems issues will not arise in the future. Failurecould hinder our ability to adequately protectmarket and maintain the integrity of our
information systemssell products and data, or to defend against cybersecurity attacks,services and may result in a material adverse effect on our results of operations, financial position and cash flows.
If we, and the third-party service providers on whom we rely, are unable to defend our information technology security systems against cybersecurity attacks or prevent other privacy or data security incidents that result in security breaches that disrupt our operations or in the unintendedunintentional dissemination of sensitive personal information or proprietary or confidential information, we could be exposed to significant regulatory fines or penalties, liability or reputational damage, or experience a material adverse effect on our results of operations, financial position, and cash flows.
In the ordinary course of our business, we process, store and transmit large amounts of data, and rely on third-party service providers to do the same, including sensitive personal information as well as proprietary or confidential information relating to our business or a third-party. We have been, and will likely continue to be, regular targets of attempted cybersecurity attacks and other security threats and may be subject to breaches of our information technology security systems. Although the impact of such attacks has not been material to our operations or results of operations, financial position, or cash flow through December 31, 2019,2022, we can provide no assurance that we will be able to detect, prevent, or contain the effects of such cybersecurity attacks or other information security risks or threats in the future. A cybersecurity attack may penetrate our layered security controls and misappropriate or compromise sensitive personal information or proprietary or confidential information or that of third-parties, create system disruptions, cause shutdowns, or deploy viruses, worms, and other malicious software programs that attack our systems. A cybersecurity attack that bypasses our IT security systems, successfullyor the security of third-party service providers, could materially affect us due to the theft, destruction, loss, misappropriation or release of confidential data or intellectual property, operational or business delays resulting from the disruption of our IT systems, or negative publicity resulting in reputation or brand damage with our members, customers, providers, and other stakeholders. In certain circumstances we may rely on third party vendors to process, store and transmit large amounts of data for our businesses whose operations are subject to similar risks.
The costs to detect, prevent, eliminate or address cybersecurity threats and vulnerabilities before or after an incident could be substantial. Our remediation efforts may not be successful and could result in interruptions, delays, or cessation of service, and loss of existing or potential members.In addition, breaches of our security measures or the security measures of third-party service providers, and the unauthorized dissemination of sensitive personal information or proprietary or confidential information about us or our members or other third-parties, could expose our associates' or members’ private information and result in the risk of financial or medical identity theft, or expose us or other third-parties to a risk of loss or misuse of this information, result in significant regulatory fines or penalties, litigation and potential liability for us, damage our brand and reputation, or otherwise harm our business.
We are involved in various legal actions and governmental and internal investigations, any of which, if resolved unfavorably to us, could result in substantial monetary damages or changes in our business practices. Increased litigation and negative publicity could increase our cost of doing business.
We are or may become a party to a variety of legal actions that affect our business, including breach of contract actions, employment compensation and other labor and employment practice suits, employee benefit claims, stockholder suits and other securities laws claims, intellectual and other property claims, and tort claims.
In addition, because of the nature of the health care business, we are subject to a variety of legal actions relating to our business operations, including the design, management, and offering of products and services. These include and could include in the future:
claims relating to the methodologies for calculating premiums;
claims relating to the denial of health care benefit payments;
claims relating to the denial or rescission of insurance coverage;
challenges to the use of some software products used in administering claims;
claims relating to our administration of our Medicare Part D offerings;
medical malpractice actions brought against our employed providers or affiliated physician-owned professional groups, based on our medical necessity decisions or brought against us on the theory that we are liable for a third-party providers' alleged malpractice;
claims arising from any adverse medical consequences resulting from our recommendations about the appropriateness of providers’ proposed medical treatment plans for patients;
allegations of anti-competitive and unfair business activities;
provider disputes over compensation or non-acceptance or termination of provider contracts;
disputes related to ASO business, including actions alleging claim administration errors;
false claims litigation, such as qui tam litigationlawsuits, brought by individuals who seek to sue on behalf of the government, alleging that we, as a government contractor, submitted false claims to the government including,or retained overpayments from the government, among other allegations, resulting from coding and review practices under the Medicare risk-adjustment model;
claims related to the failure to disclose some business practices;
claims relating to customer audits and contract performance;
claims relating to dispensing of drugs associated with our in-house dispensing pharmacies; and
professional liability claims arising out of the delivery of healthcare and related services to the public.
In some cases, substantial non-economic or punitive damages as well as treble damages under the federal False Claims Act, Racketeer Influenced and Corrupt Organizations Act and other statutes may be sought.
While we currently have insurance coverage for some of these potential liabilities, other potential liabilities may not be covered by insurance, insurers may dispute coverage, or the amount of our insurance may not be enough to cover the damages awarded. In addition, some types of damages, like punitive damages, may not be covered by insurance. In some jurisdictions, coverage of punitive damages is prohibited. Insurance coverage for all or some forms of liability may become unavailable or prohibitively expensive in the future.
The health benefits industry continues to receive significant negative publicity reflecting the public perception of the industry. This publicity and perception have been accompanied by increased litigation, including some large jury awards, legislative activity, regulation, and governmental review of industry practices. These factors may materially adversely affect our ability to market our products or services, may require us to change our products or services or otherwise change our business practices, may increase the regulatory burdens under which we operate, and may require us to pay large judgments or fines. Any combination of these factors could further increase our cost of doing business and adversely affect our results of operations, financial position, and cash flows.
See "Legal Proceedings and Certain Regulatory Matters" in Note 17 to the consolidated financial statementsaudited Consolidated Financial Statements included in Item 8. - Financial Statements and Supplementary Data. We cannot predict the outcome of these matters with certainty.
As a government contractor, we are exposed to risks that may materially adversely affect our business or our willingness or ability to participate in government health care programs.
A significant portion of our revenues relates to federal and state government health care coverage programs, including the Medicare, military, and Medicaid programs. These programs accounted for approximately 87%88% of our total premiums and services revenue for the year ended December 31, 2019.2022. These programs involve various risks, as described further below.
•At December 31, 2019,2022, under our contracts with CMS we provided health insurance coverage to approximately 701,400771,900 individual Medicare Advantage members in Florida. These contracts accounted for approximately 15%14% of our total premiums and services revenue for the year ended December 31, 2019.2022. The loss of these and other CMS contracts (which are generally renewed annually) or significant changes in the Medicare programAdvantage and Prescription Drug Plan programs as a result of legislative or regulatory action, including changes to the Part D prescription drug benefit design or reductions in premium payments to us or increases in member benefits or
changes to member eligibility criteria without corresponding increases in premium payments to us, may have a material adverse effect on our results of operations, financial position, and cash flows.
At December 31, 2019, our•Our military services business, which accounted for approximately 1% of our total premiums and services revenue for the year ended December 31, 2019,2022, primarily consisted of the TRICARE T2017 East Region contract. The T2017 East Region contract is a consolidation of the former T3 North and South Regions, comprising thirty-two32 states and approximately 6six million TRICARE beneficiaries, under which delivery of health care services commenced on January 1, 2018. TheOn December 23, 2022, the Department of Defense (“DoD”) exercised its option to extend the T2017 East Region contract, is a 5 -yearadding Option Periods 6 & 7, and exercised Option Period 6 which extends the T2017 East Region contract set to expire onthrough December 31, 2023. On December 22, 2022, and iswe were notified by the DoD that we were awarded the new contract for the TRICARE East Region, with delivery of health care services expected to commence in 2024. The next generation East Region contract awards may be subject to renewals on January 1protests by unsuccessful bidders before the U.S. Court of each year during its term at the government's option.Federal Claims. The loss of the TRICAREcurrent T2017 East Region contract or an overturn of the award of the new East Region contract to us, should either occur, may have a material adverse effect on our results of operations, financial position, and cash flows.
There is a possibility of temporary or permanent suspension from participating in government health care programs, including Medicare and Medicaid, if we are convicted of fraud or other criminal conduct in the performance of a health care program or if there is an adverse decision against us under the federal False Claims Act. As a government contractor, we may be subject to qui tam litigation brought by individuals who seek to sue on behalf of the government, alleging that the government contractor submitted false claims to the government. Litigation of this nature is filed under seal to allow the government an opportunity to investigate and to decide if it wishes to intervene and assume control of the litigation. If the government does not intervene, the lawsuit is unsealed, and the individual may continue to prosecute the action on his or her own.
•CMS uses a risk-adjustment model which adjusts premiums paid to Medicare Advantage, or MA, plans according to health status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997 (BBA) and the Benefits Improvement and Protection Act of 2000 (BIPA), generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to reflect theaccount for certain demographic characteristics and health status of our enrolled membership.members. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information from hospital inpatient, hospital outpatient, and physician providers to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data, collected from providers, to calculate the health status-related risk-adjusted premium payment to MA plans, which CMS further adjusts for coding pattern differences between the health plans and the government fee-for-service (FFS) program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model. These compliance efforts include the internal contract level audits described in more detail below, as well as ordinary course reviews of our internal business processes.
CMS is phasing-in the process of calculating risk scores using diagnoses data from the Risk Adjustment Processing System, or RAPS, to diagnoses data from the Encounter Data System, or EDS. The RAPS process requires MA plans to apply a filter logic based on CMS guidelines and only submit diagnoses that satisfy those guidelines. For submissions through EDS, CMS requires MA plans to submit all the encounter data and CMS will apply the risk adjustment filtering logic to determine the risk scores. For 2019, 25% of the risk score was calculated from claims data submitted through EDS. CMS will increase that percentage to 50% in 2020 and has proposed to increase that percentage to 75% in 2021. The phase-in from RAPS to EDS could result in different risk scores from each dataset as a result of plan processing issues, CMS processing issues, or filtering logic differences between RAPS and EDS, and could have a material adverse effect on our results of operations, financial position, or cash flows.
CMS and the Office of the Inspector General of Health and Human Services, or HHS-OIG, are continuing to perform audits of various companies’ selected MA contracts related to this risk adjustment diagnosis data.
data submissions. We refer to these audits as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices whichthat influence the calculation of health status-related premium payments to MA plans.
In 2012, CMS released a “Notice of Final Payment Error Calculation Methodology for Part C Medicare Advantage Risk Adjustment Data Validation (RADV) Contract-Level Audits.” The payment error calculation methodology provided that, in calculating the economic impact of audit results for an MA contract, if any,contract-level RADV methodology that would extrapolate the results of each CMS RADV audit sample to the audited MA contract’s entire health status-related risk adjusted premium amount for the year under audit. In doing so, CMS recognized “that the documentation standard used in RADV audits to determine a contract’s payment error (medical records) is different from the documentation standard used to develop the Part C risk-adjustment model (FFS claims).” To correct for this difference, CMS stated that it would apply a “Fee-for-Service Adjuster (FFS Adjuster)” as “an offset to the preliminary recovery amount.” This adjuster would be “calculated by CMS based on a RADV-like review of records submitted to support FFS claims data.” CMS stated that this methodology would apply to audits beginning with PY 2011. Humana relied on CMS’s 2012 guidance in submitting MA bids to CMS. Humana also launched a “Self-Audits” program in 2013 that applied CMS’s 2012 RADV audit methodology and included an estimated FFS Adjuster. Humana completed Self-Audits for PYs 2011-2016 and reported results to CMS.
In October 2018, however, CMS issued a proposed rule announcing possible changes to the RADV audit sample would bemethodology, including elimination of the FFS Adjuster. CMS proposed applying its revised methodology, including extrapolated recoveries without application of a FFS Adjuster, to RADV audits dating back to PY 2011. On January 30, 2023, CMS published a final rule related to the entire MA contract afterRADV audit methodology (Final RADV Rule). The Final RADV Rule confirmed CMS’s decision to eliminate the FFS Adjuster. The Final RADV Rule states CMS’s intention to extrapolate results from CMS and HHS-OIG RADV audits beginning with PY 2018, rather than PY 2011 as proposed. However, CMS’s Final RADV Rule does not adopt a comparisonspecific sampling, extrapolation or audit methodology. CMS instead stated its general plan to rely on “any statistically valid method . . . that is determined to be well-suited to a particular audit.”
Humana is considering its legal options with respect to CMS’s changed position on the FFS Adjuster and seeking clarity regarding our compliance obligations in light of the audit resultsFinal RADV Rule. We believe that the Final RADV Rule fails to a similar auditaddress adequately the statutory requirement of the government’s traditional fee-for-service Medicare program, or Medicare FFS. We refer to the process of accounting for errorsactuarial equivalence. Further, Humana’s actuarially certified bids through PY 2023 preserved Humana’s position that CMS
should apply an FFS Adjuster in FFS claims as the "FFS Adjuster." This comparison ofany RADV audit resultsthat CMS intends to extrapolate. We expect CMS to apply the FFS error rate is necessary to determine the economic impact, if any, ofFinal RADV audit results because the government used the Medicare FFS program data set, including any attendant errors that are present in that data set, to estimate the costs of various health status conditions and to set the resulting adjustments to MA plans’ payment rates in order to establish actuarial equivalence in payment rates as required under the Medicare statute. CMS already makes other adjustments to payment rates based on a comparison of coding pattern differences between MA plans and Medicare FFS data (such as for frequency of coding for certain diagnoses in MA plan data versus the Medicare FFS program dataset).
The final RADV extrapolation methodology,Rule, including the first application of extrapolated audit results to determine audit settlements is expected to be applied to CMS RADV contract level audits conducted for contract year 2011 and subsequent years. CMS is currently conducting RADV contract level audits for certain of our Medicare Advantage plans.
Estimated audit settlements are recorded as a reduction of premiums revenue in our consolidated statements of income, based upon available information. We perform internal contract level audits based on the RADV audit methodology prescribed by CMS. Included in these internal contract level audits is an audit of our Private Fee-For Service business which we used to represent a proxy of the FFS Adjuster which has not yet been finalized. We based our accrual of estimated audit settlements for each contract year on the results of these internal contract level audits and update our estimates as each audit is completed. Estimates derived from these results were not material to our results of operations, financial position, or cash flows. We report the results of these internal contract level audits to CMS, including identified overpayments, if any.
On October 26, 2018, CMS issued a proposed rule and accompanying materials (which we refer to as the “Proposed Rule”) related to, among other things, the RADV audit methodology described above. If implemented, the Proposed Rule would use extrapolation in RADV audits applicable to payment year 2011 contract-level audits and all subsequent audits, without the application of a FFS Adjuster, to audit findings. We believe thatCMS and HHS-OIG RADV audits conducted for PY 2018 and subsequent years. The Final RADV Rule, including the Proposed Rule fails to address adequately the statutory requirementlack of actuarial equivalence, and have provided substantive comments to CMS on the Proposed Rule as part of the notice-and-comment rulemaking process. Whether, and to what extent, CMS finalizes the Proposed Rule,a FFS Adjuster, and any related regulatory, industry or company reactions, could have a material adverse effect on our results of operations, financial position, or cash flows.
In addition, as part of our internal compliance efforts, we routinely perform ordinary course reviews of our internal business processes related to, among other things, our risk coding and data submissions in connection with the risk-risk adjustment model. These reviews may also result in the identification of errors and the submission of corrections to CMS that may, either individually or in the aggregate, be material. As such, the result of these reviews may have a material adverse effect on our results of operations, financial position, or cash flows.
We believe that CMS' statementsAs we explore our legal options and policies regarding the requirementcompliance obligations, we remain committed to report and return identified overpayments received by MA plans are inconsistent with CMS' 2012 RADV audit methodology, and the Medicare statute's requirements. These statements and policies, such as certain statements contained in the preamble to CMS’ final rule release regarding Medicare Advantage and Part D prescription drug benefit program regulations for Contract Year 2015 (which we refer to as the "Overpayment Rule"), and the Proposed
Rule, appear to equate each Medicare Advantage risk adjustment data error with an “overpayment” without addressing the principles underlying the FFS Adjuster referenced above. On September 7, 2018, the Federal District Court for the District of Columbia vacated CMS's Overpayment Rule, concluding that it violated the Medicare statute, including the requirement for actuarial equivalence, and that the Overpayment Rule was also arbitrary and capricious in departing from CMS's RADV methodology without adequate explanation (among other reasons). CMS has appealed the decision to the Circuit Court of Appeals.
We will continue to work withworking alongside CMS to ensurepromote the integrity of the MA program as well as affordability and cost certainty for our members. It is critical that MA plans are paid accurately and that payment model principles, including the application of a FFS Adjuster, are in accordance with the requirements of the Social Security Act, which, if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows.
•Our CMS contracts which cover members’ prescription drugs under Medicare Part D contain provisions for risk sharing and certain payments for prescription drug costs for which we are not at risk. These provisions, certain of which are described below, affect our ultimate payments from CMS.
The premiums from CMS are subject to risk corridor provisions which compare costs targeted in our annual bids to actual prescription drug costs, limited to actual costs that would have been incurred under the standard coverage as defined by CMS. Variances exceeding certain thresholds may result in CMS making additional payments to us or require us to refund to CMS a portion of the premiums we received (known as a “risk corridor”). We estimate and recognize an adjustment to premiums revenue related to the risk corridor payment settlement based upon pharmacy claims experience. The estimate of the settlement associated with these risk corridor provisions requires us to consider factors that may not be certain, including member eligibility differences with CMS. Our estimate of the settlement associated with the Medicare Part D risk corridor provisions was a net payable of $170 million at December 31, 2019 and 2018.
Reinsurance and low-income cost subsidies represent payments from CMS in connection with the Medicare Part D program for which we assume no risk. Reinsurance subsidies represent payments for CMS’s portion of claims costs which exceed the member’s out-of-pocket threshold, or the catastrophic coverage level. Low-income cost subsidies represent payments from CMS for all or a portion of the deductible, the coinsurance and co-payment amounts above the out-of-pocket threshold for low-income beneficiaries. Monthly prospective payments from CMS for reinsurance and low-income cost subsidies are based on assumptions submitted with our annual bid. A reconciliation and settlement of CMS’s prospective subsidies against actual prescription drug costs we paid is made after the end of the applicable year.
Settlement of the reinsurance and low-income cost subsidies as well as the risk corridor payment is based on a reconciliation made approximately 9 months after the close of each calendar year. This reconciliation process requires us to submit claims data necessary for CMS to administer the program. Our claims data may not pass CMS’s claims edit processes due to various reasons, including discrepancies in eligibility or classification of low-income members. To the extent our data does not pass CMS’s claim edit processes, we may bear the risk for all or a portion of the claim which otherwise may have been subject to the risk corridor provision or payment which we would have otherwise received as a low-income subsidy or reinsurance claim. In addition, in the event the settlement represents an amount CMS owes us, there is a negative impact on our cash flows and financial condition as a result of financing CMS’s share of the risk. The opposite is true in the event the settlement represents an amount we owe CMS.Further, legislative or regulatory changes to how actual prescription drug costs are
reported or calculated or other changes to the Part D prescription drug benefit design may lower reinsurance or low-income cost subsidies paid by CMS and may have a material adverse effect on our results of operations, financial position, or cash flows.
•We are also subject to various other governmental audits and investigations. Under state laws, our HMOs and health insurance companies are audited by state departments of insurance for financial and contractual compliance. Our HMOs are audited for compliance with health services by state departments of health. Audits and investigations, including audits of risk adjustment data, are also conducted by state attorneys general, CMS, HHS-OIG, the Office of Personnel Management, the Department of Justice, the Department of Labor, and the Defense Contract Audit Agency. All of these activities could result in the loss of licensure or the right to participatetemporary or permanent exclusion from participating in various government health care programs (such as Medicare and Medicaid), including a limitation on our ability to market or sell products, the imposition of fines, penalties and other civil and criminal sanctions, or changes in our business practices. The outcome of any current or future governmental or internal investigations cannot be accurately predicted, nor can we predict any resulting penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities. Nevertheless, it is reasonably possible that any such outcome of
litigation, penalties, fines or other sanctions could be substantial, and the outcome of these matters may have a material adverse effect on our results of operations, financial position, and cash flows. Certain of these matters could also affect our reputation. In addition, disclosure of any adverse investigation or audit results or sanctions could negatively affect our industry or our reputation in various markets and make it more difficult for us to sell our products and services.
Our business activities are subject to substantial government regulation. New laws or regulations, or legislative, judicial, or regulatory changes in existing laws or regulations or their manner of application could increase our cost of doing business and may have a material adverse effect on our results of operations, (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting our ability to expand into new markets, increasing our medical and operating costs by, among other things, requiring a minimum benefit ratio on insured products, lowering our Medicare payment rates and increasing our expenses associated with assessments); our financial position (including our ability to maintain the value of our goodwill); and ouror cash flows.
The Health Care Reform Law and Other Current
New Laws or Regulations, or Future Legislative, Judicial or Regulatory Changes
We are and will continue to be regularly subject to new laws and regulations, changes to existing laws and regulations, and judicial determinations that impact the interpretation and applicability of those laws and regulations. The Patient Protection and Affordable Care Act and The Health Care and Education Reconciliation Act of 2010 (which we collectively refer to as the Health Care Reform Law), the Families First Coronavirus Response Act (the “Families First Act”), the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), and the Inflation Reduction Act of 2022 (the “Inflation Reduction Act”), and related regulations, are examples of laws which have enacted significant reforms to various aspects of the U.S. health insurance industry. Certain significant provisions of the Health Care Reform Law include,industry, including among others, mandated coverage requirements, mandated benefits and guarantee issuance associated with commercial medical insurance, rebates to policyholders based on minimum benefit ratios, adjustments to Medicare Advantage premiums, the establishment of federally facilitated or state-based exchanges coupled with programs designed to spread risk among insurers, and the introduction of plan designs based on set actuarial values. In addition,values, and changes to the Health Care Reform Law established insurance industry assessments, including an annual health insurance industry fee. The annual health insurance industry fee was suspended in 2019, but will resume for calendar year 2020, not be deductible for income tax purposes, and significantly increase our effective tax rate. In 2018, the fee levied on the health insurance industry was $14.3 billion. Under current law, the health industry fee will be permanently repealed beginning in calendar year 2021. Part D prescription drug benefit design.
It is reasonably possible that the Health Care Reform Lawthese laws and related regulations, as well as other current or future legislative, judicial or regulatory changes (including further legislative or regulatory action taken in response to COVID-19), including restrictions on our ability to manage our provider network or otherwise operate our business, or restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage business profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, increases in member benefits or changes to member eligibility criteria without corresponding increases in premium payments to us, or increases in regulation of our prescription drug benefit businesses, or changes to the Part D prescription drug benefit design may have a material adverse effect on our results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting our ability to expand into new markets, increasing our medical and operating costs, further lowering our Medicare payment rates and increasing
our expenses associated with assessments); our financial position (including our ability to maintain the value of our goodwill); and our cash flows.
Additionally, potential legislative changes or judicial determinations, including activities to repeal or replace these laws and regulations, including the Health Care Reform Law or declare all or certain portions of the Health Care Reform Lawthese laws and regulations unconstitutional createsor contrary to law, create uncertainty for our business, and we cannot predict when, or in what form, such legislative changes or judicial determinations may occur.
Health Insurance Portability and Accountability Act (HIPAA) and the Health Information Technology for Economic and Clinical Health Act (HITECH Act)
The use of individually identifiable health data by our business is regulated at federal and state levels. These laws and rules are changed frequently by legislation or administrative interpretation. Various state laws address the use and maintenance of individually identifiable health data. Most are derived from the privacy provisions in the federal Gramm-Leach-Bliley Act and the Health Insurance Portability and Accountability Act, or HIPAA. HIPAA includes
administrative provisions directed at simplifying electronic data interchange through standardizing transactions, establishing uniform health care provider, payer, and employer identifiers, and seeking protections for the confidentiality and security of patient data. The rules do not provide for complete federal preemption of state laws, but rather preempt all inconsistent state laws unless the state law is more stringent.
These regulations set standards for the security of electronic health information, including requirements that insurers provide customers with notice regarding how their non-public personal information is used, including an opportunity to "opt out" of certain disclosures. Violations of these rules could subject us to significant criminal and civil penalties, including significant monetary penalties. Compliance with HIPAA regulations requires significant systems enhancements, training and administrative effort. HIPAA can also expose us to additional liability for violations by our business associates (e.g., entities that provide services to health plans and providers).
The HITECH Act, one part of the American Recovery and Reinvestment Act of 2009, significantly broadened and strengthened the scope of the privacy and security regulations of HIPAA.HIPAA and imposes additional limits on the use and disclosure of protected health information, or PHI. Among other requirements, the HITECH Act and HIPAA mandate individual notificationrequires us and other covered entities to report any unauthorized release or use of or access to PHI to any impacted individuals and to HHS in those instances where the eventunauthorized activity poses a significant risk of a breachfinancial, reputational or other harm to the individuals, and to notify the media in any states where 500 or more people are impacted by any unauthorized release or use of unsecured, individually identifiable health information, provides enhanced penalties for HIPAA violations,or access to PHI, requires business associates to comply with certain provisions of the HIPAA privacy and security rule, and grants enforcement authority to state attorneys general in addition to the HHS Office of Civil Rights.
In addition, there are numerous federal and state laws and regulations addressing patient and consumer privacy concerns, including unauthorized access or theft of personal information. State statutes and regulations vary from state to state and could impose additional penalties. Violations of HIPAA or applicable federal or state laws or regulations could subject us to significant criminal or civil penalties, including significant monetary penalties. Compliance with HIPAA and other privacy regulations requires significant systems enhancements, training and administrative effort.
American Recovery and Reinvestment Act of 2009 (ARRA)
On February 17, 2009, the American Recovery and Reinvestment Act of 2009, or ARRA, was enacted into law. In addition HIPAA can also expose us to including a temporary subsidyadditional liability for health care continuation coverage issued pursuant to the Consolidated Omnibus Budget Reconciliation Act, or COBRA, ARRA also expands and strengthens the privacy and security provisions of HIPAA and imposes additional limits on the use and disclosure of protected health information, or PHI. Among other things, ARRA requires us and other covered entities to report any unauthorized release or use of or access to PHI to any impacted individuals and to HHS in those instances where the unauthorized activity poses a significant risk of financial, reputational or other harm to the individuals, and to notify the media in any states where 500 or more people are impactedviolations by any unauthorized release or use of or access to PHI. ARRA also requiresour business associates (e.g., entities that provide services to comply with certain HIPAA provisions. ARRA also establishes higher civilhealth plans and criminal penalties for covered entities and business associates who fail to comply with HIPAA’s provisions and requires HHS to issue regulations implementing its privacy and security enhancements. providers).
Corporate Practice of Medicine and Other Laws
As a corporate entity, Humana Inc. is not licensed to practice medicine. Many states in which we operate through our subsidiaries limit the practice of medicine to licensed individuals or professional organizations comprised of licensed individuals, and business corporations generally may not exercise control over the medical decisions of physicians. Statutes and regulations relating to the practice of medicine, fee-splitting between physicians and referral sources, and similar issues vary widely from state to state. Under management agreements between certain of our subsidiaries and affiliated physician-owned professional groups, these groups retain sole responsibility for all medical decisions, as well as for hiring and managing physicians and other licensed healthcare providers, developing operating policies and procedures, implementing professional standards and controls, and maintaining malpractice insurance. We believe that our health services operations comply with applicable state statutes regarding corporate practice of medicine, fee-splitting, and similar issues. However, any enforcement actions by governmental officials alleging non-compliance with these statutes, which could subject us to penalties or
restructuring or reorganization of our business, may result in a material adverse effect on our results of operations, financial position, or cash flows.
Anti-Kickback, Physician Self-Referral, and Other Fraud and Abuse Laws
AWe are subject to various federal law commonly referredand state healthcare fraud and abuse laws including the federal False Claims Act (the “False Claims Act”), the federal anti-kickback statute (the “Anti-Kickback Statute”), the federal “Stark Law,” and related state laws. Potential sanctions for violating these laws include recoupment or reduction of government reimbursement amounts, civil penalties, treble damages, and exclusion from participating in the Medicare and Medicaid programs or other government healthcare programs. The False Claims Act prohibits knowingly submitting, conspiring to assubmit, or causing to be submitted, false claims, records, or statements to the “Anti-Kickback Statute”federal government, or intentionally failing to return overpayments, in connection with reimbursement by federal government programs. The Anti-Kickback Statute prohibits the offer, payment, solicitation, or receipt of any form of remuneration to induce, or in return for, the referral of business under Medicare or other governmental health program patients or patient care opportunities, or in return for the purchase, lease, or order of items or services that are covered by Medicare or other federal governmental health programs. Because the prohibitions contained in the Anti-Kickback Statute apply to the furnishing of items or services for which payment is made in “whole or in part,” the Anti-Kickback Statute could be implicated if any portion of an item or service we provide is covered by any of the state or federal health benefit programs described above. Violation of these provisions constitutes a felony criminal offense and applicable sanctions could include exclusion from the Medicare and Medicaid programs.
Section 1877 of the Social Security Act, commonly known as the “Starkprogram. The Stark Law” prohibits physicians subject to certain exceptions described below, from referring Medicare or Medicaid patientsbeneficiaries for certain services to anany entity providing “designated health services” in which the physician, or an immediate family member, has an ownership or investment interest or with which the physician, or an immediate family member has entered into a compensation arrangement. These prohibitions, contained in the Omnibus Budget Reconciliation Act of 1993, commonly known as “Stark II,” amended prior federal physician self-referral legislation known as “Stark I” by expanding the list of designated health services to a total of 11 categories of health services. The professional groups with which we are affiliated provide one or more of these designated health services. Persons or entities found to be in violation of the Stark Law are subject to denial of payment for services furnished pursuant to an improper referral, civil monetary penalties, and exclusion fromphysician, has a financial relationship, unless the Medicare and Medicaid programs.financial relationship fits within a permissible exception.
Many states also have enacted laws similar in scope and purpose to the Anti-Kickback Statute and, in more limited instances, the Stark Law, that are not limited to services for which Medicare or Medicaid payment is made. In addition, most states have statutes, regulations, or professional codes that restrict a physician from accepting various kinds of remuneration in exchange for making referrals. These laws vary from state to state and have seldom been interpreted by the courts or regulatory agencies. In states that have enacted these statutes, we believe that regulatory authorities and state courts interpreting these statutes may regard federal law under the Anti-Kickback Statute and the Stark Law as persuasive.
We believe that our operations comply with the Anti-Kickback Statute, the Stark Law, and similar federal or state laws addressing fraud and abuse. These laws are subject to modification and changes in interpretation, and are enforced by authorities vested with broad discretion. We continually monitor developments in this area. If these laws are interpreted in a manner contrary to our interpretation or are reinterpreted or amended, or if new legislation is enacted with respect to healthcare fraud and abuse, illegal remuneration, or similar issues, we may be required to restructure our affected operations to maintain compliance with applicable law. There can be no assurances that any such restructuring will be possible or, if possible, would not have a material adverse effect on our results of operations, financial position, or cash flows.
Environmental
We are subject to various federal, state, and local laws and regulations relating to the protection of human health and the environment. If an environmental regulatory agency finds any of our facilities to be in violation of environmental laws, penalties and fines may be imposed for each day of violation and the affected facility could be forced to cease operations. We could also incur other significant costs, such as cleanup costs or claims by third parties, as a result of violations of, or liabilities under, environmental laws. Although we believe that our environmental practices, including waste handling and disposal practices, are in material compliance with applicable laws, future claims or violations, or changes in environmental laws, could have a material adverse effect on our results of operations, financial position or cash flows.
State Regulation of Insurance-Relatedour Products and Services
Laws in each of the states (and Puerto Rico) in which we operate our HMOs, PPOs and other health insurance-related services regulate our operations including: capital adequacy and other licensing requirements, policy language describing benefits, mandated benefits and processes, entry, withdrawal or re-entry into a state or market, rate increases, delivery systems, utilization review procedures, quality assurance, complaint systems, enrollment requirements, claim payments, marketing, and advertising. The HMO, PPO, and other health insurance-related products we offer are sold under licenses issued by the applicable insurance regulators.
Our licensed insurance subsidiaries are also subject to regulation under state insurance holding company and Puerto Rico regulations. These regulations generally require, among other things, prior approval and/or notice of new products, rates, benefit changes, and certain material transactions, including dividend payments, purchases or sales of assets, intercompany agreements, and the filing of various financial and operational reports.
Certain of our healthcare services businesses require a Certificate of Need, or CON, to operate in certain states. These states restrict the entry of new providers or services and the expansion of existing providers or services in their state through a CON process, which is periodically evaluated and updated as required by applicable state law. To the extent that we require a CON or other similar approvals to expand our operations, our expansion could be adversely affected by our inability to obtain the necessary approval. To the extent laws in these CON states change,
including the elimination of the CON requirement, the intangible value associated with these CONs may be impaired.
Any failure by us to manage acquisitions, divestitures and other significant transactions successfully may have a material adverse effect on our results of operations, financial position, and cash flows.
As part of our business strategy, we frequently engage in discussions with third parties regarding possible investments, acquisitions, divestitures, strategic alliances, joint ventures, and outsourcing transactions and often enter into agreements relating to such transactions in order to further our business objectives. In order to pursue our acquisition strategy successfully, we must identify suitable candidates for and successfully complete transactions, some of which may be large and complex, and manage post-closing issues such as the integration of acquired companies or employees. Integration and other risks can be more pronounced for larger and more complicated transactions, transactions outside of our core business space, or if multiple transactions are pursued simultaneously. The failure to successfully integrate acquired entities and businesses or failure to produce results consistent with the financial model used in the analysis of our acquisitions, investments, joint ventures or strategic alliancestransactions may cause asset write-offs, restructuring costs or other expenses and may have a material adverse effect on our results of operations, financial position, and cash flows. If we fail to identify and complete successfully transactions that further our strategic objectives, we may be required to expend resources to develop products and technology internally. In addition, from time to time, we evaluate alternatives for our businesses that do not meet our strategic, growth or profitability objectives, and we may divest or wind down such businesses. There can be no assurance that we will be able to complete any such divestiture on terms favorable to us. Theus, and the divestiture of certain businesses could result, individually or in the aggregate, in the recognition of material losses and a material adverse effect on our results of operations. In addition, divestitures may result in continued financial exposure to the divested businesses following the completion of the transaction. For example, in connection with a disposition, we may enter into transition or administrative service agreements, coinsurance arrangements, vendor relationships or other strategic relationships with the divested business, or we may agree to provide certain indemnities to the purchaser in any such transaction, each of which may result in additional expense and could have a material adverse effect on our result of operations.
If we fail to develop and maintain satisfactory relationships with the providers of care to our members, our business may be adversely affected.
We employ or contract with physicians, hospitals and other providers to deliver health care to our members. Our products encourage or require our customers to use these contracted providers. A key component of our integrated care delivery strategy is to increase the number of providers who share medical cost risk with us or have financial incentives to deliver quality medical services in a cost-effective manner.
In any particular market, providers could refuse to contract with us, demand higher payments, or take other actions that could result in higher health care costs for us, less desirable products for customers and members or difficulty meeting regulatory or accreditation requirements. In some markets, some providers, particularly hospitals, physician specialty groups, physician/hospital organizations, or multi-specialty physician groups, may have significant market positions and negotiating power. In addition, physician or practice management companies, which aggregate physician practices for administrative efficiency and marketing leverage, may compete directly with us. If these providers refuse to contract with us, use their market position to negotiate unfavorable contracts with us or place us at a competitive
disadvantage, or do not enter into contracts with us that encourage the delivery of quality medical services in a cost-effective manner, our ability to market products or to be profitable in those areas may be adversely affected.
In some situations, we have contracts with individual or groups of primary care providers for an actuarially determined, fixed fee per month to provide a basket of required medical services to our members. This type of contract is referred to as a “capitation” contract. The inability of providers to properly manage costs under these capitation arrangements can result in the financial instability of these providers and the termination of their relationship with us. In addition, payment or other disputes between a primary care provider and specialists with whom the primary care provider contracts can result in a disruption in the provision of services to our members or a reduction in the services available to our members. The financial instability or failure of a primary care provider to pay other providers for services rendered could lead those other providers to demand payment from us even though we have made our regular fixed payments to the primary provider. There can be no assurance that providers with whom we contract will properly manage the costs of services, maintain financial solvency or avoid disputes with other providers. Any of these events may have a material adverse effect on the provision of services to our members and our results of operations, financial position, and cash flows.
The success of our healthcare services businesses depends on our ability, and the ability of our affiliated physician-owned professional groups and management services organizations, to recruit, hire, acquire, contract with, and retain physicians, nurses and other medical professionals who are experienced in providing care services to older adults. The market to acquire or manage physician practices, and to employ or contract with individual physicians, nurses and other medical professionals is, and is expected to remain, highly competitive, and the performance of our healthcare services businesses may be adversely impacted if we, and our affiliated physician-owned professional groups and management services organizations, are unable to attract, maintain satisfactory relationships with, and retain physicians, nurses and other medical professionals, or if these businesses are unable to retain patients following the departure of a physician, nurses or other medical professional. In addition, our healthcare services businesses contract with competitors of our health benefits businesses, and these businesses could suffer if they are unable to maintain relationships with these companies, or fail to adequately price their contracts with these third-party payers.
We face significant competition in attracting and retaining talented employees. Further, managing succession for, and retention of, key executives is critical to our success, and our failure to do so could adversely affect our businesses, operating results and/or future performance.
Our success depends on our ability to attract, develop and retain qualified employees and executives, including those with diverse backgrounds, experiences and skill sets, to operate and expand our business. We face intense competition for qualified employees, and there can be no assurance that we will be able to attract and retain such employees or that such competition among potential employers will not result in increasing salaries. In addition, while we have development and succession plans in place for our key employees and executives, these plans do not guarantee the services of our key employees and executives will continue to be available to us. If we are unable to attract, develop, retain and effectively manage the development and succession plans for key employees and executives, our business, results of operations and future performance could be adversely affected.
Our pharmacy business is highly competitive and subjects us to regulations and distribution and supply chain risks in addition to those we face with our core health benefits businesses.
Our in-house dispensing pharmacy business competes with locally owned drugstores, retail drugstore chains, supermarkets, discount retailers, membership clubs, internet companies and other mail-order and long-term care pharmacies.
Our pharmacy business also subjects us to extensive federal, state, and local regulation. The practice of pharmacy is generally regulated at the state level by state boards of pharmacy. Many of the states where we deliver pharmaceuticals, including controlled substances, have laws and regulations that require out-of-state mail-order pharmacies to register with that state’s board of pharmacy. Federal agencies further regulate our pharmacy operations, requiring registration with the U.S. Drug Enforcement Administration and individual state controlled substance authorities in order to dispense controlled substances. In addition, the FDA inspects facilities in connection with procedures to effect recalls of prescription drugs. The Federal Trade Commission also has requirements for mail-order sellers of goods. The U.S. Postal Service, or USPS, has statutory authority to restrict the transmission of drugs and medicines through the mail to a degree that may have an adverse effect on our mail-order operations. The USPS historically has exercised this statutory authority only with respect to controlled substances. If the USPS restricts our ability to deliver drugs through the mail, alternative means of delivery are available to us. However, alternative means of delivery could be significantly more expensive. The U.S. Department of Transportation has regulatory authority to impose restrictions on drugs inserted in the stream of commerce. These regulations generally do not apply to the USPS and its operations. In addition, we are subject to CMS rules regarding the administration of our PDP plans and intercompany pricing between our PDP plans and our pharmacy business.
We are also subject to risks inherent in the packaging and distribution of pharmaceuticals and other health care products, including manufacturing or other supply issues that could impact the availability of such products, and the application of state laws and regulations related to the operation of internet and mail-order pharmacies. The failure to adhere to these laws and regulations maypharmacies, violations of which could expose us to civil and criminal penalties.penalties, and manufacturing, distribution or other supply chain disruptions (including disruptions that occur as a result of catastrophes, including acts of
terrorism, public health emergencies, epidemics or pandemics (such as the spread of COVID-19), or natural disasters (such as hurricanes and earthquakes) which could occur more frequently or with more intense effects as a result of the impacts of global climate change), each of which could impact the availability or cost of supplying of such products.
Changes in the prescription drug industry pricing benchmarks may adversely affect our financial performance.
Contracts in the prescription drug industry generally use certain published benchmarks to establish pricing for prescription drugs. These benchmarks include average wholesale price, which is referred to as “AWP,” average selling price, which is referred to as “ASP,” and wholesale acquisition cost. It is uncertain whether payors, pharmacy providers, pharmacy benefit managers, or PBMs, and others in the prescription drug industry will continue to utilize AWP as it has previously been calculated, or whether other pricing benchmarks will be adopted for establishing prices within the industry. Legislation may lead to changes in the pricing for Medicare and Medicaid programs. Regulators have conducted investigations into the use of AWP for federal program payment, and whether the use of AWP has inflated drug expenditures by the Medicare and Medicaid programs. Federal and state proposals have sought to change the basis for calculating payment of certain drugs by the Medicare and Medicaid programs. Adoption of ASP in lieu of AWP as the measure for determining payment by Medicare or Medicaid programs for the drugs sold in our in-house dispensing
pharmacy business may reduce the revenues and gross margins of this business which may result in a material adverse effect on our results of operations, financial position, and cash flows.
If we do not continue to earn and retain purchase discounts and volume rebates from pharmaceutical manufacturers at current levels, our gross margins may decline.
We have contractual relationships with pharmaceutical manufacturers or wholesalers that provide us with purchase discounts and volume rebates on certain prescription drugs dispensed through our in-house dispensing and specialty pharmacies. These discounts and volume rebates are generally passed on to clients in the form of steeper price discounts. Changes in existing federal or state laws or regulations or in their interpretation by courts and agencies or the adoption of new laws or regulations relating to patent term extensions, and purchase discount and volume rebate arrangements with pharmaceutical manufacturers, may reduce the discounts or volume rebates we receive and materially adversely impact our results of operations, financial position, and cash flows.
Our ability to obtain funds from certain of our licensed subsidiaries is restricted by state insurance regulations.
Because we operate as a holding company, we are dependent upon dividends and administrative expense reimbursements from our subsidiaries to fund the obligations of Humana Inc., our parent company. Certain of our insurance subsidiaries operate in states that regulate the payment of dividends, loans, administrative expense reimbursements or other cash transfers to Humana Inc., and require minimum levels of equity as well as limit investments to approved securities. The amount of dividends that may be paid to Humana Inc. by these insurance subsidiaries, without prior approval by state regulatory authorities, or ordinary dividends, is limited based on the entity's level of statutory income and statutory capital and surplus. In most states, prior notification is provided before paying a dividend even if approval is not required. Actual dividends paid may vary due to consideration of excess statutory capital and surplus and expected future surplus requirements related to, for example, premium volume and product mix. Dividends from our non-insurance companies such as in our Healthcare ServicesCenterWell segment are generally not restricted by Departments of Insurance. In the event that we are unable to provide sufficient capital to fund the obligations of Humana Inc., our results of operations, financial position, and cash flows may be materially adversely affected.
Downgrades in our debt ratings, should they occur, may adversely affect our business, results of operations, and financial condition.
Claims paying ability, financial strength, and debt ratings by recognized rating organizations are an increasingly important factor in establishing the competitive position of insurance companies. Ratings information is broadly disseminated and generally used throughout the industry. We believe ourHistorically, rating agencies take action to lower ratings due to, among other things, perceived concerns about liquidity or solvency, the competitive environment in the insurance industry, the inherent uncertainty in determining reserves for future claims, paying abilitythe outcome of pending litigation and financial strength ratings are an important factorregulatory investigations, and possible changes in marketing our products to certain of our customers. In addition, our debt ratings impact both the cost and availability of future borrowings.methodology or criteria applied by the rating agencies. Each of the rating agencies reviews its ratings periodically and there can be no assurance that current ratings will be maintained in the future. Our ratings reflect each rating agency’s opinion of our financial strength, operating performance, and ability to meet our debt obligations or obligations to policyholders, but are not evaluations directed toward the protection of investors in our common stock and should not be relied upon as such.
Historically, rating agencies take action to lower ratings due to, among other things, perceived concerns about liquidity or solvency, the competitive environment in the insurance industry, the inherent uncertainty in determining reserves for future claims, the outcome of pending litigation and regulatory investigations, and possible changes in the methodology or criteria applied by the rating agencies. In addition, rating agencies have come under regulatory and public scrutiny over the ratings assigned to various fixed-income products. As a result, rating agencies may (i) become more conservative in their methodology and criteria, (ii) increase the frequency or scope of their credit reviews, (iii) request additional information from the companies that they rate, or (iv) adjust upward the capital and other requirements employed in the rating agency models for maintenance of certain ratings levels.
We believe that somecertain of our customers place importance on our creditclaims paying ability, financial strength, and debt ratings, and we may lose customers and compete less successfully if our ratings were to be downgraded. In addition, our credit ratings affectimpact our ability to obtain future borrowings and investment capital on favorable terms. If our credit ratings were to be lowered, our cost of borrowing likely would
increase, our sales and earnings could decrease, and our results of operations, financial position, and cash flows may be materially adversely affected.
The securities and credit markets may experience volatility and disruption, which may adversely affect our business.
VolatilityOngoing volatility or disruption in the securities and credit markets could impact our investment portfolio. We evaluate our investment securities for impairment on a quarterly basis. This review is subjective and requires a high degree of judgment. For the purpose of determining gross realized gains and losses, the cost of investment securities sold is based upon specific identification. For debt securities held, we recognize an impairment loss in income when the fair value of the debt security is less than the carrying value and we have the intent to sell the debt security or it is more likely than not that we will be required to sell the debt security before recovery of our amortized cost basis, or if a credit loss has occurred. When we do not intend to sell or are not required to sell a security in an unrealized loss position, potential other-than-temporarycredit related impairments are considered using a variety of factors, including the length of time and extent to which the fair value has been less than cost;cost, adverse conditions specifically related to the industry, geographic area or financial condition of the issuer or underlying collateral of a security; payment structure of the security; changes in credit rating of the security by the rating agencies; the volatility of the fair value changes; and changes in fair value of the security after the balance sheet date. For debt securities, we take into account expectations of relevant market and economic data. We continuously review our investment portfolios and there is a continuing risk that declines in fair value may occur and additional material realized losses from sales or other-than-temporarycredit related impairments may be recorded in future periods.
We believe our cash balances, investment securities, operating cash flows, and funds available under our credit agreement or from other public or private financing sources, taken together, provide adequate resources to fund ongoing operating and regulatory requirements, acquisitions, future expansion opportunities, and capital expenditures for at least the next twelve months, as well as to refinance or repay debt, and repurchase shares. However, continuing adverse securities and credit market conditions may significantly affect the availability of credit. While there is no assurance in the current economic environment, including the heightened uncertainty created by the COVID-19 pandemic, we have no reason to believe the lenders participating in our credit agreement will not be willing and able to provide financing in accordance with the terms of the agreement.
Our access to additional credit will depend on a variety of factors such as market conditions, the general availability of credit, both to the overall market and our industry, our credit ratings and debt capacity, as well as the possibility that customers or lenders could develop a negative perception of our long or short-term financial prospects. Similarly, our access to funds could be limited if regulatory authorities or rating agencies were to take negative actions against us. If a combination of these factors were to occur, we may not be able to successfully obtain additional financing on favorable terms or at all.
The spread of, and response to, COVID-19 underscores certain risks we face, including those discussed above, and the ongoing, heightened uncertainty created by the pandemic precludes any prediction as to the ultimate adverse impact to us of COVID-19.
COVID-19 underscores certain risks we face, including those discussed above.As the COVID-19 pandemic continues, the premiums we charge may prove to be insufficient to cover the cost of health care services delivered to our members, each of which could be impacted by many factors, including the impacts that we have experienced, and may continue to experience, to our revenues due to limitations on our ability to implement clinical initiatives to manage health care costs and chronic conditions of our members, and appropriately document their risk profiles, as a result of our members being unable or unwilling to see their providers due to actions taken to mitigate the spread of COVID-19; increased costs that may result from higher utilization rates of medical facilities and services and other increases in associated hospital and pharmaceutical costs; and shifts in our premium and medical claims cost trends to reflect the demographic impact of higher mortality during the COVID-19 pandemic. In addition, we are offering,
and have been mandated by legislative and regulatory action (including the Families First Act and CARES Act) to provide, certain expanded benefit coverage to our members, such as waiving, or reimbursing, certain costs for COVID-19 testing, vaccinations and treatment. These measures taken by us, or governmental action, to respond to the ongoing impact of COVID-19 (including further expansion or modification of the services delivered to our members, the adoption or modification of regulatory requirements associated with those services and the costs and challenges associated with ensuring timely compliance with such requirements), and the potential for widespread testing, treatments and the distribution and administration of COVID-19 vaccines, could adversely impact our profitability.
The spread and impact of COVID-19 and additional variants, or actions taken to mitigate this spread, could have material and adverse effects on our ability to operate effectively, including as a result of the complete or partial closure of facilities or labor shortages. Disruptions in public and private infrastructure, including communications, availability of in-person sales and marketing channels, financial services and supply chains, could materially and adversely disrupt our normal business operations. A significant subset of our and our third party providers’ employee populations are in a remote work environment in an effort to mitigate the spread of COVID-19, which may exacerbate certain risks to our business, including an increased demand for information technology resources, increased risk of phishing and other cybersecurity attacks, and increased risk of unauthorized dissemination of sensitive personal, or proprietary and/or confidential information. The continued COVID-19 pandemic has severely impacted global economic activity, including the businesses of some of our commercial customers, and caused significant volatility and negative pressure in the financial markets. In addition to disrupting our operations, these developments may adversely affect the timing of commercial customer premium collections and corresponding claim payments, the value of our investment portfolio, or future liquidity needs.
The ongoing, heightened uncertainty created by the pandemic precludes any prediction as to the ultimate adverse impact to us of COVID-19. We are continuing to monitor the spread of COVID-19, changes to our benefit coverages, and the ongoing costs and business impacts of dealing with COVID-19, including the potential costs and impacts associated with lifting, or reimposing, restrictions on movement and economic activity, the timing and degree in resumption of demand for deferred healthcare services, the pace of administration of COVID-19 vaccines and the effectiveness of those vaccines, and related risks. The magnitude and duration of the pandemic remains uncertain, and its ultimate impact on our business, results of operations, financial position, and cash flows could be material.
ITEM 1B. UNRESOLVED STAFF COMMENTS
None.
ITEM 2. PROPERTIES
Our principal executive office is located in the Humana Building, 500 West Main Street, Louisville, Kentucky 40202. In addition to the headquarters in Louisville, Kentucky, we maintain other principal operating facilities used for customer service, enrollment, and/or claims processing and certain other corporate functions in Louisville, Kentucky; Green Bay, Wisconsin; Tampa, Florida; Cincinnati, Ohio; San Antonio, Texas; and San Juan, Puerto Rico.Rico; Atlanta, Georgia; Mooresville, North Carolina and Austin, Texas.
We owned or leased numerous medical centers and administrative offices at December 31, 2019.2022. The medical centers we operate are primarily located in Florida and Texas, including full-service, multi-specialty medical centers staffed by primary care providers and medical specialists. Of these medical centers, approximately 185289 of these facilities are leased or subleased to our contracted providers to operate.
ITEM 3. LEGAL PROCEEDINGS
We are party to a variety of legal actions in the ordinary course of business, certain of which may be styled as class-action lawsuits. Among other matters, this litigation may include employment matters, claims of medical malpractice, bad faith, nonacceptance or termination of providers, anticompetitive practices, improper rate setting, provider contract rate disputes, qui tam litigation brought by individuals seeking to sue on behalf of the government, failure to disclose network discounts and various other provider arrangements, general contractual matters, intellectual property matters, and challenges to subrogation practices. For a discussion of our material legal actions, including those not in the ordinary course of business, see “Legal Proceedings and Certain Regulatory Matters” in Note 17 to the consolidated financial statementsaudited Consolidated Financial Statements included in Item 8. – Financial Statements and Supplementary Data. We cannot predict the outcome of these suits with certainty.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
PART II
ITEM 5. MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Market Information
Our common stock trades on the New York Stock Exchange under the symbol HUM.
Holders of our Capital Stock
As of January 31, 2020,2023, there were 2,1001,707 holders of record of our common stock and 229,470634,739 beneficial holders of our common stock.
Dividends
The following table provides details of dividend payments, excluding dividend equivalent rights, in 20182021 and 2019,2022, under our Board approved quarterly cash dividend policy:
|
| | | | | | |
Record Date | | Payment Date | | Amount per Share | | Total Amount |
| | | | | | (in millions) |
2018 payments | | | | | | |
12/29/2017 | | 1/26/2018 | | $0.40 | | $55 |
3/30/2018 | | 4/27/2018 | | $0.50 | | $69 |
6/29/2018 | | 7/27/2018 | | $0.50 | | $69 |
9/28/2018 | | 10/26/2018 | | $0.50 | | $69 |
2019 payments | | | | | | |
12/31/2018 | | 1/25/2019 | | $0.50 | | $68 |
3/29/2019 | | 4/26/2019 | | $0.55 | | $74 |
6/28/2019 | | 7/26/2019 | | $0.55 | | $74 |
9/30/2019 | | 10/25/2019 | | $0.55 | | $73 |
| | | | | | | | | | | | | | | | | | | | |
Record Date | | Payment Date | | Amount per Share | | Total Amount |
| | | | | | (in millions) |
2021 payments | | | | | | |
12/31/2020 | | 1/29/2021 | | $0.6250 | | $81 |
3/31/2021 | | 4/30/2021 | | $0.7000 | | $90 |
6/30/2021 | | 7/30/2021 | | $0.7000 | | $90 |
9/30/2021 | | 10/29/2021 | | $0.7000 | | $90 |
2022 payments | | | | | | |
12/31/2021 | | 1/28/2022 | | $0.7000 | | $90 |
3/31/2022 | | 4/29/2022 | | $0.7875 | | $100 |
6/30/2022 | | 7/29/2022 | | $0.7875 | | $100 |
9/30/2022 | | 10/28/2022 | | $0.7875 | | $100 |
On
In October 24, 2019,2022, the Board declared a cash dividend of $0.55$0.7875 per share that was paidpayable on January 31, 202027, 2023 to stockholders of record on December 31, 2019,2021 for an aggregate amount of $73$98 million. In February 2023, the Board declared a cash dividend of $0.8850 per share payable on April 28, 2023 to stockholders of record on March 31, 2023. Declaration and payment of future quarterly dividends is at the discretion of our Board and may be adjusted as business needs or market conditions change.
In February 2020, the Board declared a cash dividend of $0.625 per share payable on April 24, 2020 to stockholders of record on March 31, 2020.
Stock Total Return Performance
The following graph compares our total return to stockholders with the returns of the Standard & Poor’s Composite 500 Index (“S&P 500”) and the Dow Jones US Select Health Care Providers Index (“Peer Group”) for the five years ended December 31, 2019.2022. The graph assumes an investment of $100 in each of our common stock, the S&P 500, and the Peer Group on December 31, 2014,2017, and that dividends were reinvested when paid.
| | | 12/31/2014 | | 12/31/2015 | | 12/31/2016 | | 12/31/2017 | | 12/31/2018 | | 12/31/2019 | | 12/31/2017 | | 12/31/2018 | | 12/31/2019 | | 12/31/2020 | | 12/31/2021 | | 12/31/2022 |
HUM | $ | 100 |
| | $ | 125 |
| | $ | 144 |
| | $ | 177 |
| | $ | 205 |
| | $ | 265 |
| HUM | $ | 100 | | | $ | 116 | | | $ | 150 | | | $ | 169 | | | $ | 192 | | | $ | 213 | |
S&P 500 | $ | 100 |
| | $ | 101 |
| | $ | 113 |
| | $ | 138 |
| | $ | 132 |
| | $ | 174 |
| S&P 500 | $ | 100 | | | $ | 96 | | | $ | 126 | | | $ | 149 | | | $ | 191 | | | $ | 157 | |
Peer Group | $ | 100 |
| | $ | 106 |
| | $ | 107 |
| | $ | 135 |
| | $ | 149 |
| | $ | 183 |
| Peer Group | $ | 100 | | | $ | 110 | | | $ | 135 | | | $ | 160 | | | $ | 199 | | | $ | 186 | |
The stock price performance included in this graph is not necessarily indicative of future stock price performance.
Issuer Purchases of Equity Securities
The following table provides information about purchases by us during the three months ended December 31, 20192022 of equity securities that are registered by us pursuant to Section 12 of the Exchange Act:
| | | | | | | | | | | | | | | | | | | | | | | |
Period | Total Number of Shares Purchased (1) | | Average Price Paid per Share | | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1)(2) | | Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (1) (2) (3) |
October 2022 | — | | | $ | — | | | — | | | $ | 2,000,000,000 | |
November 2022 | 1,518,996 | | | 534.02 | | | 1,518,996 | | | 1,150,000,000 | |
December 2022 | 353,604 | | | 534.02 | | | 353,604 | | | 1,000,000,000 | |
Total | 1,872,600 | | | $ | 534.02 | | | 1,872,600 | | | |
(1)On November 2, 2022, we entered into separate accelerated stock repurchase agreements, the November 2022 ASR Agreements, with Goldman Sachs & Co. LLC, or Goldman Sachs, and Mizuho Markets Americas LLC, or Mizuho, to repurchase $1 billion of our common stock as part of the $3 billion repurchase program authorized by the Board of Directors on February 18, 2021. In accordance with the November 2022 ASR Agreements, we made a payment of $1 billion ($500 million to Goldman Sachs on November 3, 2022 and $500 million to Mizuho on November 4, 2022) and received an initial delivery of 1.5 million shares of our common stock (0.760 million shares each from Goldman Sachs and Mizuho). In November 2022, we recorded the payments to Goldman Sachs and Mizuho as a reduction to stockholders’ equity, consisting of an $850 million increase in treasury stock, which reflects the value of the initial 1.5 million shares received upon initial settlement, and a $150 million decrease in capital in excess of par value, which reflects the value of stock held back by Goldman Sachs and Mizuho pending final settlement of the November 2022 ASR Agreements. Upon final settlement of the November 2022 ASR Agreements with Goldman Sachs and Mizuho on December 15, 2022 and December 16, 2022, respectively, we received an additional 0.177 million shares and 0.177 million shares, respectively, as determined by the average daily volume weighted-averages share price of our common stock during the terms of the agreements, less a discount, of $534.16 and $533.87, respectively, bringing the total shares received under the November 2022 ASR Agreements to 1.8 million. In addition, upon settlement we reclassified the $150 million value of stock initially held back by Goldman Sachs and Mizuho from capital in excess of par value to treasury stock.
(2)Excludes 0.2 million shares repurchased in connection with employee stock plans.
(3)On February 15, 2023, the Board of Directors replaced the previous share repurchase authorization of up to $3 billion (of which approximately $1 billion remained unused) with a new authorization for repurchases of up to $3 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2026.
|
| | | | | | | | | | | | | |
Period | Total Number of Shares Purchased (1) | | Average Price Paid per Share | | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1)(2) | | Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (1) (2) |
October 2019 | — |
| | $ | — |
| | — |
| | $ | 2,000,000,000 |
|
November 2019 | — |
| | — |
| | — |
| | 2,000,000,000 |
|
December 2019 | — |
| | — |
| | — |
| | 2,000,000,000 |
|
Total | — |
| | $ | — |
| | — |
| | |
| |
(1) | On July 31, 2019, we entered into an accelerated stock repurchase agreement, the July 2019 ASR, with Citibank, N.A., or Citi, to repurchase $1 billion of our common stock. On August 2, 2019, we made a payment of $1 billion to Citi and received an initial delivery of 2.7 million shares of our common stock. We recorded the payment to Citi as a reduction to stockholders’ equity, consisting of an $800 million increase in treasury stock, which reflected the value of the initial 2.7 million shares received upon initial settlement, and a $200 million decrease in capital in excess of par value, which reflected the value of stock held back by Citi pending final settlement of the July 2019 ASR. Upon final settlement of the July 2019 ASR on December 26, 2019, we received an additional 0.7 million shares as determined by the average daily volume weighted-averages share price of our common stock during the term of the agreement, less a discount, of $296.19, bringing the total shares received under the July 2019 ASR to 3.4 million. In addition, upon settlement we reclassified the $200 million value of stock initially held back by Citi from capital in excess of par value to treasury stock. |
| |
(2) | Excludes 0.2 million shares repurchased in connection with employee stock plans. |
ITEM 6. SELECTED FINANCIAL DATA[Reserved]
|
| | | | | | | | | | | | | | | | | | | |
| 2019 | | 2018 | | 2017 (a) | | 2016 (b) | | 2015 |
| (dollars in millions, except per common share results) |
Summary of Operating Results | | | | | | | | | |
Total revenues | $ | 64,888 |
| | $ | 56,912 |
| | $ | 53,767 |
| | $ | 54,379 |
| | $ | 54,289 |
|
Income from operations | 3,192 |
| | 3,100 |
| | 4,262 |
| | 1,741 |
| | 2,347 |
|
Loss (gain) on Sale of Business | — |
| | 786 |
| | — |
| | — |
| | (270 | ) |
Interest expense | 242 |
| | 218 |
| | 242 |
| | 189 |
| | 186 |
|
Other (income) expense, net | (506 | ) | | 33 |
| | — |
| | — |
| | — |
|
Income before income taxes and equity in net earnings | 3,456 |
| | 2,063 |
| | 4,020 |
| | 1,552 |
| | 2,431 |
|
Provision for income taxes | 763 |
| | 391 |
| | 1,572 |
| | 938 |
| | 1,155 |
|
Equity in net earnings of Kindred at Home | 14 |
| | 11 |
| | — |
| | — |
| | — |
|
Net income | $ | 2,707 |
| | $ | 1,683 |
| | $ | 2,448 |
| | $ | 614 |
| | $ | 1,276 |
|
Basic earnings per common share | $ | 20.20 |
| | $ | 12.24 |
| | $ | 16.94 |
| | $ | 4.11 |
| | $ | 8.54 |
|
Diluted earnings per common share | $ | 20.10 |
| | $ | 12.16 |
| | $ | 16.81 |
| | $ | 4.07 |
| | $ | 8.44 |
|
Dividends declared per common share | $ | 2.20 |
| | $ | 2.00 |
| | $ | 1.60 |
| | $ | 1.16 |
| | $ | 1.15 |
|
Financial Position | | | | | | | | | |
Cash and investments | $ | 15,432 |
| | $ | 12,780 |
| | $ | 16,344 |
| | $ | 13,675 |
| | $ | 11,681 |
|
Total assets | 29,074 |
| | 25,413 |
| | 27,178 |
| | 25,396 |
| | 24,678 |
|
Benefits payable | 6,004 |
| | 4,862 |
| | 4,668 |
| | 4,563 |
| | 4,976 |
|
Debt | 5,666 |
| | 6,069 |
| | 4,920 |
| | 4,092 |
| | 4,093 |
|
Stockholders’ equity | 12,037 |
| | 10,161 |
| | 9,842 |
| | 10,685 |
| | 10,346 |
|
Cash flows from operations | $ | 5,284 |
| | $ | 2,173 |
| | $ | 4,051 |
| | $ | 1,936 |
| | $ | 868 |
|
Key Financial Indicators | | | | | | | | | |
Benefit ratio | 85.6 | % | | 83.5 | % | | 83.0 | % | | 84.9 | % | | 84.5 | % |
Operating cost ratio | 11.5 | % | | 13.3 | % | | 12.3 | % | | 13.3 | % | | 13.6 | % |
Membership | | | | | | | | | |
Total medical membership | 16,667,200 |
| | 16,576,700 |
| | 14,003,100 |
| | 14,230,200 |
| | 14,222,800 |
|
Total specialty membership | 5,425,900 |
| | 6,072,300 |
| | 6,986,000 |
| | 6,961,200 |
| | 7,221,800 |
|
| |
(a) | Included in operating expenses is $936 million (or $4.31 per diluted common stock) associated with the merger termination fee and related costs, net. Under the terms of the Agreement and Plan of Merger with Aetna Inc., and certain wholly owned subsidiaries of Aetna Inc., which we collectively refer to as Aetna, we received a breakup fee of $1 billion from Aetna included in this amount. |
| |
(b) | Includes a reduction in premiums revenue of $583 million ($367 million after tax, or $2.43 per diluted common share) associated with the write-off of commercial risk corridor receivables. Also includes benefits expense of $505 million ($318 million after tax, or $2.11 per diluted common share) for reserve strengthening associated with our non-strategic closed block of long-term care insurance policies, which were sold in 2018. |
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
For discussion of 20172020 items and year-over-year comparisons between 20182021 and 20172020 that are not included in this 2019 Form2022 10-K and were not impacted by our segment realignment, refer to "Item 7. – Management Discussion and Analysis of Financial Condition and Results of Operations" found in our Form 10-K for the year ended December 31, 2018,2021, that was filed with the Securities and Exchange Commission on February 21, 2019.17, 2022.
Executive Overview
General
Humana Inc., headquartered in Louisville, Kentucky, is a leading health and well-being company committed to helping our millions of medical and specialty members achieve their best health. Our successful history in care delivery and health plan administration is helping us create a new kind of integrated care with the power to improve health and well‐being and lower costs. Our efforts are leading to a better quality of life for people with Medicare, families, individuals, military service personnel, and communities at large. To accomplish that, we support physicians and other health care professionals as they work to deliver the right care in the right place for their patients, our members. Our range of clinical capabilities, resources and tools, such as in‐home care, behavioral health, pharmacy services, data analytics and wellness solutions, combine to produce a simplified experience that makes health care easier to navigate and more effective.
OurThe health benefits industry relies on two key statistics to measure performance. The benefit ratio, which is computed by taking total benefits expense as a percentage of premiums revenue, represents a statistic used to measure underwriting profitability. The operating cost ratio, which is computed by taking total operating costs, excluding Merger termination fee and related costs, net, and depreciation and amortization, as a percentage of total revenue less investment income, represents a statistic used to measure administrative spending efficiency.
Sale of Hospice and Personal Care Divisions
On August 11, 2022, we completed the sale of a 60% interest in Humana’s Kindred at Home Hospice subsidiary, or KAH Hospice, to Clayton, Dubilier & Rice, or CD&R, for cash proceeds of approximately $2.7 billion, net of cash disposed, including debt repayments from KAH Hospice to Humana of $1.9 billion. In connection with the sale we recognized a pre-tax gain, net of transaction costs, of $237 million which is reported as a gain on sale of KAH Hospice in the accompanying consolidated statements of income for the year ended December 31, 2022.
Kindred at Home Acquisition
On August 17, 2021, we acquired the remaining 60% interest in Kindred at Home, or KAH, the nation’s largest home health and hospice provider, from TPG Capital and Welsh, Carson, Anderson & Stowe, two private equity funds, for an enterprise value of $8.2 billion, which includes our equity value of $2.4 billion associated with our 40% minority ownership interest. The remeasurement to fair value of our previously held 40% equity method investment with a carrying value of approximately $1.3 billion, resulted in a $1.1 billion gain recognized in "Other (income) expense, net". KAH has locations in 40 states, providing extensive geographic coverage with approximately 65% overlap with our individual Medicare Advantage membership. We paid the approximate $5.8 billion transaction price (net of our existing equity stake) through a combination of debt financing, the assumption of existing KAH indebtedness and parent company cash.
COVID-19
The emergence and spread of the novel coronavirus, or COVID-19, beginning in the first quarter of 2020 has impacted our business. During periods of increased incidences of COVID-19, a reduction in non-COVID-19 hospital admissions for non-emergent and elective medical care have resulted in lower overall healthcare system utilization. At the same time, COVID-19 treatment and testing costs increased utilization. During 2022, we experienced lower overall utilization of the healthcare system than anticipated, as the reduction in COVID-19 utilization following the increased incidence associated with the Omicron variant outpaced the increase in non-COVID-19 utilization. The
significant disruption in utilization during 2020 also impacted our ability to implement clinical initiatives to manage health care costs and chronic conditions of our members, and appropriately document their risk profiles, and, as such, significantly affected our 2021 revenue under the risk adjustment payment model for Medicare Advantage plans. Finally, changes in utilization patterns and actions taken in 2020 and 2021 as a result of the COVID-19 pandemic, including the suspension of certain financial recovery programs for a period of time and shifting the timing of claim payments and provider capitation surplus payments, impacted our claim reserve development and operating cash flows for 2020 and 2021.
Value Creation Initiatives
During 2022, in order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our healthcare services capabilities in 2023, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, we recorded charges of $473 million included within operating costs in the consolidated statement of income for the year ended December 31, 2022. These charges primarily relate to $248 million in asset impairments, including software and abandonment, and $116 million of severance charges in connection with workforce optimization. The remainder of the charges primarily relate to external consulting fees. These charges were recorded at the corporate level and not allocated to the segments.
Business Segments
We manageDuring December 2022, we realigned our business with threereportablebusinesses into two distinct segments: Insurance and CenterWell. The Insurance segment includes the businesses that were previously included in the Retail and Group and Specialty and Healthcare Services. Beginning January 1, 2018, we exited the individual commercial fully-insured medical health insurance business,segments, as well as certain otherthe Pharmacy Benefit Manager, or PBM, business in 2018, and therefore no longer report separately the Individual Commercial segment and the Other Businesses categorywhich was previously included in the current year. Previously,Healthcare Services segment. The CenterWell segment (formerly Healthcare Services) represents our payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. In addition to the Other Businesses categorynew segment classifications being utilized to assess performance and allocate resources, we believe this simpler structure will create greater collaboration across the Insurance and CenterWell businesses and will accelerate work that is underway to centralize and integrate operations within the organization.Prior period segment financial information has been recast to conform to the 2022 presentation. For a recast of prior period segment financial information, refer to Note 18 to the audited Consolidated Financial Statements included businesses that were not individually reportable because they did not meet the quantitative thresholds required by generally accepted accounting principles, primarily our closed-blockin Part II, Item 8, "Financial Statements and Supplementary Data" of commercial long-term care insurance policies which were sold in 2018. The this Form 10-K.
Our tworeportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the chief operating decision maker,Chief Operating Decision Maker, to assess performance and allocate resources. See For segment financial information, refer to Note 18 to the consolidated financial statementsaudited Consolidated Financial Statements included in Part II, Item 8. - Financial8, "Financial Statements and Supplementary Data for segment financial information.Data" of this Form 10-K.
The RetailInsurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts. In addition, the Retail segment also includesaccounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. The Group and SpecialtyThis segment consistsalso includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO products.ASO. In addition, our Group and SpecialtyInsurance segment includes our military services business, primarily our TRICARE T2017T-2017 East Region contract. contract, as well as the operations of our PBM business.
The Healthcare ServicesCenterWell segment includes our pharmacy, provider services, offeredand home solutions operations. The segment also includes our strategic partnerships with WCAS to our health plan membersdevelop and operate senior-focused, payor-agnostic, primary care centers, as well as to third parties, including pharmacy solutions, provider services, and clinical care service, such as home health and other services and capabilities to promote wellness and advance population health, including our minority investmentownership interest in Kindred at Home.hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs.
The results of each segment are measured by income before income taxes and equity in net (losses) earnings from Kindred at Home,equity method investments, or segment earnings. Transactions between reportable segments primarily consist of sales of services rendered
by our Healthcare ServicesCenterWell segment, primarily pharmacy, provider, and clinical carehome services, to our Retail and Group and SpecialtyInsurance segment customers. Intersegment sales and expenses are recorded at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations.
Seasonality
COVID-19 disrupted the pattern of our quarterly earnings and operating cash flows largely due to the temporary deferral of non-essential care which resulted in reductions in non-COVID-19 hospital admissions and lower overall healthcare system utilization during higher levels of COVID-19 hospital admissions. At the same time, during periods of increased incidences of COVID-19, COVID-19 treatment and testing costs increase. Similar impacts and seasonal disruptions from either higher or lower utilization are expected to persist as we respond to and recover from the COVID-19 global health crisis.
One of the product offerings of our RetailInsurance segment is Medicare stand-alone prescription drug plans, or PDPs,PDP, under the Medicare Part D program. Our quarterly RetailInsurance segment earnings and operating cash flows are impacted by the Medicare Part D benefit design and changes in the composition of our membership. The Medicare Part D benefit design results in coverage that varies as a member’s cumulative out-of-pocket costs pass through successive stages of a member’s plan period, which begins annually on January 1 for renewals. These plan designs generally result in us sharing a greater portion of the responsibility for total prescription drug costs in the early stages and less in the latter stages. As a result, the PDP benefit ratio generally decreases as the year progresses. In addition, the number of low income senior members as well as year-over-year changes in the mix of membership in our stand-alonestandalone PDP products affects the quarterly benefit ratio pattern.
The Insurance segment also experiences seasonality in the fully-insured product offering. The effect on the Insurance's segment benefit ratio is opposite of the Medicare stand-alone PDP impact, with the benefit ratio increasing as fully-insured members progress through their annual deductible and maximum out-of-pocket expenses.
In addition, the RetailInsurance segment also experiences seasonality in the operating cost ratio as a result of costs incurred in the second half of the year associated with the Medicare marketing season.
Our Group and Specialty segment also experiences seasonality in the benefit ratio pattern. However, the effect is opposite of Medicare stand-alone PDP in the Retail segment, with the Group and Specialty segment’s benefit ratio increasing as fully-insured members progress through their annual deductible and maximum out-of-pocket expenses.
Aetna Merger
On February 16, 2017, under the terms of the Agreement and Plan of Merger, or Merger Agreement, with Aetna Inc., and certain wholly owned subsidiaries of Aetna Inc., which we collectively refer to as Aetna, we received a breakup fee of $1 billion from Aetna, which is included in our consolidated statement of income in the line captioned "Merger termination fee and related costs, net."
Acquisitions and DivestituresHighlights
In the first quarter of 2020, we acquired privately held Enclara Healthcare, or Enclara, one of the nation’s largest hospice pharmacy and benefit management providers for cash consideration of approximately $707 million, net of cash received.•The purchase accounting is incomplete due to the timing of the availability of information.
Also in the first quarter of 2020, our Partners in Primary Care wholly-owned subsidiary entered into a strategic partnership with Welsh, Carson, Anderson & Stowe, or WCAS, to accelerate the expansion of our primary care model. The WCAS partnership is expected to open approximately 50 payor-agnostic, senior-focused primary care centers over 3 years beginning in 2020. Partners in Primary Care committed to the acquisition of a non-controlling interest in the approximately $600 million entity. In addition, the agreement includes a series of put and call options through which WCAS may require us to purchase their interest in the entity and, through which we may acquire WCAS’s interest over the next 5 - 10 years.
In the third quarter of 2018, we completed the sale of our wholly-owned subsidiary KMG America Corporation, or KMG, to Continental General Insurance Company, or CGIC, a Texas-based insurance company wholly owned by HC2 Holdings, Inc., a diversified holding company. KMG's subsidiary, Kanawha Insurance Company, or KIC, included our closed block of non-strategic commercial long-term care policies. Upon closing, we funded the transaction with
approximately $190 million of parent company cash contributed into KMG, subject to customary adjustments, in addition to the transfer of approximately $160 million of statutory capital with the sale.
Also in the third quarter of 2018, we, along with TPG Capital, or TPG, and WCAS (together, the "Sponsors"), completed the acquisitions of Kindred and Curo, respectively, merging Curo with the hospice business of Kindred at Home. As part of these transactions, we acquired a 40% minority interest in Kindred at Home, a leading home health and hospice company, for total cash consideration of approximately $1.1 billion.
In the second quarter of 2018, we acquired Family Physicians Group, or FPG, for cash consideration of approximately $185 million, net of cash received. FPG is one of the largest at-risk providers serving Medicare Advantage and Managed Medicaid HMO patients in Greater Orlando, Florida with a footprint that includes clinics located in Lake, Orange, Osceola and Seminole counties. The acquisition of FPG advances ourOur strategy of helping physicians and clinicians evolve from treating health episodically to managing health holistically.
In the first quarter of 2018, we acquired the remaining equity interest in MCCI Holdings, LLC, or MCCI, a privately held management service organization headquartered in Miami, Florida, which primarily coordinates medical care for Medicare Advantage beneficiaries in Florida and Texas. The purchase price consisted primarily of $169 million cash, as well as our existing investment in MCCI and a note receivable and a revolving note with an aggregate balance of $383 million.
These transactions are more fully discussed in Note 3 and Note 4 to the consolidated financial statements.
Highlights
Our 2019 results reflect the continued implementation of our strategy to offeroffers our members affordable health care combined with a positive consumer experience in growing markets. At the core of this strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics. Our approach to primary, physician-directed care for our members aims to provide quality care that is consistent, integrated, cost-effective, and member-focused, provided by both employed physicians and physicians with network contract arrangements. The model is designed to improve health outcomes and affordability for individuals and for the health system as a whole, while offering our members a simple, seamless healthcare experience. We believe this strategy is positioning us for long-term growth in both membership and earnings. We offer providers a continuum of opportunities to increase the integration of care and offer assistance to providers in transitioning from a fee-for-service to a value-based arrangement. These include performance bonuses, shared savings and shared risk relationships. At December 31, 2019,2022, approximately 2,407,0003,175,500 members, or 67%70%, of our individual Medicare Advantage members were in value-based relationships under our integrated care delivery model, as compared to 2,039,1003,009,600 members, or 67%68%, at December 31, 2018.2021.
•On February 1, 2023, Centers for Medicare & Medicaid Services, or CMS, issued its preliminary 2024 Medicare Advantage and dual demonstration program membership enrolled in a Humana chronic care management program was 868,800 at December 31, 2019, an increase of 21.3% from 716,000 at December 31, 2018. These members may not be unique to each program since members havePart D payment rates and proposed policy changes, collectively, the ability to enroll in multiple programs. The increase is driven by our improved process for identifying and enrolling members inAdvance Notice. CMS has invited public comment on the appropriate program atAdvance Notice before publishing final rates on or before April 3, 2023, or the right time, coupled with growth in Special Needs Plans, or SNP, membership.
| |
• | On February 5, 2020, after the stock market closed, the Centers for Medicare and Medicaid Services (“CMS”) issued Part II of the 2021 Advance Notice of Methodological Changes for Medicare Advantage Capitation Rates and Part C and Part D Payment Policies (the “Advance Notice”). CMS has invited public comment on the Advance Notice before publishing final rates on April 6, 2020 (the “Final Notice”).
|
Final Notice. In the Advance Notice, CMS estimates Medicare Advantage plans across the sector will, on average, experience a 0.93 percent increase2.27% decrease in benchmark funding based on proposals included therein. As indicated by CMS, its estimate excludes the impact of fee-for-service county rebasing/repricing becausere-pricing since the related impact is dependent upon finalization of certain data, which will be available with the publication of the Final Notice. Further the benchmark decrease excludes MA risk score trend as individual plans’ experience will vary. Based on ourthe company’s preliminary analysis using the same factors CMS included in its estimate, the components of
which are detailed on CMS’CMS’s website, we anticipate that the proposals in the Advance Notice would result, on average, in a change to our benchmark funding relatively in line with CMS’ estimate.
Also on February 5, 2020, CMS issued a proposed rule (which we refer toestimate, with the exception of Humana's Medicare Star Ratings for bonus year 2024, which led the company’s peers, as well as the “2021 Proposed Rule”)Risk Model Revision and Normalization Adjustment, which the company continues to analyze. With respect to the Risk Model Revision and Normalization adjustment, CMS provided detail to the company indicating an average impact to Humana relatively in line with the average negative 3.12% industry impact. The company continues to analyze the Advance Notice, including CMS’ estimate of the Humana specific impact related to the administration of the MARisk Model Revision and Part D programs, including, among other things, the Agency’s implementation of recent legislation removing the limitationNormalization adjustment, which is likely to have a more negative impact on MA eligibility for end-stage-renal-disease, or ESRD, Medicare-eligible beneficiaries beginning in 2021, allowing for Medicare Advantageindividual plans to offer additional supplemental benefits including telehealth, and addressing opioid recoveryspecific membership cohorts with greater risk score trend, and treatment. The 2021 Proposed Rule also recognizes the potential opportunity to create new options for beneficiaries, including ESRD beneficiaries, and their access to care through greater flexibility around current network adequacy requirements. CMS has invited public comments to the 2021 Proposed Rule on or before April 6, 2020.
The Advance Notice and the 2021 Proposed Rule are subject to the required notice and comment period, and we cannot predict when or to what extent CMS will adopt the proposals in the Advance Notice or the 2021 Proposed Rule. We will be drawing upon ourits program expertise to provide CMS formal commentary on the impact of both the Advance Notice and the 2021 Proposed Rule and the related impact uponon Medicare beneficiaries’ quality of care and service to ourits members through the MA and Part D programs.Medicare Advantage program.
•Net income was $2.7$2.8 billion, for 2019 compared to $1.7 billion in 2018 and earningsor $22.08 per diluted common share, increased $7.94 from $12.16 earningsand $2.9 billion, or $22.67 per diluted common share, in 2018 to $20.10 earnings per diluted common share in 2019.2022 and 2021, respectively. This comparison was primarilysignificantly impacted by higher segment earningsthe gain on KAH equity method investment recognized in our Retail and Healthcare Services segments, partially offset by lower Group and Specialty segment earnings. These changes were further favorably impacted by theAugust 2021, put/call valuation adjustments associated with our investmentnon-consolidating minority interest investments, transaction and integration costs, the change in Kindred at Homethe fair value of publicly-traded equity securities, charges associated with productivity initiatives related to previously disclosed $1 billion value creation plan, and by a lower number of shares used to compute dilutive earnings per share, primarily reflecting share repurchases. In addition, year-over-year comparison to 2019 was impacted by the lossnet gain on the sale of KMGKAH Hospice. The impact of $786 million recognized in 2018.
Contributingthese adjustments to our Retail segment revenue growthconsolidated income before income taxes and equity in net (losses) earnings and diluted earnings per common share was our individual and group Medicare Advantage membership, which increased 550,700 members, or 15.5%, from 3,561,800 members at December 31, 2018 to 4,112,500 members at December 31, 2019.
Our operating cash flow of $5.3 billion for 2019 improved from $2.2 billion for 2018, reflecting the significant impact of increasing premiums and enrollment, as premiums generally are collected in advance of claim payments by a period of up to several months. The year-over-year comparison was further impacted by the timing of other working capital changes, higher earnings in 2019 versus 2018, and the negative impact on 2018 cash flows resulting from the funding of reinsurance transactions in connection with the sale of KMG.
In July 2019, the Board of Directors approved a $3.0 billion share repurchase authorization with an expiration date of June 30, 2022. We subsequently entered into an agreement with a third-party financial institution on July 31, 2019, to effect a $1.0 billion ASR program under the authorization. Under the terms of this program, which was completed in the fourth quarter of 2019, we repurchased approximately 3,376,200 shares at an average price, after a discount, of $296.19. Aside from the completion of the ASR program, we have not completed any open market stock repurchases. As of February 19, 2020, we had a remaining repurchase authorization of $2.0 billion.
In August 2019, we issued $500 million of 3.125% senior notes due August 15, 2029, and $500 million of 3.950% senior notes due August 15, 2049. Our net proceeds, reducedfollows for the underwriters discount2022 and commission and offering expenses, were $987 million. We used the net proceeds from this offering, together with available cash, to repay the $650 million outstanding amount due under our term note in August 2019, and the $400 million aggregate principal amount of our 2.625% senior notes due on its maturity date of October 1, 2019.2021 periods:
In 2019 we initiated an involuntary workforce optimization program that will allow us to promote operational excellence, accelerate our strategy, fund critical initiatives and advance our growth objectives. As a result we recorded estimated charges of $47 million, or $0.26 per diluted common share, on the corporate level, included
| | | | | | | | | | | |
| 2022 | | 2021 |
| (in millions) |
Consolidated income before income taxes and equity in net (losses) earnings: | | | |
Gain on Kindred at Home equity method investment | $ | — | | | $ | (1,129) | |
Gain on sale of KAH Hospice | (237) | | | — | |
Charges associated with productivity initiatives related to the previously disclosed $1 billion value creation plan | 473 | | | — | |
Put/call valuation adjustments associated with our non consolidating minority interest investments | 68 | | | 597 | |
Transaction and integration costs | 105 | | | 128 | |
Change in the fair value of publicly-traded equity securities | 123 | | | 341 | |
| $ | 532 | | | $ | (63) | |
| | | |
| 2022 | | 2021 |
Diluted earnings per common share: | | | |
Gain on Kindred at Home equity method investment | $ | — | | | $ | (8.73) | |
Gain on sale of KAH Hospice | (1.86) | | | — | |
Charges associated with productivity initiatives related to the previously disclosed $1 billion value creation plan | 3.72 | | | — | |
Put/call valuation adjustments associated with our non consolidating minority interest investments | 0.53 | | | 4.62 | |
Transaction and integration costs | 0.83 | | | 0.99 | |
Change in the fair value of publicly-traded equity securities | 0.97 | | | 2.63 | |
Tax impact of all transactions | (1.52) | | | (1.93) | |
| $ | 2.67 | | | $ | (2.42) | |
with operating costs in the condensed consolidated statements of income. We expect this liability to be primarily paid within 12 months.
Health Care Reform
We are and will continue to be regularly subject to new laws and regulations, changes to existing laws and regulations, and judicial determinations that impact the interpretation and applicability of those laws and regulations. The Health Care Reform Law, the Families First Act, the CARES Act, and the Inflation Reduction Act, and related regulations, are examples of laws which haveenacted significant reforms to various aspects of the U.S. health insurance industry. Certain significant provisions of the Health Care Reform Law include,industry, including, among others, mandated coverage requirements, mandated benefits and guarantee issuance associated with commercial medical insurance, rebates to policyholders based on minimum benefit ratios, adjustments to Medicare Advantage premiums, the establishment of federally facilitated or state-based exchanges coupled with programs designed to spread risk among insurers, and the introduction of plan designs based on set actuarial values. In addition,values, and changes to the Health Care Reform Law established insurance industry assessments, including an annual health insurance industry fee. The annual health insurance industry fee was suspended in 2019, but will resume for calendar year 2020, not be deductible for income tax purposes, and significantly increase our effective tax rate. In 2018, the fee levied on the health insurance industry was $14.3 billion. Under current law, the health industry fee will be permanently repealed beginning in calendar year 2021. Part D prescription drug benefit design.
It is reasonably possible that the Health Care Reform Lawthese laws and related regulations, as well as other current or future legislative, judicial or regulatory changes (including further legislative or regulatory action taken in response to COVID-19) including restrictions on our ability to manage our provider network or otherwise operate our business, or restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, increases in member benefits or changes to member eligibility criteria without corresponding increases in premium payments to us, or increases in regulation of our prescription drug benefit businesses, in the aggregate may have a material adverse effect on our results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting our ability to expand into new markets, increasing our medical and operating costs, further lowering our Medicare payment rates and increasing our expenses associated with assessments); our financial position (including our ability to maintain the value of our goodwill); and our cash flows.
We intend for the discussion of our financial condition and results of operations that follows to assist in the understanding of our financial statements and related changes in certain key items in those financial statements from year to year, including the primary factors that accounted for those changes. Transactions between reportable segments primarily consist of sales of services rendered by our Healthcare ServicesCenterWell segment, primarily pharmacy, provider services, and clinical care services,home solutions, to our Retail and Group and SpecialtyInsurance segment customers and are described in Note 18 to the consolidated financial statementsaudited Consolidated Financial Statements included in Item 8. – Financial Statements and Supplementary Data in this 20192022 Form 10-K.
Comparison of Results of Operations for 20192022 and 20182021
Certain financial data on a consolidated basis and for our segments was as follows for the years ended December 31, 20192022 and 2018:2021:
Consolidated
|
| | | | | | | | | | | | | | | |
| | | | Change |
| | 2019 | | 2018 | | Dollars | | Percentage |
| | (dollars in millions, except per common share results) | | |
Revenues: | | | | | | | | |
Premiums: | | | | | | | | |
Retail | | $ | 56,254 |
| | $ | 48,108 |
| | $ | 8,146 |
| | 16.9 | % |
Group and Specialty | | 6,694 |
| | 6,803 |
| | (109 | ) | | (1.6 | )% |
Individual Commercial | | — |
| | 8 |
| | (8 | ) | | (100.0 | )% |
Other Businesses | | — |
| | 22 |
| | (22 | ) | | (100.0 | )% |
Total premiums | | 62,948 |
| | 54,941 |
| | 8,007 |
| | 14.6 | % |
Services: | | | | | | | | |
Retail | | 17 |
| | 11 |
| | 6 |
| | 54.5 | % |
Group and Specialty | | 790 |
| | 835 |
| | (45 | ) | | (5.4 | )% |
Healthcare Services | | 632 |
| | 607 |
| | 25 |
| | 4.1 | % |
Other Businesses | | — |
| | 4 |
| | (4 | ) | | (100.0 | )% |
Total services | | 1,439 |
| | 1,457 |
| | (18 | ) | | (1.2 | )% |
Investment income | | 501 |
| | 514 |
| | (13 | ) | | (2.5 | )% |
Total revenues | | 64,888 |
| | 56,912 |
| | 7,976 |
| | 14.0 | % |
Operating expenses: | | | | | | | | |
Benefits | | 53,857 |
| | 45,882 |
| | 7,975 |
| | 17.4 | % |
Operating costs | | 7,381 |
| | 7,525 |
| | (144 | ) | | (1.9 | )% |
Depreciation and amortization | | 458 |
| | 405 |
| | 53 |
| | 13.1 | % |
Total operating expenses | | 61,696 |
| | 53,812 |
| | 7,884 |
| | 14.7 | % |
Income from operations | | 3,192 |
| | 3,100 |
| | 92 |
| | 3.0 | % |
Loss on sale of business | | — |
| | 786 |
| | (786 | ) | | (100.0 | )% |
Interest expense | | 242 |
| | 218 |
| | 24 |
| | 11.0 | % |
Other (income) expense, net | | (506 | ) | | 33 |
| | (539 | ) | | (1633.3 | )% |
Income before income taxes and equity in net earnings | | 3,456 |
| | 2,063 |
| | 1,393 |
| | 67.5 | % |
Provision for income taxes | | 763 |
| | 391 |
| | 372 |
| | 95.1 | % |
Equity in net earnings of Kindred at Home | | 14 |
| | 11 |
| | 3 |
| | 27.3 | % |
Net income | | $ | 2,707 |
| | $ | 1,683 |
| | $ | 1,024 |
| | 60.8 | % |
Diluted earnings per common share | | $ | 20.10 |
| | $ | 12.16 |
| | $ | 7.94 |
| | 65.3 | % |
Benefit ratio (a) | | 85.6 | % | | 83.5 | % | | | | 2.1 | % |
Operating cost ratio (b) | | 11.5 | % | | 13.3 | % | | | | (1.8 | )% |
Effective tax rate | | 22.0 | % | | 18.9 | % | | | | 3.1 | % |
| |
(a) | Represents total benefits expense as a percentage of premiums revenue. |
| |
(b) | Represents total operating costs, excluding depreciation and amortization, as a percentage of total revenues less investment income. |
Summary | | | | | | | | | | | | | | | | | | | | | | | |
| | | Change |
| 2022 | | 2021 | | Dollars | | Percentage |
| (dollars in millions, except per common share results) | | |
Revenues: | | | | | | | |
Premiums: | | | | | | | |
Insurance | $ | 87,712 | | | $ | 79,822 | | | $ | 7,890 | | | 9.9 | % |
| | | | | | | |
Total premiums revenue | 87,712 | | | 79,822 | | | 7,890 | | | 9.9 | % |
Services: | | | | | | | |
Insurance | 850 | | | 853 | | | (3) | | | (0.4) | % |
CenterWell | 3,926 | | | 2,202 | | | 1,724 | | | 78.3 | % |
| | | | | | | |
Total services revenue | 4,776 | | | 3,055 | | | 1,721 | | | 56.3 | % |
Investment income | 382 | | | 187 | | | 195 | | | 104.3 | % |
Total revenues | 92,870 | | | 83,064 | | | 9,806 | | | 11.8 | % |
Operating expenses: | | | | | | | |
Benefits | 75,690 | | | 69,199 | | | 6,491 | | | 9.4 | % |
Operating costs | 12,671 | | | 10,121 | | | 2,550 | | | 25.2 | % |
| | | | | | | |
Depreciation and amortization | 709 | | | 596 | | | 113 | | | 19.0 | % |
Total operating expenses | 89,070 | | | 79,916 | | | 9,154 | | | 11.5 | % |
Income from operations | 3,800 | | | 3,148 | | | 652 | | | 20.7 | % |
Gain on sale of KAH Hospice | (237) | | | — | | | 237 | | | 100.0 | % |
Interest expense | 401 | | | 326 | | | 75 | | | 23.0 | % |
Other expense (income), net | 68 | | | (532) | | | 600 | | | 112.8 | % |
Income before income taxes and equity in net (losses) earnings | 3,568 | | | 3,354 | | | 214 | | | 6.4 | % |
Provision for income taxes | 762 | | | 485 | | | 277 | | | 57.1 | % |
Equity in net (losses) earnings | (4) | | | 65 | | | (69) | | | (106.2) | % |
Net income | $ | 2,802 | | | $ | 2,934 | | | $ | (132) | | | (4.5) | % |
Diluted earnings per common share | $ | 22.08 | | | $ | 22.67 | | | $ | (0.59) | | | (2.6) | % |
Benefit ratio (a) | 86.3 | % | | 86.7 | % | | | | (0.4) | % |
Operating cost ratio (b) | 13.7 | % | | 12.2 | % | | | | 1.5 | % |
Effective tax rate | 21.4 | % | | 14.2 | % | | | | 7.2 | % |
Net income for 2019 was $2.7 billion, or $20.10 per diluted common share, compared to $1.7 billion, or (a)$12.16Represents total benefits expense as a percentage of premiums revenue.
(b) per diluted common share, in 2018. This increase primarily was impacted by our Medicare Advantage businessRepresents total operating costs, excluding depreciation and Healthcare Services segment,amortization, as well as by previously implemented productivity initiatives that led to significant operating cost efficiencies in 2019. These impacts were partially offset by strategic investments in our integrated care delivery model, the impacta percentage of higher compensation accruals for the Annual Incentive Plan, or AIP, offered to employees across all levels of the company, lower Group and Specialty segment earnings, increased spending associated with the 2020 Medicare Annual Election Period, or AEP, and the impact of workforce optimization. These changes were further favorably impacted by the put/call valuation adjustments associated with ourtotal revenues less investment in Kindred at Home and by a lower number of shares used to compute dilutive earnings per share, primarily reflecting share repurchases. In addition, 2019 was impacted by the loss on the sale of KMG recognized in 2018.income.
Premiums Revenue
Consolidated premiums revenue increased $8.0$7.9 billion, or 14.6%9.9%, from $54.9$79.8 billion for 2018in the 2021 period to $62.9$87.7 billion for 2019in the 2022 period primarily due to higher premiums in the Retail segment, driven by higher premium revenues from ourindividual Medicare Advantage business resulting fromand state-based contracts membership growth and higher per member premiums associated with individual Medicare Advantage. These increases wereAdvantage and commercial fully-insured medical premiums, partially offset by declining year-over-year membership associated with the impactgroup commercial medical products and the phase-out of declining stand-alone PDP membership, as well as lower premiumsCOVID-19 sequestration relief in the Group and Specialty segment as discussed in the detailed segment results discussion that follows.2022 period.
Services Revenue
Consolidated services revenue decreased $18 million,increased $1.7 billion, or 1.2%56.3%, from $1.5$3.1 billion for 2018in the 2021 period to $1.4$4.8 billion for 2019,in the 2022 period primarily due to a decreasethe impact of our home solutions revenues which reflect the acquisition of the remaining 60% interest in services revenue in the Group and Specialty segment,KAH during August 2021 partially offset by an increasethe divestiture of the 60% ownership interest in the Healthcare Services segment as detailed in the segment results discussion that follows.KAH Hospice during August 2022.
Investment Income
Investment income was $501 million for 2019, decreasing $13increased $195 million, or 2.5%104.3%, from 2018, primarily$187 million in the 2021 period to $382 million in the 2022 period primarily due to lower realized capital gains, partially offset by higher average invested balances and interest rates.mark to market losses on our publicly traded equity securities during the 2022 period compared to the 2021 period.
Benefits Expense
Consolidated benefits expense was $53.9 billion for 2019, an increase of $8.0increased $6.5 billion, or 17.4%9.4%, from 2018 reflecting an increase$69.2 billion in the Retail and Group and Specialty segments benefits expense as discussed2021 period to $75.7 billion in the detailed segment results discussion that follows. As more fully described herein under the section entitled "Benefits Expense Recognition", actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. We experienced favorable medical claims reserve development related to prior fiscal years of $336 million in 2019 and $503 million in 2018.
2022 period. The consolidated benefit ratio for 2019 was 85.6%, an increase of 210decreased 40 basis points from 201886.7% in the 2021 period to 86.3% in the 2022 period primarily due to higher per member individual Medicare Advantage premiums and lower inpatient utilization associated with the suspension of the health insurance industry fee in 2019, which was contemplated in the pricing and benefit design of our products,individual Medicare Advantage business. These factors were partially offset by lower favorable prior-period medical claims reserve development. Further, the 2022 period ratio reflects a shift in line of business mix, with continued growth in certain government programs, which carry a higher benefits expense ratio, combined with a decline in Medicare stand-alone PDP, which has a lower benefits expense ratio.
Consolidated benefits expense included $415 million of favorable prior-period medical claims reserve development an increase in the Group2022 period and Specialty benefit ratio as discussed$825 million of favorable prior-period medical claims reserve development in the detailed segment results discussion that follows, and the shift in Medicare membership mix due to the loss of stand-alone PDP members and significant growth in Medicare Advantage members. These increases were partially offset by engaging our Medicare Advantage members in clinical programs, as well as ensuring they are appropriately documented under the CMS risk-adjustment model, and lower than expected medical costs as compared to the assumptions used in the pricing of our individual Medicare Advantage business for 2019. Favorable prior-period2021 period. Prior-period medical claims reserve development decreased the consolidated benefit ratio by approximately 50 basis points in 2019the 2022 period and 90decreased the consolidated benefit ratio by approximately 100 basis points in 2018.
the 2021 period.
Operating Costs
Our segments incur both direct and shared indirect operating costs. We allocate the indirect costs shared by the segments primarily as a function of revenues. As a result, the profitability of each segment is interdependent.
Consolidated operating costs decreased $144 million,increased $2.6 billion, or 1.9%25.2%, from 2018 to $7.4$10.1 billion in 2019 reflecting a decrease in operating coststhe 2021 period to $12.7 billion in the Retail and the Group and Specialty segments as discussed in the detailed segment results discussion that follows.
2022 period. The consolidated operating cost ratio for 2019 was 11.5%, decreasing 180increased 150 basis points from 13.3%12.2% in 2018the 2021 period to 13.7% in the 2022 period. The ratio increase was primarily due to the impact of the consolidation of KAH operations, which have a significantly higher operating cost ratio than our historical consolidated operating cost ratio, the net impact of charges associated with initiatives undertaken associated with our value creation initiatives, as well as the impact of higher marketing spend in 2022 to support individual Medicare Advantage growth. These increases were partially offset by scale efficiencies associated with growth in individual Medicare Advantage membership.
Depreciation and Amortization
Depreciation and amortization increased $113 million, or 19.0%, from $596 million in the 2021 period to $709 million in the 2022 period primarily due to capital expenditures.
Interest Expense
Interest expense increased $75 million, or 23.0%, from $326 million in the 2021 period to $401 million in the 2022 period primarily due to higher average borrowings outstanding partially offset by lower interest rates.
Income Taxes
Our effective tax rate during 2022 was 21.4% compared to the effective tax rate of 14.2% in 2021. The year-over-year increase in the effective income tax rates is primarily due to the impact of the August 2021 acquisition of the remaining 60% interest in KAH. In that period, we recognized a $1.1 billion mark-to-market gain related to our previously held 40% investment in KAH. This unrealized gain was not taxable, thereby reducing the effective income tax rate for the 2021 period. The increase is partially offset by the August 2022 disposition of our 60% interest in KAH Hospice, which resulted in an increase to our tax basis in both the shares sold and the shares retained, thereby reducing the effective income tax rate for the 2022 period. For a complete reconciliation of the federal statutory rate to the effective tax rate, refer to Note 12 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.
Insurance Segment | | | | | | | | | | | | | | | | | | | | | | | |
| | | Change |
| 2022 | | 2021 | | Members | | % |
Membership: | | | | | | | |
Individual Medicare Advantage | 4,565,600 | | | 4,409,100 | | | 156,500 | | | 3.5 | % |
Group Medicare Advantage | 565,100 | | | 560,600 | | | 4,500 | | | 0.8 | % |
Medicare stand-alone PDP | 3,551,300 | | | 3,606,200 | | | (54,900) | | | (1.5) | % |
Total Medicare | 8,682,000 | | | 8,575,900 | | | 106,100 | | | 1.2 | % |
Medicare Supplement | 313,600 | | | 331,900 | | | (18,300) | | | (5.5) | % |
Commercial fully-insured | 556,300 | | | 674,600 | | | (118,300) | | | (17.5) | % |
Total fully-insured | 869,900 | | | 1,006,500 | | | (136,600) | | | (13.6) | % |
Medicaid and other | 1,137,300 | | | 940,100 | | | 197,200 | | | 21.0 | % |
Military services | 5,959,900 | | | 6,049,000 | | | (89,100) | | | (1.5) | % |
ASO | 430,100 | | | 495,500 | | | (65,400) | | | (13.2) | % |
Total Medical Membership | 17,079,200 | | | 17,067,000 | | | 12,200 | | | 0.1 | % |
Total Specialty Membership | 5,194,800 | | | 5,294,300 | | | (99,500) | | | (1.9) | % |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | Change | |
| 2022 | | 2021 | | $ | | % | |
| (in millions) | |
Premiums and Services Revenue: | | | | | | | | |
Premiums: | | | | | | | | |
Individual Medicare Advantage | $ | 65,591 | | | $ | 58,654 | | | $ | 6,937 | | | 11.8 | % | |
Group Medicare Advantage | 7,297 | | | 6,955 | | | 342 | | | 4.9 | % | |
Medicare stand-alone PDP | 2,269 | | | 2,371 | | | (102) | | | (4.3) | % | |
Total Medicare | 75,157 | | | 67,980 | | | 7,177 | | | 10.6 | % | |
Medicare Supplement | 743 | | | 731 | | | 12 | | | 1.6 | % | |
Commercial fully-insured | 3,733 | | | 4,271 | | | (538) | | | (12.6) | % | |
Total fully-insured | 4,476 | | | 5,002 | | | (526) | | | (10.5) | % | |
Medicaid and other | 6,376 | | | 5,109 | | | 1,267 | | | 24.8 | % | |
Specialty | 1,703 | | | 1,731 | | | (28) | | | (1.6) | % | |
Total premiums revenue | 87,712 | | | 79,822 | | | 7,890 | | | 9.9 | % | |
Services revenue | 850 | | | 853 | | | (3) | | | (0.4) | % | |
Total premiums and services revenue | $ | 88,562 | | | $ | 80,675 | | | $ | 7,887 | | | 9.8 | % | |
Income from operations | $ | 3,022 | | | $ | 2,412 | | | $ | 610 | | | 25.3 | % | |
Benefit ratio | 86.6 | % | | 87.2 | % | | | | (0.6) | % | |
Operating cost ratio | 10.4 | % | | 10.3 | % | | | | 0.1 | % | |
Income from operations
Insurance segment income from operations increased $0.6 billion, or 25.3%, from $2.4 billion in the 2021 period to $3.0 billion in the 2022 period primarily due to the same factors impacting the segment's lower benefit ratio offset by the same factors impacting the segment's higher operating cost ratio as more fully described below.
Enrollment
Individual Medicare Advantage membership increased 156,500 members, or 3.5%, from 4,409,100 members as of December 31, 2021 to 4,565,600 members as of December 31, 2022 primarily due to membership additions associated with the 2022 Annual Election Period, or AEP. The year-over-year growth was further impacted by continued enrollment resulting from special elections, age-ins, and Dual Eligible Special Need Plans, or D-SNP, membership. Individual Medicare Advantage membership includes 668,900 D-SNP members as of December 31, 2022, a net increase of 92,800 members, or 16.1%, from 576,100 members as of December 31, 2021. For the full year 2023, we anticipate a net membership growth in our individual Medicare Advantage offerings of at least 625,000 members.
Group Medicare Advantage membership increased 4,500 members, or 0.8%, from 560,600 members as of December 31, 2021 to 565,100 members as of December 31, 2022 reflecting smaller account sales and organic growth in concurrent accounts with no large accounts won or lost for the period.For the full year 2023, we anticipate a net membership decline in our group Medicare Advantage offerings of approximately 60,000 members.
Medicare stand-alone PDP membership decreased 54,900 members, or 1.5%, from 3,606,200 members as of December 31, 2021 to 3,551,300 members as of December 31, 2022 primarily due to continued intensified competition for Medicare stand-alone PDP offerings. For the full year 2023, we anticipate a net membership decline in our Medicare stand-alone PDP offerings of approximately 800,000 members.
Medicaid and other membership increased 197,200 members, or 21.0%, from 940,100 members as of December 31, 2021 to 1,137,300 members as of December 31, 2022 reflecting the suspension of state eligibility redetermination efforts due to the currently enacted public health emergency, or PHE.For the full year 2023, we anticipate a net membership growth in our state-based contracts of approximately 25,000 to 100,000 members.
Commercial fully-insured medical membership decreased 118,300 members, or 17.5%, from 674,600 members as of December 31, 2021 to 556,300 members as of December 31, 2022 reflecting the impact of pricing discipline to address COVID-19 and improve profitability.
ASO commercial medical membership decreased 65,400 members, or 13.2%, from 495,500 members as of December 31, 2021 to 430,100 members as of December 31, 2022 reflecting continued intensified competition for small group accounts, partially offset by strong retention among large group accounts. For the full year 2023, we anticipate a net membership decline in our group commercial medical offerings, which includes fully-insured and ASO, of approximately 300,000 members.
Military services membership decreased 89,100 members, or 1.5%, from 6,049,000 members as of December 31, 2021 to 5,959,900 members as of December 31, 2022. Membership includes military service members, retirees, and their families to whom we are providing healthcare services under the current TRICARE East Region contract.
Specialty membership decreased 99,500 members, or 1.9%, from 5,294,300 members as of December 31, 2021 to 5,194,800 members as of December 31, 2022 primarily due to the loss of dental and vision groups cross-sold with medical, as reflected in the loss of group fully-insured commercial medical membership above. In addition, current membership reflects the economic impact of the COVID-19 pandemic.
Premiums revenue
Insurance segment premiums revenue increased $7.9 billion, or 9.9%, from $79.8 billion in the 2021 period to $87.7 billion in the 2022 period primarily due to individual Medicare Advantage and state-based contracts membership growth and higher per member individual Medicare Advantage and commercial fully-insured medical premiums, partially offset by declining year-over-year membership associated with the group commercial medical products and the phase-out of COVID-19 sequestration relief in the 2022 period.
Services revenue
Insurance segment services revenue decreased $3 million, or 0.4%, from $853 million in the 2021 period to $850 million in the 2022 period.
Benefits expense
The Insurance segment benefit ratio decreased 60 basis points from 87.2% in the 2021 period to 86.6% in the 2022 period primarily due to higher per member individual Medicare Advantage premiums and lower inpatient utilization associated with the individual Medicare Advantage business. These factors were partially offset by lower favorable prior-period medical claims reserve development. Further, the 2022 period ratio reflects a shift in line of business mix, with continued growth in certain government programs, which carry a higher benefits expense ratio, combined with a decline in Medicare stand-alone PDP, which has a lower benefits expense ratio.
The Insurance segment benefits expense included $415 million of favorable prior-period medical claims reserve development in the 2022 period and $825 million of favorable prior-period medical claims reserve development in the 2021 period. Prior-period medical claims reserve development decreased the Insurance's segment benefit ratio by approximately 50 basis points in the 2022 period and decreased the Insurance's segment benefit ratio by approximately 100 basis points in the 2021 period.
Operating costs
The Insurance segment operating cost ratio increased 10 basis points from 10.3% in the 2021 period to 10.4% in the 2022 period primarily due to strategic investments to position the segment for long-term success, including the impact of higher marketing spend in the 2022 period to support individual Medicare Advantage growth. These factors were partially offset by scale efficiencies associated with growth in the individual Medicare Advantage membership.
CenterWell Segment | | | | | | | | | | | | | | | | | | | | | | | |
| | | Change |
| 2022 | | 2021 | | Dollars | | Percentage |
| (in millions) | | |
Revenues: | | | | | | | |
Services: | | | | | | | |
Home solutions | $ | 2,333 | | | $ | 1,166 | | | $ | 1,167 | | | 100.1 | % |
Pharmacy | 1,025 | | | 623 | | | 402 | | | 64.5 | % |
Provider services | 568 | | | 413 | | | 155 | | | 37.5 | % |
Total services revenue | 3,926 | | | 2,202 | | | 1,724 | | | 78.3 | % |
Intersegment revenues: | | | | | | | |
Home solutions | 553 | | | 352 | | | 201 | | | 57.1 | % |
Pharmacy | 9,841 | | | 9,024 | | | 817 | | | 9.1 | % |
Provider services | 2,979 | | | 2,476 | | | 503 | | | 20.3 | % |
Total intersegment revenues | 13,373 | | | 11,852 | | | 1,521 | | | 12.8 | % |
Total services and intersegment revenues | $ | 17,299 | | | 14,054 | | | 3,245 | | | 23.1 | % |
Income from operations | $ | 1,291 | | | $ | 938 | | | $ | 353 | | | 37.6 | % |
Operating cost ratio | 91.5 | % | | 92.3 | % | | | | (0.8) | % |
Income from operations
CenterWell segment income from operations increased $353 million, or 37.6%, from $938 million in the 2021 period to $1.3 billion in the 2022 period primarily due primarily due to the same factors impacting the increase in services revenue and intersegment revenues as well as the same factors impacting the segment's lower operating cost ratio in the 2022 period as more fully described below.
Services revenue
CenterWell segment services revenue increased $1.7 billion, or 78.3%, from $2.2 billion in the 2021 period to $3.9 billion in the 2022 period primarily due to the impact of our home solutions revenues which reflect the acquisition of the remaining 60% interest in KAH during August 2021 partially offset by the divestiture of the 60% ownership interest in KAH Hospice during August 2022.
Intersegment revenues
CenterWell segment intersegment revenues increased $1.5 billion, or 12.8%, from $11.9 billion in the 2021 period to $13.4 billion in the 2022 period primarily due to individual Medicare Advantage membership growth, combined with the impact of greater mail-order pharmacy penetration for Medicare Advantage members, which lead to higher pharmacy revenues, as well as higher revenues associated with growth in our provider business.
Operating costs
The CenterWell segment operating cost ratio decreased 80 basis points from 92.3% in the 2021 period to 91.5% in the 2022 period primarily represents the consolidation of KAH operations for the entire 2022 period compared to the partial 2021 period due to timing of the previously disclosed transaction. The KAH operations have a lower operating cost ratio than other businesses within the segment. The year-over-year favorability was further impacted by our pharmacy operations partially offset by investments in KAH to abate the pressures of the current nursing labor environment as well as the divestiture of the 60% interest in KAH Hospice during August 2022.
Comparison of Results of Operations for 2021 and 2020
Certain financial data on a consolidated basis and for our segments reflect our segment realignment and are recast as follows for the years ended December 31, 2021 and 2020:
Consolidated
| | | | | | | | | | | | | | | | | | | | | | | |
| | | Change |
| 2021 | | 2020 | | Dollars | | Percentage |
| (dollars in millions, except per common share results) | | |
Revenues: | | | | | | | |
Premiums: | | | | | | | |
Insurance | $ | 79,822 | | | $ | 73,584 | | | $ | 6,238 | | | 8.5 | % |
Corporate | — | | | 602 | | | (602) | | | (100.0) | % |
Total premiums revenue | 79,822 | | | 74,186 | | | 5,636 | | | 7.6 | % |
Services: | | | | | | | |
Insurance | 853 | | | 813 | | | 40 | | | 4.9 | % |
CenterWell | 2,202 | | | 1,002 | | | 1,200 | | | 119.8 | % |
| | | | | | | |
Total services revenue | 3,055 | | | 1,815 | | | 1,240 | | | 68.3 | % |
Investment income | 187 | | | 1,154 | | | (967) | | | (83.8) | % |
Total revenues | 83,064 | | | 77,155 | | | 5,909 | | | 7.7 | % |
Operating expenses: | | | | | | | |
Benefits | 69,199 | | | 61,628 | | | 7,571 | | | 12.3 | % |
Operating costs | 10,121 | | | 10,052 | | | 69 | | | 0.7 | % |
| | | | | | | |
Depreciation and amortization | 596 | | | 489 | | | 107 | | | 21.9 | % |
Total operating expenses | 79,916 | | | 72,169 | | | 7,747 | | | 10.7 | % |
Income from operations | 3,148 | | | 4,986 | | | (1,838) | | | (36.9) | % |
| | | | | | | |
Interest expense | 326 | | | 283 | | | 43 | | | 15.2 | % |
Other (income) expense, net | (532) | | | 103 | | | 635 | | | 616.5 | % |
Income before income taxes and equity in net earnings | 3,354 | | | 4,600 | | | (1,246) | | | (27.1) | % |
Provision for income taxes | 485 | | | 1,307 | | | (822) | | | (62.9) | % |
Equity in net earnings | 65 | | | 74 | | | (9) | | | (12.2) | % |
Net income | $ | 2,934 | | | $ | 3,367 | | | $ | (433) | | | (12.9) | % |
Diluted earnings per common share | $ | 22.67 | | | $ | 25.31 | | | $ | (2.64) | | | (10.4) | % |
Benefit ratio (a) | 86.7 | % | | 83.1 | % | | | | 3.6 | % |
Operating cost ratio (b) | 12.2 | % | | 13.2 | % | | | | (1.0) | % |
Effective tax rate | 14.2 | % | | 28.0 | % | | | | (13.8) | % |
(a)Represents total benefits expense as a percentage of premiums revenue.
(b)Represents total operating costs, excluding depreciation and amortization, as a percentage of total revenues less investment income.
Premiums Revenue
Consolidated premiums increased $5.6 billion, or 7.6%, from $74.2 billion in the 2020 period to $79.8 billion in the 2021 period primarily due to higher premium revenues from Medicare Advantage and state-based contracts membership growth, higher per member Medicare Advantage premiums as a result of the improving CMS benchmark rate for 2021, net of Medicare Risk Adjustment (MRA) headwinds resulting from COVID-19 related utilization disruption in 2020, as well as the additional quarter impact of Medicare sequestration relief in 2021 that was not enacted until the second quarter of 2020. These increases were partially offset by declining stand-alone PDP, group commercial medical, and group Medicare Advantage membership, as well as the 2020 impact of the receipt of commercial risk corridor receivables previously written off.
Services Revenue
Consolidated services revenue increased $1.2 billion, or 68.3%, from $1.8 billion in the 2020 period to $3.1 billion in the 2021 period primarily due to higher home solutions revenues associated with consolidation of Kindred at Home earnings.
Investment Income
Investment income decreased $967 million, or 83.8%, from $1.2 billion in the 2020 period to $187 million in the 2021 period primarily due to a significant decrease in the fair value of our publicly-traded equity securities investments.
Benefits Expense
Consolidated benefits expense increased $7.6 billion, or 12.3%, from $61.6 billion in the 2020 period to $69.2 billion in the 2021 period. The consolidated benefit ratio increased 360 basis points from 83.1% in the 2020 period to 86.7% in the 2021 period. These increases reflect the termination in 2021 of the non-deductible health insurance industry fee which, along with a portion of the related tax benefit, was contemplated in the pricing and benefit design of our products, and COVID-19 impacts, including the impact of the deferral of non-essential care, net of meaningful COVID-19 treatment and testing costs, our pandemic relief efforts in 2020, as well as 2021 MRA headwinds resulting from this COVID-19 related utilization disruption in 2020. The year over year increase further reflects the 2020 impact of the receipt of commercial risk corridor receivables that were previously written off, and the 2021 impact associated with the competitive nature of the group Medicare Advantage business, particularly in large group accounts that were recently procured, as well as in the stand-alone PDP business. These factors were partially offset by higher favorable prior-period medical claims reserve development in 2021.
The higher favorable prior-period medical claims reserve development was primarily attributable to the reversal of actions taken in 2020, including the suspension of certain financial recovery programs for a period of time impacting our claim payment patterns. The suspension during 2020 was intended to provide financial and administrative relief for providers facing unprecedented strain as a result of the COVID-19 pandemic. The favorable prior-period medical claims reserve development decreased the consolidated benefit ratio by approximately 100 basis points in the 2021 period versus approximately 40 basis points in the 2020 period.
Operating Costs
Our segments incur both direct and shared indirect operating costs. We allocate the indirect costs shared by the segments primarily as a function of revenues. As a result, the profitability of each segment is interdependent.
Consolidated operating costs increased $0.07 billion, or 0.7%, from $10.05 billion in the 2020 period to $10.12 billion in the 2021 period. The consolidated operating cost ratio decreased 100 basis points from 13.2% in the 2020 period to 12.2% in the 2021 period. The ratio decrease was primarily due to the termination of the non-deductible health insurance industry fee in 2019,2021, as well as lower COVID-19 related administrative costs in 2021 compared to 2020. Administrative costs in 2020 included costs associated with personal protective equipment, member response efforts, and the build-out of infrastructure necessary to support employees working remotely. The decrease was
further impacted by scale efficiencies associated with growth in our individual Medicare Advantage membership, and significant operating cost efficiencies in 20192021 from previously implemented productivity initiatives, as well as the impact of a $200 million contribution to the Humana Foundation in the first half of 2020 to support communities served by the Company, particularly those with social and health disparities. These factors were partially offset by the consolidation of Kindred at Home operations as the business has a significantly higher operating cost ratio than our historical consolidated operating cost ratio, continued strategic and technology modernization investments made to position us for long-term success, transaction and integration costs associated with the Kindred at Home transaction, as well as the 2020 impact of the receipt of the commercial risk corridor receivables that were previously written off. The non-deductible health insurance industry fee impacted the operating cost ratio by 160 basis points in the 2020 period.
Depreciation and Amortization
Depreciation and amortization increased $107 million, or 21.9%, from $489 million in the 2020 period to $596 million in the 2021 period primarily due to capital expenditures.
Interest Expense
Interest expense increased $43 million, or 15.2%, from $283 million in the 2020 period to $326 million in the 2021 period from borrowings to fund the KAH acquisition.
Income Taxes
Our effective tax rate during 2021 was 14.2% compared to the effective tax rate of 28.0% in 2020. The change was primarily due to the non-taxable gain we recognized on our previously held Kindred at Home equity method investment from our acquisition of the remaining ownership interest in the business in August 2021 and the termination of the non-deductible health insurance industry fee in 2021.
Insurance Segment | | | | | | | | | | | | | | | | | | | | | | | |
| | | Change |
| 2021 | | 2020 | | Members | | % |
Membership: | | | | | | | |
Individual Medicare Advantage | 4,409,100 | | | 3,962,700 | | | 446,400 | | | 11.3 | % |
Group Medicare Advantage | 560,600 | | | 613,200 | | | (52,600) | | | (8.6) | % |
Medicare stand-alone PDP | 3,606,200 | | | 3,866,700 | | | (260,500) | | | (6.7) | % |
Total Medicare | 8,575,900 | | | 8,442,600 | | | 133,300 | | | 1.6 | % |
Medicare Supplement | 331,900 | | | 335,600 | | | (3,700) | | | (1.1) | % |
Commercial fully-insured | 674,600 | | | 777,400 | | | (102,800) | | | (13.2) | % |
Total fully-insured | 1,006,500 | | | 1,113,000 | | | (106,500) | | | (9.6) | % |
Medicaid and other | 940,100 | | | 772,400 | | | 167,700 | | | 21.7 | % |
Military services | 6,049,000 | | | 5,998,700 | | | 50,300 | | | 0.8 | % |
ASO | 495,500 | | | 504,900 | | | (9,400) | | | (1.9) | % |
Total Medical Membership | 17,067,000 | | | 16,831,600 | | | 235,400 | | | 1.4 | % |
Total Specialty Membership | 5,294,300 | | | 5,310,300 | | | (16,000) | | | (0.3) | % |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | Change | |
| 2021 | | 2020 | | $ | | % | |
| (in millions) | |
Premiums and Services Revenue: | | | | | | | | |
Premiums: | | | | | | | | |
Individual Medicare Advantage | $ | 58,654 | | | $ | 51,697 | | | $ | 6,957 | | | 13.5 | % | |
Group Medicare Advantage | 6,955 | | | 7,774 | | | (819) | | | (10.5) | % | |
Medicare stand-alone PDP | 2,371 | | | 2,742 | | | (371) | | | (13.5) | % | |
Total Medicare | 67,980 | | | 62,213 | | | 5,767 | | | 9.3 | % | |
Medicare Supplement | 731 | | | 688 | | | 43 | | | 6.3 | % | |
Commercial fully-insured | 4,271 | | | 4,761 | | | (490) | | | (10.3) | % | |
Total fully-insured | 5,002 | | | 5,449 | | | (447) | | | (8.2) | % | |
Medicaid and other | 5,109 | | | 4,223 | | | 886 | | | 21.0 | % | |
Specialty | 1,731 | | | 1,699 | | | 32 | | | 1.9 | % | |
Total premiums revenue | 79,822 | | | 73,584 | | | 6,238 | | | 8.5 | % | |
Services revenue | 853 | | | 813 | | | 40 | | | 4.9 | % | |
Total premiums and services revenue | $ | 80,675 | | | $ | 74,397 | | | $ | 6,278 | | | 8.4 | % | |
Income from operations | $ | 2,412 | | | $ | 3,120 | | | $ | (708) | | | (22.7) | % | |
Benefit ratio | 87.2 | % | | 84.1 | % | | | | 3.1 | % | |
Operating cost ratio | 10.3 | % | | 12.3 | % | | | | (2.0) | % | |
Income from operations
Insurance segment income from operations decreased $0.7 billion, or 22.7%, from $3.1 billion in the 2020 period to $2.4 billion in the 2021 period primarily due to the same factors impacting the segment's higher benefit ratio offset by the same factors impacting the segment's lower operating cost ratio as more fully described below.
Enrollment
Individual Medicare Advantage membership increased 446,400 members, or 11.3%, from 3,962,700 members as of December 31, 2020 to 4,409,100 members as of December 31, 2021 primarily due to membership additions associated with the previous Annual Election Period, or AEP, and Open Election Period, or OEP, for Medicare beneficiaries. The membership growth was further impacted by continued enrollment resulting from special elections, age-ins, and Dual Eligible Special Need Plans, or D-SNP, members. The OEP sales period, which ran from January 1 to March 31, 2021 added approximately 36,000 members compared to the 2020 OEP that added approximately 30,000 members. Individual Medicare Advantage membership includes 576,100 D-SNP members as of December 31, 2021, a net increase of 170,000 members, or 42%, from 406,100 members as of December 31, 2020.
Group Medicare Advantage membership decreased 52,600 members, or 8.6%, from 613,200 members as of December 31, 2020 to 560,600 members as of December 31, 2021 primarily due to the net loss of certain large accounts in January 2021, partially offset by continued growth in small group accounts.
Medicare stand-alone PDP membership decreased 260,500 members, or 6.7%, from 3,866,700 members as of December 31, 2020 to 3,606,200 members as of December 31, 2021 primarily due to anticipated declines as a result of the Walmart Value plan no longer being the low cost leader in 2021.
Medicaid and other membership increased 167,700 members, or 21.7%, from 772,400 members as of December 31, 2020 to 940,100 members as of December 31, 2021 primarily reflecting additional enrollment as a result of the suspension of state eligibility redetermination efforts due to the currently-enacted Public Health Emergency, as well as our acquisition of the remaining 50% ownership interest in Wisconsin health care company iCare.
Commercial fully-insured medical membership decreased 102,800 members, or 13.2%, from 777,400 members as of December 31, 2020 to 674,600 members as of December 31, 2021 reflecting lower small group quoting activity and sales attributable to depressed economic activity from the COVID-19 pandemic, partially offset by higher retention of existing customers, particularly in larger groups. The portion of commercial fully-insured medical membership in small group accounts was approximately 50% at December 31, 2021 and 54% at December 31, 2020.
ASO commercial medical membership decreased 9,400 members, or 1.9%, from 504,900 members as of December 31, 2020 to 495,500 members as of December 31, 2021. Small group membership comprised 43% of ASO commercial medical membership at December 31, 2021 and 45% at December 31, 2020. The membership change reflects intensified competition for small group accounts, partially offset by strong retention among large group accounts.
Military services membership increased 50,300 members, or 0.8%, from 5,998,700 members as of December 31, 2020 to 6,049,000 members as of December 31, 2021. Membership includes military service members, retirees, and their families to whom we are providing healthcare services under the current TRICARE East Region contract.
Specialty membership decreased 16,000 members, or 0.3%, from 5,310,300 members as of December 31, 2020 to 5,294,300 members as of December 31, 2021 primarily due to the loss of dental and vision groups cross-sold with medical, as reflected in the loss of commercial fully-insured medical membership described above. The decrease also reflects the impact of the economic downturn driven by the COVID-19 pandemic.
Premiums revenue
Insurance segment premiums increased $6.2 billion, or 8.5%, from $73.6 billion in the 2020 period to $79.8 billion in the 2021 period primarily due to higher premium revenues from Medicare Advantage and state-based contracts membership growth, higher per member Medicare Advantage premiums as a result of the improving CMS benchmark rate for 2021, net of Medicare Risk Adjustment (MRA) headwinds resulting from COVID-19 related
utilization disruption in 2020, as well as the additional quarter impact of Medicare sequestration relief in 2021 that was not enacted until the second quarter of 2020. These increases were partially offset by declining Medicare stand-alone PDP, commercial fully insured, and group Medicare Advantage membership.
Services revenue
Insurance segment services revenue increased $40 million, or 4.9%, from $813 million in the 2020 period to $853 million in the 2021 period primarily due to higher TRICARE services revenue partially offset by lower ASO membership described previously.
Benefits expense
The Insurance segment benefit ratio increased 310 basis points from 84.1% in the 2020 period to 87.2% in the 2021 period. This increase reflects the termination in 2021 of the non-deductible health insurance industry fee which, along with a portion of the related tax benefit, was contemplated in the pricing and benefit design of our products, and COVID-19 impacts, including the impact of the deferral of non-essential care, net of meaningful COVID-19 treatment and testing costs, our pandemic relief efforts in 2020, as well as 2021 MRA headwinds resulting from this COVID-19 related utilization disruption in 2020. The year over year increase further reflects the 2021 impact associated with the competitive nature of the group Medicare Advantage business, particularly in large group accounts that were recently procured, as well as in the stand-alone PDP business. These factors were partially offset by higher favorable prior-period medical claims reserve development in 2021.
The Insurance segment benefits expense included $825 million of favorable prior-period medical claims reserve development in the 2021 period and $313 million of favorable prior-period medical claims reserve development in the 2021 period. Prior-period medical claims reserve development decreased the Insurance's segment benefit ratio by approximately 100 basis points in the 2021 period and decreased the Insurance's segment benefit ratio by approximately 40 basis points in the 2020 period.
The higher favorable prior-period medical claims reserve development was primarily attributable to the reversal of actions taken in 2020, including the suspension of certain financial recovery programs for a period of time impacting our claim payment patterns. The suspension during 2020 was intended to provide financial and administrative relief for providers facing unprecedented strain as a result of the COVID-19 pandemic.
Operating costs
The Insurance segment operating cost ratio decreased 200 basis points from 12.3% in the 2020 period to 10.3% in the 2022 period primarily due to the termination of the non-deductible health insurance industry fee in 2021, lower COVID-19 related administrative costs, as previously discussed, scale efficiencies associated with growth in our individual Medicare Advantage membership, as well as operating cost efficiencies driven by previously implemented productivity initiatives. These improvements were partially offset by continued strategic investments made in our integrated care delivery model, the impact of higher compensation expense accruals in 20192021 to position us for the AIP offered to employees across all levels, increased spending associated with the Medicare AEP, and charges associated with workforce optimization.long-term success. The higher compensation accruals resulted from our continued strong performance, including customer satisfaction as measured by the net promoter score, along with higher than anticipated individual Medicare Advantage membership growth. The nondeductiblenon-deductible health insurance industry fee impacted the operating cost ratio by approximately 180160 basis points in 2018.the 2020 period.
Depreciation and Amortization
Depreciation and amortization in 2019 totaled $458
CenterWell Segment
| | | | | | | | | | | | | | | | | | | | | | | |
| | | Change |
| 2021 | | 2020 | | Dollars | | Percentage |
| (in millions) | | |
Revenues: | | | | | | | |
Services: | | | | | | | |
Home solutions | $ | 1,166 | | | $ | 107 | | | $ | 1,059 | | | 989.7 | % |
Pharmacy | 623 | | | 567 | | | 56 | | | 9.9 | % |
Provider services | 413 | | | 328 | | | 85 | | | 25.9 | % |
Total services revenue | 2,202 | | | 1,002 | | | 1,200 | | | 119.8 | % |
Intersegment revenues: | | | | | | | |
Home solutions | 352 | | | 279 | | | 73 | | | 26.2 | % |
Pharmacy | 9,024 | | | 7,928 | | | 1,096 | | | 13.8 | % |
Provider services | 2,476 | | | 2,268 | | | 208 | | | 9.2 | % |
Total intersegment revenues | 11,852 | | | 10,475 | | | 1,377 | | | 13.1 | % |
Total services and intersegment revenues | 14,054 | | | 11,477 | | | 2,577 | | | 22.5 | % |
Income from operations | $ | 938 | | | $ | 624 | | | $ | 314 | | | 50.3 | % |
Operating cost ratio | 92.3 | % | | 93.3 | % | | | | (1.0) | % |
Income from operations
CenterWell segment income from operations increased $314 million, compared to $405or 50.3%, from $624 million in 2018, an increase of 13.1%, primarily duethe 2020 period to capital expenditures.
Interest Expense
Interest expense was $242$938 million for 2019 compared to $218 million for 2018, an increase of $24 million, or 11.0% The increase was primarily due to the higher average borrowings outstanding including the impact of the borrowings under the November 2018 term loan agreement and senior notes issued in August 2019.
Income Taxes
Our effective tax rate during 2019 was 22.0% compared to the effective tax rate of 18.9% in 2018. This change primarily reflects the impact of the suspension of the non-deductible health insurance industry fee in 2019 as well as the deferred tax benefit recognized in 2018 from the loss on sale of KMG. The effective income tax rate in 2018 reflected a $430 million deferred tax benefit, resulting from the loss on the sale of KMG attributable to its original tax basis and subsequent capital contributions to fund accumulated losses. See Note 12 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data for a complete reconciliation of the federal statutory rate to the effective tax rate.
|
| | | | | | | | | | | | |
| | | | Change |
| | 2019 | | 2018 | | Members | | Percentage |
Membership: | | | | | | | | |
Medical membership: | | | | | | | | |
Individual Medicare Advantage | | 3,587,200 |
| | 3,064,000 |
| | 523,200 |
| | 17.1 | % |
Group Medicare Advantage | | 525,300 |
| | 497,800 |
| | 27,500 |
| | 5.5 | % |
Medicare stand-alone PDP | | 4,365,200 |
| | 5,004,300 |
| | (639,100 | ) | | (12.8 | )% |
Total Retail Medicare | | 8,477,700 |
| | 8,566,100 |
| | (88,400 | ) | | (1.0 | )% |
State-based Medicaid | | 469,000 |
| | 341,100 |
| | 127,900 |
| | 37.5 | % |
Medicare Supplement | | 298,400 |
| | 254,300 |
| | 44,100 |
| | 17.3 | % |
Total Retail medical members | | 9,245,100 |
| | 9,161,500 |
| | 83,600 |
| | 0.9 | % |
|
| | | | | | | | | | | | | | | |
| | | | Change |
| | 2019 | | 2018 | | Dollars | | Percentage |
| | (in millions) |
Premiums and Services Revenue: | | | | | | | | |
Premiums: | | | | | | | | |
Individual Medicare Advantage | | $ | 43,128 |
| | $ | 35,656 |
| | $ | 7,472 |
| | 21.0 | % |
Group Medicare Advantage | | 6,475 |
| | 6,103 |
| | 372 |
| | 6.1 | % |
Medicare stand-alone PDP | | 3,165 |
| | 3,584 |
| | (419 | ) | | (11.7 | )% |
Total Retail Medicare | | 52,768 |
| | 45,343 |
| | 7,425 |
| | 16.4 | % |
State-based Medicaid | | 2,898 |
| | 2,255 |
| | 643 |
| | 28.5 | % |
Medicare Supplement | | 588 |
| | 510 |
| | 78 |
| | 15.3 | % |
Total premiums | | 56,254 |
| | 48,108 |
| | 8,146 |
| | 16.9 | % |
Services | | 17 |
| | 11 |
| | 6 |
| | 54.5 | % |
Total premiums and services revenue | | $ | 56,271 |
| | $ | 48,119 |
| | $ | 8,152 |
| | 16.9 | % |
Segment earnings | | $ | 2,235 |
| | $ | 1,733 |
| | $ | 502 |
| | 29.0 | % |
Benefit ratio | | 86.4 | % | | 85.1 | % | | | | 1.3 | % |
Operating cost ratio | | 9.4 | % | | 11.1 | % | | | | (1.7 | )% |
Segment Earnings
Retail segment earnings were $2.2 billion in 2019, an increase of $502 million, or 29.0%, compared to $1.7 billion in 2018 primarily reflecting a lower operating cost ratio, partially offset by the higher benefit ratio as more fully described below. As expected, the higher-than-anticipated individual Medicare Advantage membership growth during the previous AEP had a muted impact on the segment's earnings in 2019. While new Medicare Advantage members increase revenue, on average, they have a break even impact on segment earnings in the first year as they were not previously engaged in clinical programs or appropriately documented under the CMS risk adjustment model, and accordingly, carry a higher benefit ratio.
Enrollment
Individual Medicare Advantage membership increased 523,200 members, or 17.1%, from 3,064,000 members as of December 31, 2018 to 3,587,200 members as of December 31, 2019, primarily due to membership additions associated with the 2019 AEP and Open Election Period, or OEP, for Medicare beneficiaries. The OEP sales period, which ran from January 1 to March 31, added approximately 43,700 members. Since the conclusion of the OEP, enrollment continued to increase due to strong sales to age-ins and those eligible for Dual Eligible Special Need Plans, or D-SNP. Individual Medicare Advantage membership includes 288,200 D-SNP members as of December 31, 2019, a net increase of 69,600, or 31.8%, from 218,600 December 31, 2018. For the full year 2020, we anticipate a net membership increase in our Individual Medicare Advantage offerings of 270,000 members to 330,000 members.
Group Medicare Advantage membership increased 27,500 members, or 5.5%, from 497,800 members as of December 31, 2018 to 525,300 members as of December 31, 2019, primarily due to net membership additions associated with the 2019 AEP for Medicare beneficiaries. For the full year 2020, we anticipate a net membership increase in our Group Medicare Advantage offerings of approximately 90,000 members.
Medicare stand-alone PDP membership decreased 639,100 members, or 12.8%, from 5,004,300 members as of December 31, 2018 to 4,365,200 members as of December 31, 2019, primarily reflecting net declines during the 2019 AEP for Medicare beneficiaries. The anticipated decline primarily was due to the competitive nature of the industry and the pricing discipline we have employed, which resulted in us no longer being the low cost plan in any market for 2019. For the full year 2020, we anticipate a net membership decline in our Medicare stand-alone PDP offerings of approximately 550,000 members.
State-based Medicaid membership increased 127,900 members, or 37.5%, from 341,100 members as of December 31, 2018 to 469,000 members as of December 31, 2019, primarily driven by the statewide award of a comprehensive contract under the Managed Medical Assistance, or MMA, program in Florida. Our January 31, 2020 state-based contracts membership was 608,000, representing growth of 139,000, or 30%, from December 31, 2019. This growth primarily reflects the impact of terminating the reinsurance agreement with CareSource effective January 1, 2020, which ceded all risk for our Kentucky Medicaid contract.
Premiums revenue
Retail segment premiums increased $8.1 billion, or 16.9%, from 2018 to 20192021 period primarily due to Medicare Advantage membership growth and higher per member premiums, as well as increased state-based contracts membership. These favorable items were partially offset by the decline in membership in our stand-alone PDP offerings.
Benefits expense
The Retail segment benefit ratioconsolidation of 86.4% for 2019 increased 130 basis points from 85.1% in 2018 primarily due to the suspension of the health insurance industry fee in 2019 which was contemplated in the pricing and benefit design of our products, lower favorable prior-period medical claims reserve development, as well as the shift in Medicare membership mix due to the loss of stand-alone PDP members and the significant growth in Medicare Advantage members. These increases were partially offset by engaging our Medicare Advantage members in clinical programs as well as ensuring they are appropriately documented under the CMS risk adjustment model, lower than expected medical costs as compared to the assumptions used in the pricing of ourKindred at Home earnings, individual Medicare Advantage business for 2019, and the impact of a less severe flu season experienced in the first quarter of 2019 comparedstate-based contracts membership growth leading to that in the first quarter of 2018.
The Retail segment’s benefits expense for 2019 included the beneficial effect of $386 million in favorable prior-year medical claims reserve development versus $398 million in 2018. This favorable prior-year medical claims reserve development decreased the Retail segment benefit ratio by approximately 70 basis points in 2019 versus approximately 80 basis points in 2018.
Operating costs
The Retail segment operating cost ratio of 9.4% for 2019 decreased 170 basis points from 11.1% in 2018 primarily due to the suspension of the health insurance industry fee in 2019, as well as scale efficiencieshigher pharmacy revenues, higher revenues associated with growth in our Medicare Advantage membership, and significant operating cost efficiencies in 2019 driven by previously implemented productivity initiatives. These improvements were partially offset byprovider business, as well as the strategic investments in our integrated care delivery model,factors that drove the impact of higher compensation expense accruals in 2019 for the AIP as a result of our continued strong performance, and increased spending associated with the Medicare AEP.
The non-deductible health insurance industry fee increased the operating cost ratio by approximately 190 basis points in 2018.
Group and Specialty Segment
|
| | | | | | | | | | | | |
| | | | Change |
| | 2019 | | 2018 | | Members | | Percentage |
Membership: | | | | | | | | |
Medical membership: | | | | | | | | |
Fully-insured commercial group | | 908,600 |
| | 1,004,700 |
| | (96,100 | ) | | (9.6 | )% |
ASO | | 529,200 |
| | 481,900 |
| | 47,300 |
| | 9.8 | % |
Military services | | 5,984,300 |
| | 5,928,600 |
| | 55,700 |
| | 0.9 | % |
Total group medical members | | 7,422,100 |
| | 7,415,200 |
| | 6,900 |
| | 0.1 | % |
Specialty membership (a) | | 5,425,900 |
| | 6,072,300 |
| | (646,400 | ) | | (10.6 | )% |
| |
(a) | Specialty products include dental, vision, and other supplemental health products. Members included in these products may not be unique to each product since members have the ability to enroll in multiple products. |
|
| | | | | | | | | | | | | | | |
| | | | Change |
| | 2019 | | 2018 | | Dollars | | Percentage |
| | (in millions) | | |
Premiums and Services Revenue: | | | | | | | | |
Premiums: | | | | | | | | |
Fully-insured commercial group | | $ | 5,123 |
| | $ | 5,444 |
| | $ | (321 | ) | | (5.9 | )% |
Specialty | | 1,571 |
| | 1,359 |
| | 212 |
| | 15.6 | % |
Total premiums | | 6,694 |
| | 6,803 |
| | (109 | ) | | (1.6 | )% |
Services | | 790 |
| | 835 |
| | (45 | ) | | (5.4 | )% |
Total premiums and services revenue | | $ | 7,484 |
| | $ | 7,638 |
| | $ | (154 | ) | | (2.0 | )% |
Segment earnings | | $ | 28 |
| | $ | 361 |
| | $ | (333 | ) | | (92.2 | )% |
Benefit ratio | | 86.0 | % | | 79.7 | % | | | | 6.3 | % |
Operating cost ratio | | 22.0 | % | | 23.6 | % | | | | (1.6 | )% |
Segment Earnings
Group and Specialty segment earnings were $28 million in 2019, a decrease of $333 million, or 92.2%, from $361 million in 2018 primarily due to a higher benefit ratio, along with lower military services business earnings. Earnings comparisons related to the military services business were unfavorably impacted by the receipt of certain contractual incentives and adjustments in 2018 related to the previous TRICARE contract which did not recur in 2019. These decreases were partially offset by the improvement in thedeclining operating cost ratio as more fully described below.
EnrollmentServices revenue
Fully-insured commercial group medicalCenterWell segment services revenue increased $1.2 billion, or 119.8%, from $1.0 billion in the 2020 period to $2.2 billion in the 2021 period primarily due to consolidation of Kindred at Home earnings. The 2021 period further reflects higher revenue from growth in the number of primary care clinics serving third party payors, and additional pharmacy revenues associated with the acquisition of Enclara which was closed during the first quarter of 2020.
Intersegment revenues
CenterWell segment intersegment revenues increased $1.4 billion, or 13.1%, from $10.5 billion in the 2020 period to $11.9 billion in the 2021 period primarily due to individual Medicare Advantage and state-based contracts membership decreased 96,100 members, or 9.6% from 1,004,700 members as of December 31, 2018 primarily reflecting lower membership in small group accounts due in part to more small group accounts selecting level-funded ASO products in 2019,growth, as well as the loss of certain large group accounts due to the competitive pricing environment. The portion of group fully-insured commercial medical membership in small group accounts was approximately 59% at December 31, 2019 and 61% at December 31, 2018.
Group ASO commercial medical membership increased 47,300 members, or 9.8%, from 481,900 members as of December 31, 2018 to 529,200 members as of December 31, 2019 reflecting more small group accounts selecting level-funded ASO products in 2019, partially offset by the loss of certain large group accounts as a
result of continued discipline in pricing of services for self-funded accounts amid a highly competitive environment.
Military services membership increased 55,700 members, or 0.9%, from 5,928,600 members as of December 31, 2018 to 5,984,300 members as of December 31, 2019. Membership includes military service members, retirees, and their families to whom we provide healthcare services under the current T2017 TRICARE East Region contract. The current contract, which covers thirty-two states, became effective on January 1, 2018.
Specialty membership decreased 646,400 members, or 10.6%, from 6,072,300 as of December 31, 2018 to 5,425,900 members as of December 31, 2019 primarily due to the loss of certain group accounts, including one jumbo account, offering stand-alone dental and vision products.
Premiums revenue
Group and Specialty segment premiums decreased $109 million, or 1.6%, from $6.8 billion in 2018 to $6.7 billion in 2019, primarily due to a decline in our fully-insured group commercial and specialty membership as well as the exit of our voluntary benefit and financial protection products in connection with the sale of KMG in 2018. These decreases were partially offset by higher stop-loss revenues related to our level-funded ASO accounts resulting from membership growth in this product and higher per member premiums across the fully-insured business.
Services revenue
Group and Specialty segment services revenue decreased $45 million, or 5.4%, from 2018 to 2019 primarily due to the impact of certain contractual incentives and adjustments related to the previous TRICARE contract received in 2018, which did not recur in 2019.
Benefits expense
The Group and Specialty segment benefit ratio increased 630 basis points from 79.7% in 2018 to 86.0% in 2019 primarily due to the impact of the continued migration of fully-insured group members to level-funded ASO products in 2019 resulting in a membership mix transformation, the suspension of the health insurance industry fee in 2019 which was contemplated in the pricing and benefit design of our products, and unfavorable prior-year medical claims reserve development driven by provider settlements. The benefit ratio was further negatively impacted by adjustments to dental network contracted rates resulting from dental network recontracting and expansion to position the business for the future.
The Group and Specialty segment’s benefits expense included the unfavorable effect of $50 million in prior-year medical claims reserve development in 2019 versus the beneficial effect of $46 million in favorable prior-year medical claims reserve development in 2018. This unfavorable prior-year medical claims reserve development increased the Group and Specialty segment benefit ratio by approximately 70 basis points in 2019 while the favorable prior-year medical claims reserve development decreased the Group and Specialty segment benefit ratio by approximately 70 basis points in 2018.
Operating costs
The Group and Specialty segment operating cost ratio of 22.0% for 2019 decreased 160 basis points from 23.6% for 2018, primarily due to the suspension of the health insurance industry fee in 2019, significant operating cost efficiencies in 2019 driven by previously implemented productivity initiatives, as well as the exit of our voluntary benefit and financial protection products in connection with the sale of KMG in 2018, which carried a higher operating cost ratio. These improvements were offset by the higher compensation expense accruals in 2019 for the AIP as a result of our continued strong consolidated performance.
The non-deductible health insurance industry fee increased the operating cost ratio by approximately 160 basis points in 2018.
Healthcare Services Segment
|
| | | | | | | | | | | | | | | |
| | | | Change |
| | 2019 | | 2018 | | Dollars | | Percentage |
| | (in millions) | | |
Revenues: | | | | | | | | |
Services: | | | | | | | | |
Clinical care services | | $ | 140 |
| | $ | 176 |
| | $ | (36 | ) | | (20.5 | )% |
Pharmacy solutions | | 186 |
| | 203 |
| | (17 | ) | | (8.4 | )% |
Provider services | | 306 |
| | 228 |
| | 78 |
| | 34.2 | % |
Total services revenues | | 632 |
| | 607 |
| | 25 |
| | 4.1 | % |
Intersegment revenues: | | | | | | | | |
Pharmacy solutions | | 22,189 |
| | 20,514 |
| | 1,675 |
| | 8.2 | % |
Provider services | | 2,344 |
| | 1,994 |
| | 350 |
| | 17.6 | % |
Clinical care services | | 616 |
| | 662 |
| | (46 | ) | | (6.9 | )% |
Total intersegment revenues | | 25,149 |
| | 23,170 |
| | 1,979 |
| | 8.5 | % |
Total services and intersegment revenues | | $ | 25,781 |
| | 23,777 |
| | $ | 2,004 |
| | 8.4 | % |
Segment earnings | | $ | 789 |
| | $ | 754 |
| | $ | 35 |
| | 4.6 | % |
Operating cost ratio | | 96.4 | % | | 96.3 | % | | | | 0.1 | % |
Segment Earnings
| |
• | Healthcare Services segment earnings were $789 million in 2019, an increase of $35 million, or 4.6%, from 2018. This increase primarily was due to higher earnings from our pharmacy operations and clinical operations, and higher earnings from Kindred at Home operations. These factors were partially offset by additional investments in new clinical assets associated with our provider services business.
|
Script Volume
| |
• | Humana Pharmacy Solutions® script volumes for the Retail and Group and Specialty segment membership increased to approximately 456 million in 2019, up 3.6% versus scripts of approximately 440 million in 2018. The increase primarily reflects growth associated with higher Medicare Advantage and state-based contracts membership, partially offset by the decline in stand-alone PDP membership.
|
Services revenue
Services revenue increased $25 million, or 4.1%, from 2018 to $632 million for 2019 primarily due to revenue growth from our provider services business.
Intersegment revenues
Intersegment revenues increased $1.98 billion, or 8.5%, from 2018 to $25 billion for 2019 primarily due to strong Medicare Advantage membership growth, These increases were partially offset by the loss of intersegment revenues associated with the decline in stand-alone PDP membership. Intersegment revenuesand group Medicare Advantage membership as previously discussed.
Operating costs
The CenterWell segment operating cost ratio decreased 100 basis points from 93.3% in 2019 were further impacted by higher revenuesthe 2020 period to 92.3% in the 2021 period primarily due to consolidation of Kindred at Home operations which have a lower operating cost ratio than other businesses within the segment, the 2020 impact associated with COVID-19 administrative related costs, including expenses associated with additional safety measures taken for our pharmacy, provider, and home solutions teams who continued to provide services to members throughout the crisis, as well as operational improvements in our provider services business, reflecting the previously disclosed acquisitions of MCCI and FPG.
Operating costs
The Healthcare Services segmentlargely related to Conviva, along with operating cost ratioefficiencies driven by previously implemented productivity initiatives in 2021. The decrease further reflects the impact of 96.4% for 2019 was relatively unchanged from 96.3% for 2018.additional investments in the segment's provider business during 2020 related to marketing and AEP initiatives. These decreases were partially offset by increased administrative costs in the pharmacy operations as a result of incremental spend to accelerate growth within the business, increased utilization levels in our provider business in 2021 compared to levels in 2020 amid the COVID-19 pandemic, as well as increased pharmacy labor-related overtime costs due to weather disruptions occurring in the first quarter of 2021.
Liquidity
Historically, our primary sources of cash have included receipts of premiums, services revenue, and investment and other income, as well as proceeds from the sale or maturity of our investment securities, and borrowings. Our primary uses of cash historically have included disbursements for claims payments, operating costs, interest on borrowings, taxes, purchases of investment securities, acquisitions, capital expenditures, repayments on borrowings, dividends, and share repurchases. Because premiums generally are collected in advance of claim payments by a period of up to several months, our business normally should produce positive cash flows during periods of increasing premiums and enrollment. Conversely, cash flows would be negatively impacted during periods of decreasing premiums and enrollment. From period to period, our cash flows may also be affected by the timing of working capital items including premiums receivable, benefits payable, and other receivables and payables. Our cash flows are impacted by the timing of payments to and receipts from CMS associated with Medicare Part D subsidies for which we do not assume risk. The use of cash flows may be limited by regulatory requirements of state departments of insurance (or comparable state regulators) which require, among other items, that our regulated subsidiaries maintain minimum levels of capital and seek approval before paying dividends from the subsidiaries to the parent. Our use of cash flows derived from our non-insurance subsidiaries, such as in our Healthcare ServicesCenterWell segment, is generally not restricted by state departments of insurance (or comparable state regulators).
For additional information on our liquidity risk, please refer to Item 1A. – Risk Factors in this 20192022 Form 10-K.
Cash and cash equivalents increased to $4.1$5.1 billion at December 31, 20192022 from $2.3$3.4 billion at December 31, 2018.2021. The change in cash and cash equivalents for the years ended December 31, 2019, 20182022, 2021 and 20172020 is summarized as follows:
| | | | | | | | | | | | | | | | | |
| 2022 | | 2021 | | 2020 |
| (in millions) |
Net cash provided by operating activities | $ | 4,587 | | | $ | 2,262 | | | $ | 5,639 | |
Net cash used in investing activities | (1,006) | | | (6,556) | | | (3,065) | |
Net cash (used in) provided by financing activities | (1,914) | | | 3,015 | | | (1,955) | |
Increase (decrease) in cash and cash equivalents | $ | 1,667 | | | $ | (1,279) | | | $ | 619 | |
|
| | | | | | | | | | | |
| 2019 | | 2018 | | 2017 |
| (in millions) |
Net cash provided by operating activities | $ | 5,284 |
|
| $ | 2,173 |
|
| $ | 4,051 |
|
Net cash used in investing activities | (1,278 | ) |
| (3,087 | ) |
| (2,941 | ) |
Net cash used in financing activities | (2,295 | ) |
| (785 | ) |
| (945 | ) |
Increase (decrease) in cash and cash equivalents | $ | 1,711 |
|
| $ | (1,699 | ) |
| $ | 165 |
|
Cash Flow from Operating Activities
The changeCash flows provided by operations of $4.6 billion in operatingthe 2022 period increased $2.3 billion from cash flows overprovided by operations of $2.3 billion in the three year2021 period primarily results from the corresponding change in the timing of working capital items, earnings, and enrollment activity as discussed below. The increase in operating cash flows in 2019 reflect the significant impacts of increasing premiums and enrollment, as premiums generally are collected in advance of claim payments by a period of updue to several months, higher earnings in 2022, exclusive of the timing of other working capital items, and the impact of an approximately $245 million payment related to reinsuring certain voluntary benefit and financial protection products to a third party in connection withgain on the sale of KMGKAH Hospice recognized in 2018.
The decreasethe 2022 period and the gain on the KAH equity method investment recognized in operating cash flowsthe 2021 period, combined with positive working capital impacts in 2018 primarily was due to2022, and the receipt of the merger termination fee in 2017, net of related expenses and taxes paid, funding the reinsurance of certain voluntary benefit and financial protection products to a third party in connection2021 period impact associated with the salepay down of KMGclaims inventory and capitation for provider surplus amounts earned in 20182020 and the timing of working capital items.additional provider support.
The most significant drivers of changes in our working capital are typically the timing of payments of benefits expense and receipts for premiums. We illustrate these changes withBenefits expense includes claim payments, capitation payments, pharmacy costs net of rebates, allocations of certain centralized expenses and various other costs incurred to provide health insurance coverage to members, as well as estimates of future payments to hospitals and others for medical care and other supplemental benefits provided on or prior to the following summaries ofbalance sheet date. For additional information regarding our benefits payable and receivables.
The detailbenefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of benefits payable was as follows at December 31, 2019, 2018 and 2017:
|
| | | | | | | | | | | | | | | | | | | |
| | | | | | | Change |
| 2019 | | 2018 | | 2017 | | 2019 | | 2018 |
| (in millions) |
IBNR (1) | $ | 4,150 |
| | $ | 3,361 |
| | $ | 3,154 |
| | $ | 789 |
| | $ | 207 |
|
Reported claims in process (2) | 628 |
| | 617 |
| | 614 |
| | 11 |
| | 3 |
|
Other benefits payable (3) | 1,226 |
| | 884 |
| | 900 |
| | 342 |
| | (16 | ) |
Total benefits payable | $ | 6,004 |
| | $ | 4,862 |
| | $ | 4,668 |
| | 1,142 |
| | 194 |
|
Payables from disposition |
|
|
|
|
|
|
|
|
| 58 |
|
Change in benefits payable per cash flow statement resulting in cash from operations |
|
|
|
|
|
| $ | 1,142 |
|
| $ | 252 |
|
| |
(1) | IBNR represents an estimate of benefits payable for claims incurred but not reported (IBNR) at the balance sheet date and includes unprocessed claim inventories. The level of IBNR is primarily impacted by membership levels, medical claim trends and the receipt cycle time, which represents the length of time between when a claim is initially incurred and when the claim form is received and processed (i.e. a shorter time span results in a lower IBNR). IBNR includes unprocessed claims inventories. |
| |
(2) | Reported claims in process represents the estimated valuation of processed claims that are in the post claim adjudication process, which consists of administrative functions such as audit and check batching and handling, as well as amounts owed to our pharmacy benefit administrator which fluctuate due to bi-weekly payments and the month-end cutoff. |
| |
(3) | Other benefits payable include amounts owed to providers under capitated and risk sharing arrangements. |
The increase in benefits payable in 2019 and 2018 was primarily due to an increase in IBNR, mainly as a result of Medicare Advantage membership growth. In addition, 2019 was impacted by an increase in the amounts owed to providers under capitated and risk sharing arrangements.
this Form 10-K.
The detail of total net receivables was as follows at December 31, 2019, 20182022, 2021 and 2017:2020:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | Change |
| 2022 | | 2021 | | 2020 | | 2022 | 2021 |
| (in millions) | |
Medicare | $ | 1,260 | | | $ | 1,214 | | | $ | 928 | | | $ | 46 | | $ | 286 | |
Commercial and other | 383 | | | 579 | | | 122 | | | (196) | | 457 | |
Military services | 101 | | | 104 | | | 160 | | | (3) | | (56) | |
Allowance for doubtful accounts | (70) | | | (83) | | | (72) | | | 13 | | (11) | |
Total net receivables | $ | 1,674 | | | $ | 1,814 | | | $ | 1,138 | | | (140) | | 676 | |
Reconciliation to cash flow statement: | | | | | | | | |
Change in receivables from disposition (acquisition) of business | | | | | | | 194 | | (396) | |
| | | | | | | | |
Change in receivables per cash flow statement resulting in cash used by operations | | | | | | | $ | 54 | | $ | 280 | |
|
| | | | | | | | | | | | | | | | | | | |
| | | | | | | Change |
| 2019 | | 2018 | | 2017 | | 2019 | | 2018 |
| (in millions) |
Medicare | $ | 835 |
| | $ | 836 |
| | $ | 511 |
| | $ | (1 | ) | | $ | 325 |
|
Commercial and other | 162 |
| | 135 |
| | 273 |
| | 27 |
| | (138 | ) |
Military services | 128 |
| | 123 |
| | 166 |
| | 5 |
| | (43 | ) |
Allowance for doubtful accounts | (69 | ) | | (79 | ) | | (96 | ) | | 10 |
| | 17 |
|
Total net receivables | $ | 1,056 |
| | $ | 1,015 |
| | $ | 854 |
| | 41 |
| | 161 |
|
Reconciliation to cash flow statement: | | | | | | | | | |
Change in receivables from acquisition | | | | | | | (12 | ) | | — |
|
Change in receivables disposed from sale of business | | | | | | | 3 |
| | 3 |
|
Change in receivables per cash flow statement resulting in cash used by operations | | | | | | | $ | 32 |
| | $ | 164 |
|
The changes in Medicare receivables are impactedfor both the 2022 period and the 2021 period reflect individual Medicare Advantage membership growth and the typical pattern caused by changes in revenue associated with individual and group Medicare membership changes as well as the timing of accruals and related collections associated with the CMS risk-adjustment model.
The decrease in commercialCommercial and other receivables and the allowance for doubtful accounts for 2022 primarily relates to the KAH Hospice disposition. The increase in Commercial and other receivables in 2018 as compared to 2017, was due2021 primarily to a decrease in our receivable associated with the commercial risk adjustment provision of the Health Care Reform Law. This decrease corresponds with our exit from the Individual Commercial business.
Military services receivables at December 31, 2019, 2018, and 2017 primarily consist of administrative services only fees owed from the federal government for administrative services provided under our TRICARE contracts. The 2017 balance also includes transition-in receivables under our T2017 East Region contract collected in 2018.
Many provisions of the Health Care Reform Law became effective in 2014, including the non-deductible health insurance industry fee. The annual health insurance industry fee was suspended for the calendar year 2017, but resumed in calendar year 2018.The annual health insurance industry fee was again suspended in 2019, but will resume for calendar year 2020, not be deductible for income tax purposes, and significantly increase our effective tax rate. Under current law, the health industry fee will be permanently repealed beginning in calendar year 2021. We paid the federal government annual health insurance industry fees of $1.04 billion in 2018.
In additionrelates to the timing of payments of benefits expense, receipts for premiums and services revenues, and amounts due under the health insurance industry fee provisions of the Health Care Reform Law, other items impacting operating cash flows include income tax payments and the timing of payroll cycles.Kindred at Home acquisition.
Cash Flow from Investing Activities
During 2022, we acquired various businesses totaling to approximately $337 million, net of cash received.
During 2021, we acquired Kindred at Home and other primary care businesses for cash consideration of approximately $4.2 billion, net of cash received.
During 2020, we acquired Enclara Healthcare, a hospice, pharmacy and benefit provider, for cash consideration of approximately $709 million, net of cash received.
During 2022, we completed the sale of a 60% interest in Humana’s Kindred at Home Hospice subsidiary, or KAH Hospice, to Clayton, Dubilier & Rice, or CD&R, for cash proceeds of approximately $2.7 billion, net of cash disposed, including debt repayments from KAH Hospice to Humana of $1.9 billion. In connection with the sale, we recognized a pre-tax gain, net of transaction costs, of $237 million which is reported as a gain on sale of KAH Hospice in the accompanying consolidated statement of income for the year ended December 31, 2022.
Our ongoing capital expenditures primarily relate to our information technology initiatives, support of services in our provider services operations including medical and administrative facility improvements necessary for activities such as the provision of care to members, claims processing, billing and collections, wellness solutions, care coordination, regulatory compliance and customer service. Total capital expenditures, excluding acquisitions, were $736$1.1 billion, $1.3 billion and $964 million in 2019, $612 million in 2018,the 2022, 2021 and $524 million in 2017.2020 periods, respectively.
In 2018, we completed the saleNet purchases of our wholly-owned subsidiary KMG to CGIC. Upon closing, we funded the transaction with approximately $190 million of parent company cash contributed into KMG, subject to customary adjustments, in addition to the transfer of approximately $160 million of statutory capital with the sale. Total cash and cash equivalents, including parent company funding, disposed at the time of sale, was $805 million. See Note 3 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data
During 2018 we paid cash consideration of approximatelyinvestment securities were $2.3 billion, $1.1 billion, to acquire a 40% minority interest$1.4 billion in Kindred at Home, $169 million to acquire the remaining interest in MCCI,2022, 2021 and $185 million to acquire all of FPG, as discussed in Notes 3 and 4 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data.
We reinvested a portion of our operating cash flows in investment securities, primarily investment-grade fixed income securities, totaling $542 million, $221 million, and $2.4 billion, during 2019, 2018 and 20172020 periods, respectively.
Cash Flow from Financing Activities
Our financing cash flows are significantly impacted by the timing of claims payments and the related receipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk. Monthly prospective payments from CMS for reinsurance and low-income cost subsidies are based on assumptions submitted with our annual bid. Settlement of the reinsurance and low-income cost subsidies is based on a reconciliation made approximately 9 months after the close of each calendar year. ClaimsReceipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk were higher than claim payments by $2 billion in the 2022 period and claim payments were $560 million higher than receipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk during 2019by $261 million and $653$938 million higher during 2018. Receipts from CMS associated with Medicare Part D claims subsidies for which we do not assume risk were $1.9 billion higher than claims payments during 2017.in the 2021 and 2020 periods, respectively. Our net payable from CMS for CMS subsidies and brand name prescription drug discounts was $229$540 million at December 31, 20192022 compared to a net payablereceivable of $331 million$1.4 billion at December 31, 2018.2021.
Under our administrative services only TRICARE contract, reimbursements from the federal government exceeded health care costcosts payments for which we do not assume risk by $25 million in the 2022 period and health care costs payments for which we do not assume risk exceeded reimbursements from the federal government by $63$45 million and $1 million in 2019the 2021 and reimbursements2020 periods, respectively.
In December 2022, we repaid $600 million aggregate principal amount of our 3.150% senior notes due on their maturity date of December 1, 2022 and $400 million aggregate principal amount of our 2.900% senior notes due on their maturity date of December 15, 2022.
In November 2022, we issued $500 million of 5.750% unsecured senior notes due March 1, 2028 and $750 million of 5.875% unsecured senior notes due March 1, 2033. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $1.2 billion.
In March 2022, we issued $750 million of 3.700% unsecured senior notes due March 23, 2029. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $744 million.
In August 2021, we issued $1.5 billion of 0.650% unsecured senior notes due August 3, 2023, $750 million of 1.350% unsecured senior notes due February 3, 2027 and $750 million of 2.150% unsecured senior notes due February 3, 2032. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $2,984 million.
In December 2020, we repaid $400 million aggregate principal amount of our 2.500% senior notes due on their maturity date of December 15, 2020.
In March 2020, we issued $600 million of 4.500% senior notes due April 1, 2025 and $500 million of 4.875% senior notes due April 1, 2030. Our net proceeds, reduced for the underwriters' discounts and commissions and offering expenses paid, were $1,088 million.
In August 2022, we repaid the $2.0 billion October 2021 Term Loan Agreement without a prepayment penalty due.
In October 2021, we entered into a $2.0 billion term loan agreement and applied the proceeds to finance the repayment in full of the outstanding assumed Kindred at Home debt.
In August 2021, we borrowed $500 million under the delayed draw term loan agreement, which was used, in combination with other debt financing, to fund the approximate $5.8 billion transaction price of Kindred at Home.
In March 2020, we drew $1 billion on the existing term loan commitment at the time, which was repaid in November 2020.
We entered into a commercial paper program in October 2014. Net repayments from issuance of commercial paper were $376 million in 2022 and the maximum principal amount outstanding at any one time during 2022 was $1.5 billion. Net proceeds from the federal
government exceeded health care cost payments for which we do not assume risk by $38issuance of commercial paper were $352 million in 20182021 and $11the maximum principal amount outstanding at any one time during 2021 was $1.2 billion. Net proceeds from issuance of commercial paper were $295 million in 2017.
Claims payments associated with cost sharing provisions of2020 and the Health Care Reform Law for which we do not assume risk were $25 million in 2018. Claims payments associated with cost sharing provisions of the Health Care Reform Law for which we do not assume risk were higher than reimbursements from HHS by $44 million in 2017.maximum principal amount outstanding at any one time during 2020 was $600 million.
We repurchased common shares for $1.07$2.10 billion, $1.09 billion$79 million and $3.37$1.82 billion in 2019, 20182022, 2021 and 20172020, respectively, under share repurchase plans authorized by the Board of Directors and in connection with employee stock plans.
As discussed further below, weWe paid dividends to stockholders of $291$392 million in 2019, $2652022, $354 million in 2018,2021, and $220$323 million in 2017.
We entered into a commercial paper program in October 2014. Net repayments of commercial paper were $360 million in 2019 and the maximum principal amount outstanding at any one time during 2019 was $801 million. Net proceeds from the issuance of commercial paper were $485 million in 2018 and the maximum principal amount outstanding at any one time during 2018 was $923 million. Net repayments of commercial paper were $153 million in 2017 and the maximum principal amount outstanding at any one time during 2017 was $500 million.
In November 2018, we entered into a $1.0 billion term note agreement with a bank at a variable rate of interest due within one year. For a detailed discussion of our debt please refer to Note 13 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data.
In August 2019, we issued $500 million of 3.125% senior notes due August 15, 2029 and $500 million of 3.950% senior notes due August 15, 2049. Our net proceeds, reduced for the underwriters' discount and commission and offering expenses paid were $987 million. We used the net proceeds from this offering, together with available cash, to repay the $650 million outstanding amount due under our term note in August 2019, and the $400 million aggregate principal amount of our 2.625% senior notes due on maturity at October 1, 2019. In December 2017, we issued $400 million of 2.50% senior notes due December 15, 2020 and $400 million of 2.90% senior notes due December 15, 2022. Our net proceeds, reduced for the underwriters' discount and commission and offering expenses paid as of December 31, 2017, were $794 million. We used the net proceeds, together with available cash, to fund the redemption of our $300 million aggregate principal amount of 6.30% senior notes maturing in August 2018 and our $500 million aggregate principal amount of 7.20% senior notes maturing in June 2018 at 100% of the principal amount plus applicable premium for early redemption and accrued and unpaid interest to the redemption date, for cash totaling approximately $829 million.2020.
The remainder of the cash used in or provided by financing activities in 2019, 2018,2022, 2021, and 20172020 primarily resulted from debt issuance costs, proceeds from stock option exercises and the change in book overdraft.
Future Sources and Uses of Liquidity
Dividends
For a detailed discussion of dividends to stockholders, please refer to Note 16 to the consolidated financial statementsaudited Consolidated Financial Statements included in Part II, Item 8. – Financial8, "Financial Statements and Supplementary Data.Data" of this Form 10-K.
Stock Repurchases
For a detailed discussion of stock repurchases, please refer to Note 16 to the consolidated financial statementsaudited Consolidated Financial Statements included in Part II, Item 8. – Financial8, "Financial Statements and Supplementary Data.Data" of this Form 10-K.
Debt
In February 2020, we entered into a new $1 billion term loan commitment with a bank that allows for up to three draws with the initial draw at a minimum of $300 million that matures 1 year after the first draw, subject to a 1 year extension. Following any initial draw, any unused commitments in excess of $300 million expire on June 30, 2020,
with the remaining commitments of up to $300 million available until September 30, 2020. If the initial drawhas not been made by June 30, 2020, then all commitments expire on June 30, 2020. The facility fee, interest rate and financial covenants are consistent with those of our revolving credit agreement. There is no prepayment penalty.
For a detailed discussion of our debt, including our senior notes, term loans, credit agreement and commercial paper program, please refer to Note 13 to the consolidated financial statementsaudited Consolidated Financial Statements included in Part II, Item 8. – Financial8, "Financial Statements and Supplementary Data.
Acquisitions and Divestiture
For a detailed discussionData" of our acquisitions and divestitures, please refer to Notes 3 and 4 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data
this Form 10-K.
Liquidity Requirements
We believe our cash balances, investment securities, operating cash flows, and funds available under our credit agreement and our commercial paper program or from other public or private financing sources, taken together, provide adequate resources to fund ongoing operating and regulatory requirements, acquisitions, future expansion opportunities, and capital expenditures for at least the next twelve months, as well as to refinance or repay debt, and repurchase shares.
Adverse changes in our credit rating may increase the rate of interest we pay and may impact the amount of credit available to us in the future. Our investment-grade credit rating at December 31, 20192022 was BBB+ according to Standard & Poor’s Rating Services, or S&P, and Baa3 according to Moody’s Investors Services, Inc., or Moody’s. A downgrade by S&P to BB+ or by Moody’s to Ba1 triggers an interest rate increase of 25 basis points with respect to $250 million of our senior notes. Successive one notch downgrades increase the interest rate an additional 25 basis points, or annual interest expense by $1 million, up to a maximum 100 basis points, or annual interest expense by $3 million.
In addition, we operate as a holding company in a highly regulated industry. Humana Inc., our parent company, is dependent upon dividends and administrative expense reimbursements from our subsidiaries, most of which are subject to regulatory restrictions. We continue to maintain significant levels of aggregate excess statutory capital and surplus in our state-regulated operating subsidiaries. Cash, cash equivalents, and short-term investments at the parent company increaseddecreased to $1.4$0.9 billion at December 31, 20192022 from $578 million$1.3 billion at December 31, 2018.2021. This increasedecrease primarily reflects insurancecommon stock repurchases, repayment of the October 2021 Term Loan Agreement, repayment of maturing senior notes, capital expenditures, repayment of borrowings under the commercial paper program, capital contributions to certain subsidiaries, cash dividends non-insurance subsidiaries' profitsto shareholders and acquisitions, partially offset by net proceeds from debt issuance, partially offset by common stock repurchases,the senior notes, proceeds from the sale of investment securities, dividends from insurance subsidiaries' capital contributions, repayment of debtsubsidiaries, and capital expenditures.cash from certain non-insurance subsidiaries within our CenterWell segment. Our use of operating cash derived from our non-insurance subsidiaries, such as our Healthcare ServicesCenterWell segment, is generally not restricted by Departments of Insurance (or comparable state regulatory agencies).regulators. Our regulated insurance subsidiaries paid dividends to theour parent company of $1.8$1.3 billion in 2019, $2.32022, $1.6 billion in 2018,2021, and $1.4$1.3 billion in 2017.2020. Subsidiary capital requirements from significant premium growth has impacted the amount of regulated subsidiary dividends over the last two years. Refer to our parent company financial statements and accompanying notes in Schedule I - Parent Company Financial Information. The amount of ordinary dividends that may be paid to our parent company in 2020 2023 is approximately $1 $1.8 billion, in the aggregate. Actual dividends paid may vary due to consideration of excess statutory capital and surplus and expected future surplus requirements related to, for example, premium volume and product mix.
Regulatory Requirements
For a detailed discussion of our regulatory requirements, including aggregate statutory capital and surplus as well as dividends paid from the subsidiaries to theour parent, please refer to Note 16 to the consolidated financial statementsto the audited Consolidated Financial Statements included in Part II, Item 8. – Financial8, "Financial Statements and Supplementary Data.Data" of this Form 10-K.
Contractual Obligations
We are contractually obligated to make payments for years subsequent to December 31, 2019 as follows:
|
| | | | | | | | | | | | | | | | | | | | |
| | Payments Due by Period |
| | Total | | Less than 1 Year | | 1-3 Years | | 3-5 Years | | More than 5 Years |
| | (in millions) |
Debt | | $ | 5,700 |
| | $ | 700 |
| | $ | 1,000 |
| | $ | 600 |
| | $ | 3,400 |
|
Interest (1) | | 3,348 |
| | 226 |
| | 418 |
| | 349 |
| | 2,355 |
|
Operating leases (2) | | 501 |
| | 133 |
| | 215 |
| | 83 |
| | 70 |
|
Purchase obligations (3) | | 2,503 |
| | 922 |
| | 1,136 |
| | 346 |
| | 99 |
|
Future policy benefits payable and other long-term liabilities (4) | | 478 |
| | 26 |
| | 226 |
| | 65 |
| | 161 |
|
Total | | $ | 12,530 |
| | $ | 2,007 |
| | $ | 2,995 |
| | $ | 1,443 |
| | $ | 6,085 |
|
| |
(1) | Interest includes the estimated contractual interest payments under our debt agreements. |
| |
(2) | We lease facilities, computer hardware, and other furniture and equipment under long-term operating leases that are noncancelable and expire on various dates through 2046. We sublease facilities or partial facilities to third party tenants for space not used in our operations which partially mitigates our operating lease commitments. See also Note 10 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data.
|
| |
(3) | Purchase obligations include agreements to purchase services, primarily information technology related services, or to make improvements to real estate, in each case that are enforceable and legally binding on us and that specify all significant terms, including: fixed or minimum levels of service to be purchased; fixed, minimum or variable price provisions; and the appropriate timing of the transaction. Purchase obligations exclude agreements that are cancelable without penalty. |
| |
(4) | Includes future policy benefits payable ceded to third parties through 100% coinsurance agreements as more fully described in Note 19 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data. We expect the assuming reinsurance carriers to fund these obligations and reflected these amounts as reinsurance recoverables included in other long-term assets on our consolidated balance sheet. Amounts payable in less than one year are included in trade accounts payable and accrued expenses in the consolidated balance sheet. |
Off-Balance Sheet Arrangements
As of December 31, 2019,2022, we were not involved in any special purpose entity, or SPE, transactions. For a detailed discussion of off-balance sheet arrangements, please refer to Note 17 to the consolidated financial statementsaudited Consolidated Financial Statements included in Part II, Item 8. – Financial8, "Financial Statements and Supplementary Data.Data" of this Form 10-K.
Guarantees and Indemnifications
For a detailed discussion of our guarantees and indemnifications, please refer to Note 17 to the consolidated financial statementsaudited Consolidated Financial Statements included in Part II, Item 8. – Financial8, "Financial Statements and Supplementary Data.Data" of this Form 10-K.
Government Contracts
For a detailed discussion of our government contracts, including our Medicare, Military, and Medicaid and state-based contracts, please refer to Note 17 to the consolidated financial statementsaudited Consolidated Financial Statements included in Part II, Item 8. – Financial8, "Financial Statements and Supplementary Data.Data" of this Form 10-K.
Critical Accounting Policies and Estimates
The discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements and accompanying notes, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements and accompanying notes requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. We continuously evaluate our estimates and those critical accounting policies primarily related to benefits expense and revenue recognition as well as accounting for impairments related to our investment securities, goodwill, indefinite-lived and long-lived assets. These estimates are based on knowledge of current events and anticipated future events and, accordingly, actual results ultimately may differ from those estimates. We believe the following critical accounting policies involve the most significant judgments and estimates used in the preparation of our consolidated financial statements.
Benefits Expense Recognition
Benefits expense is recognized in the period in which services are provided and includes an estimate of the cost of services which have been incurred but not yet reported, or IBNR. IBNR represents a substantial portion of our benefits payable as follows:
|
| | | | | | | | | | | | | |
| December 31, 2019 | | Percentage of Total | | December 31, 2018 | | Percentage of Total |
| (dollars in millions) |
IBNR | $ | 4,150 |
| | 69.1 | % | | $ | 3,361 |
| | 69.1 | % |
Reported claims in process | 628 |
| | 10.5 | % | | 617 |
| | 12.7 | % |
Other benefits payable | 1,226 |
| | 20.4 | % | | 884 |
| | 18.2 | % |
Total benefits payable | $ | 6,004 |
| | 100.0 | % | | $ | 4,862 |
| | 100.0 | % |
Our reserving practice is to consistently recognize the actuarial best point estimate within a level of confidence required by actuarial standards. For further discussion of our reserving methodology, including our use of completion and claims per member per month trend factors to estimate IBNR, refer to Note 2 to the consolidated financial statementsaudited Consolidated Financial Statements included in Part II, Item 8. – Financial8, "Financial Statements and Supplementary Data.Data" of this Form 10-K.
The completion and claims per member per month trend factors are the most significant factors impacting the IBNR estimate. The portion of IBNR estimated using completion factors for claims incurred prior to the most recent two months is generally less variable than the portion of IBNR estimated using trend factors. The following table illustrates the sensitivity of these factors assuming moderately adverse experience and the estimated potential impact on our operating results caused by reasonably likely changes in these factors based on December 31, 20192022 data:
| | | | | | | | | | | | | | | | | | | | |
Completion Factor (a): | | Claims Trend Factor (b): |
Factor Change (c) | | Decrease in Benefits Payable | | Factor Change (c) | | Decrease in Benefits Payable |
(dollars in millions) |
0.90% | | $588 | | 3.50% | | $479 |
0.80% | | $522 | | 3.25% | | $445 |
0.70% | | $457 | | 3.00% | | $411 |
0.60% | | $392 | | 2.75% | | $376 |
0.50% | | $326 | | 2.50% | | $342 |
0.40% | | $261 | | 2.25% | | $308 |
0.30% | | $196 | | 2.00% | | $274 |
0.20% | | $131 | | 1.75% | | $239 |
0.10% | | $65 | | 1.50% | | $205 |
0.05% | | $33 | | 1.25% | | $171 |
0.03% | | $16 | | 1.00% | | $137 |
|
| | | | | | |
Completion Factor (a): | | Claims Trend Factor (b): |
Factor Change (c) | | Decrease in Benefits Payable | | Factor Change (c) | | Decrease in Benefits Payable |
(dollars in millions) |
0.70% | | $(308) | | (3.00)% | | $(270) |
0.60% | | $(264) | | (2.75)% | | $(248) |
0.50% | | $(220) | | (2.50)% | | $(225) |
0.40% | | $(176) | | (2.25)% | | $(203) |
0.30% | | $(132) | | (2.00)% | | $(180) |
0.20% | | $(88) | | (1.75)% | | $(158) |
0.10% | | $(44) | | (1.50)% | | $(135) |
(a)Reflects estimated potential changes in benefits payable at December 31, 2022 caused by changes in completion factors for incurred months prior to the most recent two months. | |
(a) | Reflects estimated potential changes in benefits payable at December 31, 2019 caused by changes in completion factors for incurred months prior to the most recent two months. |
(b)Reflects estimated potential changes in benefits payable at December 31, 2022 caused by changes in annualized claims trend used for the estimation of per member per month incurred claims for the most recent two months.
| |
(b) | Reflects estimated potential changes in benefits payable at December 31, 2019 caused by changes in annualized claims trend used for the estimation of per member per month incurred claims for the most recent two months. |
| |
(c) | The factor change indicated represents the percentage point change. |
(c)The factor change indicated represents the percentage point change.
The following table provides a historical perspective regarding the accrual and payment of our benefits payable, excluding military services.payable. Components of the total incurred claims for each year include amounts accrued for current year estimated benefits expense as well as adjustments to prior year estimated accruals. Refer to Note 11 to the consolidated financial statementsaudited Consolidated Financial Statements included in Part II, Item 8. – Financial8, "Financial Statements and Supplementary DataData" of this Form 10-K for Retail and Group and Specialty segment tables including information about incurred and paid claims development as of December 31, 2019,2022, net of reinsurance, as well as cumulative claim frequency and the total of IBNR included within the net incurred claims amounts.
| | | | 2019 | | 2018 | | 2017 | | 2022 | | 2021 | | 2020 |
| | (in millions) | | | (in millions) |
Balances at January 1 | | $ | 4,862 |
| | $ | 4,668 |
| | $ | 4,563 |
| Balances at January 1 | | $ | 8,289 | | | $ | 8,143 | | | $ | 6,004 | |
| Less: Reinsurance recoverables | | (95 | ) | | (70 | ) | | (76 | ) | Less: Reinsurance recoverables | | — | | | — | | | (68) | |
Balances at January 1, net | | 4,767 |
| | 4,598 |
| | 4,487 |
| Balances at January 1, net | | 8,289 | | | 8,143 | | | 5,936 | |
Acquisitions | | Acquisitions | | — | | | 42 | | | — | |
Incurred related to: | | | | | | | Incurred related to: | |
Current year | | 54,193 |
| | 46,385 |
| | 44,001 |
| Current year | | 76,105 | | | 70,024 | | | 61,941 | |
Prior years | | (336 | ) | | (503 | ) | | (483 | ) | Prior years | | (415) | | | (825) | | | (313) | |
Total incurred | | 53,857 |
| | 45,882 |
| | 43,518 |
| Total incurred | | 75,690 | | | 69,199 | | | 61,628 | |
Paid related to: | | | | | | | Paid related to: | | | | | | |
Current year | | (48,421 | ) | | (41,736 | ) | | (39,496 | ) | Current year | | (67,287) | | | (62,149) | | | (54,003) | |
Prior years | | (4,267 | ) | | (3,977 | ) | | (3,911 | ) | Prior years | | (7,428) | | | (6,946) | | | (5,418) | |
Total paid | | (52,688 | ) | | (45,713 | ) | | (43,407 | ) | Total paid | | (74,715) | | | (69,095) | | | (59,421) | |
| Reinsurance recoverable | | 68 |
| | 95 |
| | 70 |
| Reinsurance recoverable | | — | | | — | | | — | |
Balances at December 31 | | $ | 6,004 |
| | $ | 4,862 |
| | $ | 4,668 |
| Balances at December 31 | | $ | 9,264 | | | $ | 8,289 | | | $ | 8,143 | |
The following table summarizes the changes in estimate for incurred claims related to prior years attributable to our key assumptions. As previously described, our key assumptions consist of trend and completion factors estimated using an assumption of moderately adverse conditions. The amounts below represent the difference between our original estimates and the actual benefits expense ultimately incurred as determined from subsequent claim payments.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Favorable Development by Changes in Key Assumptions |
| 2022 | | 2021 | | 2020 |
| Amount | | Factor Change (a) | | Amount | | Factor Change (a) | | Amount | | Factor Change (a) |
| (dollars in millions) |
Trend factors | $ | (387) | | | (0.6) | % | | $ | (361) | | | (3.3) | % | | $ | (167) | | | (1.9) | % |
Completion factors | (28) | | | — | % | | (464) | | | (0.9) | % | | (146) | | | (0.3) | % |
Total | $ | (415) | | | | | $ | (825) | | | | | $ | (313) | | | |
|
| | | | | | | | | | | | | | | | | | | | |
| Favorable Development by Changes in Key Assumptions |
| 2019 | | 2018 | | 2017 |
| Amount | | Factor Change (a) | | Amount | | Factor Change (a) | | Amount | | Factor Change (a) |
| (dollars in millions) |
Trend factors | $ | (233 | ) | | (3.1 | )% | | $ | (229 | ) | | (3.3 | )% | | $ | (279 | ) | | (2.7 | )% |
Completion factors | (103 | ) | | (0.3 | )% | | (274 | ) | | (0.8 | )% | | (204 | ) | | (0.7 | )% |
Total | $ | (336 | ) | | | | $ | (503 | ) | | | | $ | (483 | ) | | |
(a)The factor change indicated represents the percentage point change. | |
(a) | The factor change indicated represents the percentage point change. |
As previously discussed, our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. We experienced favorable medical claims reserve development related to prior fiscal years of $336$415 million in 2019, $5032022, $825 million in 2018,2021, and $483$313 million in 2017. The table below details our favorable medical claims reserve development related to prior fiscal years by segment for 2019, 2018, and 2017.
|
| | | | | | | | | | | | | | | | | | | |
| (Favorable) Unfavorable Medical Claims Reserve Development | | Change |
| 2019 | | 2018 | | 2017 | | 2019 | | 2018 |
| (in millions) |
Retail Segment | $ | (386 | ) | | $ | (398 | ) | | $ | (386 | ) | | $ | 12 |
| | $ | (12 | ) |
Group and Specialty Segment | 50 |
| | (46 | ) | | (40 | ) | | 96 |
| | (6 | ) |
Individual Commercial Segment | — |
| | (57 | ) | | (56 | ) | | 57 |
| | (1 | ) |
Other Businesses | — |
| | (2 | ) | | (1 | ) | | 2 |
| | (1 | ) |
Total | $ | (336 | ) | | $ | (503 | ) | | $ | (483 | ) | | $ | 167 |
| | $ | (20 | ) |
2020.The favorable medical claims reserve development for 2019, 2018,2022, 2021, and 20172020 primarily reflects the consistent application of trend and completion factors estimated using an assumption of moderately adverse conditions. In addition, the higher prior year favorable development for the year ended December 31, 2021 was primarily attributable to the reversal of actions taken in 2020, including the suspension of certain financial recovery programs for a period of time impacting our claim payment patterns. The suspension during 2020 was intended to provide financial and administrative relief for providers facing unprecedented strain as a result of the COVID-19 pandemic. Our favorable development for each of the years presented above is discussed further in Note 11 to the consolidated financial statementsaudited Consolidated Financial Statements included in Item 8. – Financial Statements and Supplementary Data.
We continually adjust our historical trend and completion factor experience with our knowledge of recent events that may impact current trends and completion factors when establishing our reserves. Because our reserving practice is to consistently recognize the actuarial best point estimate using an assumption of moderately adverse
conditions as required by actuarial standards, there is a reasonable possibility that variances between actual trend and completion factors and those assumed in our December 31, 20192022 estimates would fall towards the middle of the ranges previously presented in our sensitivity table.
There was no benefit expense excluded from the previous table for the years ended December 31, 2019 and 2018. Benefits expense reduced by $22 million associated with future policy benefits for the year ended December 31, 2017 was excluded from the previous table.
Revenue Recognition
We generally establish one-year commercial membership contracts with employer groups, subject to cancellation by the employer group on 30-day written notice. Our Medicare contracts with CMS renew annually. Our military services contracts with the federal government and certain contracts with various state Medicaid programs generally are multi-year contracts subject to annual renewal provisions.
We receive monthly premiums from the federal government and various states according to government specified payment rates and various contractual terms. We bill and collect premiumpremiums from employer groups and members in our Medicare and other individual products monthly. Changes in premium revenues resulting from the periodic changes in risk-adjustment scores derived from medical diagnoses for our membership are estimated by projecting the ultimate annual premium and recognized ratably during the year with adjustments each period to reflect changes in the ultimate premium.
Premiums revenue is estimated by multiplying the membership covered under the various contracts by the contractual rates. Premiums revenue is recognized as income in the period members are entitled to receive services, and is net of estimated uncollectible amounts, retroactive membership adjustments, and adjustments to recognize rebates under the minimum benefit ratios required under the Health Care Reform Law. We estimate policyholder rebates by projecting calendar year minimum benefit ratios for the small group and large group markets, as defined by the Health Care Reform Law using a methodology prescribed by HHS, separately by state and legal entity. Medicare Advantage products are also subject to minimum benefit ratio requirements under the Health Care Reform Law. Estimated calendar year rebates recognized ratably during the year are revised each period to reflect current experience. Retroactive membership adjustments result from enrollment changes not yet processed, or not yet reported by an employer group or the government. We routinely monitor the collectability of specific accounts, the aging of receivables, historical retroactivity trends, estimated rebates, as well as prevailing and anticipated economic conditions, and reflect any required adjustments in current operations. Premiums received prior to the service period are recorded as unearned revenues.
Medicare Risk-Adjustment Provisions
CMS utilizesuses a risk-adjustment model which apportionsadjusts premiums paid to Medicare Advantage, or MA, plans according to health severity.status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997(BBA)1997 (BBA) and the Benefits Improvement and Protection Act of 2000 (BIPA), generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to account for enrollees with predictably higher costs.certain demographic characteristics and health status of our enrolled members. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information from hospital inpatient, hospital outpatient, and physician providers to CMS within prescribed deadlines. The CMS risk-adjustment model uses thisthe diagnosis data, collected from providers, to calculate the health status-related risk-adjusted premium payment to MA plans. Rates paid to MA plans, are established under an actuarial bid model, including a process that bases our payments on a comparison of our beneficiaries’ risk scores, derived from medical diagnoses, to those enrolled inwhich CMS further adjusts for coding pattern differences between the government’s Medicare FFShealth plans and the government fee-for-service (FFS) program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately document all medical data, including the diagnosis data submitted with claims. CMS is phasing-in the processIn addition, we conduct medical record reviews as part of calculating risk scores using diagnoses data from the Risk Adjustment Processing System, or RAPS, to diagnoses data from the Encounter Data System, or EDS. The RAPS process requires MA plans to apply a filter logic based on CMS guidelines and only submit diagnoses that satisfy those guidelines. For submissions through EDS, CMS requires MA plans to submit all the encounterour data and CMS will applypayment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment filtering logicmodel. For additional information, refer to determine the risk scores. For 2019, 25% of the risk score was calculated from claims data submitted through EDS. CMS will increase that percentage to 50% in 2020 and has proposed to increase that percentage to 75% in 2021. The phase-in from RAPS to EDS could result in different risk scores from each dataset as a result of plan processing issues, CMS processing issues, or filtering logic differences between RAPS and EDS, and could have a material adverse effect on our results of operations, financial position, or cash flows. We estimate risk-adjustment revenues based on medical diagnoses for our membership. The risk-adjustment model, including CMS changesNote 17 to the submission process, is more fully describedaudited Consolidated Financial Statements included in Part II, Item 1. – Business under the section titled “Individual Medicare,”8, "Financial Statements and inSupplementary Data" and Part I, Item 1A. - Risk Factors.
1A, "Risk Factors" of this Form 10-K.
Investment Securities
Investment securities totaled $11.4$14.3 billion, or 39%33% of total assets at December 31, 2019,2022, and $10.4$14.0 billion, or 41%31% of total assets at December 31, 2018.2021. The investment portfolio was primarily comprised of debt securities, detailed below, at December 31, 20192022 and entirely at December 31, 2018.2021. The fair value of debtinvestment securities were as follows at December 31, 20192022 and 2018:2021:
| | | | 12/31/2019 | | Percentage of Total | | 12/31/2018 | | Percentage of Total | | 12/31/2022 | | Percentage of Total | | 12/31/2021 | | Percentage of Total |
| | | | | | | | | |
| | (dollars in millions) | | | (dollars in millions) |
U.S. Treasury and other U.S. government corporations and agencies: | | | | | | | | | U.S. Treasury and other U.S. government corporations and agencies: | |
U.S. Treasury and agency obligations | | $ | 354 |
| | 3.1 | % | | $ | 417 |
| | 4.0 | % | U.S. Treasury and agency obligations | | $ | 1,039 | | | 7.3 | % | | $ | 602 | | | 4.3 | % |
Mortgage-backed securities | | 3,710 |
| | 32.6 | % | | 2,544 |
| | 24.4 | % | Mortgage-backed securities | | 3,230 | | | 22.6 | % | | 3,229 | | | 23.1 | % |
Tax-exempt municipal securities | | 1,463 |
| | 12.9 | % | | 2,771 |
| | 26.5 | % | Tax-exempt municipal securities | | 728 | | | 5.1 | % | | 841 | | | 6.0 | % |
Mortgage-backed securities: | | | | | | | | | Mortgage-backed securities: | |
Residential | | — |
| | — | % | | 55 |
| | 0.5 | % | Residential | | 401 | | | 2.8 | % | | 367 | | | 2.6 | % |
Commercial | | 804 |
| | 7.1 | % | | 523 |
| | 5.0 | % | Commercial | | 1,399 | | | 9.8 | % | | 1,410 | | | 10.1 | % |
Asset-backed securities | | 1,093 |
| | 9.6 | % | | 985 |
| | 9.4 | % | Asset-backed securities | | 1,731 | | | 12.2 | % | | 1,348 | | | 9.6 | % |
Corporate debt securities | | 3,947 |
| | 34.7 | % | | 3,142 |
| | 30.2 | % | Corporate debt securities | | 5,726 | | | 40.2 | % | | 5,700 | | | 40.8 | % |
Total debt securities | | $ | 11,371 |
| | 100.0 | % | | $ | 10,437 |
| | 100.0 | % | Total debt securities | | 14,254 | | | 100.0 | % | | 13,497 | | | 96.6 | % |
Common stock | | Common stock | | 7 | | | — | % | | 475 | | | 3.4 | % |
Total investment securities | | Total investment securities | | $ | 14,261 | | | 100.0 | % | | $ | 13,972 | | | 100.0 | % |
Approximately 96% of our debt securities were investment-grade quality, with a weighted average credit rating of AAAA- by S&P at December 31, 2019.2022. Most of the debt securities that were below investment-grade were rated BB,BB-, the higher end of the below investment-grade rating scale. Tax-exempt municipal securities were diversified among general obligation bonds of states and local municipalities in the United States as well as special revenue bonds issued by municipalities to finance specific public works projects such as utilities, water and sewer, transportation, or education. Our general obligation bonds are diversified across the United States with no individual
state exceeding 1% of our total debt securities. Our investment policy limits investments in a single issuer and requires diversification among various asset types.
Gross unrealized losses and fair values aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position were as follows at December 31, 2019:2022:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Less than 12 months | | 12 months or more | | Total |
| Fair Value | | Gross Unrealized Losses | | Fair Value | | Gross Unrealized Losses | | Fair Value | | Gross Unrealized Losses |
|
| (in millions) |
| | | | | | | | | | | |
U.S. Treasury and other U.S. government corporations and agencies: | | | | | | | | | | | |
U.S. Treasury and agency obligations | $ | 512 | | | $ | (5) | | | $ | 397 | | | $ | (50) | | | $ | 909 | | | $ | (55) | |
Mortgage-backed securities | 1,231 | | | (104) | | | 1,683 | | | (367) | | | 2,914 | | | (471) | |
Tax-exempt municipal securities | 64 | | | (2) | | | 615 | | | (36) | | | 679 | | | (38) | |
Mortgage-backed securities: | | | | | | | | | | | |
Residential | 124 | | | (16) | | | 274 | | | (60) | | | 398 | | | (76) | |
Commercial | 243 | | | (13) | | | 1,157 | | | (142) | | | 1,400 | | | (155) | |
Asset-backed securities | 620 | | | (32) | | | 1,011 | | | (46) | | | 1,631 | | | (78) | |
Corporate debt securities | 1,625 | | | (98) | | | 3,825 | | | (730) | | | 5,450 | | | (828) | |
Total debt securities | $ | 4,419 | | | $ | (270) | | | $ | 8,962 | | | $ | (1,431) | | | $ | 13,381 | | | $ | (1,701) | |
|
| | | | | | | | | | | | | | | | | | | | | | | | |
| | Less than 12 months | | 12 months or more | | Total |
| | Fair Value | | Gross Unrealized Losses | | Fair Value | | Gross Unrealized Losses | | Fair Value | | Gross Unrealized Losses |
|
| | (in millions) |
| December 31, 2019 | | | | | | | | | | | |
| U.S. Treasury and other U.S. government corporations and agencies: | | | | | | | | | | | |
| U.S. Treasury and agency obligations | $ | 48 |
| | $ | — |
| | $ | 23 |
| | $ | — |
| | $ | 71 |
| | $ | — |
|
| Mortgage-backed securities | 315 |
| | (1 | ) | | 204 |
| | (2 | ) | | 519 |
| | (3 | ) |
| Tax-exempt municipal securities | 58 |
| | — |
| | 75 |
| | — |
| | 133 |
| | — |
|
| Mortgage-backed securities: | | | | | | | | | | | |
| Residential | — |
| | — |
| | — |
| | — |
| | — |
| | — |
|
| Commercial | 118 |
| | — |
| | 36 |
| | — |
| | 154 |
| | — |
|
| Asset-backed securities | 20 |
| | — |
| | 607 |
| | (3 | ) | | 627 |
| | (3 | ) |
| Corporate debt securities | 589 |
| | (2 | ) | | 155 |
| | — |
| | 744 |
| | (2 | ) |
| Total debt securities | $ | 1,148 |
| | $ | (3 | ) | | $ | 1,100 |
| | $ | (5 | ) | | $ | 2,248 |
| | $ | (8 | ) |
UnderBeginning on January 1, 2020, we adopted the new current expected credit losses, or CECL, model which retained many similarities from the previous other-than-temporary impairment model except eliminating from consideration in the impairment analysis the length of time over which the fair value had been less than cost. Also, under the CECL model, expected losses on available for sale debt securities held, we recognizeare recognized through an impairment lossallowance for credit losses rather than as reductions in income in an amount equal to the full difference between the amortized cost basis andof the securities. For debt securities whose fair value whenis less than their amortized cost which we do not intend to sell or are not required to sell, we evaluate the expected cash flows to be received as compared to amortized cost and determine if an expected credit loss has occurred. In the event of an expected credit loss, only the amount of the impairment associated with the expected credit loss is recognized in income with the remainder, if any, of the loss recognized in other comprehensive income. To the extent we have the intent to sell the debt security or it is more likely than not we will be required to sell the debt security before recovery of our amortized cost basis. However, ifbasis, we do not intendrecognize an impairment loss in income in an amount equal to sell the debt security, we evaluatefull difference between the expected cash flows to be received as compared to amortized cost basis and determine if athe fair value.
Potential expected credit loss has occurred. In the event of a credit loss, only the amount of the impairment associated with the credit loss is recognized currently in income with the remainder of the loss recognized in other comprehensive income.
When we do not intend to sell a security in an unrealized loss position, potential other-than-temporary impairment is considered using a variety of factors, including the length of time and extent to which the fair value has been less than cost; adverse conditions specifically related to the industry, geographic area or financial condition of the issuer or underlying collateral of a debt security; changes in the quality of the debt security's credit enhancement; payment structure of the debt security; changes in credit rating of the debt security by the rating agencies; the volatilityfailure of the fair value changes;issuer to make scheduled principal or interest payments on the debt security and changes in fair value of the security after the balance sheet date.prepayment speeds. For debt securities, we take into account expectations of relevant market and economic data. For example, with respect to mortgage and asset-backed securities, such data includes underlying loan level data and structural features such as seniority and other forms of credit enhancements. A decline in fair value is considered other-than-temporary when we do not expect to recover the entire amortized cost basis of the security. We estimate the amount of the expected credit loss component of a debt security as the difference between the amortized cost and the present value of the expected cash flows of the security. The present value is determined using the best estimate of future cash flows discounted at the implicit interest rate at the date of purchase. The expected credit loss cannot exceed the full difference between the amortized cost basis and the fair value.
The risks inherent in assessing the impairment of an investment include the risk that market factors may differ from our expectations, facts and circumstances factored into our assessment may change with the passage of time, or
we may decide to subsequently sell the investment. The determination of whether a decline in the value of an investment is other than temporaryrelated to a credit event requires us to exercise significant diligence and judgment. The discovery of new information and the passage of time can significantly change these judgments. The status of the general economic environment and significant changes in the national securities markets influence the determination of fair value and the assessment of investment impairment. There is a continuing risk that declines in fair value may occur and additional material realized losses from sales or other-than-temporaryexpected credit loss impairments may be recorded in future periods.
All issuers of debt securities we own that were trading at an unrealized loss at December 31, 20192022 remain current on all contractual payments. After taking into account these and other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates in the current markets since the time the debt securities were purchased. At December 31, 2019,2022, we did not intend to sell theany debt securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell these debt securities before recovery of their amortized cost basis. As a result,Additionally, we believedid not record any material credit allowances for debt securities that the securities withwere in an unrealized loss were not other-than-temporarily impairedposition at December 31, 2019. There were no material other-than-temporary impairments in 2019, 2018,2022, 2021 or 2017.2020.
Goodwill, Indefinite-lived and Long-lived Assets
At December 31, 2019,2022, goodwill, indefinite-lived and other long-lived assets represented 21%33% of total assets and 50%92% of total stockholders’ equity, compared to 23%38% and 58%104%, respectively, at December 31, 2018.2021. The decrease in goodwill, indefinite-lived and other long-lived assets is primarily attributable to our August 2022 sale of KAH Hospice.
WeFor goodwill, we are required to test at least annually for impairment at a level of reporting referred to as the reporting unit, and more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. A reporting unit either is our operating segments or one level below the operating segments, referred to as a component, which comprise our reportable segments. A component is considered a reporting unit if the component constitutes a business for which discrete financial information is available that is regularly reviewed by management. We are required to aggregate the components of an operating segment into one reporting unit if they have similar economic characteristics. Goodwill is assigned to the reporting unit that is expected to benefit from a specific acquisition.
We use the one-step processperform a quantitative assessment to review goodwill for impairment to determine both the existence and amount of goodwill impairment, if any. Our strategy, long-range business plan, and annual planning process support our goodwill impairment tests. These tests are performed, at a minimum, annually in the fourth quarter, and are based on an evaluation of future discounted cash flows. We rely on this discounted cash flow analysis to determine fair value. However outcomes from the discounted cash flow analysis are compared to other market approach valuation methodologies for reasonableness. We use discount rates that correspond to a market-based weighted-average cost of capital and terminal growth rates that correspond to long-term growth prospects, consistent with the long-term inflation rate. Key assumptions in our cash flow projections, including changes in membership, premium yields, medical and operating cost trends, and certain government contract extensions, are consistent with those utilized in our long-range business plan and annual planning process. If these assumptions differ from actual, including the impact of the Health Care Reform Law or changes in Governmentgovernment reimbursement rates, the estimates underlying our goodwill impairment tests could be adversely affected. Goodwill impairment tests completed in each of the last three years did not result in an impairment loss. The fair value of our reporting units with significant goodwill exceeded carrying amounts by a substantial margin. A 100 basis point increaseHowever, unfavorable changes in the discount rate would not havekey assumptions or combinations of assumptions including a significant impact on the amount of margin for any of our reporting units with significant goodwill, with the exception of our clinical and provider reporting units in our Healthcare Services segment. Our clinical and provider reporting units primarily provide services to our Retail members. A significant increase in the discount rate, decrease in the long-term growth rate or substantial reductionsreduction in our underlying cash flow assumptions, including revenue growth rates, medical and operating cost trends, and projected operating income could have a significant negative impact on the estimated fair value of these reporting units. The clinical reporting unit had a fair value of $544 million which exceeded its carrying value of $533 million by $11 million or 2%. If the discount rate increased 100 basis points, then the clinical reporting unit would incur an impairment loss of approximately $62 million. The provider reporting unit had a fair value of $2.3 billion which exceeded its carrying value of $1.3 billion by $1.0 billion or 78%. The provider reporting unit estimate of fair value relies on multiple assumptions regarding the underlying long-term cash flows, any one of which may be significantly impacted by future changes in estimates and may negatively impact fair value. The clinicalour home solutions and provider reporting units, accountwhich accounted for $524 million$4.3 billion and $761 million, respectively,$1.1 billion of goodwill.goodwill, respectively. Impairment tests completed for 2019, 2018,2022, 2021, and 20172020 did not result in an impairment loss.
Indefinite-lived intangible assets relate to Certificate of Needs (CON) and Medicare licenses acquired in connection with our August 2021 KAH acquisition with a carrying value of $1.4 billion at December 31, 2022. Like
goodwill, we are required to test at least annually for impairment and more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. These tests are performed, at a minimum, annually in the fourth quarter. If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized. Fair values of indefinite-lived intangible assets are determined based on the income approach. Impairment tests completed for 2022 did not result in a material impairment loss. These charges reflect the amount by which the carrying value exceeded its estimated fair value. Impairment tests completed for 2021 did not result in an impairment loss. The fair values of the assets were measured using Level 3 inputs, such as projected revenues and operating cash flows.
Long-lived assets consist of property and equipment and other finite-liveddefinite-lived intangible assets. These assets are depreciated or amortized over their estimated useful life, and are subject to impairment reviews. We periodically review long-lived assets whenever adverse events or changes in circumstances indicate the carrying value of the asset may not be recoverable. In assessing recoverability, we must make assumptions regarding estimated future cash flows and other factors to determine if an impairment loss may exist, and, if so, estimate fair value. We also must estimate and make assumptions regarding the useful life we assign to our long-lived assets. If these estimates or their related assumptions
change in the future, we may be required to record impairment losses or change the useful life, including accelerating depreciation or amortization for these assets. ThereOther than the $248 million of asset impairment charges as a result of our value creation initiatives as described in Footnote 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K, there were no materialother impairment losses in the last three years.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Our earnings and financial position are exposed to financial market risk, including those resulting from changes in interest rates.
The level of our pretax earnings is subject to market risk due to changes in interest rates and the resulting impact on investment income and interest expense. In the past we have, and in the future we may enter into interest rate swap agreements depending on market conditions and other factors. Amounts borrowed underUnder the revolving credit portion ofagreements, at our $2.0 billion unsecuredoption, we can borrow on either a competitive advance basis or a revolving credit agreement bearbasis. The revolving credit portion bears interest at either LIBOR plus a spread or the base rate plus a spread. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based on LIBOR, at our option. The revolving credit agreements provide for the transition from LIBOR and do not require amendment in connection with such transition. There were no borrowings outstanding under our credit agreementagreements at December 31, 20192022 or December 31, 2018.2021.
Interest rate risk also represents a market risk factor affecting our consolidated financial position due to our significant investment portfolio, consisting primarily of fixed maturity securities of investment-grade quality with a weighted average S&P credit rating of AAAA- at December 31, 2019.2022. Our net unrealized position increased $415decreased $1.7 billion from a net unrealized gain position of $57 million fromat December 31, 2021 to a net unrealized loss position of $204 million$1.7 billion at December 31, 2018 to a net unrealized gain position of $211 million at December 31, 2019.2022. At December 31, 2019,2022, we had gross unrealized losses of $8 million$1.7 billion on our investment portfolio primarily due to an increase in market interest rates since the time the securities were purchased. ThereWe did not record any material credit allowances for debt securities that were no material other-than-temporary impairmentsin an unrealized loss position during 2019.2022 and 2021. While we believe that these impairments are temporarywill be recovered and we currently do not have the intent to sell such securities, given the current market conditions and the significant judgments involved, there is a continuing risk that future declines in fair value may occur and material realized losses from sales or other-than-temporarycredit loss impairments may be recorded in future periods.
Duration is the time-weighted average of the present value of the bond portfolio’s cash flow. Duration is indicative of the relationship between changes in fair value and changes in interest rates, providing a general indication of the sensitivity of the fair values of our fixed maturity securities to changes in interest rates. However, actual fair values may differ significantly from estimates based on duration. The average duration of our investment portfolio, including cash and cash equivalents, was approximately 2.53.2 years as of December 31, 20192022 and 2.93.6 years
as of December 31, 2018.2021. Based on the duration including cash equivalents, a 1% increase in interest rates would generally decrease the December 31, 2022 fair value of our securities by approximately $373$603 million.
We have also evaluated the impact on our investment income and interest expense resulting from a hypothetical change in interest rates of 100, 200, and 300 basis points over the next twelve-month period, as reflected in the following table. The evaluation was based on our investment portfolio and our outstanding indebtedness at December 31, 20192022 and 2018.2021. Our investment portfolio consists of cash, cash equivalents, and investment securities. The modeling technique used to calculate the pro forma net change in pretax earnings considered the cash flows related to fixed income investments and debt, which are subject to interest rate changes during a prospective twelve-month period. This evaluation measures parallel shifts in interest rates and may not account for certain unpredictable events that may affect interest income, including unexpected changes of cash flows into and out of the portfolio, changes in the asset allocation, including shifts between taxable and tax-exempt securities, and spread changes specific to various investment categories.categories and the mix of short-term versus long-term debt. In the past ten years, changes in 10 year US treasury rates during the year have not exceeded 300 basis points, have changed between 200 and 300 basis points once, have changed between 100 and 200 basis points four times, and have changed by less than 100 basis points five times.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Increase (decrease) in pretax earnings given an interest rate decrease of X basis points | | Increase (decrease) in pretax earnings given an interest rate increase of X basis points |
| | (300) | | (200) | | (100) | | 100 | | 200 | | 300 |
| | (in millions) |
As of December 31, 2022 | | | | | | | | | | | | |
Investment income (a) | | $ | (276) | | | $ | (184) | | | $ | (92) | | | $ | 93 | | | $ | 186 | | | $ | 281 | |
Interest expense (b) | | 56 | | | 37 | | | 19 | | | (19) | | | (37) | | | (57) | |
Pretax | | $ | (220) | | | $ | (147) | | | $ | (73) | | | $ | 74 | | | $ | 149 | | | $ | 224 | |
As of December 31, 2021 | | | | | | | | | | | | |
Investment income (a) | | $ | (46) | | | $ | (29) | | | $ | (15) | | | $ | 71 | | | $ | 142 | | | $ | 213 | |
Interest expense (b) | | 7 | | | 7 | | | 7 | | | (35) | | | (70) | | | (105) | |
Pretax | | $ | (39) | | | $ | (22) | | | $ | (8) | | | $ | 36 | | | $ | 72 | | | $ | 108 | |
(a)As of December 31, 2022, none of our investments had interest rates below 1%. As of December 31, 2021, some of our investments had interest rates below 1% , so the assumed hypothetical change in pretax earnings does not reflect the full 1% point reduction.
(b)The interest rate under our senior notes, which represent 90% of total debt, is fixed, unaffected by changes in interest rates. We had $500 million and $2.5 billion of variable rate term loans at December 31, 2022 and December 31, 2021, respectively, used to fund the August 2021 KAH acquisition. There were no borrowings outstanding under the credit agreement at December 31, 2022 or December 31, 2021. There was $595 million and $955 million outstanding under our commercial paper program at December 31, 2022 and 2021, respectively. As of December 31, 2022, our interest rate under our commercial paper program was not less than 1%. As of December 31, 2021, our interest rate under our commercial paper program was less than 1% so the assumed hypothetical change in pretax earnings does not reflect the full 1% point reduction.
|
| | | | | | | | | | | | | | | | | | | | | | | | |
| | Increase (decrease) in pretax earnings given an interest rate decrease of X basis points | | Increase (decrease) in pretax earnings given an interest rate increase of X basis points |
| | (300) | | (200) | | (100) | | 100 | | 200 | | 300 |
| | (in millions) |
As of December 31, 2019 | | | | | | | | | | | | |
Investment income (a) | | $ | (150 | ) | | $ | (133 | ) | | $ | (79 | ) | | $ | 78 |
| | $ | 157 |
| | $ | 235 |
|
Interest expense (b) | | 10 |
| | 9 |
| | 4 |
| | (4 | ) | | (9 | ) | | (13 | ) |
Pretax | | $ | (140 | ) | | $ | (124 | ) | | $ | (75 | ) | | $ | 74 |
| | $ | 148 |
| | $ | 222 |
|
As of December 31, 2018 | | | | | | | | | | | | |
Investment income (a) | | $ | (154 | ) | | $ | (114 | ) | | $ | (57 | ) | | $ | 58 |
| | $ | 116 |
| | $ | 175 |
|
Interest expense (b) | | 31 |
| | 20 |
| | 10 |
| | (10 | ) | | (20 | ) | | (31 | ) |
Pretax | | $ | (123 | ) | | $ | (94 | ) | | $ | (47 | ) | | $ | 48 |
| | $ | 96 |
| | $ | 144 |
|
| |
(a) | As of December 31, 2019 and 2018, some of our investments had interest rates below 2% so the assumed hypothetical change in pretax earnings does not reflect the full 2% point reduction. |
| |
(b) | The interest rate under our senior notes is fixed. There were no borrowings outstanding under the credit agreement at December 31, 2019 or December 31, 2018. There was $300 million and $645 million outstanding under our commercial paper program at December 31, 2019 and 2018, respectively. As of December 31, 2019, our interest rate under our commercial paper program was less than 3% so the assumed hypothetical change in pretax earnings does not reflect the full 3% point reduction. |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Humana Inc.
CONSOLIDATED BALANCE SHEETS | | | December 31, | | December 31, |
| 2019 | | 2018 | | 2022 | | 2021 |
| (in millions, except share amounts) | | (in millions, except share amounts) |
ASSETS | | | | ASSETS | |
Current assets: | | | | Current assets: | |
Cash and cash equivalents | $ | 4,054 |
| | $ | 2,343 |
| Cash and cash equivalents | $ | 5,061 | | | $ | 3,394 | |
Investment securities | 10,972 |
| | 10,026 |
| Investment securities | 13,881 | | | 13,192 | |
Receivables, less allowance for doubtful accounts of $69 in 2019 and $79 in 2018 | 1,056 |
| | 1,015 |
| |
Receivables, net of allowances of $70 in 2022 and $83 in 2021 | | Receivables, net of allowances of $70 in 2022 and $83 in 2021 | 1,674 | | | 1,814 | |
Other current assets | 3,806 |
| | 3,564 |
| Other current assets | 5,567 | | | 6,493 | |
Total current assets | 19,888 |
| | 16,948 |
| Total current assets | 26,183 | | | 24,893 | |
Property and equipment, net | 1,955 |
| | 1,735 |
| Property and equipment, net | 3,221 | | | 3,073 | |
Long-term investment securities | 406 |
| | 411 |
| Long-term investment securities | 380 | | | 780 | |
Goodwill | 3,928 |
| | 3,897 |
| Goodwill | 9,142 | | | 11,092 | |
Equity method investment in Kindred at Home | 1,063 |
| | 1,047 |
| |
Equity method investments | | Equity method investments | 749 | | | 141 | |
Other long-term assets | 1,834 |
| | 1,375 |
| Other long-term assets | 3,380 | | | 4,379 | |
Total assets | $ | 29,074 |
| | $ | 25,413 |
| Total assets | $ | 43,055 | | | $ | 44,358 | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | |
LIABILITIES AND STOCKHOLDERS' EQUITY | | LIABILITIES AND STOCKHOLDERS' EQUITY | | | |
Current liabilities: | | | | Current liabilities: | |
Benefits payable | $ | 6,004 |
| | $ | 4,862 |
| Benefits payable | $ | 9,264 | | | $ | 8,289 | |
Trade accounts payable and accrued expenses | 3,754 |
| | 3,067 |
| Trade accounts payable and accrued expenses | 5,238 | | | 4,509 | |
Book overdraft | 225 |
| | 171 |
| Book overdraft | 298 | | | 326 | |
Unearned revenues | 247 |
| | 283 |
| Unearned revenues | 286 | | | 254 | |
Short-term debt | 699 |
| | 1,694 |
| Short-term debt | 2,092 | | | 1,953 | |
Total current liabilities | 10,929 |
| | 10,077 |
| Total current liabilities | 17,178 | | | 15,331 | |
Long-term debt | 4,967 |
| | 4,375 |
| Long-term debt | 9,034 | | | 10,541 | |
Future policy benefits payable | 206 |
| | 219 |
| |
Other long-term liabilities | 935 |
| | 581 |
| Other long-term liabilities | 1,473 | | | 2,383 | |
Total liabilities | 17,037 |
| | 15,252 |
| Total liabilities | 27,685 | | | 28,255 | |
Commitments and contingencies (Note 17) |
| |
| Commitments and contingencies (Note 17) | | | |
Stockholders’ equity: | | | | |
Stockholders' Equity: | | Stockholders' Equity: | |
Preferred stock, $1 par; 10,000,000 shares authorized; none issued | — |
| | — |
| Preferred stock, $1 par; 10,000,000 shares authorized; none issued | — | | | — | |
Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,629,992 shares issued at December 31, 2019 and 198,594,841 shares issued at December 31, 2018 | 33 |
| | 33 |
| |
Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,666,598 shares issued at December 31, 2022 and 198,648,742 shares issued at December 31, 2021 | | Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,666,598 shares issued at December 31, 2022 and 198,648,742 shares issued at December 31, 2021 | 33 | | | 33 | |
Capital in excess of par value | 2,820 |
| | 2,535 |
| Capital in excess of par value | 3,246 | | | 3,082 | |
Retained earnings | 17,483 |
| | 15,072 |
| Retained earnings | 25,492 | | | 23,086 | |
Accumulated other comprehensive income (loss) | 156 |
| | (159 | ) | |
Treasury stock, at cost, 66,524,771 shares at December 31, 2019 and 63,028,169 shares at December 31, 2018 | (8,455 | ) | | (7,320 | ) | |
Total stockholders’ equity | 12,037 |
| | 10,161 |
| |
Total liabilities and stockholders’ equity | $ | 29,074 |
| | $ | 25,413 |
| |
Accumulated other comprehensive (loss) income | | Accumulated other comprehensive (loss) income | (1,304) | | | 42 | |
Treasury stock, at cost, 73,691,955 shares at December 31, 2022 and 69,846,758 shares at December 31, 2021 | | Treasury stock, at cost, 73,691,955 shares at December 31, 2022 and 69,846,758 shares at December 31, 2021 | (12,156) | | | (10,163) | |
Total stockholders' equity | | Total stockholders' equity | 15,311 | | | 16,080 | |
Noncontrolling interests | | Noncontrolling interests | 59 | | | 23 | |
Total equity | | Total equity | 15,370 | | | 16,103 | |
Total liabilities and equity | | Total liabilities and equity | $ | 43,055 | | | $ | 44,358 | |
The accompanying notes are an integral part of the consolidated financial statements.
Humana Inc.
CONSOLIDATED STATEMENTS OF INCOME
| | | For the year ended December 31, | | For the year ended December 31, |
| 2019 | | 2018 | | 2017 | | 2022 | | 2021 | | 2020 |
| (in millions, except per share results) | | (in millions, except per share results) |
Revenues: | | | | | | Revenues: | |
Premiums | $ | 62,948 |
| | $ | 54,941 |
| | $ | 52,380 |
| Premiums | $ | 87,712 | | | $ | 79,822 | | | $ | 74,186 | |
Services | 1,439 |
| | 1,457 |
| | 982 |
| Services | 4,776 | | | 3,055 | | | 1,815 | |
Investment income | 501 |
| | 514 |
| | 405 |
| Investment income | 382 | | | 187 | | | 1,154 | |
Total revenues | 64,888 |
| | 56,912 |
| | 53,767 |
| Total revenues | 92,870 | | | 83,064 | | | 77,155 | |
Operating expenses: | | | | | | Operating expenses: | | | | | |
Benefits | 53,857 |
| | 45,882 |
| | 43,496 |
| Benefits | 75,690 | | | 69,199 | | | 61,628 | |
Operating costs | 7,381 |
| | 7,525 |
| | 6,567 |
| Operating costs | 12,671 | | | 10,121 | | | 10,052 | |
Merger termination fee and related costs, net | — |
| | — |
| | (936 | ) | |
| Depreciation and amortization | 458 |
| | 405 |
| | 378 |
| Depreciation and amortization | 709 | | | 596 | | | 489 | |
Total operating expenses | 61,696 |
| | 53,812 |
| | 49,505 |
| Total operating expenses | 89,070 | | | 79,916 | | | 72,169 | |
Income from operations | 3,192 |
| | 3,100 |
| | 4,262 |
| Income from operations | 3,800 | | | 3,148 | | | 4,986 | |
Loss on sale of business | — |
| | 786 |
| | — |
| |
Gain on sale of KAH Hospice | | Gain on sale of KAH Hospice | (237) | | | — | | | — | |
Interest expense | 242 |
| | 218 |
| | 242 |
| Interest expense | 401 | | | 326 | | | 283 | |
Other (income) expense, net | (506 | ) | | 33 |
| | — |
| |
Income before income taxes and equity in net earnings | 3,456 |
| | 2,063 |
| | 4,020 |
| |
Other expense (income), net | | Other expense (income), net | 68 | | | (532) | | | 103 | |
Income before income taxes and equity in net (losses) earnings | | Income before income taxes and equity in net (losses) earnings | 3,568 | | | 3,354 | | | 4,600 | |
Provision for income taxes | 763 |
| | 391 |
| | 1,572 |
| Provision for income taxes | 762 | | | 485 | | | 1,307 | |
Equity in net earnings of Kindred at Home | 14 |
| | 11 |
| | — |
| |
Equity in net (losses) earnings | | Equity in net (losses) earnings | (4) | | | 65 | | | 74 | |
Net income | $ | 2,707 |
| | $ | 1,683 |
| | $ | 2,448 |
| Net income | $ | 2,802 | | | $ | 2,934 | | | $ | 3,367 | |
Net loss (income) attributable to noncontrolling interests | | Net loss (income) attributable to noncontrolling interests | 4 | | | (1) | | | — | |
Net income attributable to Humana | | Net income attributable to Humana | $ | 2,806 | | | $ | 2,933 | | | $ | 3,367 | |
Basic earnings per common share | $ | 20.20 |
| | $ | 12.24 |
| | $ | 16.94 |
| Basic earnings per common share | $ | 22.20 | | | $ | 22.79 | | | $ | 25.47 | |
Diluted earnings per common share | $ | 20.10 |
| | $ | 12.16 |
| | $ | 16.81 |
| Diluted earnings per common share | $ | 22.08 | | | $ | 22.67 | | | $ | 25.31 | |
The accompanying notes are an integral part of the consolidated financial statements.
Humana Inc.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
|
| | | | | | | | | | | |
| For the year ended December 31, |
| 2019 | | 2018 | | 2017 |
| (in millions) |
Net income | $ | 2,707 |
|
| $ | 1,683 |
|
| $ | 2,448 |
|
Other comprehensive income (loss): | | | | | |
Change in gross unrealized investment losses/gains | 450 |
| | (189 | ) | | 149 |
|
Effect of income taxes | (105 | ) | | 51 |
| | (55 | ) |
Total change in unrealized investment gains/losses, net of tax | 345 |
| | (138 | ) | | 94 |
|
Reclassification adjustment for net realized gains included in investment income | (34 | ) | | (53 | ) | | (14 | ) |
Effect of income taxes | 8 |
| | 17 |
| | 5 |
|
Total reclassification adjustment, net of tax | (26 | ) | | (36 | ) | | (9 | ) |
Other comprehensive income (loss), net of tax | 319 |
| | (174 | ) | | 85 |
|
Comprehensive income attributable to our equity method investment in Kindred at Home | (4 | ) | | (4 | ) | | — |
|
Comprehensive income | $ | 3,022 |
| | $ | 1,505 |
| | $ | 2,533 |
|
| | | | | | | | | | | | | | | | | |
| For the year ended December 31, |
| 2022 | | 2021 | | 2020 |
| (in millions) |
Net income attributable to Humana | $ | 2,806 | | | $ | 2,933 | | | $ | 3,367 | |
Other comprehensive income (loss): | | | | | |
Change in gross unrealized investment (losses) gains | (1,819) | | | (356) | | | 393 | |
Effect of income taxes | 418 | | | 81 | | | (89) | |
Total change in unrealized investment (losses) gains, net of tax | (1,401) | | | (275) | | | 304 | |
Reclassification adjustment for net realized losses (gains) included in investment income | 72 | | | (103) | | | (90) | |
Effect of income taxes | (17) | | | 23 | | | 20 | |
Total reclassification adjustment, net of tax | 55 | | | (80) | | | (70) | |
Other comprehensive (loss) income, net of tax | (1,346) | | | (355) | | | 234 | |
Comprehensive income attributable to equity method investments | — | | | 6 | | | 1 | |
Comprehensive income attributable to Humana | $ | 1,460 | | | $ | 2,584 | | | $ | 3,602 | |
The accompanying notes are an integral part of the consolidated financial statements.
Humana Inc.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Common Stock | | Capital In Excess of Par Value | | Retained Earnings | | Accumulated Other Comprehensive Income (Loss) | | Treasury Stock | | Total Stockholders' Equity | | Noncontrolling Interests | | Total Equity |
| Issued Shares | | Amount | | | |
| (dollars in millions, share amounts in thousands) |
Balances, January 1, 2020 | 198,630 | | | 33 | | | 2,820 | | | 17,483 | | | 156 | | | (8,455) | | | 12,037 | | | — | | | 12,037 | |
Net income | | | | | | | 3,367 | | | | | | | 3,367 | | | — | | | 3,367 | |
Impact of adopting accounting standard | | | | | | | (2) | | | | | | | (2) | | | — | | | (2) | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
Other comprehensive income | | | | | | | | | 235 | | | | | 235 | | | | | 235 | |
Common stock repurchases | — | | | | | (263) | | | | | | | (1,557) | | | (1,820) | | | | | (1,820) | |
Dividends and dividend equivalents | | | | | | | (331) | | | | | | | (331) | | | | | (331) | |
Stock-based compensation | | | | | 181 | | | | | | | | | 181 | | | | | 181 | |
Restricted stock unit vesting | 19 | | | — | | | (59) | | | | | | | 59 | | | — | | | | | — | |
Stock option exercises | — | | | — | | | 26 | | | | | | | 35 | | | 61 | | | | | 61 | |
Balances, December 31, 2020 | 198,649 | | | 33 | | | 2,705 | | | 20,517 | | | 391 | | | (9,918) | | | 13,728 | | | — | | | 13,728 | |
Net income | | | | | | | 2,933 | | | | | | | 2,933 | | | 1 | | | 2,934 | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
Acquisition | | | | | | | | | | | | | — | | | 22 | | | 22 | |
Other comprehensive loss | | | | | | | | | (349) | | | | | (349) | | | | | (349) | |
Common stock repurchases | — | | | | | 262 | | | | | | | (341) | | | (79) | | | | | (79) | |
Dividends and dividend equivalents | | | | | — | | | (364) | | | | | | | (364) | | | | | (364) | |
Stock-based compensation | | | | | 180 | | | | | | | | | 180 | | | | | 180 | |
Restricted stock unit vesting | — | | | — | | | (81) | | | | | | | 81 | | | — | | | | | — | |
Stock option exercises | — | | | — | | | 16 | | | | | | | 15 | | | 31 | | | | | 31 | |
Balances, December 31, 2021 | 198,649 | | | 33 | | | 3,082 | | | 23,086 | | | 42 | | | (10,163) | | | 16,080 | | | 23 | | | 16,103 | |
Net income | | | | | | | 2,806 | | | | | | | 2,806 | | | (4) | | | 2,802 | |
Distribution to noncontrolling interest holders, net | | | | | | | | | | | | | — | | | (1) | | | (1) | |
Sale of KAH Hospice | | | | | | | | | | | | | — | | | (11) | | | (11) | |
Acquisition | | | | | | | | | | | | | — | | | 52 | | | 52 | |
Other comprehensive loss | | | | | | | | | (1,346) | | | | | (1,346) | | | | | (1,346) | |
Common stock repurchases | — | | | | | — | | | | | | | (2,096) | | | (2,096) | | | | | (2,096) | |
Dividends and dividend equivalents | | | | | — | | | (400) | | | | | | | (400) | | | | | (400) | |
Stock-based compensation | | | | | 216 | | | | | | | | | 216 | | | | | 216 | |
Restricted stock unit vesting | 18 | | | — | | | (78) | | | | | | | 78 | | | — | | | | | — | |
Stock option exercises | — | | | — | | | 26 | | | | | | | 25 | | | 51 | | | | | 51 | |
Balances, December 31, 2022 | 198,667 | | | 33 | | | 3,246 | | | 25,492 | | | (1,304) | | | (12,156) | | | 15,311 | | | 59 | | | 15,370 | |
The accompanying notes are an integral part of the consolidated financial statements.
|
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| Common Stock | | Capital In Excess of Par Value | | Retained Earnings | | Accumulated Other Comprehensive Income (Loss) | | Treasury Stock | | Total Stockholders’ Equity |
| Issued Shares | | Amount | |
| (dollars in millions, share amounts in thousands) |
Balances, January 1, 2017 | 198,495 |
| | $ | 33 |
| | $ | 2,562 |
| | $ | 11,454 |
| | $ | (66 | ) | | $ | (3,298 | ) | | $ | 10,685 |
|
Net income |
| |
| |
| | 2,448 |
| |
| |
| | 2,448 |
|
Other comprehensive income |
| |
| |
| |
| | 85 |
| |
| | 85 |
|
Common stock repurchases |
| |
| | (200 | ) | |
| |
| | (3,165 | ) | | (3,365 | ) |
Dividends and dividend equivalents |
| |
| | — |
| | (232 | ) | |
| |
| | (232 | ) |
Stock-based compensation |
| |
| | 157 |
| |
| |
| |
| | 157 |
|
Restricted stock unit vesting | — |
| | — |
| | (138 | ) | |
| |
| | 138 |
| | — |
|
Stock option exercises | 77 |
| | — |
| | 64 |
| |
| |
| | — |
| | 64 |
|
Balances, December 31, 2017 | 198,572 |
| | 33 |
| | 2,445 |
| | 13,670 |
| | 19 |
| | (6,325 | ) | | 9,842 |
|
Net income |
| | | | | | 1,683 |
| | | | | | 1,683 |
|
Other comprehensive loss |
| | | | | | (4 | ) | | (178 | ) | | | | (182 | ) |
Common stock repurchases |
| | | | 50 |
| | | | | | (1,140 | ) | | (1,090 | ) |
Dividends and dividend equivalents |
| | | | — |
| | (277 | ) | | | | | | (277 | ) |
Stock-based compensation |
| | | | 137 |
| | | | | | | | 137 |
|
Restricted stock unit vesting | — |
| | — |
| | (145 | ) | | | | | | 145 |
| | — |
|
Stock option exercises | 23 |
| | — |
| | 48 |
| | | | | | — |
| | 48 |
|
Balances, December 31, 2018 | 198,595 |
| | 33 |
| | 2,535 |
| | 15,072 |
| | (159 | ) | | (7,320 | ) | | 10,161 |
|
Net income | | | | | | | 2,707 |
| | | | | | 2,707 |
|
Other comprehensive income | | | | | | |
|
| | 315 |
| | | | 315 |
|
Common stock repurchases | | | | | 150 |
| | | | | | (1,220 | ) | | (1,070 | ) |
Dividends and dividend equivalents | | | | | — |
| | (296 | ) | | | | | | (296 | ) |
Stock-based compensation | | | | | 163 |
| | | | | | | | 163 |
|
Restricted stock unit vesting | 32 |
| | — |
| | (48 | ) | | | | | | 48 |
| | — |
|
Stock option exercises | 3 |
| | — |
| | 20 |
| | | | | | 37 |
| | 57 |
|
Balances, December 31, 2019 | 198,630 |
| | $ | 33 |
| | $ | 2,820 |
| | $ | 17,483 |
| | $ | 156 |
| | $ | (8,455 | ) | | $ | 12,037 |
|
Humana Inc.
CONSOLIDATED STATEMENTS OF CASH FLOW
| | | | | | | | | | | | | | | | | |
| For the year ended December 31, |
| 2022 | | 2021 | | 2020 |
| (in millions) |
Cash flows from operating activities | | | | | |
Net income | $ | 2,802 | | | $ | 2,934 | | | $ | 3,367 | |
Adjustments to reconcile net income to net cash provided by operating activities: | | | | | |
Gain on sale of KAH Hospice | (237) | | | — | | | — | |
Loss (gain) on investment securities, net | 205 | | | 130 | | | (838) | |
Gain on Kindred at Home equity method investment | — | | | (1,129) | | | — | |
Equity in net losses (earnings) | 4 | | | (65) | | | (74) | |
Stock-based compensation | 216 | | | 180 | | | 181 | |
Depreciation | 749 | | | 640 | | | 528 | |
Amortization | 96 | | | 73 | | | 88 | |
Impairment of property and equipment | 248 | | | — | | | — | |
(Benefit) provision for deferred income taxes | (100) | | | 15 | | | 195 | |
Changes in operating assets and liabilities, net of effect of businesses acquired and dispositions: | | | | | |
Receivables | (54) | | | (280) | | | (85) | |
Other assets | (463) | | | (491) | | | (581) | |
Benefits payable | 975 | | | 104 | | | 2,139 | |
Other liabilities | 44 | | | 176 | | | 599 | |
Unearned revenues | 32 | | | (65) | | | 71 | |
Other, net | 70 | | | 40 | | | 49 | |
Net cash provided by operating activities | 4,587 | | | 2,262 | | | 5,639 | |
Cash flows from investing activities | | | | | |
Proceeds from sale of KAH Hospice, net | 2,701 | | | — | | | — | |
Acquisitions, net of cash and cash equivalents acquired | (337) | | | (4,187) | | | (709) | |
Purchases of property and equipment, net | (1,120) | | | (1,316) | | | (964) | |
Purchases of investment securities | (6,049) | | | (7,197) | | | (9,125) | |
Proceeds from maturities of investment securities | 1,365 | | | 2,597 | | | 4,986 | |
Proceeds from sales of investment securities | 2,434 | | | 3,547 | | | 2,747 | |
Net cash used in investing activities | (1,006) | | | (6,556) | | | (3,065) | |
Cash flows from financing activities | | | | | |
Receipts (withdrawals) from contract deposits, net | 1,993 | | | (306) | | | (939) | |
Proceeds from issuance of senior notes, net | 1,982 | | | 2,984 | | | 1,088 | |
Repayment of senior notes | (1,000) | | | — | | | (400) | |
(Repayments) proceeds from issuance of commercial paper, net | (376) | | | 352 | | | 295 | |
Proceeds from term loan | — | | | 2,500 | | | 1,000 | |
Repayment of term loan | (2,000) | | | (2,078) | | | (1,000) | |
Debt issue costs | (6) | | | (31) | | | — | |
Common stock repurchases | (2,096) | | | (79) | | | (1,820) | |
Dividends paid | (392) | | | (354) | | | (323) | |
Change in book overdraft | (28) | | | 6 | | | 95 | |
Other, net | 9 | | | 21 | | | 49 | |
Net cash (used in) provided by financing activities | (1,914) | | | 3,015 | | | (1,955) | |
Increase (decrease) in cash and cash equivalents | 1,667 | | | (1,279) | | | 619 | |
Cash and cash equivalents at beginning of period | 3,394 | | | 4,673 | | | 4,054 | |
Cash and cash equivalents at end of period | $ | 5,061 | | | $ | 3,394 | | | $ | 4,673 | |
Humana Inc.
CONSOLIDATED STATEMENTS OF CASH FLOW—(Continued)
| | | | | | | | | | | | | | | | | |
| For the year ended December 31, |
| 2022 | | 2021 | | 2020 |
Supplemental cash flow disclosures: | (in millions) |
Interest payments | $ | 354 | | | $ | 285 | | | $ | 258 | |
Income tax payments, net | $ | 758 | | | $ | 227 | | | $ | 1,132 | |
Details of businesses acquired in purchase transactions: | | | | | |
Fair value of assets acquired, net of cash acquired | $ | 460 | | | $ | 9,804 | | | $ | 819 | |
Less: Fair value of liabilities assumed | (70) | | | (3,235) | | | (110) | |
Less: Noncontrolling interests acquired | (53) | | | (22) | | | — | |
Less: Remeasured existing Kindred at Home equity method investment | — | | | (2,360) | | | — | |
Cash paid for acquired businesses, net of cash acquired | $ | 337 | | | $ | 4,187 | | | $ | 709 | |
The accompanying notes are an integral part of the consolidated financial statements.
Humana Inc.
CONSOLIDATED STATEMENTS OF CASH FLOW
|
| | | | | | | | | | | |
| For the year ended December 31, |
| 2019 | | 2018 | | 2017 |
| (in millions) |
Cash flows from operating activities |
| |
| |
|
Net income | $ | 2,707 |
| | $ | 1,683 |
| | $ | 2,448 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
| |
| |
|
Loss on sale of business | — |
| | 786 |
| | — |
|
Net realized capital gains | (62 | ) | | (90 | ) | | (14 | ) |
Equity in net earnings of Kindred at Home | (14 | ) | | (11 | ) | | — |
|
Stock compensation | 163 |
| | 137 |
| | 157 |
|
Depreciation | 505 |
| | 444 |
| | 410 |
|
Amortization | 70 |
| | 90 |
| | 75 |
|
Provision for deferred income taxes | 162 |
| | 194 |
| | 132 |
|
Changes in operating assets and liabilities, net of effect of businesses acquired and dispositions: |
| |
| |
|
Receivables | (32 | ) | | (164 | ) | | 426 |
|
Other assets | 118 |
| | (484 | ) | | (582 | ) |
Benefits payable | 1,142 |
| | 252 |
| | 105 |
|
Other liabilities | 471 |
| | (676 | ) | | 641 |
|
Unearned revenues | (36 | ) | | (95 | ) | | 98 |
|
Other | 90 |
| | 107 |
| | 155 |
|
Net cash provided by operating activities | 5,284 |
| | 2,173 |
| | 4,051 |
|
Cash flows from investing activities |
| |
| |
|
Acquisitions, net of cash acquired | — |
| | (354 | ) | | (31 | ) |
Purchase of equity method investment in Kindred at Home | — |
| | (1,095 | ) | | — |
|
Cash transferred in sale of business | — |
| | (805 | ) | | — |
|
Purchases of property and equipment | (736 | ) | | (612 | ) | | (524 | ) |
Purchases of investment securities | (6,361 | ) | | (4,687 | ) | | (6,265 | ) |
Maturities of investment securities | 1,733 |
| | 972 |
| | 1,111 |
|
Proceeds from sales of investment securities | 4,086 |
| | 3,494 |
| | 2,768 |
|
Net cash used in investing activities | (1,278 | ) | | (3,087 | ) | | (2,941 | ) |
Cash flows from financing activities |
|
| |
|
| |
|
|
(Receipts) withdrawals from contract deposits, net | (623 | ) | | (640 | ) | | 1,823 |
|
Proceeds from issuance of senior notes, net | 987 |
| | — |
| | 1,779 |
|
(Repayments) proceeds from issuance of commercial paper, net | (360 | ) | | 485 |
| | (153 | ) |
Proceeds from term loan | — |
| | 1,000 |
| | — |
|
Repayment of term loan | (650 | ) | | (350 | ) | | — |
|
Repayment of long-term debt | (400 | ) | | — |
| | (800 | ) |
Common stock repurchases | (1,070 | ) | | (1,090 | ) | | (3,365 | ) |
Dividends paid | (291 | ) | | (265 | ) | | (220 | ) |
Change in book overdraft | 54 |
| | 30 |
| | (71 | ) |
Proceeds from stock option exercises & other | 58 |
| | 45 |
| | 62 |
|
Net cash used in financing activities | (2,295 | ) | | (785 | ) | | (945 | ) |
Increase (decrease) in cash and cash equivalents | 1,711 |
| | (1,699 | ) | | 165 |
|
Cash and cash equivalents at beginning of period | 2,343 |
| | 4,042 |
| | 3,877 |
|
Cash and cash equivalents at end of period | $ | 4,054 |
| | $ | 2,343 |
| | $ | 4,042 |
|
Humana Inc.
CONSOLIDATED STATEMENTS OF CASH FLOW—(Continued)
|
| | | | | | | | | | | |
| For the year ended December 31, |
| 2019 | | 2018 | | 2017 |
Supplemental cash flow disclosures: | (in millions) |
Interest payments | $ | 212 |
| | $ | 195 |
| | $ | 216 |
|
Income tax payments, net | $ | 518 |
| | $ | 631 |
| | $ | 1,498 |
|
Details of businesses acquired in purchase transactions: | | | | | |
Fair value of assets acquired, net of cash acquired | $ | 28 |
| | $ | 392 |
| | $ | 31 |
|
Less: Fair value of liabilities assumed | (28 | ) | | (38 | ) | | — |
|
Cash paid for acquired businesses, net of cash acquired | $ | — |
| | $ | 354 |
| | $ | 31 |
|
The accompanying notes are an integral part of the consolidated financial statements.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. REPORTING ENTITY
Nature of Operations
Humana Inc., headquartered in Louisville, Kentucky, is a leading health and well-being company committed to helping our millions of medical and specialty members achieve their best health. Our successful history in care delivery and health plan administration is helping us create a new kind of integrated care with the power to improve health and well‐being and lower costs. Our efforts are leading to a better quality of life for people with Medicare, families, individuals, military service personnel, and communities at large. To accomplish that, we support physicians and other health care professionals as they work to deliver the right care in the right place for their patients, our members. Our range of clinical capabilities, resources and tools, such as in‐home care, behavioral health, pharmacy services, data analytics and wellness solutions, combine to produce a simplified experience that makes health care easier to navigate and more effective. References throughout these notes to consolidated financial statements to “we,” “us,” “our,” “Company,” and “Humana,” mean Humana Inc. and its subsidiaries. We derived approximately 82% of our total premiums and services revenue from contracts with the federal government in 2019,2022, including 15%14% related to our federal government contracts with the Centers for Medicare and Medicaid Services, or CMS, to provide health insurance coverage for individual Medicare Advantage members in Florida. CMS is the federal government’s agency responsible for administering the Medicare program.
Business Segment Realignment
During December 2022, we realigned our businesses into two distinct segments: Insurance and CenterWell. The Insurance segment includes the businesses that were previously included in the Retail and Group and Specialty segments, as well as the Pharmacy Benefit Manager, or PBM, business which was previously included in the Healthcare Services segment. The CenterWell segment (formerly Healthcare Services) represents our payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. In addition to the new segment classifications being utilized to assess performance and allocate resources, we believe this simpler structure will create greater collaboration across the Insurance and CenterWell businesses and will accelerate work that is underway to centralize and integrate operations within the organization.Prior period segment financial information has been recast to conform to the 2022 presentation. For a recast of prior period segment financial information, refer to Note 18 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
Our financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. Our consolidated financial statements include the accounts of Humana Inc. and subsidiaries that the Company controls, including variable interest entities associated with medical practices for which we are the primary beneficiary. We do not own many of our medical practices but instead enter into exclusive management agreements with the affiliated Professional Associations, or P.A.s, that operate these medical practices. Based upon the provisions of these agreements, these affiliated P.A.s are variable interest entities and we are the primary beneficiary, and accordingly we consolidate the affiliated P.A.s. All significant intercompany balances and transactions have been eliminated.
The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill.goodwill and indefinite-lived intangible assets. These estimates are based
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.
Workforce OptimizationValue Creation Initiatives
We initiated involuntary workforce reduction programs during 2019During 2022, in order to create capacity to fund growth and 2017, as well as a voluntary early retirement program during 2017. These programs impacted approximately 1,000 associatesinvestment in 2019our Medicare Advantage business and 3,600 associatesfurther expansion of our healthcare services capabilities in 2017.2023, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, we recorded charges of $47$473 million included within operating costs in 2019 and $148 million in 2017. Payments under these programs are made upon termination during the early retirement or severance pay period. The 2017 workforce optimization obligation was $12 million at December 31, 2018 and was fully settled as of December 31, 2019. The remaining 2019 workforce optimization obligation was $45 million as of December 31, 2019.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Aetna Merger
On February 16, 2017, under the terms of the Agreement and Plan of Merger, or Merger Agreement, with Aetna Inc., and certain wholly owned subsidiaries of Aetna Inc., which we collectively refer to as Aetna, we received a breakup fee of $1 billion from Aetna, which is included in our consolidated statement of income for the year ended December 31, 2022. These charges primarily relate to $248 million in asset impairments, including software and abandonment, and $116 million of severance charges in connection with workforce optimization. The remainder of the charges primarily relate to external consulting fees. These charges were recorded at the corporate level and not allocated to the segments.
COVID-19
The emergence and spread of the novel coronavirus, or COVID-19, beginning in the line captioned "Merger termination feefirst quarter of 2020 has impacted our business. During periods of increased incidences of COVID-19, a reduction in non-COVID-19 hospital admissions for non-emergent and relatedelective medical care have resulted in lower overall healthcare system utilization. At the same time, COVID-19 treatment and testing costs net."increased utilization. During 2022, we experienced lower overall utilization of the healthcare system than anticipated, as the reduction in COVID-19 utilization following the increased incidence associated with the Omicron variant outpaced the increase in non-COVID-19 utilization. The significant disruption in utilization during 2020 also impacted our ability to implement clinical initiatives to manage health care costs and chronic conditions of our members, and appropriately document their risk profiles, and, as such, significantly affected our 2021 revenue under the risk adjustment payment model for Medicare Advantage plans. Finally, changes in utilization patterns and actions taken in 2020 and 2021 as a result of the COVID-19 pandemic, including the suspension of certain financial recovery programs for a period of time and shifting the timing of claim payments and provider capitation surplus payments, impacted our claim reserve development and operating cash flows for 2020 and 2021.
Health Care Reform
The Patient Protection and Affordable Care Act and The Health Care and Education Reconciliation Act of 2010 (which we collectively refer to as the Health Care Reform Law) enacted significant reforms to various aspects of the U.S. health insurance industry. Certain of these reforms became effective January 1, 2014, including an annual insurance industry premium-based fee and the establishment of federally-facilitated or state-based exchanges. Operating results for our individual commercial medical business compliant with the Health Care Reform Law were challenged primarily due to unanticipated modifications in the program subsequent to the passing of the Health Care Reform Law, resulting in higher covered population morbidity and the ensuing enrollment and claims issues causing volatility in claims experience. As a result of these and other factors, we exited our individual commercial medical business effective January 1, 2018.
The annual premium-based fee on health insurers is not deductible for tax purposes. We estimate a liability for the health insurance industry fee and record it in full once qualifying insurance coverage is provided in the applicable calendar year in which the fee is payable with a corresponding deferred cost that is amortized ratably to expense over the same calendar year. We record the liability for the health insurance industry fee in trade accounts payable and accrued expenses and record the deferred cost in other current assets in our consolidated financial statements. We pay the health insurance industry fee in September or October of each year. The Consolidated Appropriations Act enacted on December 18, 2015, included a one year suspension in 2017 of the health insurance industry fee. In 2018, we paid the federal government $1.04 billion for the annual health insurance industry fee attributed to calendar year 2018. The Continuing Resolution bill, H.R. 195, enacted on January 22, 2018, included a one year suspension in 2019 of the health insurance industry fee, but the fee will resume forresumed in calendar year 2020. The Further Consolidated Appropriations Act, 2020, enacted on December 20, 2019, permanently repealed the health insurance industry fee beginning in calendar year 2021.
The annual premium-based fee on health insurers was not deductible for tax purposes. We estimated a liability for the health insurance industry fee and recorded it in full once qualifying insurance coverage was provided in the applicable calendar year in which the fee was payable with a corresponding deferred cost that was amortized ratably to expense over the same calendar year. We recorded the liability for the health insurance industry fee in trade accounts payable and accrued expenses and recorded the deferred cost in other current assets in our consolidated financial statements. We paid the health insurance industry fee in September or October of each year. We paid the federal government $1.18 billion for the annual health insurance industry fee attributed to calendar year 2020.
On November 2, 2017, we filed suit against the United States of America in the United States Court of Federal Claims, on behalf of our health plans seeking recovery from the federal government of approximately $611 million in payments under the risk corridor premium stabilization program established under Health Care Reform, for years 2014, 2015 and 2016. On April 27, 2020, the U.S. Supreme Court ruled that the government is obligated to pay the losses under this risk corridor program and that Congress did not implicitly repeal the obligation under its appropriations riders. In September 2020, we received a $609 million payment from the U.S Government pursuant
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
to the judgement issued by the Court of Federal Claims on July 7, 2020. The $609 million payment received from the U.S Government and approximately $31 million in related fees and expenses are reflected in Premiums revenue and Operating costs, respectively, in our consolidated statements of income for the year ended December 31, 2020 and reported in the Corporate segment.
Cash and Cash Equivalents
Cash and cash equivalents include cash, time deposits, money market funds, commercial paper, other money market instruments, and certain U.S. Government securities with an original maturity of three months or less. Carrying value approximates fair value due to the short-term maturity of the investments.
Investment Securities
Investment securities, which consist primarily of debt and equity securities, are stated at fair value. Our debt securities have been categorized as available for sale and, as a result, are stated at fair value. Investmentsale. Debt securities available for current operations, as well as our equity securities, are classified as current assets. Investmentassets, and debt securities available forto fund our long-term insurance productsprofessional and professionalother self-insurance liability funding requirements, as well as restricted statutory deposits, are classified as long-term assets. For the purpose of determining realized gross realized gains and losses whichfor debt securities sold, that are included as a component of investment income in the consolidated statements of income, the cost of investment securities sold is based upon specific identification. Unrealized holding gains and losses for debt securities, net of applicable deferred taxes, are included in other comprehensive income or loss as a component of stockholders’ equity and comprehensive income until realized from a sale or other-than-temporary impairment.an expected credit loss is recognized. For the purpose of determining gross gains and losses for equity securities, changes in fair value at the reporting date are included as a component of investment income in the consolidated statements of income.
UnderBeginning on January 1, 2020, we adopted the new current expected credit losses, or CECL, model which retained many similarities from the previous other-than-temporary impairment model except eliminating from consideration in the impairment analysis the length of time over which the fair value had been less than cost. Also, under the CECL model, expected losses on available for sale debt securities held, we recognizeare recognized through an impairment lossallowance for credit losses rather than as reductions in income in an amount equal to the full difference between the amortized cost basis andof the securities. For debt securities whose fair value whenis less than their amortized cost which we do not intend to sell or are not required to sell, we evaluate the expected cash flows to be received as compared to amortized cost and determine if an expected credit loss has occurred. In the event of an expected credit loss, only the amount of the impairment associated with the expected credit loss is recognized in income with the remainder, if any, of the loss recognized in other comprehensive income. To the extent we have the intent to sell the debt security or it is more likely than not we will be required to sell the debt security before recovery of our amortized cost basis. However, ifbasis, we do not intendrecognize an impairment loss in income in an amount equal to sell the debt security, we evaluatefull difference between the expected cash flows to be received as compared to amortized cost basis and determine if athe fair value.
Potential expected credit loss has occurred. In the event of a credit loss,
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
only the amount of the impairment associated with the credit loss is recognized currently in income with the remainder of the loss recognized in other comprehensive income.
When we do not intend to sell a security in an unrealized loss position, potential other-than-temporary impairment is considered using a variety of factors, including the length of time and extent to which the fair value has been less than cost; adverse conditions specifically related to the industry, geographic area or financial condition of the issuer or underlying collateral of a debt security; changes in the quality of the debt security's credit enhancement; payment structure of the debt security; changes in credit rating of the debt security by the rating agencies; the volatilityfailure of the fair value changes;issuer to make scheduled principal or interest payments on the debt security and changes in fair value of the security after the balance sheet date.prepayment speeds. For debt securities, we take into account expectations of relevant market and economic data. For example, with respect to mortgage and asset-backed securities, such data includes underlying loan level data and structural features such as seniority and other forms of credit enhancements. A decline in fair value is considered other-than-temporary when we do not expect to recover the entire amortized cost basis of the security. We estimate the amount of the expected credit loss component of a debt security as the difference between the amortized cost and the present value of the expected cash flows of the security. The present value is determined using the best estimate of future cash flows discounted at the implicit interest rate at the date of purchase. The expected credit loss cannot exceed the full difference between the amortized cost basis and the fair value.
Receivables and Revenue Recognition
We generally establish one-year commercial membership contracts with employer groups, subject to cancellation by the employer group on 30-day written notice. Our Medicare contracts with CMS renew annually.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Our military services contracts with the federal government and certain contracts with various state Medicaid programs generally are multi-year contracts subject to annual renewal provisions.
Premiums Revenue
We receive monthly premiums from the federal government and various states according to government specified payment rates and various contractual terms. We bill and collect premium from employer groups and members in our Medicare and other individual products monthly. Changes in premium revenues resulting from the periodic changes in risk-adjustment scores derived from medical diagnoses for our membership are estimated by projecting the ultimate annual premium and are recognized ratably during the year, with adjustments each period to reflect changes in the ultimate premium. Receivables or payables are classified as current or long-term in our consolidated balance sheet based on the timing of the expected settlement.
Premiums revenue is estimated by multiplying the membership covered under the various contracts by the contractual rates. Premiums revenue is recognized as income in the period members are entitled to receive services and is net of estimated uncollectible amounts, retroactive membership adjustments, and adjustments to recognize rebates under the minimum benefit ratios required under the Health Care Reform Law. We estimate policyholder rebates by projecting calendar year minimum benefit ratios for the small group and large group markets, as defined by the Health Care Reform Law using a methodology prescribed by Health and Human Services, or HHS, separately by state and legal entity. Medicare Advantage and Medicaid products are also subject to minimum benefit ratio requirements. Estimated calendar year rebates recognized ratably during the year are revised each period to reflect current experience. Retroactive membership adjustments result from enrollment changes not yet processed, or not yet reported by an employer group or the government. We routinely monitor the collectability of specific accounts, the aging of receivables, historical retroactivity trends, estimated rebates, as well as prevailing and anticipated economic conditions, and reflect any required adjustments in current operations. Premiums received prior to the service period are recorded as unearned revenues.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Medicare Part D
We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with CMS. The payments we receive monthly from CMS and members, which are determined from our annual bid, represent amounts for providing prescription drug insurance coverage. We recognize premiums revenue for providing this insurance coverage ratably over the term of our annual contract. Our CMS payment is subject to risk sharing through the Medicare Part D risk corridor provisions. In addition, receipts for reinsurance and low-income cost subsidies as well as receipts for certain discounts on brand name prescription drugs in the coverage gap represent payments for prescription drug costs for which we are not at risk.
The risk corridor provisions compare costs targeted in our bids to actual prescription drug costs, limited to actual costs that would have been incurred under the standard coverage as defined by CMS. Variances exceeding certain thresholds may result in CMS making additional payments to us or require us to refund to CMS a portion of the premiums we received. As risk corridor provisions are considered in our overall annual bid process, we estimate and recognize an adjustment to premiums revenue related to these provisions based upon pharmacy claims experience. We record a receivable or payable at the contract level and classify the amount as current or long-term in our consolidated balance sheets based on the timing of expected settlement.
Reinsurance and low-income cost subsidies represent funding from CMS in connection with the Medicare Part D program for which we assume no risk. Reinsurance subsidies represent funding from CMS for its portion of prescription drug costs which exceed the member’s out-of-pocket threshold, or the catastrophic coverage level. Low-income cost subsidies represent funding from CMS for all or a portion of the deductible, the coinsurance and co-payment amounts above the out-of-pocket threshold for low-income beneficiaries. Monthly prospective payments from CMS for reinsurance and low-income cost subsidies are based on assumptions submitted with our annual bid. A reconciliation and related settlement of CMS’s prospective subsidies against actual prescription drug costs we paid is made after the end of the year. The Health Care Reform Law mandates consumer discounts of 50% on brand name prescription drugs for Part D plan participants in the coverage gap. These discounts are funded by CMS and pharmaceutical manufacturers while we administer the application of these funds. We account for these subsidies
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
and discounts as a deposit in our consolidated balance sheets and as a financing activity under receipts (withdrawals) from contract deposits, net in our consolidated statements of cash flows. For 2019, subsidy and discount payments of $11.8 billion exceeded reimbursements of $11.2 billion by $0.6 billion. For 2018, subsidy and discount payments of $10.3 billion exceeded reimbursements of $9.6 billion by $0.7 billion. For 2017, subsidy and discount reimbursements of $12.1 billion exceeded payments of $10.2 billion by $1.9 billion.
| | | | | | | | | | | | | | | | | | |
| 2022 | | 2021 | | 2020 | |
| (in millions) | |
Part D subsidy/discount payments | $ | (16,530) | | | $ | (14,889) | | | $ | (13,348) | | |
Part D subsidy/discount reimbursements | 18,498 | | | 14,628 | | | 12,410 | | |
Net reimbursements (payments) | $ | 1,968 | | | $ | (261) | | | $ | (938) | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
We do not recognize premiums revenue or benefit expenses for these subsidies or discounts. Receipt and payment activity is accumulated at the contract level and recorded in our consolidated balance sheets in other current assets or trade accounts payable and accrued expenses depending on the contract balance at the end of the reporting period.
Settlement of the reinsurance and low-income cost subsidies as well as the risk corridor payment is based on a reconciliation made approximately 9 months after the close of each calendar year. Settlement with CMS for brand name prescription drug discounts is based on a reconciliation made approximately 14 to 18 months after the close of each calendar year. We continue to revise our estimates with respect to the risk corridor provisions based on subsequent period pharmacy claims data. See Note 7 for detail regarding amounts recorded to our consolidated balance sheets related to the risk corridor settlement and subsidies from CMS with respect to the Medicare Part D program.
Services Revenue
Patient services revenue
Patient services include injury and illness care and related services as well as other healthcare services related to pharmacy, provider services, and home solutions services, such as home health and other services and capabilities to promote wellness and advance population health.
For our pharmacy business, external pharmacy revenues include the cost of pharmaceuticals (net of rebates), a negotiated dispensing fee and customer needsco-payments for drugs dispensed through our CenterWell Pharmacy (our mail- order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell Senior Primary Care clinics. Pharmacy products are billed to customers based on the number of transactions occurring during the billing period. Services revenues related to product revenues from dispensing prescriptions are recorded when the prescription or as required by law. Patientproduct is shipped.
Our provider services business recognizes revenues for certain value-based arrangements. Under these value-based arrangements, we enter into agreements with health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our patients. In exchange, we receive a premium that is typically paid on a per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which we are obligated to provide integrated health care services are provided to the customer and areour patients. Fee-for-service revenue is recognized at agreed upon rates, net of contractual allowances.allowances, as the performance obligation is completed on the date of service.
For our home solutions businesses, revenues include net patient services revenue recorded based upon established billing rates, net of contractual allowances, discounts, or other implicit price concessions, and are recognized as performance obligations are satisfied, which is in the period services are rendered.
For the year ended December 31, 2022, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price), was not material. Further, revenue expected to be recognized in any future year related to remaining performance obligations is not material.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Administrative services fees
Administrative services fees cover the processing of claims, offering access to our provider networks and clinical programs, and responding to customer service inquiries from members of self-funded groups. Revenues from providing administration services, also known as administrative services only, or ASO, are recognized in the period services are performed and are net of estimated uncollectible amounts. ASO fees are estimated by multiplying the membership covered under the various contracts by the contractual rates. Under ASO contracts, self-funded employers retain the risk of financing substantially all of the cost of health benefits. However, many ASO customers purchase stop loss insurance coverage from us to cover catastrophic claims or to limit aggregate annual costs. Accordingly, we have recorded premiums revenue and benefits expense related to these stop loss insurance contracts. We routinely monitor the collectability of specific accounts, the aging of receivables, as well as prevailing and anticipated economic conditions, and reflect any required adjustments in current operations. ASO fees received prior to the service period are recorded as unearned revenues.
Under our TRICARE contracts with the Department of Defense (DoD) we provide administrative services, including offering access to our provider networks and clinical programs, claim processing, customer service, enrollment, and other services, while the federal government retains all of the risk of the cost of health benefits. We account for revenues under our contracts net of estimated health care costs similar to an administrative services fee only agreement. Our contracts include fixed administrative services fees and incentive fees and penalties. Administrative services fees are recognized as services are performed.
Our TRICARE members are served by both in-network and out-of-network providers in accordance with our contracts. We pay health care costs related to these services to the providers and are subsequently reimbursed by the DoD for such payments. We account for the payments of the federal government’s claims and the related reimbursements under deposit accounting in our consolidated balance sheets and as a financing activity under receipts (withdrawals) from contract deposits,net in our consolidated statements of cash flows. For 2019, health care cost payments of approximately $6.5 billion exceeded reimbursements of approximately $6.4 billion by $63 million. For 2018, health care cost reimbursements and payments were each approximately $5.6 billion, with reimbursements exceeding payments by $38 million for the year. For 2017, health care cost reimbursements and payments were each approximately $3.4 billion with reimbursements exceeding payments by $11 million for the year.
| | | | | | | | | | | | | | | | | |
| 2022 | | 2021 | | 2020 |
| (in millions) |
Health care cost payments | $ | (7,110) | | | $ | (6,943) | | | $ | (6,253) | |
Health care cost reimbursements | 7,135 | | | 6,898 | | | 6,252 | |
Net reimbursements (payments) | $ | 25 | | | $ | (45) | | | $ | (1) | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
Receivables
Receivables, including premium receivables, patient services revenue receivables, and ASO fee receivables, are shown net of allowances for estimated uncollectible accounts, retroactive membership adjustments, and contractual allowances.
At December 31, 20192022 and 2018,2021, accounts receivable related to services were $141$291 million and $123$475 million, respectively. For the yearyears ended December 31, 2019,2022, 2021 and 2020, we had 0no material bad-debt expense and there were 0no material contract assets, contract liabilities or deferred contract costs recorded on the consolidated balance sheet at December 31, 2019.2022 and 2021.
For the year ended December 31, 2019, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price), was not material. Further, revenue expected to be recognized in any future year related to remaining performance obligations was not material.
Other Current Assets
Other current assets includesinclude amounts associated with Medicare Part D as discussed above and in Note 7, rebates due from pharmaceutical manufacturers and other amounts due within one year. We accrue pharmaceutical rebates as they are earned based on contractual terms and usage of the product. The balance of pharmaceutical rebates receivable was $1.3$2.0 billion at December 31, 20192022 and 2018.2021.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Policy Acquisition Costs
Policy acquisition costs are those costs that relate directly to the successful acquisition of new and renewal insurance policies. Such costs include commissions, costs of policy issuance and underwriting, and other costs we incur to acquire new business or renew existing business. We expense policy acquisition costs related to our employer-group prepaid health services policies as incurred. These short-duration employer-group prepaid health services policies typically have a 1-year term and may be canceled upon 30 days notice by the employer group.
Life insurance, annuities, certain health and other supplemental, and, prior to the sale of our wholly-owned subsidiary, KMG America Corporation, or KMG, in 2018, long term care policies sold to individuals are accounted for as long-duration insurance products because they are expected to remain in force for an extended period beyond one year and premium received in the earlier years is intended to pay anticipated benefits to be incurred in future years. As a result, we defer policy acquisition costs, primarily consisting of commissions, and amortize them over the estimated life of the policies in proportion to premiums earned. Deferred acquisition costs are reviewed to determine if they are recoverable from future income.
Long-Lived Assets
Property and equipment is recorded at cost. Gains and losses on sales or disposals of property and equipment are included in operating costs.costs in our consolidated income statements. Certain costs related to the development or purchase of internal-use software are capitalized. Depreciation is computed using the straight-line method over estimated useful lives ranging from 3 to 10 years for equipment, 3 to 5 years for computer software, and 10 to 20 years for buildings. Improvements to leased facilities are depreciated over the shorter of the remaining lease term or the anticipated life of the improvement.
We periodically review long-lived assets, including property and equipment and other definite-lived intangible assets, for impairment whenever adverse events or changes in circumstances indicate the carrying value of the asset may not be recoverable. Losses are recognized for a long-lived asset to be held and used in our operations when the undiscounted future cash flows expected to result from the use of the asset are less than its carrying value. We recognize an impairment loss based on the excess of the carrying value over the fair value of the asset. A long-lived asset held for sale is reported at the lower of the carrying amount or fair value less costs to sell. Depreciation expense is not recognized on assets held for sale. Losses are recognized for a long-lived asset to be abandoned when the asset ceases to be used. In addition, we periodically review the estimated lives of all long-lived assets for reasonableness.
Equity Method Investments
We use the equity method of accounting for equity investments in companies where we are able to exercise significant influence, but not control, over operating and financial policies of the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as our ownership interest, representation on the board of directors, organizational structure, participation in policy-making decisions and material intra-entity transactions.
Generally, under the equity method, original investments in these entities are recorded at cost and subsequently adjusted by our share of equity in income or losses after the date of acquisition as well as capital contributions to and distributions from these companies. Our proportionate share of the net income or loss of these companies is included in consolidated net income. Investment amounts in excess of our share of an investee'sinvestee’s net assets are amortized over the life of the related asset creating the excess. Excess goodwill is not amortized.
We evaluate equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable. Factors considered by us when reviewing an equity method investment for impairment include the length of time (duration) and the extent (severity) to which the fair value of the equity method investment has been less than carrying value, the investee’s financial condition and near-term prospects and the intent and ability to hold the investment for a period of time sufficient to allow for anticipated recovery. An impairment that is other-than-temporary is recognized in the period identified.
SeeAdditional detail regarding our equity method investments is included in Note 4 for further information.4.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Goodwill and Definite-Lived Intangible Assets
Goodwill represents the unamortized excess of cost over the fair value of the net tangible and other intangible assets acquired. We are required to test at least annually for impairment at a level of reporting referred to as the
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
reporting unit, and more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. A reporting unit either is our operating segments or one level below the operating segments, referred to as a component, which comprise our reportable segments. A component is considered a reporting unit if the component constitutes a business for which discrete financial information is available that is regularly reviewed by management. We aggregate the components of an operating segment into one reporting unit if they have similar economic characteristics. Goodwill is assigned to the reporting units that are expected to benefit from the specific synergies of the business combination.
We use the one-step processperform a quantitative assessment to review goodwill for impairment to determine both the existence and amount of goodwill impairment, if any. Impairment tests are performed, at a minimum, in the fourth quarter of each year supported by our long-range business plan and annual planning process. We rely on an evaluation of future discounted cash flows to determine fair value of our reporting units. The fair value of our reporting units with significant goodwill exceeded carrying amounts byamounts. However, unfavorable changes in key assumptions or combinations of assumptions including a substantial margin. A 100 basis point increase in the discount rate would not have a significant impact on the amount of margin for any of our reporting units with significant goodwill, with the exception of our clinical and provider reporting units in our Healthcare Services segment. Our clinical and provider reporting units primarily provide services to our Retail members. A significant increase in the discount rate, decrease in the long-term growth rate or substantial reductionsreduction in our underlying cash flow assumptions, including revenue growth rates, medical and operating cost trends, and projected operating income could have a significant negative impact on the estimated fair value of these reporting units. The clinical reporting unit had a fair value of $544 million which exceeded its carrying value of $533 million by $11 million or 2%. If the discount rate increased 100 basis points, then the clinical reporting unit would incur an impairment loss of approximately $62 million. The provider reporting unit had a fair value of $2.3 billion which exceeded its carrying value of $1.3 billion by $1.0 billion or 78%. The provider reporting unit estimate of fair value relies on multiple assumptions regarding the underlying long-term cash flows, any one of which may be significantly impacted by future changes in estimates and may negatively impact fair value. The clinicalour home solutions and provider reporting units, accountwhich accounted for $524 million$4.3 billion and $761 million, respectively,$1.1 billion of goodwill.goodwill, respectively. Impairment tests completed for 2019, 2018,2022, 2021, and 20172020 did not result in an impairment loss.
Intangible assets with indefinite lives relate to Certificate of Needs (CON) and Medicare licenses acquired as part of our acquisition of Kindred at Home, or KAH, and are included within other long-term assets in the consolidated balance sheet at December 31, 2022 and December 31, 2021. See Note 3 for further information. We are required to annually compare the fair values of other indefinite-lived intangible assets to their carrying amounts. If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized. Fair values of indefinite-lived intangible assets are determined based on the income approach. Impairment tests completed for 2022 did not result in a material impairment loss. These charges reflect the amount by which the carrying value exceeded its estimated fair value. Impairment tests completed for 2021 did not result in an impairment loss. The fair values of the assets were measured using Level 3 inputs, such as projected revenues and operating cash flows.
Definite-lived intangible assets primarily relate to acquired customer contracts/relationships and are included with other long-term assets in the consolidated balance sheets. Definite-lived intangible assets are amortized over the useful life generally using the straight-line method. We review definite-lived intangible assets for impairment under our long-lived asset policy.
Benefits Payable and Benefits Expense Recognition
Benefits expense includes claim payments, capitation payments, pharmacy costs net of rebates, allocations of certain centralized expenses and various other costs incurred to provide health insurance coverage to members, as well as estimates of future payments to hospitals and others for medical care and other supplemental benefits provided on or prior to the balance sheet date. Capitation payments represent monthly contractual fees disbursed to primary care and other providers who are responsible for providing medical care to members. Pharmacy costs represent payments for members’ prescription drug benefits, net of rebates from drug manufacturers. Receivables for such pharmacy rebates are included in other current assets in our consolidated balance sheets. Other supplemental benefits include dental, vision, and other supplemental health products.
We estimate the costs of our benefits expense payments using actuarial methods and assumptions based upon claim payment patterns, medical cost inflation, historical developments such as claim inventory levels and claim receipt patterns, and other relevant factors, and record benefit reserves for future payments. We continually review estimates of future payments relating to claims costs for services incurred in the current and prior periods and make necessary adjustments to our reserves.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Benefits expense is recognized in the period in which services are provided and includes an estimate of the cost of services which have been incurred but not yet reported, or IBNR. Our reserving practice is to consistently recognize the actuarial best point estimate within a level of confidence required by actuarial standards. Actuarial standards of practice generally require a level of confidence such that the liabilities established for IBNR have a greater probability of being adequate versus being insufficient, or such that the liabilities established for IBNR are sufficient to cover obligations under an assumption of moderately adverse conditions. Adverse conditions are situations in which the actual claims are expected to be higher than the otherwise estimated value of such claims at the time of the estimate. Therefore, in many situations, the claim amounts ultimately settled will be less than the estimate that satisfies the actuarial standards of practice.
We develop our estimate for IBNR using actuarial methodologies and assumptions, primarily based upon historical claim experience. Depending on the period for which incurred claims are estimated, we apply a different method in determining our estimate. For periods prior to the most recent two months, the key assumption used in estimating our IBNR is that thea completion factor pattern remains consistent over a rolling 12-month period after adjusting for known changes in claim inventory levels and known changes in claim payment processes. Completion factors result from the calculation ofmethod uses historical paid claims patterns to estimate the percentage of claims incurred during a given period that have historically been adjudicated as of the reporting period. Changes in claim inventory levels and known changes in claim payment processes are taken into account in these estimates. For the most recent two months, the incurred claims are estimated primarily from a trend analysis based upon per member per month claims trends developed from our historical experience in the preceding months, adjusted for known changes in estimates of hospital admissions, recent hospital and drug utilization data, provider contracting changes, changes in benefit levels, changes in member cost sharing, changes in medical management processes, product mix, and workday seasonality.
The completion factor method is used for the months of incurred claims prior to the most recent two months because the historical percentage of claims processed for those months is at a level sufficient to produce a consistently reliable result. Conversely, for the most recent two months of incurred claims, the volume of claims processed historically is not at a level sufficient to produce a reliable result, which therefore requires us to examine historical trend patterns as the primary method of evaluation. Changes in claim processes, including recoveries of overpayments, receipt cycle times, claim inventory levels, outsourcing, system conversions, and processing disruptions due to weather or other events affect views regarding the reasonable choice of completion factors. Claim payments to providers for services rendered are often net of overpayment recoveries for claims paid previously, as contractually allowed. Claim overpayment recoveries can result from many different factors, including retroactive enrollment activity, audits of provider billings, and/or payment errors. Changes in patterns of claim overpayment recoveries can be unpredictable and result in completion factor volatility, as they often impact older dates of service. The receipt cycle time measures the average length of time between when a medical claim was initially incurred and when the claim form was received. Increases in electronic claim submissions from providers decrease the receipt cycle time. If claims are submitted or processed on a faster (slower) pace than prior periods, the actual claim may be more (less) complete than originally estimated using our completion factors, which may result in reserves that are higher (lower) than required.
Medical cost trends potentially are more volatile than other segments of the economy. The drivers of medical cost trends include increases in the utilization of hospital facilities, physician services, new higher priced technologies and medical procedures, and new prescription drugs and therapies, as well as the inflationary effect on the cost per unit of each of these expense components. Other external factors such as government-mandated benefits or other regulatory changes, the tort liability system, increases in medical services capacity, direct to consumer advertising for prescription drugs and medical services, an aging population, lifestyle changes including diet and smoking, catastrophes, public health emergencies, epidemics and epidemicspandemics (such as the spread of COVID-19) also may impact medical cost trends. Internal factors such as system conversions, claims processing cycle times, changes in medical management practices and changes in provider contracts also may impact our ability to accurately predict estimates of historical completion factors or medical cost trends. All of these factors are considered in estimating IBNR and in estimating the per member per month claims trend for purposes of determining the reserve for the most recent two months. Additionally, we continually prepare and review follow-up studies to assess the reasonableness of the estimates generated by our process and methods over time. The results of these studies are also considered in determining the reserve for the most recent two months. Each of these factors requires significant judgment by management.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
We reassess the profitability of our contracts for providing insurance coverage to our members when current operating results or forecasts indicate probable future losses. We establish a premium deficiency reserve in current operations to the extent that the sum of expected future costs, claim adjustment expenses, and maintenance costs exceeds related future premiums under contracts without consideration of investment income. For purposes of determining premium deficiencies, contracts are grouped in a manner consistent with our method of acquiring, servicing, and measuring the profitability of such contracts. Losses recognized as a premium deficiency result in a beneficial effect in subsequent periods as operating losses under these contracts are charged to the liability previously established. Because the majority of our member contracts renew annually, we would not record a material premium deficiency reserve, except when unanticipated adverse events or changes in circumstances indicate otherwise.
We believe our benefits payable are adequate to cover future claims payments required. However, such estimates are based on knowledge of current events and anticipated future events. Therefore, the actual liability could differ materially from the amounts provided.
Future policy benefits payable
Future policy benefits payable includeincludes liabilities for long-duration insurance policies including life insurance, annuities,primarily related to certain health and other supplemental, and prior to the sale of KMG in 2018, long-term care policies sold to individuals for which some of the premium received in the earlier years is intended to pay anticipated benefits to be incurred in future years. At policy issuance, these reserves are recognized on a net level premium method based on interest rates, mortality, morbidity, and maintenance expense assumptions. Interest rates are based on our expected net investment returns on the investment portfolio supporting the reserves for these blocks of business. Mortality, a measure of expected death,insurance assumed in acquisitions, primarily life and morbidity, a measure of healthannuities in run-off status, assumptionsand are based on industry actuarial tables, modified based upon actual experience. Changesincluded in estimatesour consolidated balance sheet within other long-term liabilities. Most of these reservespolicies are recognizedsubject to reinsurance as an adjustment to benefits expensedetailed in the period the changes occur. We perform loss recognition tests at least annually in the fourth quarter, and more frequently if adverse events or changes in circumstances indicate that the level of the liability, together with the present value of future gross premiums, may not be adequate to provide for future expected policy benefits and maintenance costs.Note 19.
We adjust future policy benefits payable for the additional liability that would have been recorded if investment securities backing the liability had been sold at their stated aggregate fair value and the proceeds reinvested at current yields. We include the impact of this adjustment, if any, net of applicable deferred taxes, with the change in unrealized investment gain (loss) in accumulated other comprehensive income in stockholders’ equity. Health policies sold to individuals that conform to the Health Care Reform Law are accounted for under a short-duration model under which policy reserves are not established because premiums received in the current year are intended to pay anticipated benefits in that year. In addition, as previously underwritten members transition to plans compliant with the Health Care Reform Law, it results in policy lapses and the release of reserves for future policy benefits.
Book Overdraft
Under our cash management system, checks issued but not yet presented to banks that would result in negative bank balances when presented are classified as a current liability in the consolidated balance sheets. Changes in book overdrafts from period to period are reported in the consolidated statement of cash flows as a financing activity.
Income Taxes
We recognize an asset or liability for the deferred tax consequences of temporary differences between the tax bases of assets or liabilities and their reported amounts in the consolidated financial statements. These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. We also recognize the future tax benefits such as net operating and capital loss carryforwards as deferred tax assets. A valuation allowance is provided against these deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized. Future years’ tax expense may be increased or decreased by adjustments to the valuation allowance or to the estimated accrual for income taxes. Deferred tax assets and deferred tax liabilities are further adjusted for changes in the enacted tax rates.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
We record tax benefits when it is more likely than not that the tax return position taken with respect to a particular transaction will be sustained. A liability, if recorded, is not considered resolved until the statute of limitations for the relevant taxing authority to examine and challenge the tax position has expired, or the tax position is ultimately settled through examination, negotiation, or litigation. We classify interest and penalties associated with uncertain tax positions in our provision for income taxes.
Noncontrolling Interests
The consolidated financial statements include all assets, liabilities, revenues and expenses of less than 100% owned affiliates that we control. Accordingly, we record noncontrolling interests in the earnings and equity of such entities. We record adjustments to noncontrolling interests for the allocable portion of income or loss to which the noncontrolling interest holders are entitled based upon their portion of the subsidiaries they own. Distributions to holders of noncontrolling interests are adjusted to the respective noncontrolling interest holders’ balances. Noncontrolling interests, which relate to the minority ownership held by third party investors in certain of our businesses within our Insurance and CenterWell segments, are reported below net income under the heading “Net
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
income attributable to noncontrolling interests” in the consolidated statements of income and presented as a component of equity in the consolidated balance sheets.
Stock-Based Compensation
We generally recognize stock-based compensation expense, as determined on the date of grant at fair value, on a straight-line basis over the period during which an employee is required to provide service in exchange for the award (the vesting period). In addition, for awards with both time and performance-based conditions, we generally recognize compensation expense on a straight line basis over the vesting period when it is probable that the performance condition will be achieved. We estimate expected forfeitures and recognize compensation expense only for those awards which are expected to vest. We estimate the grant-date fair value of stock options using the Black-Scholes option-pricing model.
Additional detail regarding our stock-based compensation plans is included in Note 14.
Earnings Per Common Share
We compute basic earnings per common share on the basis of the weighted-average number of unrestricted common shares outstanding. Diluted earnings per common share is computed on the basis of the weighted-average number of unrestricted common shares outstanding plus the dilutive effect of outstanding employee stock options and restricted shares, or units, using the treasury stock method.
Additional detail regarding earnings per common share is included in Note 15.
Fair Value
Assets and liabilities measured at fair value are categorized into a fair value hierarchy based on whether the inputs to valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our own assumptions about the assumptions market participants would use. The fair value hierarchy includes three levels of inputs that may be used to measure fair value as described below.
Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities include securities that are traded in an active exchange market.
Level 2 – Observable inputs other than Level 1 prices such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities include debt securities with quoted prices that are traded less frequently than exchange-traded instruments as well as debt securities whose value is determined using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.
Level 3 – Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes assets and liabilities whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting our own assumptions about the assumptions market participants would use as well as those requiring significant management judgment.
Fair value of actively traded debt and equity securities are based on quoted market prices. Fair value of other debt securities are based on quoted market prices of identical or similar securities or based on observable inputs like interest rates generally using a market valuation approach, or, less frequently, an income valuation approach and are generally classified as Level 2. Fair value of privately held investment grade debt securities are estimated using a variety of valuation methodologies, including both market and income approaches, where an observable quoted market does not exist and are generally classified as Level 3. For privately-held investment grade debt securities, such methodologies include reviewing the value ascribed to the most recent financing, comparing the security with
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
securities of publicly-traded companies in similar lines of business with similar credit characteristics, and reviewing the underlying financial performance including estimating discounted cash flows.
We obtain at least one price for each security from a third party pricing service. These prices are generally derived from recently reported trades for identical or similar securities, including adjustments through the reporting date based upon observable market information. When quoted prices are not available, the third party pricing
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
service may use quoted market prices of comparable securities or discounted cash flow analysis, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include benchmark yields, reported trades, credit spreads, broker quotes, default rates, and prepayment speeds. We are responsible for the determination of fair value and as such we perform analysis on the prices received from the third party pricing service to determine whether the prices are reasonable estimates of fair value. Our analysis includes a review of monthly price fluctuations as well as a quarterly comparison of the prices received from the pricing service to prices reported by our third party investment adviser. In addition, on a quarterly basis we examine the underlying inputs and assumptions for a sample of individual securities across asset classes, credit rating levels, and various durations.
Fair value of privately held debt securities are estimated using a variety of valuation methodologies, including both market and income approaches, where an observable quoted market does not exist and are generally classified as Level 3. For privately-held debt securities, such methodologies include reviewing the value ascribed to the most recent financing, comparing the security with securities of publicly-traded companies in similar lines of business, and reviewing the underlying financial performance including estimating discounted cash flows.
Recently Issued Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In February 2016, the FASB issued new guidance related to accounting for leases which requires lessees to record assets and liabilities reflecting the leased assets and lease obligations, respectively, while following the dual model for recognition in statements of income requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). We adopted the new standard effective January 1, 2019, as allowed, using the modified retrospective approach. We elected the practical expedients of not reassessing whether any expired or existing contracts are or contain leases, not reassessing the lease classification for any expired or existing leases and not reassessing any initial direct costs for existing leases. In addition, we elected the practical expedient to not separate lease and nonlease components for all of our asset classes. We made a permitted accounting policy election to not apply the new guidance to leases with an initial term of 12 months or less. We recognize those lease payments in the condensed consolidated statement of income on a straight-line basis over the lease term. As of January 1, 2019, the adoption of the standard resulted in recognition of lease liabilities of approximately $470 million and right-of-use, or ROU, assets of $436 million, which equals the lease liabilities net of accrued rent and lease incentives. The standard does not materially affect our results of operations, cash flows and liquidity. See Note 10 for further information.
In March 2017, the FASB issued new guidance that amends the accounting for premium amortization on purchased callable debt securities by shortening the amortization period. This amended guidance requires the premium to be amortized to the earliest call date instead of maturity date. The new guidance was effective for us beginning with annual and interim periods in 2019. This guidance did not have a material impact on our results of operations, financial condition or cash flows.
In February 2018, the FASB issued guidance which allows a reclassification from accumulated other comprehensive
income to retained earnings for stranded tax effects resulting from the December 22, 2017 enactment of the Tax Cuts and Jobs Act. The new guidance is effective for us beginning January 1, 2019, with early adoption permitted. We early adopted this guidance in the first quarter of 2018 and it did not have a material impact on our results of operations, financial condition or cash flows.
Accounting Pronouncements Effective in Future Periods
In June 2016,November 2020, the FASB issued guidance introducing a new modelAccounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for recognizing credit losses on financial instruments based on an estimate of current expected credit losses.Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The guidance isamendments in ASU 2020-11 have extended the original effective date by one year, and now the amendments are required for usour interim and annual reporting periods beginning January 1, 2020. The new current expected credit losses (CECL) model generally calls for the immediate recognition of all expected credit losses and applies to loans, accounts and trade receivables as well as other financial assets measured at amortized cost, loan commitments and off-balance sheet credit exposures, debt securities and other financial assets
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
measured at fair value through other comprehensive income, and beneficial interests in securitized financial assets.after December 15, 2022. The new guidance replaces the current incurred loss model for measuring expected credit losses, requires expected losses on available for sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities, and provides for additional disclosure requirements. Our investment portfolio consists primarily of available for sale debt securities. We adopted the new standard effective January 1, 2020. Due to the high concentration of our financial assets measured at amortized cost being with the federal government resulting in zero nonpayment risk as well as our available for sale debt securities primarily being in an unrealized gain position, the adoption of the new standard did not have a material impact on our results of operations, financial condition, or cash flows.
In September 2018, the FASB issued new guidance relatedrelates to accounting for long-duration contracts of insurers which revises key elements of the measurement models and disclosure requirements for long-duration contracts issued by insurers, including the amortization of deferred contract acquisition costs and reinsurers.the measurement of liabilities for future policy benefits using current, rather than locked-in, assumptions. The new guidance, limited to our Medicare supplement product which represent less than 1% of consolidated premiums and services revenue, is effective for us beginning with annual and interim periods in 2022, with earlier2023 and is to be applied to contracts in force on the basis of their existing carrying value amounts at the beginning of the earliest period presented. The adoption permitted, and requires retrospective application to previously issued annual and interim financial statements. We are currently evaluatingof the new standard in 2023 did not have a material impact on our consolidated results of operations, financial position and cash flows.
There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.
3. ACQUISITIONS AND DIVESTITURES
Recent Transactions
In the first quarter of 2020, we acquired privately held Enclara Healthcare, or Enclara, one of the nation’s largest hospice pharmacy and benefit management providers for cash consideration of approximately $707 million, net of cash received.The purchase accounting is incomplete due to the timing of the availability of information.
Also in the first quarter of 2020, our Partners in Primary Care wholly-owned subsidiary entered into a strategic partnership with Welsh, Carson, Anderson & Stowe, or WCAS, to accelerate the expansion of our primary care model. The WCAS partnership is expected to open approximately 50 payor-agnostic, senior-focused primary care centers over 3 years beginning in 2020. Partners in Primary Care committed to the acquisition of a non-controlling interest in the approximately $600 million entity. In addition, the agreement includes a series of put and call options through which WCAS may require us to purchase their interest in the entity and, through which we may acquire WCAS’s interest over the next 5 - 10 years.
Sale of Closed Block of Commercial Long-Term Care Insurance Business
On August 9, 2018, we completed the sale of KMG to Continental General Insurance Company, or CGIC, a Texas-based insurance company wholly owned by HC2 Holdings, Inc., a diversified holding company. KMG's subsidiary, Kanawha Insurance Company, or KIC, included our closed block of non-strategic commercial long-term care policies. Upon closing, we funded the transaction with approximately $190 million of parent company cash contributed into KMG, subject to customary adjustments, in addition to the transfer of approximately $160 million of statutory capital with the sale. In connection with the sale of KMG, we recognized a pretax loss, including transaction costs, of $786 million and a corresponding $452 million tax benefit.
Prior to the sale of KMG, we entered into reinsurance contracts to transfer the risk associated with certain voluntary benefit and financial protection products previously issued primarily by KIC to a third party. We transferred approximately $245 million of cash to the third party and recorded a commensurate reinsurance recoverable as a result of these transactions. The reinsurance recoverable was included as part of the net assets disposed. There was no material impact to operating results from these reinsurance transactions.
KMG revenues and net income for the 2018 period prior to the date of sale was $182 million and $47 million, respectively. KMG revenues and net loss were $261 million and $117 million, respectively, for the year ended December 31, 2017.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
3. ACQUISITIONS AND DIVESTITURES
TheOn August 11, 2022, we completed the sale of a 60% interest in Humana’s Kindred at Home Hospice subsidiary, or KAH Hospice, to Clayton, Dubilier & Rice, or CD&R, for cash proceeds of approximately $2.7 billion, net of cash disposed, including debt repayments from KAH Hospice to Humana of $1.9 billion. In connection with the sale, we recognized a pre-tax gain, net of transaction costs, of $237 million which is reported as a gain on sale of KAH Hospice in the accompanying consolidated statement of income for the year ended December 31, 2022.
In June 2022, we classified KAH Hospice as held-for-sale and aggregated KAH Hospice’s assets and liabilities of KMG that wereseparately on the balance sheet. The assets, liabilities and noncontrolling interest disposed of on August 9, 201811, 2022 were as follows:
| | | | | |
| |
| (in millions) |
| |
Cash and cash equivalents | $ | 73 | |
Receivables, net of allowances | 194 | |
Other current assets | 20 | |
Property and equipment, net | 44 | |
Goodwill | 2,331 | |
Other assets | 960 | |
Total assets | $ | 3,622 | |
| |
| |
Trade accounts payable and accrued expenses | $ | 245 | |
Other long-term liabilities | 285 | |
Total liabilities | $ | 530 | |
Noncontrolling interest | $ | 11 | |
|
| | | |
| August 9, 2018 |
Assets | (in millions) |
Cash and cash equivalents | $ | 805 |
|
Receivables, net | 3 |
|
Investment securities | 1,576 |
|
Other assets | 1,085 |
|
Total assets disposed | $ | 3,469 |
|
Liabilities | |
Benefits payable | $ | 58 |
|
Trade accounts payable and accrued expenses | 70 |
|
Future policy benefits payable | 2,573 |
|
Total liabilities disposed | $ | 2,701 |
|
Other Acquisitionsassets included $866 million identifiable intangibles consisting of Medicare licenses and DivestituresCON.
In
Prior to the first quartersale of 2018,a 60% interest in KAH Hospice on August 11, 2022, as discussed above, KAH Hospice revenues and pretax earnings through the date of sale for the year ended December 31, 2022, were $958 million and $150 million, respectively. KAH Hospice revenues and pretax earnings for the year ended December 31, 2021, were $582 million and $113 million, respectively.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
On August 17, 2021, we acquired the remaining equity60% interest in MCCI Holdings, LLC,Kindred at Home, or MCCI,KAH, the nation’s largest home health and hospice provider, from TPG Capital, or TPG, and Welsh, Carson, Anderson & Stowe, or WCAS, two private equity funds, for an enterprise value of $8.2 billion, which included our equity value of $2.4 billion associated with our 40% minority ownership interest. The remeasurement to fair value of our previously held 40% equity method investment with a privately held management service organization and healthcare provider headquartered in Miami, Florida, that primarily coordinates medical care for Medicare Advantage beneficiaries in Florida and Texas. The purchase price consisted primarilycarrying value of $169 million cash, as well as our existing investment in MCCI and a note receivable and a revolving note with an aggregate balance of $383 million. Thisapproximately $1.3 billion, resulted in a purchase$1.1 billion gain recognized in "Other (income) expense, net". We paid the approximate $5.8 billion transaction price allocation to goodwill(net of $483 million, other intangibleour existing equity stake) through a combination of debt financing, the assumption of existing KAH indebtedness and parent company cash. The final fair values of KAH’s assets acquired and liabilities assumed at the date of $80 million, and net tangible assets of $24 million. The goodwill was assigned to the Retail and Healthcare Services segments. The other intangible assets, which primarily consist of customer contracts, have an estimated weighted average useful life of 8 years. Goodwill and other intangible assetsacquisition are amortizablesummarized as deductible expense for tax purposes.follows:
In the second quarter of 2018, we acquired Family Physicians Group, or FPG, for cash consideration of approximately $185 million, net of cash received. FPG serves Medicare Advantage and Managed Medicaid HMO patients in Greater Orlando, Florida with a footprint that includes clinics located in Lake, Orange, Osceola and Seminole counties. This resulted in a purchase price allocation to goodwill of $133 million, other intangible assets of $38 million and net tangible assets of $14 million. The goodwill was assigned to the Retail and Healthcare Services segments. The other intangible assets, which primarily consist of customer contracts, have an estimated weighted average useful life of 4.9 years. The purchase price allocations for MCCI and FPG are final. | | | | | |
| |
| (in millions) |
Cash and cash equivalents | $ | 278 | |
Receivables | 381 | |
Other current assets | 61 | |
Property and equipment | 74 | |
Goodwill | 5,771 | |
Other intangible assets | 2,312 | |
Other long-term assets | 172 | |
Total assets acquired | $ | 9,049 | |
Current liabilities | $ | 410 | |
Long term debt | 2,078 | |
Other long-term liabilities | 369 | |
Total liabilities assumed | $ | 2,857 | |
Noncontrolling interests | 22 | |
Net assets acquired | $ | 6,170 | |
During 20192022, 2021, and 2018,2020 we acquired other health and wellness related businesses which other than the impacts to goodwill, individually or in the aggregate, have not had a material impact on our results of operations, financial condition, or cash flows. The results of operations and financial condition of these businesses have been included in our consolidated statements of income and consolidated balance sheets from the respective acquisition dates. Acquisition-related costs recognized in each of 2019, 20182022, 2021 and 20172020 were not material to our results of operations. Goodwill and other intangible assetsFor asset acquisitions the goodwill acquired areis partially amortizable as deductible expenses for tax purposes. The pro forma financial information assuming the acquisitions had occurred as of the beginning of the calendar year prior to the year of acquisition, as well as the revenues and earnings generated during the year of acquisition, were not material for disclosure purposes.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
4. EQUITY METHOD INVESTMENT
In the third quarterPrior to our acquisition of 2018,KAH in August 2021, we along with TPG Capital, or TPG, and Welsh, Carson, Anderson & Stowe, or WCAS (together, the "Sponsors"), completed the acquisitions of Kindred Healthcare, Inc., or Kindred, and privately-held Curo Health Services, or Curo, respectively, merging Curo with the hospice business of the Kindred at Home Division, or Kindred at Home. As part of these transactions, we acquired a 40% minority interest in Kindred at Home, a leading home health and hospice company, for total cash consideration of approximately $1.1 billion.
We accountaccounted for our 40% investment in Kindred at HomeKAH using the equity method of accounting. Our share of income or loss was reported as equity in net (losses) earnings in our consolidated statements of income.
We completed the sale of a 60% interest in KAH Hospice on August 11, 2022 and account for our 40% minority ownership in hospice operations using the equity method of accounting. This investment iswas reflected as "Equityin equity method investment in Kindred at Home"investments in our December 31, 2022 consolidated balance sheets,sheet, with our share of income or loss reported as "Equityequity in net (losses) earnings of Kindred at Home" in our consolidated statements of income.
We entered into a shareholders agreement with the Sponsors that provides for certain rights and obligations of each party. The shareholders agreement with the Sponsors includes a put option under which they have the right to require us to purchase their interest in the joint venture starting at the end of year three and ending at the end of year four following the closing. Likewise, we have a call option under which we have the right to require the Sponsors to sell their interest in the joint venture to Humana beginning at the end of 2022 and ending at the end of 2023 following the closing. The put and call options, which are exercisable at a fixed EBITDA multiple and provide a minimum return on the Sponsor's investment if exercised, are measured at fair value each period using a Monte Carlo simulation. The simulation relies on assumptions around Kindred at Home's equity value, risk free interest rates, volatility, and the details specific to the put and call options. The final purchase price allocation resulted in approximately $1 billion being allocated to the investment and $236 million and $291 million allocated to the put and call options, respectively. The fair values of the put option and call option were $28 million and $557 million, respectively, at December 31, 2019. The fair values of the put option and call option were $224 million and $246 million, respectively, at December 31, 2018.
The put option is included within other long-term liabilities and the call option is included within other long term assets. The change in fair value of the put and call options for the years ended December 31, 2019 and 2018 of $(506) million and $33 million, respectively, are reported as "Other (income) expense, net" in our consolidated statements of income.
The summarized balance sheetssheet at December 31, 20192022 and 2018, andstatement of income statement for the yearperiod beginning August 11, 2022 through December 31, 2022 of KAH Hospice were as follows:
| | | | | | | | | | | | | | |
Balance sheet | December 31, 2022 | | | | | | | | | |
| | | | | | | | | | |
| (in millions) | | | | | | | | | |
Current assets | $ | 297 | | | | | | | | | | |
Non-current assets | 3,577 | | | | | | | | | | |
Current liabilities | 269 | | | | | | | | | | |
Non-current liabilities | 2,219 | | | | | | | | | | |
Shareholders' equity | 1,386 | | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | |
Statements of income | | | |
| August 11, 2022 through December 31, 2022 | | |
| (in millions) | |
Revenues | $ | 654 | | | |
Expenses | 652 | | | |
Net income | 2 | | | |
| | | |
| | | |
| | | |
Other insignificant equity method investments
In 2020, our Primary Care Organization entered into a strategic partnership with Welsh, Carson, Anderson & Stowe, or WCAS, to accelerate the expansion of our primary care model. In May 2022, we established a second strategic partnership with WCAS to develop additional centers between 2023 and 2025. As of December 31, 2022, there were 50 primary care clinics operating under the partnership and we intend to open approximately 100 additional primary clinics in future periods under the existing arrangements. In addition, the agreements include a series of put and call options through which WCAS may require us to purchase their interest in the entity, and through which we may acquire WCAS’s interest, over the next 3 to 10 years.
We have several individually immaterial equity method investments, including our strategic partnership with WCAS as described above, included within equity method investments in our consolidated balance sheets as of December 31, 2022 and 2021 with our share of income or loss reported as equity in net (losses) earnings in our consolidated statements of income for the years ended December 31, 20192022, 2021 and period beginning July 2, 2018 through December 31, 2018 of Kindred at Home were as follows:2020.
|
| | | | | | |
Balance sheets | December 31, 2019 | December 31, 2018 |
| (in millions) |
Current assets | $ | 563 |
| $ | 536 |
|
Non-current assets | 4,967 |
| 4,955 |
|
Current liabilities | 405 |
| 351 |
|
Non-current liabilities | 2,637 |
| 2,708 |
|
Shareholders' equity | 2,488 |
| 2,432 |
|
| | |
Statements of income | | |
| For the year ended December 31, 2019 | July 2, 2018 through December 31, 2018 |
| (in millions) |
Revenues | $ | 3,100 |
| $ | 1,587 |
|
Expenses | 2,835 |
| 1,451 |
|
Net income | 54 |
| 27 |
|
94
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
5. INVESTMENT SECURITIES
Investment securities classified as current and long-term were as follows at December 31, 20192022 and 2018,2021, respectively:
| | | | | | | | | | | | | | | | | | | | | | | |
| Amortized Cost | | Gross Unrealized Gains | | Gross Unrealized Losses | | Fair Value |
| (in millions) |
December 31, 2022 | | | | | | | |
U.S. Treasury and other U.S. government corporations and agencies: | | | | | | | |
U.S. Treasury and agency obligations | $ | 1,093 | | | $ | 1 | | | $ | (55) | | | $ | 1,039 | |
Mortgage-backed securities | 3,697 | | | 4 | | | (471) | | | 3,230 | |
Tax-exempt municipal securities | 765 | | | — | | | (37) | | | 728 | |
Mortgage-backed securities: | | | | | | | |
Residential | 477 | | | — | | | (76) | | | 401 | |
Commercial | 1,554 | | | — | | | (155) | | | 1,399 | |
Asset-backed securities | 1,809 | | | 1 | | | (79) | | | 1,731 | |
Corporate debt securities | 6,551 | | | 3 | | | (828) | | | 5,726 | |
Total debt securities | $ | 15,946 | | | $ | 9 | | | $ | (1,701) | | | 14,254 | |
Common stock | | | | | | | 7 | |
Total investment securities | | | | | | | $ | 14,261 | |
| | | | | | | |
December 31, 2021 | | | | | | | |
U.S. Treasury and other U.S. government corporations and agencies: | | | | | | | |
U.S. Treasury and agency obligations | $ | 611 | | | $ | 1 | | | $ | (10) | | | $ | 602 | |
Mortgage-backed securities | 3,265 | | | 33 | | | (69) | | | 3,229 | |
Tax-exempt municipal securities | 810 | | | 33 | | | (2) | | | 841 | |
Mortgage-backed securities: | | | | | | | |
Residential | 373 | | | — | | | (6) | | | 367 | |
Commercial | 1,394 | | | 27 | | | (11) | | | 1,410 | |
Asset-backed securities | 1,346 | | | 6 | | | (4) | | | 1,348 | |
Corporate debt securities | 5,641 | | | 118 | | | (59) | | | 5,700 | |
Total debt securities | $ | 13,440 | | | $ | 218 | | | $ | (161) | | | 13,497 | |
Common stock | | | | | | | 475 | |
Total investment securities | | | | | | | $ | 13,972 | |
|
| | | | | | | | | | | | | | | |
| Amortized Cost | | Gross Unrealized Gains | | Gross Unrealized Losses | | Fair Value |
| (in millions) |
December 31, 2019 | | | | | | | |
U.S. Treasury and other U.S. government corporations and agencies: | | | | | | | |
U.S. Treasury and agency obligations | $ | 353 |
| | $ | 1 |
| | $ | — |
| | $ | 354 |
|
Mortgage-backed securities | 3,628 |
| | 85 |
| | (3 | ) | | 3,710 |
|
Tax-exempt municipal securities | 1,433 |
| | 30 |
| | — |
| | 1,463 |
|
Mortgage-backed securities: | | | | | | | |
Commercial | 786 |
| | 18 |
| | — |
| | 804 |
|
Asset-backed securities | 1,093 |
| | 3 |
| | (3 | ) | | 1,093 |
|
Corporate debt securities | 3,867 |
| | 82 |
| | (2 | ) | | 3,947 |
|
Total debt securities | $ | 11,160 |
| | $ | 219 |
| | $ | (8 | ) | | $ | 11,371 |
|
December 31, 2018 | | | | | | | |
U.S. Treasury and other U.S. government corporations and agencies: | | | | | | | |
U.S. Treasury and agency obligations | $ | 419 |
| | $ | 1 |
| | $ | (3 | ) | | $ | 417 |
|
Mortgage-backed securities | 2,595 |
| | 3 |
| | (54 | ) | | 2,544 |
|
Tax-exempt municipal securities | 2,805 |
| | 3 |
| | (37 | ) | | 2,771 |
|
Mortgage-backed securities: | | | | | | | |
Residential | 55 |
| | — |
| | — |
| | 55 |
|
Commercial | 537 |
| | — |
| | (14 | ) | | 523 |
|
Asset-backed securities | 991 |
| | 1 |
| | (7 | ) | | 985 |
|
Corporate debt securities | 3,239 |
| | 1 |
| | (98 | ) | | 3,142 |
|
Total debt securities | $ | 10,641 |
| | $ | 9 |
| | $ | (213 | ) | | $ | 10,437 |
|
We also held $7 million of equity securities carried at fair value as of December 31, 2019 consisting of common stock.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
In August 2022, we purchased certain corporate debt securities of KAH Hospice subsequent to the sale. The book value and fair value are $280 million and $278 million, respectively, at December 31, 2022.
Gross unrealized losses and fair values aggregated by investment category and length of time that individual debt securities have been in a continuous unrealized loss position were as follows at December 31, 20192022 and 2018,2021, respectively:
|
| | | | | | | | | | | | | | | | | | | | | | | | |
| | Less than 12 months | | 12 months or more | | Total |
| | Fair Value | | Gross Unrealized Losses | | Fair Value | | Gross Unrealized Losses | | Fair Value | | Gross Unrealized Losses |
|
| | (in millions) |
| December 31, 2019 | | | | | | | | | | | |
| U.S. Treasury and other U.S. government corporations and agencies: | | | | | | | | | | | |
| U.S. Treasury and agency obligations | $ | 48 |
| | $ | — |
| | $ | 23 |
| | $ | — |
| | $ | 71 |
| | $ | — |
|
| Mortgage-backed securities | 315 |
| | (1 | ) | | 204 |
| | (2 | ) | | 519 |
| | (3 | ) |
| Tax-exempt municipal securities | 58 |
| | — |
| | 75 |
| | — |
| | 133 |
| | — |
|
| Mortgage-backed securities: | | | | | | | | | | | |
| Commercial | 118 |
| | — |
| | 36 |
| | — |
| | 154 |
| | — |
|
| Asset-backed securities | 20 |
| | — |
| | 607 |
| | (3 | ) | | 627 |
| | (3 | ) |
| Corporate debt securities | 589 |
| | (2 | ) | | 155 |
| | — |
| | 744 |
| | (2 | ) |
| Total debt securities | $ | 1,148 |
| | $ | (3 | ) | | $ | 1,100 |
| | $ | (5 | ) | | $ | 2,248 |
| | $ | (8 | ) |
| December 31, 2018 | | | | | | | | | | | |
| U.S. Treasury and other U.S. government corporations and agencies: | | | | | | | | | | | |
| U.S. Treasury and agency obligations | $ | 179 |
| | $ | (1 | ) | | $ | 153 |
| | $ | (2 | ) | | $ | 332 |
| | $ | (3 | ) |
| Mortgage-backed securities | 956 |
| | (16 | ) | | 1,019 |
| | (38 | ) | | 1,975 |
| | (54 | ) |
| Tax-exempt municipal securities | 809 |
| | (9 | ) | | 1,648 |
| | (28 | ) | | 2,457 |
| | (37 | ) |
| Mortgage-backed securities: | | | | | | | | | | | |
| Residential | — |
| | — |
| | 15 |
| | — |
| | 15 |
| | — |
|
| Commercial | 372 |
| | (8 | ) | | 133 |
| | (6 | ) | | 505 |
| | (14 | ) |
| Asset-backed securities | 824 |
| | (7 | ) | | 40 |
| | — |
| | 864 |
| | (7 | ) |
| Corporate debt securities | 1,434 |
| | (35 | ) | | 1,439 |
| | (63 | ) | | 2,873 |
| | (98 | ) |
| Total debt securities | $ | 4,574 |
| | $ | (76 | ) | | $ | 4,447 |
| | $ | (137 | ) | | $ | 9,021 |
| | $ | (213 | ) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Less than 12 months | | 12 months or more | | Total |
| Fair Value | | Gross Unrealized Losses | | Fair Value | | Gross Unrealized Losses | | Fair Value | | Gross Unrealized Losses |
|
| (in millions) |
December 31, 2022 | | | | | | | | | | | |
U.S. Treasury and other U.S. government corporations and agencies: | | | | | | | | | | | |
U.S. Treasury and agency obligations | $ | 512 | | | $ | (5) | | | $ | 397 | | | $ | (50) | | | $ | 909 | | | $ | (55) | |
Mortgage-backed securities | 1,231 | | | (104) | | | 1,683 | | | (367) | | | 2,914 | | | (471) | |
Tax-exempt municipal securities | 64 | | | (2) | | | 615 | | | (36) | | | 679 | | | (38) | |
Mortgage-backed securities: | | | | | | | | | | | |
Residential | 124 | | | (16) | | | 274 | | | (60) | | | 398 | | | (76) | |
Commercial | 243 | | | (13) | | | 1,157 | | | (142) | | | 1,400 | | | (155) | |
Asset-backed securities | 620 | | | (32) | | | 1,011 | | | (46) | | | 1,631 | | | (78) | |
Corporate debt securities | 1,625 | | | (98) | | | 3,825 | | | (730) | | | 5,450 | | | (828) | |
Total debt securities | $ | 4,419 | | | $ | (270) | | | $ | 8,962 | | | $ | (1,431) | | | $ | 13,381 | | | $ | (1,701) | |
| | | | | | | | | | | |
December 31, 2021 | | | | | | | | | | | |
U.S. Treasury and other U.S. government corporations and agencies: | | | | | | | | | | | |
U.S. Treasury and agency obligations | $ | 201 | | | $ | (3) | | | $ | 355 | | | $ | (7) | | | $ | 556 | | | $ | (10) | |
Mortgage-backed securities | 2,082 | | | (49) | | | 556 | | | (20) | | | 2,638 | | | (69) | |
Tax-exempt municipal securities | 68 | | | (1) | | | 34 | | | (1) | | | 102 | | | (2) | |
Mortgage-backed securities: | | | | | | | | | | | |
Residential | 358 | | | (6) | | | 8 | | | — | | | 366 | | | (6) | |
Commercial | 295 | | | (4) | | | 400 | | | (7) | | | 695 | | | (11) | |
Asset-backed securities | 530 | | | (3) | | | 425 | | | (1) | | | 955 | | | (4) | |
Corporate debt securities | 1,456 | | | (28) | | | 769 | | | (31) | | | 2,225 | | | (59) | |
Total debt securities | $ | 4,990 | | | $ | (94) | | | $ | 2,547 | | | $ | (67) | | | $ | 7,537 | | | $ | (161) | |
Approximately 96% of our debt securities were investment-grade quality, with a weighted average credit rating of AAAA- by S&P at December 31, 2019.2022. Most of the debt securities that were below investment-grade were rated BB,BB-, the higher end of the below investment-grade rating scale. Tax-exempt municipal securities were diversified among general obligation bonds of states and local municipalities in the United States as well as special revenue bonds issued by municipalities to finance specific public works projects such as utilities, water and sewer, transportation, or education. Our general obligation bonds are diversified across the United States with no individual state exceeding 1% of our total debt securities. Our investment policy limits investments in a single issuer and requires diversification among various asset types.
Our unrealized loss from all debt securities was generated from approximately 2351,625 positions out of a total of approximately 1,5151,710 positions at December 31, 2019.2022. All issuers of debt securities we own that were trading at an
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
unrealized loss at December 31, 20192022 remain current on all contractual payments. After taking into account these and other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates in the current markets since the time the debt securities were purchased. At December 31, 2019,2022, we did not intend to sell theany debt securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
will be required to sell these debt securities before recovery of their amortized cost basis. As a result,Additionally, we believedid not record any material credit allowances for debt securities that the securities withwere in an unrealized loss were not other-than-temporarily impairedposition at December 31, 2019.2022, 2021 or 2020.
The detail of realized gains (losses) related to investment securities and included within investment income was as follows for the years ended December 31, 2019, 2018,2022, 2021, and 2017:2020:
|
| | | | | | | | | | | |
| 2019 | | 2018 | | 2017 |
| (in millions) |
Gross realized gains | $ | 129 |
| | $ | 106 |
| | $ | 35 |
|
Gross realized losses | (67 | ) | | (16 | ) | | (21 | ) |
Net realized capital gains | $ | 62 |
| | $ | 90 |
| | $ | 14 |
|
| | | | | | | | | | | | | | | | | |
| 2022 | | 2021 | | 2020 |
| (in millions) |
Gross gains on investment securities | $ | 62 | | | $ | 219 | | | $ | 110 | |
Gross losses on investment securities | (144) | | | (8) | | | (18) | |
Gross gains on equity securities | 51 | | | 23 | | | 746 | |
Gross losses on equity securities | (174) | | | (364) | | | — | |
Net recognized (losses) gains on investment securities | $ | (205) | | | $ | (130) | | | $ | 838 | |
There were 0 material other-than-temporary impairments in 2019, 2018, or 2017.The gains and losses related to equity securities for the years ended December 31, 2022, 2021 and 2020 was as follows:
| | | | | | | | | | | | | | | | | | | | |
| 2022 | | 2021 | | 2020 | | | |
| (in millions) | | | |
Net (losses) gains recognized on equity securities during the period | $ | (123) | | | $ | (341) | | | $ | 746 | | | | |
Less: Net losses recognized on equity securities sold during the period | (105) | | | (13) | | | — | | | | |
Unrealized (losses) gains recognized on equity securities still held at the end of the period | $ | (18) | | | $ | (328) | | | $ | 746 | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
All purchases of and proceeds from investment securities for the year ended December 31, 2020 relate to debt securities.
The contractual maturities of debt securities available for sale at December 31, 2019,2022, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.
| | | | | | | | | | | |
| Amortized Cost | | Fair Value |
| (in millions) |
Due within one year | $ | 529 | | | $ | 525 | |
Due after one year through five years | 3,399 | | | 3,210 | |
Due after five years through ten years | 3,231 | | | 2,764 | |
Due after ten years | 1,250 | | | 994 | |
Mortgage and asset-backed securities | 7,537 | | | 6,761 | |
Total debt securities | $ | 15,946 | | | $ | 14,254 | |
|
| | | | | | | |
| Amortized Cost | | Fair Value |
| (in millions) |
Due within one year | $ | 1,316 |
| | $ | 1,317 |
|
Due after one year through five years | 1,974 |
| | 2,013 |
|
Due after five years through ten years | 1,724 |
| | 1,780 |
|
Due after ten years | 639 |
| | 654 |
|
Mortgage and asset-backed securities | 5,507 |
| | 5,607 |
|
Total debt securities | $ | 11,160 |
| | $ | 11,371 |
|
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
6. FAIR VALUE
Financial Assets
The following table summarizes our fair value measurements at December 31, 20192022 and 2018,2021, respectively, for financial assets measured at fair value on a recurring basis:
| | | | | | | | | | | | | | | | | | | | | | | |
| | | Fair Value Measurements Using |
| Fair Value | | Quoted Prices in Active Markets (Level 1) | | Other Observable Inputs (Level 2) | | Unobservable Inputs (Level 3) |
| (in millions) |
December 31, 2022 | | | | | | | |
Cash equivalents | $ | 4,832 | | | $ | 4,832 | | | $ | — | | | $ | — | |
Debt securities: | | | | | | | |
U.S. Treasury and other U.S. government corporations and agencies: | | | | | | | |
U.S. Treasury and agency obligations | 1,039 | | | — | | | 1,039 | | | — | |
Mortgage-backed securities | 3,230 | | | — | | | 3,230 | | | — | |
Tax-exempt municipal securities | 728 | | | — | | | 728 | | | — | |
Mortgage-backed securities: | | | | | | | |
Residential | 401 | | | — | | | 401 | | | — | |
Commercial | 1,399 | | | — | | | 1,399 | | | — | |
Asset-backed securities | 1,731 | | | — | | | 1,731 | | | — | |
Corporate debt securities | 5,726 | | | — | | | 5,625 | | | 101 | |
Total debt securities | 14,254 | | | — | | | 14,153 | | | 101 | |
Common stock | 7 | | | 7 | | | — | | | — | |
Total invested assets | $ | 19,093 | | | $ | 4,839 | | | $ | 14,153 | | | $ | 101 | |
| | | | | | | |
December 31, 2021 | | | | | | | |
Cash equivalents | $ | 3,322 | | | $ | 3,322 | | | $ | — | | | $ | — | |
Debt securities: | | | | | | | |
U.S. Treasury and other U.S. government corporations and agencies: | | | | | | | |
U.S. Treasury and agency obligations | 602 | | | — | | | 602 | | | — | |
Mortgage-backed securities | 3,229 | | | — | | | 3,229 | | | — | |
Tax-exempt municipal securities | 841 | | | — | | | 841 | | | — | |
Mortgage-backed securities: | | | | | | | |
Residential | 367 | | | — | | | 367 | | | — | |
Commercial | 1,410 | | | — | | | 1,410 | | | — | |
Asset-backed securities | 1,348 | | | — | | | 1,348 | | | — | |
Corporate debt securities | 5,700 | | | — | | | 5,632 | | | 68 | |
Total debt securities | 13,497 | | | — | | | 13,429 | | | 68 | |
Common stock | 475 | | | 475 | | | — | | | — | |
Total invested assets | $ | 17,294 | | | $ | 3,797 | | | $ | 13,429 | | | $ | 68 | |
|
| | | | | | | | | | | | | | | |
| | | Fair Value Measurements Using |
| Fair Value | | Quoted Prices in Active Markets (Level 1) | | Other Observable Inputs (Level 2) | | Unobservable Inputs (Level 3) |
| (in millions) |
December 31, 2019 | | | | | | | |
Cash equivalents | $ | 3,660 |
| | $ | 3,660 |
| | $ | — |
| | $ | — |
|
Debt securities: | | | | | | | |
U.S. Treasury and other U.S. government corporations and agencies: | | | | | | | |
U.S. Treasury and agency obligations | 354 |
| | — |
| | 354 |
| | — |
|
Mortgage-backed securities | 3,710 |
| | — |
| | 3,710 |
| | — |
|
Tax-exempt municipal securities | 1,463 |
| | — |
| | 1,463 |
| | — |
|
Mortgage-backed securities: | | | | | | | |
Commercial | 804 |
| | — |
| | 804 |
| | — |
|
Asset-backed securities | 1,093 |
| | — |
| | 1,093 |
| | — |
|
Corporate debt securities | 3,947 |
| | — |
| | 3,947 |
| | — |
|
Total debt securities | 11,371 |
| | — |
| | 11,371 |
| | — |
|
Common stock | 7 |
| | 7 |
| | — |
| | — |
|
Total invested assets | $ | 15,038 |
| | $ | 3,667 |
| | $ | 11,371 |
| | $ | — |
|
December 31, 2018 | | | | | | | |
Cash equivalents | $ | 2,024 |
| | $ | 2,024 |
| | $ | — |
| | $ | — |
|
Debt securities: | | | | | | | |
U.S. Treasury and other U.S. government corporations and agencies: | | | | | | | |
U.S. Treasury and agency obligations | 417 |
| | — |
| | 417 |
| | — |
|
Mortgage-backed securities | 2,544 |
| | — |
| | 2,544 |
| | — |
|
Tax-exempt municipal securities | 2,771 |
| | — |
| | 2,771 |
| | — |
|
Mortgage-backed securities: | | | | | | | |
Residential | 55 |
| | — |
| | 55 |
| | — |
|
Commercial | 523 |
| | — |
| | 523 |
| | — |
|
Asset-backed securities | 985 |
| | — |
| | 985 |
| | — |
|
Corporate debt securities | 3,142 |
| | — |
| | 3,142 |
| | — |
|
Total debt securities | 10,437 |
| | — |
| | 10,437 |
| | — |
|
Total invested assets | $ | 12,461 |
| | $ | 2,024 |
| | $ | 10,437 |
| | $ | — |
|
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Our Level 3 assets had fair values of $101 million, or 0.5% of total invested assets, and $68 million, or 0.4% of total invested assets, at December 31, 2022 and 2021, respectively. During the years ended December 31, 2022 and 2021, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:
| | | | | | | | | | | | |
| For the year ended December 31, 2022 | For the year ended December 31, 2021 | | | | |
| | |
| Private Placements | | | | |
| (in millions) |
Beginning balance at January 1 | $ | 68 | | $ | — | | | | | |
Total gains or losses: | | | | | | |
Realized in earnings | — | | — | | | | | |
Unrealized in other comprehensive income | (14) | | (1) | | | | | |
Purchases | 47 | | 69 | | | | | |
Sales | — | | — | | | | | |
Settlements | — | | — | | | | | |
Balance at December 31 | $ | 101 | | $ | 68 | | | | | |
Financial Liabilities
Our debt is recorded at carrying value in our consolidated balance sheets. The carrying value of our senior notes debt outstanding, net of unamortized debt issuance costs, was $5,366 million$10.0 billion at December 31, 20192022 and $4,774 million$9.0 billion at December 31, 2018.2021. The fair value of our senior note debt was $5,916 million$9.4 billion at December 31, 20192022 and $4,885 million$10.0 billion at December 31, 2018.2021. The fair value of our senior note debt is determined based on Level 2 inputs, including quoted market prices for the same or similar debt, or if no quoted market prices are available, on the current prices estimated to be available to us for debt with similar terms and remaining maturities.
Due to the short-term nature, carrying Carrying value approximates fair value for our term noteloans and commercial paper borrowings. The outstanding commercial paper borrowings were $300 million at December 31, 2019 and we repaid the term note balance in August 2019. The term note outstandingloan and commercial paper borrowings were $1,295 million$1.1 billion at December 31, 2018.2022 and $3.5 billion at December 31, 2021.
Put and Call Options Measured at Fair Value
Our put and call options associated with our equity method investments are measured at fair value each period using a Monte Carlo simulation.
Effective April 27, 2021, with the signing of the definitive agreement to acquire the remaining 60% interest of KAH, the respective put and call options were terminated. As such, the $63 million put and $440 million call fair values as of the first quarter of 2021 were reduced to zero, resulting in $377 million in other expense (income),net in our consolidated statements of income for the year ended December 31, 2021.
The put and call options fair values associated with our Primary Care Organization strategic partnership with WCAS, which are exercisable at a fixed revenue exit multiple and provide a minimum return on WCAS' investment if exercised, are measured at fair value each reporting period using a Monte Carlo simulation. The put and call options fair values, derived from the Monte Carlo simulation, were $28$267 million and $557$10 million, respectively, at December 31, 20192022. The put and $224call options fair values, derived from the Monte Carlo simulation, were $202 million and $246$13 million, respectively, at December 31, 2018. 2021.
The significant unobservable inputs utilized in these Level 3 fair value measurements (and selected values) include the enterprise value, of Kindred at Home, annualized volatility (19.8%) and secured credit rate (2.2%).spread. Enterprise value was derived from a discounted cash flow model, which utilized significant unobservable inputs for long-term net operating profit after tax margin, or NOPAT, (12.0%)revenue, to measure underlying cash flows, weighted average cost of capital (10.0%) and long term growth rate (3.0%).rate. The calculation of NOPAT utilized net income plus after tax interest expense.
We regularly evaluate each oftable below presents the assumptions used in establishing these assetsfor December 31, 2022 and liabilities. Significant changes in2021, respectively:
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
| | | | | | | | | | | |
| December 31, 2022 | December 31, 2021 | | | |
Annualized volatility | 16.7% - 20.8% | 22.4 | % | | | |
Credit spread | 1.3% - 1.5% | 0.9 | % | | | |
Revenue exit multiple | 1.5x - 2.5x | 1.5x - 2.5x | | | |
Weighted average cost of capital | 11.5% - 12.5% | 12.5 | % | | | |
Long term growth rate | 3.0 | % | 3.0 | % | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
The assumptions used for annualized volatility, credit spread and weighted average cost of capital long term growth rates, NOPAT, volatility, credit spreads, risk free rate,reflect the lowest and underlying cash flow estimates, could result inhighest values where they differ significantly lower or higher fair value measurements. A change in oneacross the series of these assumptions is not necessarily accompanied by a change in another assumption.put and call options due to their expected exercise dates.
Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis
Certain assets and liabilities are measured at fair value on a non-recurring basis subject to fair value adjustment only in certain circumstances. As disclosed in Note 3, “Acquisitions”, we acquired MCCI, FPG, and other health and wellness related businessescompleted our acquisition of KAH during 2019, 2018, and 2017.the third quarter of 2021. The values of net tangible assets acquired and the resulting goodwill and other intangible assets were recorded at fair value primarily using Level 3 inputs. The majority of thenet tangible assets acquiredincluding receivables and accrued liabilities assumed were recorded at their carrying values as of the respective dates of acquisition, as their carrying valuesvalue which approximated their fair valuesvalue due to their short-termshort term nature. The fair valuesvalue of goodwill and other intangible assets acquired in these acquisitions were internally estimated primarily based on the income approach. The income approach estimates fair value based on the present value of the cash flowsflow that the assets arecould be expected to generate in the future. We developed internal estimates for the expected future cash flows and discount rates used in the present value calculations. calculation using inputs and significant assumptions that include historical revenues and earnings, long-term growth rate, discount rate, contributory asset charges and future tax rates, among others. The excess purchase price over the fair value of assets and liabilities acquired is recorded as goodwill.
As disclosed in Note 3, we completed the sale of a 60% interest in KAH Hospice on August 11, 2022. The carrying value of the assets and liabilities of KAH Hospice disposed approximates fair value. The amount of goodwill included in the carrying value is based on the relative fair value of KAH Hospice as compared to the total fair value of our home solutions reporting unit included within the CenterWell segment.
Other than the assets acquired and liabilities assumed in thesethe KAH and other acquisitions in Note 3, there were no other material assets or liabilities measured at fair value on a recurring or nonrecurring basis during 2019, 2018,2022, 2021, or 2017.2020.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
7. MEDICARE PART D
As discussed in Note 2, weWe cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with CMS. The accompanying consolidated balance sheets include the following amounts associated with Medicare Part D as of December 31, 20192022 and 2018.2021. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to
|
| | | | | | | | | | | | | | | | |
| | 2019 | | 2018 |
| | Risk Corridor Settlement | | CMS Subsidies/ Discounts | | Risk Corridor Settlement | | CMS Subsidies/ Discounts |
| | (in millions) |
Other current assets | | $ | 5 |
| | $ | 585 |
| | $ | 15 |
| | $ | 172 |
|
Trade accounts payable and accrued expenses | | (120 | ) | | (356 | ) | | (103 | ) | | (503 | ) |
Net current (liability) asset | | (115 | ) | | 229 |
| | (88 | ) | | (331 | ) |
Other long-term assets | | 6 |
| | — |
| | 7 |
| | — |
|
Other long-term liabilities | | (61 | ) | | — |
| | (89 | ) | | — |
|
Net long-term liability | | (55 | ) | | — |
| | (82 | ) | | — |
|
Total net (liability) asset | | $ | (170 | ) | | $ | 229 |
| | $ | (170 | ) | | $ | (331 | ) |
100
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 2022 | | 2021 |
| | Risk Corridor Settlement | | CMS Subsidies/ Discounts | | Risk Corridor Settlement | | CMS Subsidies/ Discounts |
| | (in millions) |
Other current assets | | $ | 240 | | | $ | 696 | | | $ | 363 | | | $ | 1,894 | |
Trade accounts payable and accrued expenses | | (166) | | | (1,236) | | | (68) | | | (466) | |
Net current asset (liability) | | 74 | | | (540) | | | 295 | | | 1,428 | |
Other long-term assets | | 19 | | | — | | | 5 | | | — | |
Other long-term liabilities | | (78) | | | — | | | (194) | | | — | |
Net long-term liability | | (59) | | | — | | | (189) | | | — | |
Total net asset (liability) | | $ | 15 | | | $ | (540) | | | $ | 106 | | | $ | 1,428 | |
8. PROPERTY AND EQUIPMENT, NET
Property and equipment was comprised of the following at December 31, 20192022 and 2018.2021.
|
| | | | | | | | |
| | 2019 | | 2018 |
| | (in millions) |
Land | | $ | 20 |
| | $ | 20 |
|
Buildings and leasehold improvements | | 874 |
| | 766 |
|
Equipment | | 922 |
| | 890 |
|
Computer software | | 2,799 |
| | 2,372 |
|
| | 4,615 |
| | 4,048 |
|
Accumulated depreciation | | (2,660 | ) | | (2,313 | ) |
Property and equipment, net | | $ | 1,955 |
| | $ | 1,735 |
|
| | | | | | | | | | | | | | |
| | 2022 | | 2021 |
| | (in millions) |
Land | | $ | 17 | | | $ | 17 | |
Buildings and leasehold improvements | | 1,143 | | | 1,126 | |
Equipment | | 1,246 | | | 1,148 | |
Computer software | | 3,951 | | | 3,656 | |
| | 6,357 | | | 5,947 | |
Accumulated depreciation | | (3,136) | | | (2,874) | |
Property and equipment, net | | $ | 3,221 | | | $ | 3,073 | |
Depreciation expense was $505$749 million in 2019, $4442022, $640 million in 2018,2021, and $410$528 million in 2017,2020, including amortization expense for capitalized internally developed and purchased software of $343$525 million in 2019, $2982022, $443 million in 2018,2021, and $287$351 million in 2017.2020.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
9. GOODWILL AND OTHER INTANGIBLE ASSETS
The carrying amount of goodwill for our reportable segments has been retrospectively adjusted to conform to the 2022 business segment realignment as discussed in Note 1. There was no impairment. Changes in the carrying amount of goodwill for our reportable segments for the years ended December 31, 20192022 and 20182021 were as follows:
| | | | | | | | | | | | | | | | | | | | | | | | |
| | Insurance | | CenterWell | | | | | | Total |
| | (in millions) |
Balance at January 1, 2021 | | $ | 1,892 | | | $ | 2,555 | | | | | | | $ | 4,447 | |
Acquisitions | | 398 | | | 6,247 | | | | | | | 6,645 | |
| | | | | | | | | | |
| | | | | | | | | | |
Balance at December 31, 2021 | | 2,290 | | | 8,802 | | | | | | | 11,092 | |
Acquisitions | | 182 | | | 199 | | | | | | | 381 | |
Dispositions | | — | | | (2,331) | | | | | | | (2,331) | |
| | | | | | | | | | |
Balance at December 31, 2022 | | $ | 2,472 | | | $ | 6,670 | | | | | | | $ | 9,142 | |
|
| | | | | | | | | | | | | | | | |
| | Retail | | Group and Specialty | | Healthcare Services | | Total |
| | (in millions) |
Balance at January 1, 2018 | | $ | 1,059 |
| | $ | 261 |
| | $ | 1,961 |
| | $ | 3,281 |
|
Acquisitions | | 476 |
| | — |
| | 140 |
| | 616 |
|
Balance at December 31, 2018 | | 1,535 |
| | 261 |
| | 2,101 |
| | 3,897 |
|
Acquisitions | | — |
| | — |
| | 31 |
| | 31 |
|
Balance at December 31, 2019 | | $ | 1,535 |
| | $ | 261 |
| | $ | 2,132 |
| | $ | 3,928 |
|
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
The following table presents details of our other intangible assets included in other long-term assets in the accompanying consolidated balance sheets at December 31, 20192022 and 2018.2021:
|
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Weighted Average Life | | 2019 | | 2018 |
| | Cost | | Accumulated Amortization | | Net | | Cost | | Accumulated Amortization | | Net |
| | | | (in millions) |
Other intangible assets: | | | | | | | | | | | | | | |
Customer contracts/relationships | | 8.7 years | | $ | 646 |
| | $ | 496 |
| | $ | 150 |
| | $ | 646 |
| | $ | 434 |
| | $ | 212 |
|
Trade names and technology | | 6.4 years | | 84 |
| | 84 |
| | — |
| | 84 |
| | 83 |
| | 1 |
|
Provider contracts | | 11.8 years | | 70 |
| | 44 |
| | 26 |
| | 68 |
| | 37 |
| | 31 |
|
Noncompetes and other | | 7.3 years | | 29 |
| | 28 |
| | 1 |
| | 29 |
| | 28 |
| | 1 |
|
Total other intangible assets | | 8.7 years | | $ | 829 |
| | $ | 652 |
| | $ | 177 |
| | $ | 827 |
| | $ | 582 |
| | $ | 245 |
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Weighted Average Life | | 2022 | | 2021 |
| | Cost | | Accumulated Amortization | | Net | | Cost | | Accumulated Amortization | | Net |
| | | | (in millions) |
Other intangible assets: | | | | | | | | | | | | | | |
Certificates of need | | Indefinite | | $ | 1,132 | | | $ | — | | | $ | 1,132 | | | $ | 1,771 | | | $ | — | | | $ | 1,771 | |
Medicare licenses | | Indefinite | | 286 | | | — | | | 286 | | | 522 | | | — | | | 522 | |
Customer contracts/relationships | | 9.3 years | | 929 | | | 673 | | | 256 | | | 883 | | | 620 | | | 263 | |
Trade names and technology | | 6.7 years | | 142 | | | 107 | | | 35 | | | 160 | | | 97 | | | 63 | |
Provider contracts | | 11.6 years | | 73 | | | 63 | | | 10 | | | 72 | | | 57 | | | 15 | |
Noncompetes and other | | 8.4 years | | 86 | | | 40 | | | 46 | | | 35 | | | 30 | | | 5 | |
Total other intangible assets | | 9.1 years | | $ | 2,648 | | | $ | 883 | | | $ | 1,765 | | | $ | 3,443 | | | $ | 804 | | | $ | 2,639 | |
Amortization expense for other intangible assets was approximately $70$81 million in 2019, $902022, $65 million in 2018,2021, and $75$88 million in 2017. Amortization expense for 2018 included $12 million associated with the write-off of a trade name value reflecting the re-branding of certain provider assets.2020.
The following table presents our estimate of amortization expense for each of the five next succeeding fiscal years:
| | | | | |
| (in millions) |
2023 | $ | 63 | |
2024 | 55 | |
2025 | 53 | |
2026 | 41 | |
2027 | 31 | |
|
| | | |
| (in millions) |
For the years ending December 31, | |
2020 | $ | 68 |
|
2021 | 34 |
|
2022 | 31 |
|
2023 | 18 |
|
2024 | 11 |
|
10. LEASES
We determine if a contract contains a lease by evaluating the nature and substance of the agreement. We lease facilities, computer hardware, and other furniture and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. For new lease agreements, we combine lease and nonlease components for all of our asset classes. See Note 2 for further information.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
When portions of the lease payments are not fixed or depend on an index or rate, we consider those payments to be variable in nature. Our variable lease payments include, but are not limited to, common area maintenance, taxes and insurance which are not dependent upon an index or rate. Variable lease payments are recorded in the period in which the obligation for the payment is incurred. Most leases include options to renew, with renewal terms that can extend the lease term. The exercise of lease renewal options is at our sole discretion. Certain leases also include options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.
At December 31, 2019, $410 million of operating ROURight-of-use assets are included within other long-term assets in our consolidated balance sheet. Additionally,sheets were $515 million and $678 million at December 31, 2019, $116 million2022 and $332 million of operatingDecember 31, 2021, respectively. Operating lease liabilities are included within trade accounts payable and accrued expenses and other long-term liabilities, respectively, in our consolidated balance sheetsheets were $152 million and $185 million at December 31, 2022 and December 31, 2021, respectively. Additionally, operating lease liabilities included within other long-term liabilities in our consolidated balance sheets were $456 million and $546 million at
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2022 and December 31, 2021, respectively. The classification of our operating lease liabilities is based on the remaining lease term.
For the year-endedyears ended December 31, 2019,2022, 2021 and 2020, total fixed operating lease costs, excluding short-term lease costs, were $154$183 million, $159 million and $141 million, respectively, and are included within operating costs in our consolidated statementstatements of income. Short-term lease costs were not material.material for the years ended December 31, 2022, 2021 and 2020. In addition, for the year-endedyears ended December 31, 2019,2022, 2021 and 2020, total variable operating lease costs were $82$101 million, $94 million and $92 million, respectively, and are included within operating costs in our consolidated statementstatements of income.
We sublease facilities or partial facilities to third party tenants for space not used in our operations. For the year-endedyears ended December 31, 2019,2022, 2021 and 2020, sublease rental income was $45$52 million, $43 million and $36 million, respectively, and is included within operating costs in our consolidated statementstatements of income.
The weighted average remaining lease term is 4.95.4 years with a weighted average discount rate of 4.1%3.2% at December 31, 2019.2022 and December 31, 2021. For the year-endedyears ended December 31, 2019,2022, 2021 and 2020, cash paid for amounts included in the measurement of lease liabilities included within our operating cash flows was $151 million.$191 million, $165 million and $146 million, respectively.
| | | | | | | | |
Maturity of Lease Liabilities | | December 31, 2022 |
For the years ended December 31, | | (in millions) |
2023 | | $ | 171 | |
2024 | | 141 | |
2025 | | 114 | |
2026 | | 72 | |
2027 | | 49 | |
After 2027 | | 116 | |
Total lease payments | | 663 | |
Less: Interest | | 55 | |
Present value of lease liabilities | | $ | 608 | |
|
| | | | |
Maturity of Lease Liabilities | | December 31, 2019 |
| | (in millions) |
2020 | | $ | 133 |
|
2021 | | 117 |
|
2022 | | 97 |
|
2023 | | 52 |
|
2024 | | 31 |
|
After 2024 | | 70 |
|
Total lease payments | | 500 |
|
Less: Interest | | 52 |
|
Present value of lease liabilities | | $ | 448 |
|
As most of our leases do not provide an implicit rate, we use our incremental borrowing rate, as adjusted for collateralized borrowings, based on the information available at date of adoption or commencement date in determining the present value of lease payments.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
For the year ended 2018, under prior lease disclosure requirements
We lease facilities, computer hardware, and other furniture and equipment under long-term operating leases that are noncancelable and expire on various dates through 2046. We sublease facilities or partial facilities to third party tenants for space not used in our operations. Rent with scheduled escalation terms are accounted for on a straight-line basis over the lease term. Rent expense and sublease rental income, which are recorded net as an operating cost, for all operating leases were as follows for the years ended December 31, 2018 and 2017:
|
| | | | | | | |
| 2018 | | 2017 |
| (in millions) |
Rent expense | $ | 167 |
| | $ | 204 |
|
Sublease rental income | (32 | ) | | (33 | ) |
Net rent expense | $ | 135 |
| | $ | 171 |
|
Future annual minimum payments due subsequent to December 31, 2018 under all of our noncancelable operating leases with initial terms in excess of one year are as follows:
|
| | | | | | | | | | | |
| Minimum Lease Payments | | Sublease Rental Receipts | | Net Lease Commitments |
| (in millions) |
For the years ending December 31,: | | | | | |
2019 | $ | 147 |
| | $ | (13 | ) | | $ | 134 |
|
2020 | 113 |
| | (12 | ) | | 101 |
|
2021 | 96 |
| | (10 | ) | | 86 |
|
2022 | 79 |
| | (9 | ) | | 70 |
|
2023 | 34 |
| | (9 | ) | | 25 |
|
Thereafter | 50 |
| | (23 | ) | | 27 |
|
Total | $ | 519 |
| | $ | (76 | ) | | $ | 443 |
|
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
11. BENEFITS PAYABLE
On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable excluding military services, was as follows for the years ended December 31, 2019, 20182022, 2021 and 2017:2020:
|
| | | | | | | | | | | | |
| | 2019 | | 2018 | | 2017 |
| | (in millions) |
Balances at January 1 | | $ | 4,862 |
| | $ | 4,668 |
| | $ | 4,563 |
|
Less: Reinsurance recoverables | | (95 | ) | | (70 | ) | | (76 | ) |
Balances at January 1, net | | 4,767 |
| | 4,598 |
| | 4,487 |
|
Incurred related to: | | | | | | |
Current year | | 54,193 |
| | 46,385 |
| | 44,001 |
|
Prior years | | (336 | ) | | (503 | ) | | (483 | ) |
Total incurred | | 53,857 |
| | 45,882 |
| | 43,518 |
|
Paid related to: | | | | | | |
Current year | | (48,421 | ) | | (41,736 | ) | | (39,496 | ) |
Prior years | | (4,267 | ) | | (3,977 | ) | | (3,911 | ) |
Total paid | | (52,688 | ) | | (45,713 | ) | | (43,407 | ) |
Reinsurance recoverable | | 68 |
| | 95 |
| | 70 |
|
Balances at December 31 | | $ | 6,004 |
| | $ | 4,862 |
| | $ | 4,668 |
|
| | | | | | | | | | | | | | | | | | | | |
| | 2022 | | 2021 | | 2020 |
| | (in millions) |
Balances at January 1 | | $ | 8,289 | | | $ | 8,143 | | | $ | 6,004 | |
| | | | | | |
Less: Reinsurance recoverables | | — | | | — | | | (68) | |
Balances at January 1, net | | 8,289 | | | 8,143 | | | 5,936 | |
Acquisitions | | — | | | 42 | | | — | |
Incurred related to: | | | | | | |
Current year | | 76,105 | | | 70,024 | | | 61,941 | |
Prior years | | (415) | | | (825) | | | (313) | |
Total incurred | | 75,690 | | | 69,199 | | | 61,628 | |
Paid related to: | | | | | | |
Current year | | (67,287) | | | (62,149) | | | (54,003) | |
Prior years | | (7,428) | | | (6,946) | | | (5,418) | |
Total paid | | (74,715) | | | (69,095) | | | (59,421) | |
| | | | | | |
| | | | | | |
Balances at December 31 | | $ | 9,264 | | | $ | 8,289 | | | $ | 8,143 | |
The total estimate of benefits payable for claims incurred but not reported, or IBNR, is included within the net
incurred claims amounts. At December 31, 2022, benefits payable included IBNR of approximately $5.7 billion, primarily associated with claims incurred in 2022. The cumulative number of reported claims as of December 31, 2022 was approximately 173.5 million for claims incurred in 2022, 173.3 million for claims incurred in 2021, and 149.8 million for claims incurred in 2020.
Amounts incurred related to prior years vary from previously estimated liabilities as the claims ultimately are settled. Negative amounts reported for incurred related to prior years result from claims being ultimately settled for amounts less than originally estimated (favorable development).
As previously discussed, our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. We experienced favorable medical claims reserve development related to prior fiscal years of $336$415 million in 2019, $5032022, $825 million in 2018,2021, and $483$313 million in 2017. The table below details our favorable medical claims reserve development related to prior fiscal years by segment for 2019, 2018, and 2017.
|
| | | | | | | | | | | |
| (Favorable) Unfavorable Medical Claims Reserve Development |
| 2019 | | 2018 | | 2017 |
| |
Retail Segment | $ | (386 | ) | | $ | (398 | ) | | $ | (386 | ) |
Group and Specialty Segment | 50 |
| | (46 | ) | | (40 | ) |
Individual Commercial Segment | — |
| | (57 | ) | | (56 | ) |
Other Businesses | — |
| | (2 | ) | | (1 | ) |
Total | $ | (336 | ) | | $ | (503 | ) | | $ | (483 | ) |
2020.The medical claims reserve development for 2019, 2018,2022, 2021, and 20172020 primarily reflects the consistent application of trend and completion factors estimated using an assumption of moderately adverse conditions. FavorableIn addition, the higher prior periodyear favorable development primarily resulted from our Medicare Advantage medical business. The unfavorable Group and Specialty medical claims reserve development for 2019 reflects higher than expected claims trend and provider settlements.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Benefits expense reduction of $22 million associated with long-duration future policy benefits for the year ended December 31, 20172021 was excluded fromprimarily attributable to the previous short duration benefits payable rollforward table.reversal of actions taken in 2020, including the suspension of certain financial recovery programs for a period of time impacting our claim payment patterns. The suspension during 2020 was intended to provide financial and administrative relief for providers facing unprecedented strain as a result of the COVID-19 pandemic.
Incurred and Paid Claims Development
The following discussion provides information about incurred and paid claims development for our segments as of December 31, 2019,2022, net of reinsurance, as well as cumulative claim frequency and the total of IBNR included within the net incurred claims amounts. The information about incurred and paid claims development for the years ended December 31, 20172021 and 20182020 is presented as supplementary information.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Claims frequency is measured as medical fee-for-service claims for each service encounter with a unique provider identification number. Our claims frequency measure includes claims covered by deductibles as well as claims under capitated arrangements. Claim counts may vary based on product mix and the percentage of delegated capitation arrangements.
Retail Segment
Activity in benefits payable for our Retail segment was as follows for the years ended December 31, 2019, 2018 and 2017:
|
| | | | | | | | | | | | |
| | 2019 | | 2018 | | 2017 |
| | (in millions) |
Balances at January 1 | | $ | 4,338 |
| | $ | 3,963 |
| | $ | 3,506 |
|
Less: Reinsurance recoverables | | (95 | ) | | (70 | ) | | (76 | ) |
Balances at January 1, net | | 4,243 |
| | 3,893 |
| | 3,430 |
|
Incurred related to: | | | | | | |
Current year | | 48,983 |
| | 41,323 |
| | 38,604 |
|
Prior years | | (386 | ) | | (398 | ) | | (386 | ) |
Total incurred | | 48,597 |
| | 40,925 |
| | 38,218 |
|
Paid related to: | | | | | | |
Current year | | (43,831 | ) | | (37,189 | ) | | (34,781 | ) |
Prior years | | (3,714 | ) | | (3,386 | ) | | (2,974 | ) |
Total paid | | (47,545 | ) | | (40,575 | ) | | (37,755 | ) |
Reinsurance recoverable | | 68 |
| | 95 |
| | 70 |
|
Balances at December 31 | | $ | 5,363 |
| | $ | 4,338 |
| | $ | 3,963 |
|
At December 31, 2019, benefits payable for our Retail segment included IBNR of approximately $3.6 billion, primarily associated with claims incurred in 2019. The cumulative number of reported claims as of December 31, 2019 was approximately 123.0 million for claims incurred in 2019, 109.6 million for claims incurred in 2018, and 104.7 million for claims incurred in 2017.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
The following tables provide information about incurred and paid claims development for the Retail segment as of December 31, 2019,2022, net of reinsurance.
|
| | | | | | | | | | | | |
| | Incurred Claims, Net of Reinsurance |
| | For the Years Ended December 31, |
Claims Incurred Year | | 2017 Unaudited | | 2018 Unaudited | | 2019 |
|
| (in millions) |
2017 | | $ | 38,604 |
| | $ | 38,341 |
| | $ | 38,310 |
|
2018 | |
| | 41,323 |
| | 40,984 |
|
2019 | |
| |
| | 48,983 |
|
Total | | | | | | $ | 128,277 |
|
| | | | | | | | | | | | | | | | | | | | | | | | |
| | Incurred Claims, Net of Reinsurance | | |
| | For the Years Ended December 31, | | | | |
Claims Incurred Year | | 2020 Unaudited | | 2021 Unaudited | | 2022 | | |
| | (in millions) | | | | |
2020 | | $ | 61,941 | | | $ | 61,258 | | | $ | 61,224 | | | | | |
2021 | | | | 70,066 | | | 69,698 | | | | | |
2022 | | | | | | 76,105 | | | | | |
Total | | | | | | $ | 207,027 | | | | | |
|
| | | | | | | | | | | | |
|
| Cumulative Paid Claims, Net of Reinsurance |
|
| For the Years Ended December 31, |
Claims Incurred Year |
| 2017 Unaudited | | 2018 Unaudited |
| 2019 |
|
| (in millions) |
2017 |
| $ | 34,781 |
|
| $ | 38,232 |
|
| $ | 38,310 |
|
2018 |
|
|
| 37,189 |
|
| 40,841 |
|
2019 |
|
|
|
|
| 43,831 |
|
Total |
|
|
|
|
| $ | 122,982 |
|
All outstanding benefit liabilities before 2017, net of reinsurance |
| N/A |
|
Benefits payable, net of reinsurance |
| $ | 5,295 |
|
| | | | | | | | | | | | | | | | | | | | |
| | Cumulative Paid Claims, Net of Reinsurance |
| | For the Years Ended December 31, |
Claims Incurred Year | | 2020 Unaudited | | 2021 Unaudited | | 2022 |
| | (in millions) |
2020 | | $ | 54,003 | | | $ | 60,886 | | | $ | 61,224 | |
2021 | | | | 62,149 | | | 69,252 | |
2022 | | | | | | 67,287 | |
Total | | | | | | 197,763 | |
All outstanding benefit liabilities before 2020, net of reinsurance | | N/A |
Benefits payable, net of reinsurance | | $ | 9,264 | |
For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.
Group and Specialty Segment
Activity in benefits payable for our Group and Specialty segment, excluding military services, was as follows for the years ended December 31, 2019, 2018 and 2017:
|
| | | | | | | | | | | | |
| | 2019 | | 2018 | | 2017 |
| | (in millions) |
Balances at January 1 | | $ | 517 |
| | $ | 568 |
| | $ | 579 |
|
Incurred related to: | | | | | | |
Current year | | 5,708 |
| | 5,466 |
| | 5,403 |
|
Prior years | | 50 |
| | (46 | ) | | (40 | ) |
Total incurred | | 5,758 |
| | 5,420 |
| | 5,363 |
|
Paid related to: | | | | | | |
Current year | | (5,081 | ) | | (4,957 | ) | | (4,843 | ) |
Prior years | | (553 | ) | | (514 | ) | | (531 | ) |
Total paid | | (5,634 | ) | | (5,471 | ) | | (5,374 | ) |
Balances at December 31 | | $ | 641 |
| | $ | 517 |
| | $ | 568 |
|
At December 31, 2019, benefits payable for our Group and Specialty segment included IBNR of approximately $567 million, primarily associated with claims incurred in 2019. The cumulative number of reported claims as of December 31, 2019 was approximately 9.7 million for claims incurred in 2019, 10.8 million for claims incurred in 2018, and 11.1 million for claims incurred in 2017.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
The following tables provide information about incurred and paid claims development for the Group and Specialty segment as of December 31, 2019, net of reinsurance.
|
| | | | | | | | | | | | |
| | Incurred Claims, Net of Reinsurance |
| | For the Years Ended December 31, |
Claims Incurred Year | | 2017 Unaudited | | 2018 Unaudited | | 2019 |
|
| (in millions) |
2017 | | $ | 5,403 |
| | $ | 5,358 |
| | $ | 5,372 |
|
2018 | |
| | 5,466 |
| | 5,501 |
|
2019 | |
| |
| | 5,708 |
|
Total | | | | | | $ | 16,581 |
|
|
| | | | | | | | | | | | |
|
| Cumulative Paid Claims, Net of Reinsurance |
|
| For the Years Ended December 31, |
Claims Incurred Year |
| 2017 Unaudited |
| 2018 Unaudited |
| 2019 |
|
| (in millions) |
2017 |
| $ | 4,843 |
|
| $ | 5,351 |
|
| $ | 5,372 |
|
2018 |
|
|
| 4,957 |
|
| 5,487 |
|
2019 |
|
|
|
|
| 5,081 |
|
Total |
|
|
|
|
|
| $ | 15,940 |
|
All outstanding benefit liabilities before 2017, net of reinsurance |
| N/A |
|
Benefits payable, net of reinsurance |
| $ | 641 |
|
Reconciliation to Consolidated
The reconciliation of the net incurred and paid claims development tables to benefits payable in the consolidated statement of financial position is as follows:
|
| | | |
| December 31, 2019 |
Net outstanding liabilities | |
Retail | $ | 5,295 |
|
Group and Specialty | 641 |
|
Benefits payable, net of reinsurance | 5,936 |
|
Reinsurance recoverable on unpaid claims | |
Retail | 68 |
|
Total benefits payable, gross | $ | 6,004 |
|
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
12. INCOME TAXES
The provision for income taxes consisted of the following for the years ended December 31, 2019, 20182022, 2021 and 2017:2020:
|
| | | | | | | | | | | |
| 2019 | | 2018 | | 2017 |
| (in millions) |
Current provision: | | | | | |
Federal | $ | 560 |
| | $ | 139 |
| | $ | 1,324 |
|
States and Puerto Rico | 41 |
| | 58 |
| | 116 |
|
Total current provision | 601 |
| | 197 |
| | 1,440 |
|
Deferred expense | 162 |
| | 194 |
| | 132 |
|
Provision for income taxes | $ | 763 |
| | $ | 391 |
| | $ | 1,572 |
|
| | | | | | | | | | | | | | | | | |
| 2022 | | 2021 | | 2020 |
| (in millions) |
Current provision: | | | | | |
Federal | $ | 755 | | | $ | 466 | | | $ | 1,019 | |
States and Puerto Rico | 107 | | | 4 | | | 93 | |
Total current provision | 862 | | | 470 | | | 1,112 | |
Deferred (benefit) expense | (100) | | | 15 | | | 195 | |
Provision for income taxes | $ | 762 | | | $ | 485 | | | $ | 1,307 | |
The provision for income taxes was different from the amount computed using the federal statutory rate for the years ended December 31, 2019, 20182022, 2021 and 20172020 due to the following:
|
| | | | | | | | | | | |
| 2019 | | 2018 | | 2017 |
| (in millions) |
Income tax provision at federal statutory rate | $ | 729 |
| | $ | 436 |
| | $ | 1,407 |
|
States, net of federal benefit, and Puerto Rico | 49 |
| | 42 |
| | 80 |
|
Tax exempt investment income | (6 | ) | | (11 | ) | | (22 | ) |
Health insurance industry fee | — |
| | 243 |
| | — |
|
Nondeductible executive compensation | 25 |
| | 17 |
| | 36 |
|
Tax reform | — |
| | (39 | ) | | 133 |
|
KMG sale | — |
| | (272 | ) | | — |
|
Other, net | (34 | ) | | (25 | ) | | (62 | ) |
Provision for income taxes | $ | 763 |
| | $ | 391 |
| | $ | 1,572 |
|
The tax reform law enacted on December 22, 2017 (the "Tax Reform Law") reduced the statutory federal corporate income tax rate to 21 percent from 35 percent, beginning in 2018, and required a mandatory deemed repatriation of undistributed foreign earnings. The rate reduction required a remeasurement of our net deferred tax asset. These items resulted in an estimated increase in our 2017 tax provision of approximately $133 million, including approximately $10 million for the deemed repatriation tax imposed on the undistributed earnings of our Puerto Rico operations. Revisions to our prior estimate for the income tax effects of the Tax Reform Law decreased our 2018 tax provision by approximately $39 million.
The incremental tax benefit on the sale of KMG of $272 million resulted from a tax loss higher than the loss recorded in the statement of income for the year ended December 31, 2018 due to a higher tax basis in KMG than book basis. In addition, the amount reflects our ability to carryback the capital loss to tax years 2015, 2016 and 2017 at the historical tax rate of 35 percent instead of the current tax rate of 21 percent. | | | | | | | | | | | | | | | | | |
| 2022 | | 2021 | | 2020 |
| (in millions) |
Income tax provision at federal statutory rate | $ | 750 | | | $ | 718 | | | $ | 982 | |
States, net of federal benefit, and Puerto Rico | 49 | | | 18 | | | 63 | |
Tax exempt investment income | (3) | | | (3) | | | (5) | |
Nondeductible executive compensation | 30 | | | 33 | | | 19 | |
Non-taxable KAH gain | — | | | (264) | | | — | |
Tax effect from sale of KAH Hospice | (72) | | | — | | | — | |
Health insurance industry fee | — | | | — | | | 268 | |
| | | | | |
Other, net | 8 | | | (17) | | | (20) | |
Provision for income taxes | $ | 762 | | | $ | 485 | | | $ | 1,307 | |
Deferred income tax balances reflect the impact of temporary differences between the tax bases of assets or liabilities and their reported amounts in our consolidated financial statements, and are stated at enacted tax rates expected to be in effect when the reported amounts are actually recovered or settled.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Principal components of our net deferred tax balances at December 31, 20192022 and 20182021 were as follows:
|
| | | | | | | |
| Assets (Liabilities) |
| 2019 | | 2018 |
| (in millions) |
Compensation and other accrued expense | $ | 111 |
| | $ | 89 |
|
Benefits payable | 89 |
| | 79 |
|
Net operating loss carryforward | 42 |
| | 38 |
|
Deferred acquisition costs | 22 |
| | 17 |
|
Unearned revenues | 8 |
| | 9 |
|
Other | 8 |
| | 8 |
|
Capital loss carryforward | 1 |
| | 15 |
|
Investment securities | — |
| | 44 |
|
Total deferred income tax assets | 281 |
| | 299 |
|
Valuation allowance | (45 | ) | | (54 | ) |
Total deferred income tax assets, net of valuation allowance | 236 |
| | 245 |
|
Depreciable property and intangible assets | (329 | ) | | (273 | ) |
Investment securities | (181 | ) | | — |
|
Prepaid expenses | (64 | ) | | (52 | ) |
Future policy benefits payable | (3 | ) | | (5 | ) |
Total deferred income tax liabilities | (577 | ) | | (330 | ) |
Total net deferred income tax liabilities | $ | (341 | ) | | $ | (85 | ) |
| | | | | | | | | | | |
| Assets (Liabilities) |
| 2022 | | 2021 |
| (in millions) |
Net operating loss carryforward | $ | 105 | | | $ | 291 | |
Compensation and other accrued expense | 158 | | | 186 | |
Benefits payable | 103 | | | 67 | |
Deferred acquisition costs | 43 | | | 33 | |
Jobs tax credits | 22 | | | 33 | |
Other | 16 | | | 25 | |
Unearned revenues | 7 | | | 8 | |
| | | |
Investment securities | 454 | | | — | |
| | | |
Total deferred income tax assets | 908 | | | 643 | |
Valuation allowance | (57) | | | (65) | |
Total deferred income tax assets, net of valuation allowance | 851 | | | 578 | |
Depreciable property and intangible assets | (740) | | | (1,072) | |
Prepaid expenses | (132) | | | (102) | |
Investment securities | — | | | (98) | |
Other | (6) | | | (4) | |
Total deferred income tax liabilities | (878) | | | (1,276) | |
Total net deferred income tax liabilities | $ | (27) | | | $ | (698) | |
| | | |
| | | |
| | | |
All deferred tax liabilities and assets are classified as noncurrent in our consolidated balance sheets as other long-term liabilities at December 31, 20192022 and 2018.2021.
At December 31, 2019,2022, we had approximately $114$68 million of federal net operating losses and $2 millionapproximately $1.6 billion of capitalstate and Puerto Rico net operating losses to carry forward. TheseA portion of these loss carryforwards, if not used to offset future taxable income, or capital gain, will expire from 20202031 through 2033.2038. The balance of the net operating loss carryforwards has no expiration date. Due to limitations and uncertainty regarding our ability to use some of the loss carryforwards and certain other deferred tax assets, a valuation allowance of $45$57 million was established. For the remainder of the net operating loss carryforwards and other cumulative temporary differences, based on our historical record of producing taxable income and profitability, we have concluded that future operating income will be sufficient to give rise to tax expense to recover these deferred tax assets.
We file income tax returns in the United States and Puerto Rico. The U.S. Internal Revenue Service, or IRS, has completed its examinations of our consolidated income tax returns for 20172020 and prior years. Our 20182021 tax return is in the post-filing review period under the Compliance Assurance Process, or CAP. Our 20192022 tax return is under advance review by the IRS under CAP. With a few exceptions, which are immaterial in the aggregate, we are no longer are subject to state, local and foreign tax examinations for years before 2016.2019. We are not aware of any material adjustments that may be proposed as a result of any ongoing or future examinations. We do not have material uncertain tax positions reflected in our consolidated balance sheets.
On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for the tax years beginning on or after January 1, 2023. There was no material impact on our consolidated financial statements at December 31, 2022.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
13. DEBT
The carrying value of debt outstanding was as follows at December 31, 20192022 and 2018:2021:
| | | | | | | | | | | |
| 2022 | | 2021 |
| (in millions) |
Short-term debt: | |
Commercial paper | $ | 595 | | | $ | 955 | |
Senior notes: | | | |
$1,500 million, 0.65% due August 3, 2023 | 1,497 | | | — | |
$600 million, 3.15% due December 1, 2022 | — | | | 599 | |
$400 million, 2.90% due December 15, 2022 | — | | | 399 | |
Total senior notes | 1,497 | | | 998 | |
Total short-term debt | $ | 2,092 | | | $ | 1,953 | |
| |
Long-term debt: | |
Senior notes: | |
$1,500 million, 0.65% due August 3, 2023 | — | | | 1,492 | |
$600 million, 3.85% due October 1, 2024 | 599 | | | 598 | |
$600 million, 4.50% due April 1, 2025 | 597 | | | 596 | |
$750 million 1.35% due February 3, 2027 | 745 | | | 742 | |
$600 million, 3.95% due March 15, 2027 | 597 | | | 596 | |
$500 million, 5.75% due March 1, 2028 | 494 | | | — | |
$750 million, 3.70% due March 23, 2029 | 743 | | | — | |
$500 million, 3.13% due August 15, 2029 | 496 | | | 496 | |
$500 million, 4.88% due April 1, 2030 | 495 | | | 495 | |
$750 million, 2.15% due February 3, 2032 | 743 | | | 741 | |
$750 million, 5.88% due March 1, 2033 | 739 | | | — | |
$250 million, 8.15% due June 15, 2038 | 261 | | | 261 | |
$400 million, 4.63% due December 1, 2042 | 396 | | | 396 | |
$750 million, 4.95% due October 1, 2044 | 740 | | | 740 | |
$400 million, 4.80% due March 15, 2047 | 396 | | | 395 | |
$500 million, 3.95% due August 15, 2049 | 493 | | | 493 | |
Term loans: | | | |
Term loan, due October 29, 2023 | — | | | 2,000 | |
Delayed draw term loan, due May 28, 2024 | 500 | | | 500 | |
Total long-term debt | $ | 9,034 | | | $ | 10,541 | |
|
| | | | | | | |
| 2019 | | 2018 |
| (in millions) |
Short-term debt: | |
Commercial paper | $ | 300 |
| | $ | 645 |
|
Term note | — |
| | 650 |
|
Senior notes: | | | |
$400 million, 2.625% due October 1, 2019 | — |
| | 399 |
|
$400 million, 2.50% due December 15, 2020 | 399 |
| | — |
|
Total short-term debt | $ | 699 |
| | $ | 1,694 |
|
| |
Long-term debt: | |
Senior notes: | |
$400 million, 2.50% due December 15, 2020 | $ | — |
| | $ | 398 |
|
$600 million, 3.15% due December 1, 2022 | 598 |
| | 596 |
|
$400 million, 2.90% due December 15, 2022 | 397 |
| | 396 |
|
$600 million, 3.85% due October 1, 2024 | 597 |
| | 597 |
|
$600 million, 3.95% due March 15, 2027 | 595 |
| | 594 |
|
$500 million, 3.125% due August 15, 2029 | 495 |
| | — |
|
$250 million, 8.15% due June 15, 2038 | 262 |
| | 263 |
|
$400 million, 4.625% due December 1, 2042 | 396 |
| | 396 |
|
$750 million, 4.95% due October 1, 2044 | 739 |
| | 739 |
|
$400 million, 4.80% due March 15, 2047 | 396 |
| | 396 |
|
$500 million, 3.95% due August 15, 2049 | 492 |
| | — |
|
Total long-term debt | $ | 4,967 |
| | $ | 4,375 |
|
108
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Maturities of the short-term and long-term debt for the years ending December 31, are as follows:
| | | | | |
For the years ending December 31, | (in millions) |
2023 | $ | 2,095 | |
2024 | 1,100 | |
2025 | 600 | |
2026 | — | |
2027 | 1,350 | |
Thereafter | 6,050 | |
|
| | | |
For the years ending December 31, | (in millions) |
2020 | $ | 700 |
|
2021 | — |
|
2022 | 1,000 |
|
2023 | — |
|
2024 | 600 |
|
Thereafter | 3,400 |
|
Senior Notes
In August 2019, we issued $500 million of 3.125% senior notes due August 15, 2029 and $500 million of 3.950% senior notes due August 15, 2049. Our net proceeds, reduced for the underwriters' discount and commission and offering expenses paid were $987 million. We used the net proceeds from this offering, together with available cash, to repay the $650 million outstanding amount due under our term note in August 2019, and the $400 million aggregate principal amount of our 2.625% senior notes due on its maturity date of October 1, 2019.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Our senior notes, which are unsecured, may be redeemed at our option at any time at 100% of the principal amount plus accrued interest and a specified make-whole amount. The 8.15% senior notes are subject to an interest rate adjustment if the debt ratings assigned to the notes are downgraded (or subsequently upgraded). In addition, our senior notes contain a change of control provision that may require us to purchase the notes under certain circumstances.
In December 2022, we repaid $600 million aggregate principal amount of our 3.150% senior notes due on their maturity date of December 1, 2022 and $400 million aggregate principal amount of our 2.900% senior notes due on their maturity date of December 15, 2022.
In November 2022, we issued $500 million of 5.750% unsecured senior notes due March 1, 2028 and $750 million of 5.875% unsecured senior notes due March 1, 2033. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $1.2 billion. We recognizedused the net proceeds for general corporate purposes, which included the repayment of existing indebtedness.
In March 2022, we issued $750 million of 3.700% unsecured senior notes due March 23, 2029. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $744 million. We used the net proceeds for general corporate purposes, which included the repayment of existing indebtedness, including borrowings under our commercial paper program.
Delayed Draw Term Loan Credit Agreement
In May 2021, we entered into a loss$500 million unsecured delayed draw term loan credit agreement. Under the term loan credit agreement, loans bear interest at either LIBOR plus a spread or the base rate plus a spread. The loans under the term loan credit agreement mature on extinguishmentthe third anniversary of the funding date. The LIBOR spread, currently 125 basis points, varies depending on our credit ratings ranging from 100.0 to 162.5 basis points. The term loan credit agreement provides for the transition from LIBOR and does not require amendment in connection with such transition.
In August 2021, we borrowed $500 million under the delayed draw term loan agreement, which was used, in combination with other debt financing, to fund the approximate $5.8 billion transaction price of Kindred at Home. The term loan credit agreement contains customary restrictive covenants and a financial covenant regarding maximum debt to capitalization of 60%, as well as customary events of default. We are in compliance with this financial covenant, with actual debt to capitalization of 42.0% as measured in accordance with the term loan credit agreement as of December 31, 2022.
We have other customary relationships, including financial advisory and banking, with some parties to the term loan agreement.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
October 2021 Term Loan Agreement
On October 29, 2021, we entered into a $2.0 billion term loan credit agreement, which we refer to as the October 2021 Term Loan Agreement, with certain lending banks and other financial institutions. Proceeds of the October 2021 Term Loan Agreement were applied to finance the repayment in full of the outstanding KAH debt of approximately $17 million in 2017 for$1.9 billion.
On August 16, 2022, we repaid the early redemption of senior notes, which is included in interest expense in the consolidated statements of income.$2.0 billion October 2021 Term Loan Agreement without a prepayment penalty due.
Revolving Credit AgreementAgreements
Our
In June 2021, we entered into a 5-year, $2.0$2.5 billion unsecured revolving credit agreement expires May 2022.agreement. Under the 5-year revolving credit agreement, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at either LIBOR plus a spread or the base rate plus a spread. If drawn upon, the revolving credit would revert to using the alternative base rate once LIBOR is discontinued. The LIBOR spread, currently 110.0 basis points, varies depending on our credit ratings ranging from 91.0 to 150.0 basis points. We also pay an annual facility fee regardless of utilization. This facility fee, currently 15.0 basis points, may fluctuate between 9.0 and 25.0 basis points, depending upon our credit ratings. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based on LIBOR, at our option.
The revolving credit agreement provides for the transition from LIBOR and does not require amendment in connection with such transition.
In June 2022, we entered into a 364-day $1.5 billion unsecured revolving credit agreement (replacing the 364-day $1.5 billion unsecured revolving credit agreement entered in June 2021, which expired in accordance with its terms). Under the 364-day revolving credit agreement, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at Term SOFR or the base rate plus a spread. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based Term SOFR, at our option.
The LIBOR spread, currently 110.0 basis points under the 5-year revolving credit agreements and the SOFR spread, currently 115.0 basis points under the 364-day revolving credit agreement, varies depending on our credit ratings ranging from 91.0 to 140.0 basis points under the 5-year revolving credit agreement and from 94.0 to 135.0 basis points under the 364-day revolving credit agreement. We also pay an annual facility fee regardless of utilization. This facility fee, currently 15.0 basis points, under the 5-year revolving credit agreement and 10.0 basis points under the 364-day revolving agreement, varies depending on our credit ratings ranging from 9.0 to 22.5 basis points under the 5-year revolving credit agreement and from 6.0 to 15.0 basis points under the 364-day revolving credit agreement.
The terms of the revolving credit agreementagreements include standard provisions related to conditions of borrowing which could limit our ability to borrow additional funds. In addition, the credit agreement containsagreements contain customary restrictive covenants and a financial covenant regarding maximum debt to capitalization of 50%60%, as well as customary events of default. We are in compliance with this financial covenant, with an actual debt to capitalization of 32%42.0% as measured in accordance with the revolving credit agreementagreements as of December 31, 2019.2022. Upon our agreement with one or more financial institutions, we may expand the aggregate commitments under the revolving credit agreementagreements by up to $750 million in the aggregate, to a maximum of $2.5$4.75 billion, through a $500 million incremental loan facility.across the 5-year and 364-day revolving credit agreements.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
At December 31, 2019,2022, we had 0no borrowings and 0approximately $45 million of letters of credit outstanding under the revolving credit agreement.agreements, including those of KAH. Accordingly, as of December 31, 2019,2022, we had $2$2.4 billion of remaining borrowing capacity under the 5-year revolving credit agreement and $1.5 billion of remaining borrowing capacity under the 364-day revolving credit agreement (which excludes the uncommitted $500$750 million of incremental loan facility under the credit agreement)facilities), none of which would be restricted by our financial covenant compliance requirement.
We have other customary arms-length relationships, including financial advisory and banking, with some parties to the revolving credit agreement.agreements.
Commercial Paper
Under our commercial paper program we may issue short-term, unsecured commercial paper notes privately placed on a discount basis through certain broker dealers at any timetime. On February 10, 2022, we increased the size of our commercial paper program to permit the issuance of commercial paper notes in an aggregate principal amount not to exceed $4 billion compared to the prior amount not to exceed $2 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The maximum principal amount outstanding at any one time during the year ended December 31, 20192022 was $801$1,450 million, with $300$595 million outstanding at December 31, 20192022 compared to $645$955 million outstanding at December 31, 2018.2021. The outstanding commercial paper at December 31, 20192022 had a weighted average annual interest rate of 2%4.92%.
Term NoteOther Short-term Borrowings
In November 2018, we entered intoWe are a $1.0 billion term note agreement with a bank at a variable rate of interest due withinmember, through one year. We may elect to incur interest at either the bank's base rate or LIBOR plus 115 basis points. The base rate is defined as the highersubsidiary, of the daily federal funds rate plus 50 basis points;Federal Home Loan Bank of Cincinnati, or FHLB. As a member we have the bank's prime rate; or LIBOR plus 100 basis points. The term note shares the customary terms and provisions as well as financial covenantsability to obtain short-term cash advances, subject to certain minimum collateral requirements. As of our credit agreement, as discussed above. The note was prepayable without penalty. We repaid $350 million prior to December 31, 20182022 and repaid theDecember 31, 2021, we had no outstanding balance of $650 million in August 2019.short-term FHLB borrowings
In February 2020, we entered into a new $1 billion term loan commitment with a bank that allows for up to 3 draws with the initial draw at a minimum of $300 million that matures 1 year after the first draw, subject to a 1 year extension. Following any initial draw, any unused commitments in excess of $300 million expire on June 30, 2020, with the remaining commitments of up to $300 million available until September 30, 2020. If the initial draw
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
has not been made by June 30, 2020, then all commitments expire on June 30, 2020. The facility fee, interest rate and financial covenants are consistent with those of our revolving credit agreement. There is no prepayment penalty.
14. EMPLOYEE BENEFIT PLANS
Employee Savings Plan
We have defined contribution retirement savings plans covering eligible employees which include matching contributions based on the amount of our employees’ contributions to the plans. The cost of these plans amounted to approximately $221$286 million in 2019, $1972022, $259 million in 2018,2021, and $217$236 million in 2017.2020. The Company’s cash match is invested pursuant to the participant’s contribution direction. Based on the closing price of our common stock of $366.52$512.19 on December 31, 2019,2022, approximately 11% of the retirement and savings plan’s assets were invested in our common stock, or approximately 1.61.4 million shares, representing approximately 1.2%1.1% of the shares outstanding as of December 31, 2019.2022. At December 31, 2019,2022, approximately 1.85.8 million shares of our common stock were reserved for issuance under our defined contribution retirement savings plans.
Stock-Based Compensation
We have plans under which options to purchase our common stock and restricted stock units have been granted to executive officers, directors and key employees. Awards generally require both a change in control and termination of employment within 2 years of the date of the change in control to accelerate the vesting, including those granted to retirement-eligible participants.
The terms and vesting schedules for stock-based awards vary by type of grant. Generally, the awards vest upon time-based conditions. We have also granted awards to certain employees that vest upon a combination of time and performance-based conditions. The stock awards of retirement-eligible participants are generally earned ratably over the service period for each tranche. Accordingly, upon retirement the earned portion of the current tranche will continue to vest on the originally scheduled vest date and any remaining unearned portion of the award will be forfeited. Our equity award program includes a retirement provision that generally treats employees with a combination of age and years of services with the Company totaling 65 or greater, with a minimum required age of
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
55 and a minimum requirement of 5 years of service, as retirement-eligible. Upon exercise, stock-based compensation awards are settled with authorized but unissued company stock or treasury stock.
The compensation expense that has been charged against income for these plans was as follows for the years ended December 31, 2019, 2018,2022, 2021, and 2017:2020:
|
| | | | | | | | | | | |
| 2019 | | 2018 | | 2017 |
| (in millions) |
Stock-based compensation expense by type: | | | | | |
Restricted stock | $ | 152 |
| | $ | 124 |
| | $ | 145 |
|
Stock options | 11 |
| | 13 |
| | 12 |
|
Total stock-based compensation expense | 163 |
| | 137 |
| | 157 |
|
Tax benefit recognized | (35 | ) | | (21 | ) | | (32 | ) |
Stock-based compensation expense, net of tax | $ | 128 |
| | $ | 116 |
| | $ | 125 |
|
Stock-based compensation expense for certain restricted stock in 2017 included a $29 million modification expense for certain awards. | | | | | | | | | | | | | | | | | |
| 2022 | | 2021 | | 2020 |
| (in millions) |
Stock-based compensation expense by type: | | | | | |
Restricted stock | $ | 207 | | | $ | 171 | | | $ | 171 | |
Stock options | 9 | | | 9 | | | 10 | |
Total stock-based compensation expense | 216 | | | 180 | | | 181 | |
Tax benefit recognized | (28) | | | (15) | | | (29) | |
Stock-based compensation expense, net of tax | $ | 188 | | | $ | 165 | | | $ | 152 | |
The tax benefit recognized in our consolidated financial statements is based on the amount of compensation expense recorded for book purposes, subject to limitations on the deductibility of annual compensation in excess of $500,000 per employee as mandated by the Health Care Reform Law. The actual tax benefit realized in our tax return is based on the intrinsic value, or the excess of the market value over the exercise or purchase price, of stock options exercised and restricted stock vested during the period, subject to limitations on the deductibility of annual compensation in excess of $500,000 per employee as mandated by the Health Care Reform Law. The actual tax benefit realized for the
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
deductions taken on our tax returns from option exercises and restricted stock vesting totaled $25$31 million in 2019, $492022, $28 million in 2018,2021, and $68$32 million in 2017.2020. There was no capitalized stock-based compensation expense during these years.
At December 31, 2019,2022, there were 12.511.0 million shares reserved for stock award plans under the Humana Inc. 2011 Stock Incentive Plan, or 2011 Plan, and 16.015.3 million shares reserved for stock award plans under the Humana Inc. 2019 Stock Incentive Plan, or 2019 Plan. These reserved shares included giving effect to, under the 2011 Plan, 3.83.3 million shares of common stock available for future grants assuming all stock options were granted or 1.71.4 million shares available for future grants assuming all restricted stock were granted. These reserved shares included giving effect to, under the 2019 Plan, 15.811.2 million shares of common stock available for future grants assuming all stock options were granted or 4.73.4 million shares available for future grants assuming all restricted stock were granted. Shares may be issued from authorized but unissued company stock or treasury stock.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Restricted Stock
Restricted stock is granted with a fair value equal to the market price of our common stock on the date of grant and generally vests in equal annual tranches over a three year period from the date of grant. Certain of our restricted stock grants also include performance-based conditions generally associated with return on invested capital and strategic membership growth. Restricted stock units have forfeitable dividend equivalent rights equal to the dividend paid on common stock. The weighted-average grant date fair value of our restricted stock was $302.09$430.06 in 2019, $276.622022, $381.34 in 2018,2021, and $222.35$354.66 in 2017.2020. Activity for our restricted stock was as follows for the year ended December 31, 2019:2022:
|
| | | | | | |
| Shares | | Weighted- Average Grant-Date Fair Value |
| (shares in thousands) |
Nonvested restricted stock at December 31, 2018 | 964 |
| | $ | 213.99 |
|
Granted | 503 |
| | 302.09 |
|
Vested | (421 | ) | | 239.42 |
|
Forfeited | (70 | ) | | 269.06 |
|
Nonvested restricted stock at December 31, 2019 | 976 |
| | $ | 245.21 |
|
| | | | | | | | | | | |
| Shares | | Weighted- Average Grant-Date Fair Value |
| (shares in thousands) |
Nonvested restricted stock at December 31, 2021 | 873 | | | $ | 380.55 | |
Granted | 492 | | | 430.06 | |
Vested | (449) | | | 342.42 | |
Forfeited | (103) | | | 292.28 | |
Nonvested restricted stock at December 31, 2022 | 813 | | | $ | 429.22 | |
Approximately 22%36% of the nonvested restricted stock at December 31, 20192022 included performance-based conditions.
The fair value of shares vested was $141$244 million during 2019, $2982022, $236 million during 2018,2021, and $306$191 million during 2017.2020. Total compensation expense not yet recognized related to nonvested restricted stock was $164$202 million at December 31, 2019.2022. We expect to recognize this compensation expense over a weighted-average period of approximately 1.7 years. There are no other contractual terms covering restricted stock once vested.
Stock Options
Stock options are granted with an exercise price equal to the fair market value of the underlying common stock on the date of grant. Our stock plans, as approved by the Board of Directors and stockholders, define fair market value as the average of the highest and lowest stock prices reported on the composite tape by the New York Stock Exchange on a given date. Exercise provisions vary, but most options vest in whole or in part 1 to 3 years after grant and expire 7 years after grant.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
The weighted-average fair value of each option granted during 2019, 2018,2022, 2021, and 20172020 is provided below. The fair value was estimated on the date of grant using the Black-Scholes pricing model with the weighted-average assumptions indicated below:
|
| | | | | | | | | | | |
| 2019 | | 2018 | | 2017 |
Weighted-average fair value at grant date | $ | 68.53 |
| | $ | 63.67 |
| | $ | 49.81 |
|
Expected option life (years) | 4.1 years |
| | 4.1 years |
| | 4.1 years |
|
Expected volatility | 25.5 | % | | 26.1 | % | | 27.1 | % |
Risk-free interest rate at grant date | 2.4 | % | | 2.5 | % | | 2.0 | % |
Dividend yield | 0.7 | % | | 0.7 | % | | 0.7 | % |
When valuing employee stock options, we stratify the employee population into 3 homogeneous groups that historically have exhibited similar exercise behaviors. These groups are executive officers, directors, and all other employees. We value the stock options based on the unique assumptions for each of these employee groups. | | | | | | | | | | | | | | | | | |
| 2022 | | 2021 | | 2020 |
Weighted-average fair value at grant date | $ | 113.35 | | | $ | 92.21 | | | $ | 69.73 | |
Expected option life (years) | 3.6 years | | 3.7 years | | 4.0 years |
Expected volatility | 36.1 | % | | 33.8 | % | | 24.9 | % |
Risk-free interest rate at grant date | 1.8 | % | | 0.4 | % | | 1.2 | % |
Dividend yield | 0.7 | % | | 0.7 | % | | 0.7 | % |
We calculate the expected term for our employee stock options based on historical employee exercise behavior and base the risk-free interest rate on a traded zero-coupon U.S. Treasury bond with a term substantially equal to the option’s expected term.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
The volatility used to value employee stock options is based on historical volatility. We calculate historical volatility using a simple-average calculation methodology based on daily price intervals as measured over the expected term of the option.
Activity for our option plans was as follows for the year ended December 31, 2019:2022:
|
| | | | | | |
| Shares Under Option | | Weighted-Average Exercise Price |
| (shares in thousands) |
Options outstanding at December 31, 2018 | 677 |
| | $ | 213.17 |
|
Granted | 121 |
| | 304.59 |
|
Exercised | (305 | ) | | 189.24 |
|
Forfeited | — |
| | — |
|
Options outstanding at December 31, 2019 | 493 |
| | $ | 250.46 |
|
Options exercisable at December 31, 2019 | 109 |
| | $ | 216.49 |
|
| | | | | | | | | | | |
| Shares Under Option | | Weighted-Average Exercise Price |
| (shares in thousands) |
Options outstanding at December 31, 2021 | 310 | | | $ | 339.08 | |
Granted | 65 | | | 425.32 | |
Exercised | (163) | | | 319.27 | |
Forfeited | (8) | | | 370.26 | |
Options outstanding at December 31, 2022 | 204 | | | $ | 381.37 | |
Options exercisable at December 31, 2022 | 48 | | | $ | 345.90 | |
As of December 31, 2019,2022, outstanding stock options, substantially all of which are expected to vest, had an aggregate intrinsic value of $56$26 million, and a weighted-average remaining contractual term of 4.84.9 years. As of December 31, 2019,2022, exercisable stock options had an aggregate intrinsic value of $16$8 million, and a weighted-average remaining contractual term of 3.94.1 years. The total intrinsic value of stock options exercised during 20192022 was $43$32 million, compared with $43$18 million during 20182021 and $44$51 million during 2017.2020. Cash received from stock option exercises totaled $58$51 million in 2019, $502022, $30 million in 2018,2021, and $63$61 million in 2017.2020.
Total compensation expense not yet recognized related to nonvested options was $11$7 million at December 31, 2019.2022. We expect to recognize this compensation expense over a weighted-average period of approximately 1.7 years.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
15. EARNINGS PER COMMON SHARE COMPUTATION
Detail supporting the computation of basic and diluted earnings per common share was as follows for the years ended December 31, 2019, 20182022, 2021 and 2017:2020:
| | | | | | | | | | | | | | | | | |
| 2022 | | 2021 | | 2020 |
| (dollars in millions, except per common share results, number of shares/options in thousands) |
Net income available for common stockholders | $ | 2,806 | | | $ | 2,933 | | | $ | 3,367 | |
Weighted-average outstanding shares of common stock used to compute basic earnings per common share | 126,419 | | | 128,688 | | | 132,199 | |
Dilutive effect of: | | | | | |
Employee stock options | 50 | | | 64 | | | 92 | |
Restricted stock | 625 | | | 644 | | | 721 | |
Shares used to compute diluted earnings per common share | 127,094 | | | 129,396 | | | 133,012 | |
Basic earnings per common share | $ | 22.20 | | | $ | 22.79 | | | $ | 25.47 | |
Diluted earnings per common share | $ | 22.08 | | | $ | 22.67 | | | $ | 25.31 | |
Number of antidilutive stock options and restricted stock awards excluded from computation | 205 | | | 216 | | | 238 | |
|
| | | | | | | | | | | |
| 2019 | | 2018 | | 2017 |
| (dollars in millions, except per common share results, number of shares/options in thousands) |
Net income available for common stockholders | $ | 2,707 |
| | $ | 1,683 |
| | $ | 2,448 |
|
Weighted-average outstanding shares of common stock used to compute basic earnings per common share | 134,055 |
| | 137,486 |
| | 144,493 |
|
Dilutive effect of: | | | | | |
Employee stock options | 107 |
| | 194 |
| | 172 |
|
Restricted stock | 565 |
| | 723 |
| | 920 |
|
Shares used to compute diluted earnings per common share | 134,727 |
| | 138,403 |
| | 145,585 |
|
Basic earnings per common share | $ | 20.20 |
| | $ | 12.24 |
| | $ | 16.94 |
|
Diluted earnings per common share | $ | 20.10 |
| | $ | 12.16 |
| | $ | 16.81 |
|
Number of antidilutive stock options and restricted stock awards excluded from computation | 478 |
| | 223 |
| | 539 |
|
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
16. STOCKHOLDERS’ EQUITY
Dividends
The following table provides details of dividend payments, excluding dividend equivalent rights, in 2017, 2018,2020, 2021, and 20192022, under our Board approved quarterly cash dividend policy:
| | | | | | | | | | | | | | |
Payment Date | | Amount per Share | | Total Amount |
| | | | (in millions) |
2020 | | $2.43 | | $322 |
2021 | | $2.73 | | $351 |
2022 | | $3.06 | | $390 |
|
| | | | |
Payment Date | | Amount per Share | | Total Amount |
| | | | (in millions) |
2017 | | $1.49 | | $216 |
2018 | | $1.90 | | $262 |
2019 | | $2.15 | | $289 |
Our Board of Directors may authorize the purchase of our common shares. Under our share repurchase authorization, shares may have been purchased from time to time at prevailing prices in the open market, by block purchases, through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or in privately-negotiated transactions (including pursuant to accelerated share repurchase agreements with investment banks), subject to certain regulatory restrictions on volume, pricing, and timing.
Excluding shares acquired in connection with employee stock plans, share repurchases were as follows during the years ended December 31, 2019, 20182022, 2021 and 2017.2020: